1-(PYRIDYL)-5-AZINYLPYRAZOL DERIVATIVES AND THEIR USE IN CONTROLLING UNDESIRABLE PLANT GROWTH

Description

[0001] The invention relates to the technical field of plant protection products, in particular herbicides for the selective control of weeds and grass weeds in crops and in ornamental gardens and for the general control of weeds and grass weeds in environmental areas where plant growth is disruptive.

[0002] The invention relates to substituted 1-pyridyl-5-azinylpyrazolyl-3-oxyalkyl acids, 1-pyridyl-5-azinylpyrazolyl-3-sulfanylalkyl acids, 1-pyridyl-5-azinylpyrazolyl-3-sulfinylalkyl acids and 1-pyridyl-5-azinylpyrazolyl-3-sulfonylalkyl acids and their derivatives, processes for their preparation and their use for controlling harmful plants.

[0003] The derivatives of 1-pyridyl-5-azinylpyrazolyl-3-oxyalkyl acids, 1-pyridyl-5-azinylpyrazolyl-3-sulfanylalkyl acids, 1-pyridyl-5-azinylpyrazolyl-3-sulfinylalkyl acids and 1-pyridyl-5-azinylpyrazolyl-3-sulfonylalkyl acids include in particular their esters, salts and / or amides.

[0004] The 1-pyridyl-5-azinylpyrazoles according to the invention are characterized in that they have an additional substituent in the 4-position of the pyrazole ring.

[0005] The 1-pyridyl-5-azinylpyrazolyl-3-oxyalkyl acids according to the invention and their derivatives differ from the already known 1,5-diphenylpyrazolyl-3-oxoacetic acids by a pyridyl radical (Q1-Q3) in the 1-position and a variable azinyl radical (A1-A15) in the 5-position of the pyrazole ring.

[0006] Biological effects of substituted 1,5-diphenylpyrazolyl-3-oxoacetic acids and processes for their preparation are known from the prior art. DE 2828529 A1 describes the preparation and lipid-lowering effect of 1,5-diphenylpyrazolyl-3-oxoacetic acids.

[0007] 1,5-Diphenylpyrazolyl-3-oxoacetic acids are disclosed as bactericidal agrochemicals in CN 101284815. Further syntheses and the fungicidal activity of 1,5-diphenylpyrazolyl-3-oxoacetic acids are described in Journal of Heterocyclic Chemistry (2012), 49(6), 1370-1375.

[0008] WO 2008083233 A2 describes 1,5-diphenylpyrazolyl-3-oxyalkyl acids substituted in the 4-position of the pyrazole, as well as their derivatives, as substances suitable for disrupting cell aggregates. Specifically disclosed is ethyl (4-chloro-1,5-diphenyl-1H-pyrazol-3-yl)oxyacetate.

[0009] In addition, the synthesis of some 4-chloro-1,5-diphenylpyrazolyl-3-oxyacetic acids and their ethyl esters is described in European Journal of Organic Chemistry (2011), 2011 (27), 5323-5330.

[0010] EP 0 333 131 A1 discloses plant protection agents based on pyrazolecarboxylic acid derivatives which are suitable for protection against the phototoxic effects of herbicides.

[0011] EP 1 101 764 A1 discloses 2-aryloxy-4-methyl-6-pyrazol-1-yl pyridines which are effective as herbicides.

[0012] In contrast, 1-pyridyl-5-azinylpyrazolyl-3-oxyacetic acids, 1-pyridyl-5-azinylpyrazolyl-3-oxyalkyl acids, 1-pyridyl-5-azinylpyrazolyl-3-sulfanylalkyl acids, 1-pyridyl-5-azinylpyrazolyl-3-sulfinylalkyl acids and 1-pyridyl-5-azinylpyrazolyl-3-sulfonylalkyl acids, as well as their derivatives, are unknown so far.

[0013] The object of the present invention is to provide novel pyrazole derivatives, namely 1-pyridyl-5-azinylpyrazolyl-3-oxyalkyl acids, 1-pyridyl-5-azinylpyrazolyl-3-sulfanylalkyl acids, 1-pyridyl-5-azinylpyrazolyl-3-sulfinylalkyl acids and 1-pyridyl-5-azinylpyrazolyl-3-sulfonylalkyl acids and their derivatives, which can be used as herbicides or plant growth regulators with a satisfactory herbicidal action and a broad spectrum of activity against harmful plants and / or with a high selectivity in crops.

[0014] The problem is solved by substituted 1-pyridyl-5-azinylpyrazolyl-3-oxoalkyl acids, 1-pyridyl-5-azinylpyrazolyl-3-sulfanylalkyl acids, 1-pyridyl-5-azinylpyrazolyl-3-sulfinylalkyl acids and 1-pyridyl-5-azinylpyrazolyl-3-sulfonylalkyl acids, which are characterized by a pyridyl radical in the 1-position, an azinyl radical in the 5-position and a further substituent in the 4-position of the pyrazole ring and have a very good herbicidal effect and, in addition, very good selectivities.

[0015] Surprisingly, these compounds are highly effective against a wide range of economically important grass and weed species. At the same time, the compounds demonstrate good tolerance to crops. Thus, they can be used selectively in crops while maintaining good efficacy against weeds.

[0016] The present invention therefore provides substituted 1-pyridyl-5-azinylpyrazolyl-3-oxyalkyl acids, 1-pyridyl-5-azinylpyrazolyl-3-sulfanylalkyl acids, 1-pyridyl-5-azinylpyrazolyl-3-sulfinylalkyl acids and 1-pyridyl-5-azinylpyrazolyl-3-sulfonylalkyl acids of the general formula (I) and their agrochemically acceptable salts, where A is selected from the group consisting of A1-A15 Q is selected from the group consisting of Q1-Q3 R 1< OR 1a< , NR 9< R 10< or O(CH 2 ) x O(CH 2 ) y O(CH 2 ) z H, R 1a< denotes hydrogen or (C 1 -C 6 )-alkyl, (C 3 -C 6 )-cycloalkyl, which is in each case unsubstituted or substituted by one or more substituents selected from the group consisting of halogen, (C 1 -C 6 )-alkyl, (C 1 -C 6 )-haloalkyl, (C 3 -C 6 )-cycloalkyl, (C 1 -C 6 )-alkoxy, -N=R 5< , cyano and nitro or (C 2 -C 4 )-alkenyl, (C 2 -C 4 )-alkynyl or (C 1 -C 6 )-alkyl-SO-(C 1 -C 6 )-alkyl-, (C 1 -C 6 )-alkyl-SO 2 -(C 1 -C 6 )-alkyl- or heterocyclyl, heteroaryl, aryl or heterocyclyl-(C 1- C 4 )-alkyl-, heteroaryl-(C 1- C 4 )-alkyl-, aryl-(C 1- C 4 )-alkyl-, each of which is unsubstituted or substituted by one or more substituents selected from the group consisting of halogen, (C 1 -C 6 )-alkyl, (C 1 -C 6 )-haloalkyl; R 9< means hydrogen, (C 1 -C 12 )-alkyl;R 10 < hydrogen, aryl, heteroaryl, heterocyclyl, (C 1 -C 12 )-alkyl, (C 3 -C 8 )-cycloalkyl, (C 3 -C 8 )-cycloalkyl-(C 1 -C 7 )-alkyl-, (C 2 -C 12 )-alkenyl, (C 5 -C 7 )-cycloalkenyl, (C 2 -C 12 )-Alkynyl, S(O) n R 5< , Cyano, Nitro, OR 5< , SO 2 NR 6< R 7< , CO 2 R 8< , COR 8< , NR 6< R 8< , NR 6< COR 8< , NR 6< CO 2 R 8< , NR 6< SO 2 R 8< means, where the above-mentioned alkyl, cycloalkyl, Alkenyl, cycloalkenyl and alkynyl radicals are unsubstituted or are each independently substituted by "m" radicals selected from the group consisting of hydrogen, optionally mono- or polysubstituted aryl, halogen, cyano, nitro, OR 5< , S(O) n R 5< , SO 2 NR 6< R 7< , CO 2 R 8< , CONR 6< R 8< , COR 6< , NR 6< R 8< , NR 6< COR 8< , NR 6< CONR 8< R 8< , NR 6< CO2R 8< , NR 6< SO 2 R 8< , NR 6< SO 2 NR 6< R 8< , C(R 6< )=NOR 8< ; ; or R 9< and R 10< form, with the nitrogen atom to which they are bonded, a saturated, partially or fully unsaturated five-, six- or seven-membered ring which is optionally mono- to six-fold substituted by radicals from the group consisting of halogen, (C 1 -C 6 )-alkyl, (C 1 -C 6 )-haloalkyl, OR 5< , S(O) n R 5< , CO 2 R 8< , CONR 6< R 8< , COR 6< and C(R 6< )=NOR 8< and which, in addition to this nitrogen atom, contains "r" carbon atoms, "o" oxygen atoms, "p" sulfur atoms and "q" elements from the group consisting of NR 7< , CO and NCOR 7< as ring atoms; R 5 <(C 1 -C 6 )-alkyl, (C 3 -C 6 )-cycloalkyl, (C 1 -C 6 )-haloalkyl, aryl; R 6 < hydrogen, (C 1 -C 6 )-alkyl, (C 3 -C 6 )-cycloalkyl, (C 1 -C 6 )-haloalkyl, aryl; R 7 < hydrogen, (C 1 -C 6 )-alkyl, (C 3 -C 6 )-cycloalkyl, (C 3 -C 4 )-alkenyl, (C 3 -C 4 )-alkynyl;R 8< Wasserstoff, (C 1 -C 6 )-Alkyl, (C 3 -C 6 )-Cycloalkyl, (C 3 -C 4 )-Alkenyl, (C 1 -C 6 )-Alkyl-COO(C 1 -C 2 )-Alkyl oder (C 3 -C 4 )-Alkinyl bedeutet; R 2< Wasserstoff, Cyano, (C 1 -C 6 )-Alkyl, (C 1 -C 6 )-Alkoxy-(C 1 -C 6 )-Alkyl-, (C 1 -C 6 )-Halogenalkyl, (C 1 -C 6 )-Alkoxy, (C 2 -C 6 )-Alkenyl, (C 2 -C 6 )-Halogenalkenyl, (C 2 -C 6 )-Alkinyl, (C 2 -C 6 )-Halogenalkinyl, (C 3 - C 6 )-Cycloalkyl bedeutet; R 3< Halogen, Cyano, Isocyano, NO 2 , (C 3 -C 6 )-Cycloalkyl, (C 1 -C 6 )-Alkyl, (C 1 -C 6 )-Halogenalkyl, (C 1 -C 6 )-Alkylcarbonyl-, (C 1 -C 6 )-Halogenalkylcarbonyl-, (C 1 -C 6 )-Alkyloxycarbonyl-, (C 2 - C 3 )-Alkenyl, (C 2 - C 3 )-Halogenalkenyl, (C 2 -C 3 )-Alkinyl, (C 2 - C 3 )-Halogenalkinyl, (C 1 -C 6 )-Alkyl-S(O) n und (C 1 -C 6 )-Halogenalkyl-S(O) n , CHO, NH 2 bedeutet;R 12 <halogen, cyano, isocyano, NO 2, (C 1 -C 6 )-alkyl, (C 1 -C 6 )-haloalkyl, (C 1 -C 6 )-alkylcarbonyl, (C 1 -C 6 )-haloalkylcarbonyl, (C 1 -C 6 )-alkyloxycarbonyl, (C 1 -C 6 )-alkoxy, (C 1 -C 6 )-haloalkoxy, (C 1 -C 6 )-alkyl-, S(O) n , (C 2 - C 3 )-alkenyl, (C 2 - C 3 )-haloalkenyl, (C 2 -C 3 )-alkynyl, (C 2 - C 3 )-haloalkynyl, NH 2 means; R 13< is halogen, cyano, isocyano, NO 2 , (C 1 -C 6 )-alkyl, (C 1 -C 6 )-haloalkyl, (C 1 -C 6 )-alkylcarbonyl, (C 1 -C 6 )-haloalkylcarbonyl, (C 1 -C 6 )-alkyloxycarbonyl, (C 1 -C 6 )-alkoxy, (C 1 -C 6 )-haloalkoxy, (C 1 -C 6 )-alkyl- S(O) n , (C 2 - C 3 )-alkenyl, (C 2 - C 3 )-haloalkenyl; (C 2 -C 3 )-alkynyl, (C 2 - C 3 )-haloalkynyl, NH 2 ; Y is oxygen, S(O) n ; m is 0, 1 or 2; n means 0, 1 or 2; o means 0, 1 or 2; p means 0 or 1; q means 0 or 1; r means 3, 4, 5 or 6; s means 0, 1, 2, 3 or 4; x means 1, 2, 3, 4 or 5; y means 1, 2, 3, 4 or 5;z1,2,3,4 or 5. ;

[0017] Preferred, particularly preferred, and very particularly preferred meanings for each individual substituent are described below. The remaining substituents of general formula (I), which are not mentioned below, have the meaning given above.

[0018] This results in various embodiments for the compound of general formula (I).

[0019] Bevorzugt are compounds of the general formula (I) in which A is selected from the group consisting of A1- A4, A6-A9, and A12-A15 Q is selected from the group consisting of Q1-Q3 R 1< OR 1a< , NR 9< R 10< or O(CH 2 ) x O(CH 2 ) y O(CH 2 ) z H, R 1a< denotes hydrogen or (C 1 -C 6 )-alkyl, (C 3 -C 6 )-cycloalkyl which is in each case unsubstituted or substituted and by one or more substituents selected from the group consisting of halogen, (C 1 -C 6 )-alkyl, (C 1 -C 6 )-haloalkyl, (C 3 -C 6 )-cycloalkyl, (C 1 -C 6 )-alkoxy, cyano and nitro or (C 2 -C 4 )-alkenyl, (C 2 -C 4 )-alkynyl or (C 1 -C 6 )-alkyl-SO-(C 1 -C 6 )-alkyl-, (C 1 -C 6 )-alkyl-SO 2 -(C 1 -C 6 )-alkyl-, aryl-(C 1 - C 4 )-alkyl-, which is in each case unsubstituted or substituted by one or more substituents selected from the group consisting of halogen, (C 1 -C 6 )-alkyl, (C 1 -C 6 )-haloalkyl; R 9< hydrogen, (C 1 -C 6 )-alkyl; R 10< hydrogen, phenyl, (C 1 -C 6 )-alkyl, (C 3 -C 6 )-cycloalkyl, (C 3 -C 6 )-cycloalkyl-(C 1 -C 4 )-alkyl-, (C 2 -C 4 )-alkenyl, (C 5 -C 7 )-cycloalkenyl, (C 2 -C 4 )-alkynyl,S(O) n R 5< , cyano, nitro, OR 5< , SO 2 NR 6< R 7< , CO 2 R 8< , COR 8< , NR 6< R 8<, where the above-mentioned alkyl, cycloalkyl, alkenyl, cycloalkenyl and alkynyl radicals are unsubstituted or are each independently substituted by "m" radicals selected from the group consisting of optionally mono- or polysubstituted phenyl, halogen, cyano, nitro, OR 5< , S(O) n R 5< , SO 2 NR 6< R 7< , CO 2 R 8< , CONR 6< R 8< , COR 6< , NR 6< R 8< , NR 6< COR 8< , NR 6< CONR 8< R 8< , NR 6< CO 2 R 8< or R 9< and R 10< form with the nitrogen atom to which they are attached a saturated, partially or fully unsaturated five-, six- or seven-membered ring which is optionally mono- to six-fold substituted by radicals from the group consisting of halogen, (C 1 -C 6 )-alkyl, (C 1 -C 6 )-haloalkyl, OR 5< , S(O) n R 5< , CO 2 R 8< , CONR 6< R 8< , COR 6< and C(R 6< )=NOR 8< and which, in addition to this nitrogen atom "r", contains carbon atoms,"o" contains oxygen atoms, "p" sulfur atoms and "q" elements from the group consisting of NR 7< , CO and NCOR 7< as ring atoms; , R 5< is (C 1 -C 6 )-alkyl, (C 3 -C 6 )-cycloalkyl, (C 1 -C 6 )-haloalkyl or phenyl; R 6< is hydrogen, (C 1 -C 6 )-alkyl, (C 3 -C 6 )-cycloalkyl, (C 1 -C 6 )-haloalkyl or phenyl; R 7< is hydrogen, (C 1 -C 6 )-alkyl, (C 3 -C 6 )-cycloalkyl, (C 3 -C 4 )-alkenyl or (C 3 -C 4 )-alkynyl; R 8< is hydrogen, (C 1 -C 6 )-alkyl, (C 3 -C 6 )-cycloalkyl, (C 3 -C 4 )-alkenyl or (C 3 -C 4 )-alkynyl; R 2 < hydrogen, cyano, (C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkoxy-(C 1 -C 6 )-alkyl, (C 1 -C 6 )-haloalkyl, (C 1 -C 6 )-alkoxy, (C 2 -C 4 )-alkenyl, (C 2 -C 4 )-haloalkenyl; (C 2 -C 4 )-alkynyl, (C 2 -C 4 )-haloalkynyl; (C 3 -C 6 )-cycloalkyl; R 3< Halogen, Cyano, Isocyano, NO 2 , (C 3 -C 6 )-Cycloalkyl, (C 1 -C 6 )-Alkyl, (C 1 -C 6 )-Halogenalkyl, (C 1 -C 6 )-Alkylcarbonyl, (C 1 -C 6 )-Halogenalkylcarbonyl, (C 1 -C 6 )-Alkyloxycarbonyl, (C 2 -C 3 )-Alkenyl, (C 2 -C 3 )-Halogenalkenyl, (C 2 -C 3 )-Alkinyl, (C 2 - C 3 )-Halogenalkinyl, (C 1 -C 6 )-Alkyl-S(O) n -, (C 1 -C 6 )-Halogenalkyl-S(O) n- , CHO, NH 2 bedeutet; R 12< Halogen, Cyano, Isocyano, NO 2 , (C 1 -C 6 )-Alkyl, (C 1 -C 6 )-Halogenalkyl, (C 1 -C 6 )-Alkylcarbonyl, (C 1 -C 6 )-Halogenalkylcarbonyl, (C 1 -C 6 )-Alkyloxycarbonyl, (C 1 -C 6 )-Alkoxy, (C 1 -C 6 )-Halogenalkoxy, (C 1 -C 6 )-Alkyl- S(O) n , (C 2 - C 3 )-Alkenyl, (C 2 - C 3 )-Halogenalkenyl, (C 2 -C 3 )-Alkinyl, (C 2 - C 3 )-Halogenalkinyl, NH 2 bedeutet; R 13 < halogen, cyano, isocyano, NO 2 , (C 1 -C 6 )-alkyl, (C 1 -C 6 )-haloalkyl, (C 1 -C 6 )-alkylcarbonyl, (C 1 -C 6 )-haloalkylcarbonyl, (C 1 -C 6 )-alkyloxycarbonyl, (C 1 -C 6 )-alkoxy, (C 1 -C 6 )-haloalkoxy, (C 1 -C 6 )-alkyl-S(O) n , (C 2 - C 3 )-alkenyl, (C 2 - C 3 )-haloalkenyl, (C 2 -C 3 )-alkynyl, (C 2 - C 3 )-haloalkynyl, NH 2 means; Y means oxygen, S(O) n; m0, 1, 2 means; n0, 1, 2 means; o0, 1, 2 means; p0 or 1 means; q0 or 1 means; r3, 4, 5 or 6 means; s0, 1, 2, 4 means; x1, 2, 3, 4 means; y1, 2, 3, 4 means; z1, 2, 3, 4 means. Besonders bevorzugt are compounds of the general formula (I) in which A is selected from the group consisting of A1-A4, A6 and A8

[0020] Q is selected from the group consisting of Q1-Q3 R 1< OR 1a< , NR 9< R 10< or O(CH 2 ) x O(CH 2 ) y O(CH 2 ) z H, R 1a< denotes hydrogen or (C 1 -C 4 )-alkyl, (C 3 -C 6 )-cycloalkyl which in each case is unsubstituted or substituted by one or more substituents selected from the group consisting of halogen, (C 1 -C 4 )-alkyl, (C 1 -C 4 )-haloalkyl or aryl-(C 1 - C 4 )-alkyl-, which in each case is unsubstituted or substituted by one or more substituents selected from the group consisting of halogen, (C 1 -C 4 )-alkyl, (C 1 -C 4 )-haloalkyl; R 9< hydrogen; R 10< means (C 1 -C 6 )-alkyl, S(O) n R 5< , SO 2 NR 6< R 7< , CO 2 R 8<, where the above-mentioned radicals are unsubstituted or are each independently substituted by "m" radicals selected from the group consisting of aryl, S(O) n R 5< , SO 2 NR 6< R 7< , CO 2 R 8< , NR 6< CO 2 R 8< ; R 5< means ethyl, methyl, CF 3 or CH 2 CF 3; R 6< means hydrogen;R 7< denotes hydrogen, methyl or ethyl; R 8< denotes methyl or ethyl; R 2< denotes hydrogen, (C 1 -C 6 )-alkyl, (C 1 -C 6 )-haloalkyl, (C 1 -C 6 )-alkoxy; R 3< denotes halogen, cyano, NO 2 , (C 3 -C 6 )-cycloalkyl, (C 1 -C 6 )-alkyl, (C 1 -C 6 )-haloalkyl, (C 1 -C 6 )-haloalkoxy, (C 1 -C 6 )-alkylthio; R 12< denotes fluorine, chlorine, bromine, cyano, methyl, ethyl, CF 3 , OCF 3; R 13< denotes fluorine, chlorine, bromine, cyano, methyl, ethyl, CF 3 , OCF 3; Y denotes oxygen and S(O) n m0, 1 2 means; n0, 1, 2 means; s0, 1, 2 means; x1,2 means; y1,2 means; z1,2 means. ; Ganz besonders bevorzugt are compounds of the general formula (I) in which A is selected from the group consisting of A2, A3 and A6

[0021] Q is selected from the group consisting of Q1-Q3 R 1< OR 1a< ; R 1a< hydrogen, ethyl, methyl, CF 3 CH 2 SO 2 NH-, Me 2 NSO 2 NH-, MeO 2 CCH 2 NH- R 2< hydrogen, methyl or ethyl; R 3< means fluorine, bromine, chlorine, cyano, NO 2 , methyl, cyclopropyl, CF 3 and OCF; R 12< means fluorine, chlorine, bromine, cyano, CF 3; R 13< means fluorine, chlorine, bromine, cyano, CF 3; Y means oxygen and S(O) n; n means 0, 1, 2; s means 0, 1, 2.

[0022] The present invention further relates to compounds of the formula ( Z ) where the definitions described above apply, including all preferred, particularly preferred and most particularly preferred definitions.

[0023] The present invention further relates to compounds of the formula ( Y ) where the definitions described above apply, including all preferred, particularly preferred and most particularly preferred definitions.

[0024] The present invention further relates to compounds of the formula ( W ) where the definitions described above apply, including all preferred, particularly preferred and most particularly preferred definitions.

[0025] The present invention further relates to acids of the formula ( Ia ) where the definitions described above apply, including all preferred, particularly preferred and most particularly preferred definitions.

[0026] The present invention further relates to compounds of the formula ( V ) where the definitions described above apply, including all preferred, particularly preferred and most particularly preferred definitions.

[0027] The present invention further relates to compounds of the formula ( VI ) where the definitions described above apply, including all preferred, particularly preferred and most particularly preferred definitions.

[0028] In all formulas mentioned below, the substituents and symbols, unless otherwise defined, have the same meaning as under formula ( I ) described.

[0029] Not included are combinations that contradict the laws of nature and which the expert would therefore exclude based on his knowledge.

[0030] Alkyl means saturated, straight-chain or branched hydrocarbon radicals with the specified number of carbon atoms, e.g. C 1 -C 6 alkyl such as methyl, ethyl, propyl, 1-methylethyl, butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, 3,3-dimethylbutyl, 1-ethylbutyl, 2-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-1-methylpropyl and 1-ethyl-2-methyl-propyl.

[0031] Through Halogen substitiertes Alkyl means straight-chain or branched alkyl groups, where in these groups the hydrogen atoms may be partially or completely replaced by halogen atoms, e.g. C 1 -C 2 -haloalkyl such as chloromethyl, bromomethyl, dichloromethyl, trichloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chlorofluoromethyl, dichlorofluoromethyl, chlorodifluoromethyl, 1-chloroethyl, 1-bromoethyl, 1-fluoroethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-chloro-2-fluoroethyl, 2-chloro,2-difluoroethyl, 2,2-dichloro-2-fluoroethyl, 2,2,2-trichloroethyl, pentafluoroethyl and 1,1,1-trifluoroprop-2-yl.

[0032] Alkenyl means unsaturated, straight-chain or branched hydrocarbon radicals with the specified number of carbon atoms and one double bond in any position, e.g. C 2 -C 6 -alkenyl such as ethenyl, 1-propenyl, 2-propenyl, 1-methylethenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-methyl-1-propenyl, 2-methyl-1-propenyl, 1-methyl-2-propenyl, 2-methyl-2-propenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-methyl-1-butenyl, 2-methyl-1-butenyl, 3-methyl-1-butenyl, 1-methyl-2-butenyl, 2-methyl-2-butenyl, 3-Methyl-2-butenyl, 1-Methyl-3-butenyl, 2-Methyl-3-butenyl, 3-Methyl-3-butenyl, 1,1-Dimethyl-2-propenyl, 1,2-Dimethyl-1-propenyl, 1,2-Dimethyl-2-propenyl, 1-Ethyl-1-propenyl, 1-Ethyl-2-propenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 1-methyl-1-pentenyl, 2-methyl-1-pentenyl, 3-methyl-1-pentenyl, 4-methyl-1-pentenyl, 1-methyl-2-pentenyl, 2-methyl-2-pentenyl, 3-methyl-2-pentenyl, 4-Methyl-2-pentenyl, 1-Methyl-3-pentenyl, 2-Methyl-3-pentenyl,3-Methyl-3-pentenyl, 4-Methyl-3-pentenyl, 1-Methyl-4-pentenyl, 2-Methyl-4-pentenyl, 3-Methyl-4-pentenyl, 4-Methyl-4-pentenyl, 1,1-Dimethyl-2-butenyl, 1,1-Dimethyl-3-butenyl, 1,2-Dimethyl-1-butenyl, 1,2-Dimethyl-2-butenyl, 1,2-Dimethyl-3-butenyl, 1,3-Dimethyl-1-butenyl, 1,3-Dimethyl-2-butenyl, 1,3-Dimethyl-3-butenyl, 2,2-Dimethyl-3-butenyl, 2,3-Dimethyl-1-butenyl, 2,3-Dimethyl-2-butenyl, 2,3-Dimethyl-3-butenyl, 3,3-Dimethyl-1-butenyl, 3,3-Dimethyl-2-butenyl, 1-Ethyl-1-butenyl, 1-Ethyl-2-butenyl, 1-Ethyl-3-butenyl, 2-Ethyl-1-butenyl, 2-Ethyl-2-butenyl, 2-Ethyl-3-butenyl, 1,1,2-Trimethyl-2-propenyl, 1-Ethyl-1-methyl-2-propenyl, 1-Ethyl-2-methyl-1-propenyl und 1-Ethyl-2-methyl-2-propenyl.,

[0033] Alkinyl means straight-chain or branched hydrocarbon radicals with the specified number of carbon atoms and a triple bond in any position, e.g. C 2 -C 6 -alkynyl such as ethynyl, 1-propynyl, 2-propynyl (or propargyl), 1-butynyl, 2-butynyl, 3-butynyl, 1-methyl-2-propynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 3-methyl-1-butynyl, 1-methyl-2-butynyl, 1-methyl-3-butynyl, 2-methyl-3-butynyl, 1,1-dimethyl-2-propynyl, 1-ethyl-2-propynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl, 3-methyl-1-pentynyl, 4-methyl-1-pentynyl, 1-methyl-2-pentynyl, 4-methyl-2-pentynyl, 1-methyl-3-pentynyl, 2-methyl-3-pentynyl, 1-methyl-4-pentynyl, 2-methyl-4-pentynyl, 3-methyl-4-pentynyl, 1,1-Dimethyl-2-butynyl, 1,1-Dimethyl-3-butynyl, 1,2-Dimethyl-3-butynyl, 2,2-Dimethyl-3-butynyl, 3,3-Dimethyl-1-butynyl, 1-Ethyl-2-butynyl, 1-Ethyl-3-butynyl, 2-Ethyl-3-butynyl and 1-Ethyl-1-methyl-2-propynyl.

[0034] Cycloalkyl means a carbocyclic, saturated ring system with preferably 3 to 6 ring carbon atoms, e.g. cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl. In the case of optionally substituted cycloalkyl, cyclic systems with substituents are included, which also include substituents with a double bond on the cycloalkyl radical, e.g. an alkylidene group such as methylidene. In the case of optionally substituted cycloalkyl, polycyclic aliphatic systems are also included, such as, for example, bicyclo[1.1.0]butan-1-yl, bicyclo[1.1.0]butan-2-yl, bicyclo[2.1.0]pentan-1-yl, bicyclo[2.1.0]pentan-2-yl, bicyclo[2.1.0]pentan-5-yl, bicyclo[2.2.1]hept-2-yl (norbornyl), adamantan-1-yl and adamantan-2-yl.

[0035] In the case of substituted cycloalkyl, spirocyclic aliphatic systems are also included, such as spiro[2.2]pent-1-yl, spiro[2.3]hex-1-yl, spiro[2.3]hex-4-yl, 3-spiro[2.3]hex-5-yl.

[0036] Cycloalkenyl means a carbocyclic, non-aromatic, partially unsaturated ring system with preferably 4-8 C atoms, e.g., 1-cyclobutenyl, 2-cyclobutenyl, 1-cyclopentenyl, 2-cyclopentenyl, 3-cyclopentenyl, or 1-cyclohexenyl, 2-cyclohexenyl, 3-cyclohexenyl, 1,3-cyclohexadienyl, or 1,4-cyclohexadienyl, which also includes substituents with a double bond on the cycloalkenyl radical, e.g., an alkylidene group such as methylidene. In the case of optionally substituted cycloalkenyl, the explanations for substituted cycloalkyl apply accordingly.

[0037] Alkoxy means saturated, straight-chain or branched alkoxy radicals with the specified number of carbon atoms, e.g. C 1 -C 6 -alkoxy such as methoxy, ethoxy, propoxy, 1-methylethoxy, butoxy, 1-methylpropoxy, 2-methylpropoxy, 1,1-dimethylethoxy, pentoxy, 1-methylbutoxy, 2-methylbutoxy, 3-methylbutoxy, 2,2-dimethylpropoxy, 1-ethylpropoxy, hexoxy, 1,1-dimethylpropoxy, 1,2-dimethylpropoxy, 1-methylpentoxy, 2-methylpentoxy, 3-methylpentoxy, 4-methylpentoxy, 1,1-dimethylbutoxy, 1,2-dimethylbutoxy, 1,3-dimethylbutoxy, 2,2-dimethylbutoxy, 2,3-dimethylbutoxy, 3,3-Dimethylbutoxy, 1-Ethylbutoxy, 2-Ethylbutoxy, 1,1,2-Trimethylpropoxy, 1,2,2-Trimethylpropoxy, 1-Ethyl-1-methylpropoxy and 1-Ethyl-2-methylpropoxy. Halogen-substituted alkoxy means straight-chain or branched alkoxy radicals with the specified number of carbon atoms, where the hydrogen atoms in these groups may be partially or completely replaced by halogen atoms as mentioned above, e.g.C 1 -C 2 -haloalkoxy such as chloromethoxy, bromomethoxy, dichloromethoxy, trichloromethoxy, fluoromethoxy, difluoromethoxy, trifluoromethoxy, chlorofluoromethoxy, dichlorofluoromethoxy, chlorodifluoromethoxy, 1-chloroethoxy, 1-bromomethoxy, 1-fluorethoxy, 2-fluorethoxy, 2,2-difluorethoxy, 2,2,2-trifluoroethoxy, 2-chloro-2-fluoroethoxy, 2-chloro-1,2-difluorethoxy, 2,2-dichloro-2-fluoroethoxy, 2,2,2-trichloroethoxy, pentafluoroethoxy and 1,1,1-trifluoroprop-2-oxy.

[0038] Heterocyclyl , means saturated or partially unsaturated mono-, bi- or tricyclic ring system group, consisting of C atoms and at least one heteroatom, preferably selected from N, O and / or S.

[0039] Heteroaryl , unless defined otherwise elsewhere: mono-, bi- or tricyclic heterocyclic group consisting of C atoms and at least one heteroatom, where at least one ring is aromatic. In one embodiment, at least one heteroatom is N, O or S. In one embodiment, all heteroatoms are selected from N, O or S. In one embodiment, the ring system is a 5 to 10-membered or a 5 to 6-membered ring system. In one embodiment, heteroaryl is an aromatic monocyclic ring system consisting of 5 or 6 ring atoms. In a further embodiment, heteroaryl is an aromatic monocyclic ring system containing 1 to 4 heteroatoms from the group N, O or S. Furthermore, heteroaryl can represent a bicyclic ring system consisting of 8 to 14 ring atoms or a tricyclic ring system consisting of 13 to 14 ring atoms.Examples: Furyl, Thienyl, Pyrazolyl, Imidazolyl, Triazolyl, Thiazolyl, Indolyl, Benzimidazolyl, Indazolyl, Benzofuranyl, Benzothiophenyl, Benzothiazolyl, Benzoxazolyl, Quinolinyl, Isoquinolinyl.

[0040] The term " Aryl" means an optionally substituted mono-, bi- or polycyclic aromatic system having preferably 6 to 14, in particular 6 to 10 ring C atoms, for example phenyl, naphthyl, anthryl, phenanthrenyl, and the like, preferably phenyl.

[0041] From the concept "gegebenenfalls substituiertes Aryl" Also included are multicyclic systems such as tetrahydronaphthyl, indenyl, indanyl, fluorenyl, and biphenylyl, where the bonding site is at the aromatic system. Systematically, "aryl" is generally also encompassed by the term "optionally substituted phenyl."

[0042] Die oben aufgeführten Aryle sind bevorzugt unabhängig voneinander ein- bis fünffach beispielsweise durch Wasserstoff, Halogen, Alkyl, Haloalkyl, Hydroxy, Alkoxy, Cycloalkoxy, Aryloxy, Alkoxyalkyl, Alkoxyalkoxy, Cycloalkyl, Halocycloalkyl, Aryl, Arylalkyl, Heteroaryl, Heterocyclyl, Alkenyl, Alkylcarbonyl, Cycloalkylcarbonyl, Arylcarbonyl, Heteroarylcarbonyl, Alkoxycarbonyl, Hydroxycarbonyl, Cycloalkoxycarbonyl, Cycloalkylalkoxycarbonyl, Alkoxycarbonylalkyl, Arylalkoxycarbonyl, Arylalkoxycarbonylalkyl, Alkinyl, Alkinylalkyl, Alkylalkinyl, Trisalkylsilylalkinyl, Nitro, Amino, Cyano, Haloalkoxy, Haloalkylthio, Alkylthio, Hydrothio, Hydroxyalkyl, Heteroarylalkoxy, Arylalkoxy, Heterocyclylalkoxy, Heterocyclylalkylthio, Heterocyclyloxy, Heterocyclylthio, Heteroaryloxy, Bis-alkylamino, Alkylamino, Cycloalkylamino, Hydroxycarbonylalkylamino, Alkoxycarbonylalkylamino, Arylalkoxycarbonylalkylamino, Alkoxycarbonylalkyl(alkyl)amino, Aminocarbonyl, Alkylaminocarbonyl, Bis-alkylaminocarbonyl,Cycloalkylaminocarbonyl, hydroxycarbonylalkylaminocarbonyl, alkoxycarbonylalkylaminocarbonyl, arylalkoxycarbonylalkylaminocarbonyl substituted.,

[0043] If a basic structure is substituted "by one or more residues" from a list of residues (= group) or a generically defined group of residues, this includes the simultaneous substitution by several identical and / or structurally different residues.

[0044] The term "halogen" means fluorine, chlorine, bromine, or iodine. When used for a radical, "halogen" means a fluorine, chlorine, bromine, or iodine atom.

[0045] Depending on the nature of the substituents defined above, the compounds of formula (I) exhibit acidic properties and can form salts, optionally also internal salts or adducts, with inorganic or organic bases or with metal ions. If the compounds of formula (I) carry hydroxyl, carboxyl or other groups inducing acidic properties, these compounds can be reacted with bases to form salts. Suitable bases include, for example, hydroxides, carbonates, hydrogen carbonates of alkali and alkaline earth metals, in particular those of sodium, potassium, magnesium and calcium, as well as ammonia, primary, secondary and tertiary amines with (C 1 -C 4 )-alkyl groups, mono-, di- and trialkanolamines of (C 1 -C 4 )-alkanols, choline and chlorocholine, as well as organic amines such as trialkylamines, morpholine, piperidine or pyridine.These salts are compounds in which the acidic hydrogen is replaced by a cation suitable for agriculture, for example metal salts, in particular alkali metal salts or alkaline earth metal salts, in particular sodium and potassium salts, or also ammonium salts, salts with organic amines or quaternary ammonium salts, for example with cations of the formula [NRR'R"R‴] +< , in which R to R‴ each independently represent an organic radical, in particular alkyl, aryl, aralkyl or alkylaryl. Also suitable are alkylsulfonium and alkylsulfoxonium salts, such as (C 1 -C 4 )-trialkylsulfonium and (C 1 -C 4 )-trialkylsulfoxonium salts.

[0046] The compounds of formula (I) can form salts by addition of a suitable inorganic or organic acid, such as, for example, mineral acids such as HCl, HBr, H 2 SO 4 , H 3 PO 4 or HNO 3 , or organic acids, e.g., carboxylic acids such as formic acid, acetic acid, propionic acid, oxalic acid, lactic acid or salicylic acid, or sulfonic acids such as, for example, p-toluenesulfonic acid, to a basic group such as, for example, amino, alkylamino, dialkylamino, piperidino, morpholino or pyridino. These salts then contain the conjugate base of the acid as an anion.

[0047] Suitable substituents which are present in deprotonated form, such as sulfonic acids or carboxylic acids, can form inner salts with protonatable groups, such as amino groups.

[0048] If a group is substituted multiple times by residues, this means that this group is substituted by one or more of the same or different residues mentioned.

[0049] In all formulas below, unless otherwise defined, the substituents and symbols have the same meaning as described in formula (I). Arrows in a chemical formula indicate the linkage points to the rest of the molecule.

[0050] Preferred, particularly preferred, and very particularly preferred meanings for each individual substituent are described below. The remaining substituents of general formula (I), which are not mentioned below, have the meaning given above.

[0051] The present compounds of general formula (I) have a chiral carbon atom at the second carbon of the alkyl acid structure, which is indicated in the structure shown below by the marking (*):

[0052] According to the Cahn, Ingold, and Prelog rules (CIP rules), this carbon atom can have both an (R) and an (S) configuration.

[0053] The present invention covers compounds of general formula (I) with both (S) and (R) configuration, ie the present invention covers the compounds of general formula (I) in which the carbon atom in question (1) has an (R) configuration; or (2) has an (S) configuration. Furthermore, within the scope of the present invention, (3) any mixtures of compounds of the general formula (I) which have an (R) configuration (compounds of the general formula (I-(R))) with compounds of the general formula (I) which have an (S) configuration (compounds of the general formula (IS)) are also encompassed, wherein a racemic mixture of the compounds of the general formula (I) with (R) and (S) configuration is also encompassed by the present invention.

[0054] However, in the context of the present invention, particular preference is given to compounds of the general formula (I) having (R) configuration with a selectivity of 60 to 100%, preferably 80 to 100%, in particular 90 to 100%, very particularly 95 to 100%, wherein the respective (R) compound is present with an enantioselectivity of more than 50% ee, preferably 60 to 100% ee, in particular 80 to 100% ee, very particularly 90 to 100% ee, most preferably 95 to 100% ee, based on the total content of the respective (R) compound.

[0055] Therefore, the present invention relates in particular to compounds of the general formula (I*) in which the stereochemical configuration at the carbon atom marked with (*) is present with a stereochemical purity of 60 to 100% (R), preferably 80 to 100% (R), in particular 90 to 100% (R), very particularly 95 to 100% (R).

[0056] In addition, depending on the choice of the respective radicals, further stereoelements may be present in the compounds of the general formula (I) according to the invention.

[0057] The compounds listed in the following tables are preferred. Compounds of general formula (I) with the (R) configuration are marked accordingly in the column where the radical R 2< is mentioned. For example, if R 2< = alkyl, the preferred stereochemical configuration at the carbon atom marked with (*) in general formula (I) is the (R) configuration.

[0058] If, for example, R 2< = alkoxy, the preferred stereochemical configuration at the carbon atom marked with (*) in general formula (I) is the (S) configuration. Table I: 2-Pyridyl Beispielnummer R 1< R 2< R 3< A Y (R 13< ) s I-01 OEt H Br (2-fluoropyridin-4-yl) O H I-02 OEt H Br (6-fluoropyridin-3-yl) O H I-03 OMe (R)-Me Br pyridin-3-yl O 3-F I-04 OMe (R)-Me CN pyridin-3-yl O 3-F I-05 OMe (R)-Me Br (6-fluoropyridin-3-yl) O 3-F I-06 OMe (R)-Me CN (6-fluoropyridin-3-yl) O 3-F I-07 OMe H Br (6-fluoropyridin-3-yl) O 3-F I-08 OH H Br (6-fluoropyridin-3-yl) O 3-F I-09 OMe H CN (6-fluoropyridin-3-yl) O 3-F I-10 OH (R)-Me Br (6-fluoropyridin-3-yl) O 3-F I-11 OMe (R)-Me Br (6-fluoropyridin-3-yl) O 5-F I-12 OMe H Br (6-fluoropyridin-3-yl) O 5-F I-13 OH (R)-Me Br (5 -fluoropyridin-3 -yl) O 5-F I-14 OH H Br (5 -fluoropyridin-3 -yl) O 5-F I-15 OMe (R)-Me Br (5 -fluoropyridin-3 -yl) O 3-F I-16 OMe H Br (5 -fluoropyridin-3 -yl) O 3-F I-17 OH H Br (6-fluoropyridin-3-yl) O 3-F I-18 OH (R)-Me Br (6-fluoropyridin-3-yl) O 3-F I-19 OMe (R)-Me Cl (2-fluoropyridin-4-yl) O H I-20 OH (R)-Me Cl pyrimidin-5-yl O H I-21 OH (R)-Me Cl (6-fluoropyridin-3-yl) O H I-22 OH (R)-Me Cl (6-fluoropyridin-3-yl) O H I-23 OEt H Br (6-fluoropyridin-3-yl) O 3-Cl I-24 OMe (R)-Me Br (6-fluoropyridin-3-yl) O 3-Cl I-25 OH (R)-Me Br (6-fluoropyridin-3-yl) O 3-Cl I-26 OH H Br (6-fluoropyridin-3-yl) O 3-Cl I-27 OEt (R)-Me Br (6-fluoropyridin-3-yl) O 3-Cl I-28 OMe H Br (6-fluoropyridin-3-yl) O 3-Cl I-29 -OCH 2 CH 2 OMe H Br (6-fluoropyridin-3-yl) O 3-F I-30 -OCH 2 CN H Br (6-fluoropyridin-3-yl) O 3-F I-31 -NH-allyl H Br (6-fluoropyridin-3-yl) O 3-F I-32 OEt (R)-Me Cl (6-fluoropyridin-3-yl) O 3-F I-33 OEt (R)-Me Br (6-fluoropyridin-3-yl) O 3-F I-34 -OCH 2 CH 2 O-CH 2 CH 2 OMe (R)-Me Br (6-fluoropyridin-3-yl) O 3-F I-35 -OCH 2 CH 2 OMe (R)-Me Br (6-fluoropyridin-3-yl) O 3-F I-36 -NHSO 2 N(Me) 2 H Br (6-fluoropyridin-3-yl) O 3-F I-37 -OCH 2 CH 2 O-CH 2 CH 2 OMe H Br (6-fluoropyridin-3-yl) O 3-F I-38 OEt H Cl (6-fluoropyridin-3-yl) O 3-F I-39 OEt H Br (6-fluoropyridin-3-yl) O 3-F I-40 OEt H cyclopropyl (6-fluoropyridin-3-yl) O 3-F I-41 OMe (R)-Me Cl (6-fluoropyridin-3 -yl) O 3-F I-42 OMe H cyclopropyl (6-fluoropyridin-3-yl) O 3-F I-43 OH H cyclopropyl (6-fluoropyridin-3-yl) O 3-F I-44 -NHSO 2 Me H Br (6-fluoropyridin-3-yl) O 3-F I-45 -O-N=CH(CH 3 ) 2 H Br (6-fluoropyridin-3-yl) O 3-F I-46 -CH2-pyridin-2-yl H Br (6-fluoropyridin-3-yl) O 3-F I-47 H Br (6-OMepyridin-3-yl) O 3-F I-48 H Br (6-OMepyridin-3-yl) O 3-F I-49 OMe H Br (5 -fluoropyridin-3 -yl) O 3-F I-50 OH (R)-Me Br (6-fluoropyridin-3-yl) O 3-F I-51 OEt H Br (6-fluoropyridin-3-yl) O 3-F I-52 -CH2-pyridin-2-yl (R)-Me Br (6-fluoropyridin-3-yl) O 3-F I-53 H Br (6-fluoropyridin-3-yl) O 3-F I-54 H Br (6-fluoropyridin-3-yl) O 3-F I-55 OEt H I (6-fluoropyridin-3-yl) O 3-F I-56 OEt H CF3 (6-fluoropyridin-3-yl) O 3-F I-57 OEt H nitro (6-fluoropyridin-3-yl) O 3-F I-58 OEt Me Br (6-fluoropyridin-3-yl) O H I-59 H Br (2-fluoropyridin-4-yl) O H I-60 H Br (6-fluoropyridin-3-yl) O H I-61 H Br (6-fluoropyridin-3-yl) O H I-62 H Br (6-fluoropyridin-3-yl) O H I-63 H Br (5 -fluoropyridin-3 -yl) O H I-64 H Cl (6-fluoropyridin-3-yl) O H I-65 H Br pyrimidin-5-yl S H I-66 OH H Br pyrimidin-5-yl O H I-67 prop-2-ynoxy H Cl (5 -fluoropyridin-3 -yl) O H I-68 OEt H Br (6-fluoropyridin-3-yl) O H I-69 OH H Br (6-fluoropyridin-3-yl) S H I-70 H cyclopropyl (6-fluoropyridin-3-yl) O H I-71 -OCH2CH2COOMe H cyclopropyl (5 -fluoropyridin-3 -yl) O H I-72 OH H cyclopropyl (5 -fluoropyridin-3 -yl) O H I-73 -OCH2CH2COOMe (R)-Me Br (5 -fluoropyridin-3 -yl) O H I-74 H Cl (5 -fluoropyridin-3 -yl) O H I-75 -OCH2CH2COOMe H Cl (5 -fluoropyridin-3 -yl) O H I-76 H Br (6-fluoropyridin-3-yl) O H I-77 -OCH2CH2COOMe H Br (5 -fluoropyridin-3 -yl) O H I-78 OEt H cyclopropyl (6-fluoropyridin-3-yl) O H I-79 OH (R)-Me Br (5 -fluoropyridin-3 -yl) O H I-80 H Br (5 -fluoropyridin-3 -yl) O H I-81 OH H Cl (5 -fluoropyridin-3 -yl) O H I-82 H Br (5 -fluoropyridin-3 -yl) S H I-83 OMe (R)-Me Br (5 -fluoropyridin-3 -yl) O H I-84 OH H Br (5 -fluoropyridin-3 -yl) O H I-85 OEt H Cl (6-fluoropyridin-3-yl) O H I-86 OEt H Br (6-fluoropyridin-3-yl) O H I-87 H Cl (6-fluoropyridin-3-yl) O H I-88 -OCH2CH2COOMe H Cl (6-fluoropyridin-3-yl) O H I-89 H Br (6-fluoropyridin-3-yl) O H I-90 H Br (6-fluoropyridin-3-yl) O H I-91 OEt (R)-Me Br (6-fluoropyridin-3-yl) O H I-92 H Br (6-fluoropyridin-3-yl) O H I-93 H Br (6-fluoropyridin-3-yl) O H I-94 OH Me CF3 (6-fluoropyridin-3-yl) O H I-95 -OCH 2 CH 2 SMe H Br (6-fluoropyridin-3-yl) O H I-96 -OCH 2 CH 2 OMe H Br (6-fluoropyridin-3-yl) O H I-97 H Br (6-fluoropyridin-3 -yl) O H I-98 OH H Cl (6-fluoropyridin-3-yl) O H I-99 OH H CF3 (6-fluoropyridin-3-yl) O H I-100 OEt H Cl (6-fluoropyridin-3-yl) O H I-101 OEt Me I (6-fluoropyridin-3-yl) O H I-102 OEt Me Br (6-fluoropyridin-3-yl) O H I-103 OH H I (6-fluoropyridin-3-yl) O H I-104 OEt H Br (5 -fluoropyridin-3 -yl) SO 2 H I-105 OEt H CF3 (6-fluoropyridin-3-yl) O H I-106 OEt H Br (5 -fluoropyridin-3 -yl) SO 2 H I-107 OEt Me CF3 (6-fluoropyridin-3-yl) O H I-108 H Br (6-fluoropyridin-3-yl) O H I-109 H Br (6-fluoropyridin-3-yl) O H I-110 H Br (6-fluoropyridin-3-yl) O H I-111 H Br (6-fluoropyridin-3-yl) O H I-112 H Br (6-fluoropyridin-3-yl) O H I-113 OEt H Br (6-Clpyridin-3-yl) S H I-114 H Br (6-fluoropyridin-3-yl) O H I-115 OEt H Br pyrimidin-5-yl S H I-116 -OCH2CH2COOMe H Br (6-fluoropyridin-3-yl) O H I-117 -NHCH2CH2COOMe H Br (6-fluoropyridin-3-yl) O H I-118 H Cl (6-fluoropyridin-3-yl) O H I-119 H Cl (6-fluoropyridin-3-yl) O H I-120 H Br (6-fluoropyridin-3-yl) O H I-121 OEt H I (6-fluoropyridin-3-yl) O H I-122 OH H Br (2-fluoropyridin-4-yl) O H I-123 OEt H Br (5-chloropyridin-3-yl) S H I-124 OEt H Br (5-chloropyridin-3-yl) S H I-125 OEt H Br (5-fluoropyridin-3-yl) S H I-126 OH H Br (5-chloropyridin-3-yl) S H Table II: 3-Pyridyl Beispielnummer R 1< R 2< R 3< A (R 12< ) s Y II-01 OEt H Br (6-fluoropyridin-3-yl) 2-F O II-03 OH H Br (6-fluoropyridin-3-yl) 2-F O II-04 OH R-(Me) Br (6-fluoropyridin-3-yl) 2-F O II-05 OEt R(-Me) Br (6-fluoropyridin-3-yl) 2-F O II-06 CF 3 CH 2 SO 2 NH- H Br (6-fluoropyridin-3-yl) 2-F O II-07 Me 2 NSO 2 NH- H Br (6-fluoropyridin-3-yl) 2-F O II-08 MeO 2 CCH 2 NH- H Br (6-fluoropyridin-3-yl) 2-F O II-09 OEt H Br (6-fluoropyridin-3-yl) H O II-10 OH H Br (6-fluoropyridin-3-yl) H O II-11 OH R-(Me) Br (6-fluoropyridin-3-yl) H O II-12 OEt R(-Me) Br (6-fluoropyridin-3-yl) H O II-13 CF 3 CH 2 SO 2 NH- H Br (6-fluoropyridin-3-yl) H O II-14 Me 2 NSO 2 NH- H Br (6-fluoropyridin-3-yl) H O II-15 MeO 2 CCH 2 NH- H Br (6-fluoropyridin-3-yl) 2-F O II-16 OEt H Br (pyrimidin-5-yl) 2-F O II-17 OH H Br (pyrimidin-5-yl) 2-F O II-18 OH R-(Me) Br (pyrimidin-5-yl) 2-F O II-19 OEt R(-Me) Br (pyrimdin-5-yl) 2-F O II-20 CF 3 CH 2 SO 2 NH- H Br (pyrimidin-5-yl) 2-F O II-21 Me 2 NSO 2 NH- H Br (pyrimidin-5-yl) 2-F O II-22 MeO 2 CCH 2 NH- H Br (pyrimidin-5-yl) 2-F O II-23 OEt H Br (pyrimidin-5-yl) H O II-24 OH H Br (pyrimidin-5-yl) H O II-25 OH R-(Me) Br (pyrimidin-5-yl) H O II-26 OEt R(-Me) Br (pyrimidin-5-yl) H O II-27 CF 3 CH 2 SO 2 NH- H Br (pyrimidin-5-yl) H O II-28 Me 2 NSO 2 NH- H Br (pyrimidin-5-yl) H O II-29 MeO 2 CCH 2 NH- H Br (pyridimin-5-yl) H O II-30 OH R-(Me) CF3 (6-fluoropyridin-3-yl) 2-F O II-31 OEt R-(Me) CF3 (6-fluoropyridin-3-yl) 2-F O II-32 CF 3 CH 2 SO 2 NH- H CF3 (6-fluoropyridin-3-yl) 2-F O II-33 Me 2 NSO 2 NH- H CF3 (6-fluoropyridin-3-yl) 2-F O II-34 MeO 2 CCH 2 NH- H CF3 (6-fluoropyridin-3-yl) 2-F O II-35 OEt H Br (6-fluoropyridin-3-yl) H S II-36 OMe (R)-Me Br (6-fluoropyridin-3-yl) 2-F O Table III: 4-Pyridyl Beispielnummer R 1< R 2< R 3< R 4< (R 12< ) s Y III-01 OEt H Br (6-fluoropyridin-3-yl) 2-F O III-02 OH H Br (6-fluoropyridin-3-yl) 2-F O III-03 OH R-(Me) Br (6-fluoropyridin-3-yl) 2-F O III-04 OEt R(-Me) Br (6-fluoropyridin-3-yl) 2-F O III-05 CF 3 CH 2 SO 2 NH- H Br (6-fluoropyridin-3-yl) 2-F O III-06 Me 2 NSO 2 NH- H Br (6-fluoropyridin-3-yl) 2-F O III-07 MeO 2 CCH 2 NH- H Br (6-fluoropyridin-3-yl) 2-F O III-08 OEt H Br (6-fluoropyridin-3-yl) H O Beispielnummer R 1< R 2< R 3< R 4< (R 12< ) s Y III-09 OH H Br (6-fluoropyridin-3-yl) H O III-10 OH R-(Me) Br (6-fluoropyridin-3-yl) H O III-11 OEt R-(Me) Br (6-fluoropyridin-3-yl) H O III-12 CF 3 CH 2 SO 2 NH- H Br (6-fluoropyridin-3-yl) H O III-13 Me 2 NSO 2 NH- H Br (6-fluoropyridin-3-yl) H O III-14 MeO 2 CCH 2 NH- H Br (6-fluoropyridin-3-yl) 2-H O III-15 OEt H Br (pyrimidin-5-yl) 2-F O III-15 OEt H Br (pyrimidin-5-yl) 2-F S III-16 OH H Br (pyrimidin-5-yl) 2-F S III-17 H Br (6-fluoropyridin-3-yl) 2-Cl O III-18 H Br (6-fluoropyridin-3-yl) 2-Cl O III-19 -OCH 2 CH 2 COOMe H Br (6-fluoropyridin-3-yl) 2-Cl O III-20 CF 3 CH 2 SO 2 NH- H Br (6-fluoropyridin-3-yl) 2-Cl O III-21 H Br (6-fluoropyridin-3-yl) 2-Cl O III-22 OMe (R)-Me Br (6-fluoropyridin-3-yl) 2-Cl O III-23 OH H Br (6-fluoropyridin-3-yl) 2-Cl O III-24 OEt H Br (6-fluoropyridin-3-yl) 2-Cl O III-25 H Br (6-fluoropyridin-3-yl) 2-F O III-26 H Br (6-fluoropyridin-3-yl) 2-F O III-27 -OCH 2 CH 2 COOMe H Br (6-fluoropyridin-3-yl) 2-F O III-28 H Br (6-fluoropyridin-3-yl) 2-F O

[0059] A further aspect of the invention relates to the preparation of the compounds of general formula (I) according to the invention. The compounds of the invention can be prepared in various ways.

[0060] Compounds according to the invention can be prepared, for example, from substituted 1-phenyl-5-azinyl-1H-pyrazol-3-ols (II) according to the synthesis methods listed in Scheme 1 below.

[0061] The synthesis of the compounds of the general formula ( Ib ) occurs via an amide coupling of an acid of the general formula ( Ia ) with an amine of the general formula ( II ) in the presence of an amide coupling reagent such as T3P, dicyclohexylcarbodiimide, N -(3-Dimethylaminopropyl)- N' -ethylcarbodiimide, N , N'-Carbonyldiimidazole, 2-chloro-1,3-dimethylimidazolium chloride, or 2-chloro-1-methylpyridinium iodide (see Chemistry of Peptide Synthesis, Ed. N. Leo Benoiton, Taylor & Francis, 2006, ISBN-10: 1-57444-454-9). Polymer-bound reagents such as polymer-bound dicyclohexylcarbodiimide are also suitable for this coupling reaction. The reaction preferably takes place in the temperature range between 0 °C and 80 °C, in an appropriate solvent such as dichloromethane, acetonitrile, N , N -Dimethylformamide or ethyl acetate and in the presence of a base such as triethylamine, N , N -Diisopropylethylamine or 1,8-diazabicyclo[5.4.0]undec-7-cene (see Scheme 1). For the T3P peptide coupling conditions, see Organic Process Research & Development 2009, 13, 900-906.

[0062] The synthesis of the acid of general formula (Ia) can be carried out by saponification of the compound of general formula (Ic) according to methods known to those skilled in the art (Scheme 2). The saponification can be carried out in the presence of a base or a Lewis acid. The base can be a hydroxide salt of an alkali metal (such as lithium, sodium, or potassium), and the saponification reaction preferably takes place in the temperature range between room temperature and 120 °C.

[0063] The synthesis of the compound of general formula (Ic) can be carried out by alkylating the compound of general formula (III) with a halide of general formula (IV) in the presence of a base by or analogously to methods known to the person skilled in the art (see Scheme 3). The base can be a carbonate salt of an alkali metal. Preferably, the base is a carbonate salt of an alkali metal selected from the group consisting of lithium, sodium, potassium, and cesium (such as lithium, sodium, potassium, or cesium), and the reaction preferably takes place in the temperature range between room temperature and 150°C in an appropriate solvent such as dichloromethane, acetonitrile, N , N -Dimethylformamide or ethyl acetate. See J. Med. Chem. 2011, 54(16), 5820-5835 and WO2010 / 010154. The radical "X" stands for chlorine, bromine, or iodine, for example.

[0064] In the synthesis of the compound of general formula (VI) is carried out by reaction of a pyrazolone of general formula (V) in the presence of a sulfurizing reagent such as phosphorus pentasulfide or Lawesson's reagent in an adequate solvent such as toluene (Scheme 4).

[0065] Scheme 5 describes the synthesis of the compound of general formula (V, R 3< =Cl, Br, I) by reacting a pyrazole of general formula (VII) with an electrophilic halogenating reagent of general formula (VIII) such as N-chlorosuccinimide (VIII, X =Cl), N-bromosuccinimide (VIII, X =Br), or N-iodosuccinimide (VIII, R 3< = I). In an analogous manner, other electrophilic reagents can be used, for example electrophilic nitrating reagents such as nitrating acid, nitronium tetrafluoroborate or ammonium nitrate / trifluoroacetic acid (for R 3< = NO 2 ) or electrophilic fluorinating reagents such as DAST, Selectfluor or N-Fluorobenzenesulfonimide (for R 3< = F) can be used. The reaction preferably takes place in the temperature range between 0°C and 120 °C in an adequate solvent such as N , N -Dimethylformamide, 1,2-dichloroethane or acetonitrile.

[0066] Scheme 6 describes the synthesis of the compound of general formula (Ic) by reaction of a pyrazole of general formula (Ic) with a halosuccinimide of general formula (VIII) in an appropriate solvent such as N,N-dimethylformamide.

[0067] A compound of general formula (Ic) can be prepared, for example, by reacting a compound of formula (Ic) in a suitable solvent with a metal cyanide M-CN (IX) in the presence of an adequate amount of a transition metal catalyst, in particular palladium catalysts such as palladium(O)tetrakis(triphenylphosphine) or palladium diacetate or bis(triphenylphosphine)palladium(II) dichloride, or nickel catalysts such as nickel(II) acetylacetonate or bis(triphenylphosphine)nickel(II) chloride, preferably at elevated temperature in an organic solvent such as 1,2-dimethoxyethane or N,N-dimethylformamide (Scheme 6). The radical "M" stands, for example, for magnesium, zinc, lithium, or sodium. In general, cross-coupling methods are suitable, as described in RD Larsen, Organometallics in Process Chemistry 2004 Springer Verlag, in I. Tsuji, Palladium Reagents and Catalysts 2004 Wiley, in M. Belier, C.Bolm, Transition Metals for Organic Synthesis 2004 VCH-Wiley. Other suitable synthetic methods are described in Chem. Rev. 2006, 106, 2651; Platinum Metals Review, 2009, 53, 183; Platinum Metals Review 2008, 52, 172; and Acc. Chem. Res. 2008, 41, 1486.

[0068] The 3-hydroxypyrazoles (V) can be prepared analogously to literature methods from substituted 3-azinylpropionic acid derivatives and phenylhydrazines (Scheme 7); e.g., Adv. Synth. Catal. 2014, 356, 3135-3147) or from substituted azinylacrylic acid derivatives and phenylhydrazines (Scheme 3; e.g., J. Heterocyclic Chem., 49, 130 (2012)).

[0069] The synthesis of the compounds of general formula (XII) is carried out via an amide coupling of an acid of general formula (X) with an arylhydrazine or hetarylhydrazine of general formula (XI) in the presence of an amide coupling reagent such as T3P, dicyclohexylcarbodiimide, N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide, N , N '-Carbonyldiimidazole, 2-chloro-1,3-dimethylimidazolium chloride, or 2-chloro-1-methylpyridinium iodide (see Chemistry of Peptide Synthesis, Ed. N. Leo Benoiton, Taylor & Francis, 2006, ISBN-10: 1-57444-454-9). Polymer-bound reagents such as polymer-bound dicyclohexylcarbodiimide are also suitable for this coupling reaction. The reaction preferably takes place in the temperature range between 0 °C and 80 °C, in an appropriate solvent such as dichloromethane, tetrahydrofuran, acetonitrile, N,N- Dimethylformamide or ethyl acetate and in the presence of a base such as triethylamine, N,N- Diisopropylethylamine or 1,8-diazabicyclo[5.4.0]undec-7-cene (see Scheme 7). For the T3P peptide coupling conditions, see Organic Process Research & Development 2009, 13, 900-906.

[0070] Scheme 7 describes the synthesis of the compound of general formula (V) by reacting a pyrazole of general formula (XIII) with an electrophile such as N-bromosuccinimide. The reaction preferably takes place in the temperature range between 0°C and 120°C in an appropriate solvent such as N,N-dimethylformamide, 1,2-dichloroethane, or acetonitrile.

[0071] The synthesis of 3-hydroxypyrazoles of general formula (XIII) is carried out by reacting compounds of general formula (XII) in the presence of a copper halide such as copper(I) iodide, copper(I) bromide or a base such as sodium methylate or an acid such as methanesulfonic acid to 3-hydroxypyrazoles of general formula (XIII). The reaction preferably takes place in the temperature range between 0 °C and 120 °C, in an appropriate solvent such as 1,2-dichloroethane, acetonitrile, N , N-Dimethylformamide, n-propanol or ethyl acetate. The reaction takes place preferably in N , N -Dimethylformamide instead.

[0072] Compounds of the general formula (XV) can be prepared by an amide coupling of a substituted propionic acid of the general formula (XIV) with an arylhydrazine or hetarylhydrazine of the general formula (XI) in the presence of an amide coupling reagent such as T3P, dicyclohexylcarbodiimide, N- (3-Dimethylaminopropyl)- N '-ethylcarbodiimide, N , N '-Carbonyldiimidazole, 2-chloro-1,3-dimethylimidazolium chloride or 2-chloro-1-methylpyridinium iodide. The reaction preferably takes place in the temperature range between 0 °C and 80 °C, in an adequate solvent such as dichloromethane, acetonitrile, N,N- Dimethylformamide or ethyl acetate and in the presence of a base such as triethylamine, N , N-Diisopropylethylamine or 1,8-diazabicyclo[5.4.0]undec-7-cene (see Scheme 8).

[0073] The synthesis of 3-hydroxypyrazoles of general formula (XIII) is carried out by reacting compounds of general formula (XV) in the presence of an iron halide such as iron(III) chloride. The reaction preferably takes place in the temperature range between 0 °C and 120 °C, in an appropriate solvent such as 1,2-dichloroethane, acetonitrile, N , N -Dimethylformamide or ethyl acetate.

[0074] Compounds of general formula (XVI) can be prepared by N-arylation of a 3-hydroxypyrazol of general formula (XIV) with an aryl halide in the presence of a copper halide such as copper(I) iodide. The reaction preferably takes place in the temperature range between 0 °C and 120 °C, in an appropriate solvent such as acetonitrile or N , NDimethylformamide and, in the presence of a base such as triethylamine or cesium carbonate (see Scheme 9). The compounds of general formula (XIV) can be prepared by methods known to those skilled in the art (Chem. Med. Chem. 2015, 10, 1184-1199). The radical "X"s stands, for example, for chlorine, bromine, or iodine.

[0075] The synthesis of 5-iodopyrazoles of general formula (XIV) is carried out by reacting compounds of general formula (XIII) in the presence of a base such as lithium diisopropylamide and iodine. The reaction (Scheme 7) preferably takes place in the temperature range between -78 °C and -60 °C, in an appropriate solvent such as diethyl ether and tetrahydrofuran.

[0076] A compound of formula (XIII) can be prepared, for example, by reacting a compound of formula (XVI) in a suitable solvent with an AM in the presence of an adequate amount of a transition metal catalyst, in particular palladium catalysts such as palladium diacetate or bis(triphenylphosphine)palladium(II) dichloride, or nickel catalysts such as nickel(II) acetylacetonate or bis(triphenylphosphine)nickel(II) chloride, preferably at elevated temperature in an organic solvent such as 1,2-dimethoxyethane. The radical "M" represents, for example, B(OR b< )(OR c< ), where the radicals R b< and R c< independently of one another are, for example, hydrogen, (C 1 -C 4 )-alkyl, or, when the radicals R b< and R c< are bonded together, together represent ethylene or propylene (Scheme 10).

[0077] The synthesis of the compound of general formula (XX) can be carried out by alkylating the compound of general formula (XIX) with a halide of general formula (IV) in the presence of a base by or analogously to methods known to those skilled in the art (see Scheme 11). The base can be a carbonate salt of an alkali metal (such as lithium, sodium, potassium, or cesium), and the reaction preferably takes place in the temperature range between room temperature and 150 °C in an appropriate solvent such as dichloromethane, acetonitrile, N,N- Dimethylformamide or ethyl acetate.

[0078] A compound of formula (Ic) can be prepared, for example, by reacting a compound of formula (XXI) in a suitable solvent with an AM with the addition of an adequate amount of a transition metal catalyst, in particular palladium catalysts such as palladium diacetate or bis(triphenylphosphine)palladium(II) dichloride or nickel catalysts such as nickel(II) acetylacetonate or bis(triphenylphosphine)nickel(II) chloride, preferably at elevated temperature in an organic solvent such as 1,2-dimethoxyethane. The radical "M" stands for example for Mg-Hal, Zn-Hal, Sn((C 1 -C 4 )alkyl) 3 , lithium, copper or B(OR b< )(OR c< ), where the radicals R b< and R c< independently of one another are for example hydrogen, (C 1 -C 4 )alkyl, or, when the radicals R b< and R c< are joined together, together are ethylene or propylene.

[0079] Compounds of general formula (XIX) can be prepared by diazotization or Sandmeyer reaction with the compound of general formula (XVIII) using the usual organic and inorganic nitrites such as 1,1-dimethylethyl nitrite, tert-butyl nitrite or isoamyl nitrite in the presence of usable reagents such as mixtures of copper(I) and copper(II) bromides / chloride or iodine (Scheme 11). The reaction preferably takes place in the temperature range between room temperature and 0 and 120°C in an appropriate solvent such as dichloromethane, acetonitrile, N , N -Dimethylformamide or diiodomethane. The residue "X" stands for chlorine, bromine, or iodine, for example.

[0080] Scheme 12 illustrates the synthesis of the compound of general formula (XXIII) by reacting a pyrazolone of general formula (XXII) in the presence of a sulfurizing reagent such as phosphorus pentasulfide or Lawesson's reagent in an appropriate solvent such as toluene. The compounds of general formula (XXII) are commercially available or can be prepared using methods known to those skilled in the art.

[0081] The synthesis of the compound of general formula (Id) can be carried out by reacting a 3-aminopyrazol of general formula (XXIV) with a disulfide of general formula (XXV) in the presence of an organic nitrite such as 1,1-dimethylethyl nitrite, tert-butyl nitrite or isoamyl nitrite in the presence of a metal such as copper (see Scheme 13). The reaction preferably takes place in the temperature range between room temperature and 120°C in an appropriate solvent such as dichloromethane, acetonitrile, N,N- Dimethylformamide or 1,2-dichloroethane. With R 1a < = (C 1 -C 4 )-alkyl.

[0082] The synthesis of the acid of general formula (XXIV) can be carried out by reacting the compound of general formula (XXVI) in the presence of a Lewis acid such as trifluoroacetic acid or can be prepared by methods known to those skilled in the art (Scheme 14). The reaction preferably takes place in the temperature range between room temperature and 140 °C. With R' = (C 1 -C 4 )-alkyl

[0083] The synthesis of the compounds of general formula (XXVI) is carried out via a Curtius reaction of an acid of general formula (XXVII) with an azide of general formula (XXVIII). The reaction preferably takes place in the temperature range between 0 °C and 100 °C, in an appropriate solvent such as tert-butanol and in the presence of a base such as triethylamine. N , N -Diisopropylethylamine or 1,8-diazabicyclo[5.4.0]undec-7-cene (see Scheme 15).

[0084] The synthesis of the acid of general formula (XXIX) can be prepared by saponification of the compound of general formula (XXVII) according to methods known to those skilled in the art (Scheme 16). The saponification can be carried out in the presence of a base or a Lewis acid. The base can be a hydroxide salt of an alkali metal (such as lithium, sodium, or potassium), and the saponification reaction preferably takes place in the temperature range between room temperature and 120 °C. With R' = (C 1 -C 4 )-alkyl.

[0085] Scheme 17 describes the synthesis of the compound of general formula (XXX) by reaction of a pyrazole of general formula (XXVII) with a halosuccinimide of general formula (VIII) in an appropriate solvent such as DMF. With X = halogen.

[0086] The synthesis of the compounds of general formula (XXIX) is carried out via a condensation of a diketoester of general formula (XXXI) with an arylhydrazine or hetarylhydrazine of general formula (XI) in the presence of a Brønsted acid such as acetic acid or hydrogen chloride in an appropriate solvent such as methanol, ethanol, isopropanol, n-butanol, tetrahydrofuran, dioxane, toluene, or chlorobenzene (Scheme 18). The reaction preferably takes place in the temperature range between 0 °C and 150 °C. The compounds of general formulas (XI) and (XXXI) are commercially available or can be prepared analogously to methods known to the person skilled in the art. With R' = (C 1 -C 4 )-alkyl.

[0087] Compounds of general formulas (XXXIV) and (XXXV) can be prepared by reacting a compound of formula (XXXIII) in the presence of an oxidizing agent such as mCPBA (3-chloroperbenzoic acid) in an appropriate solvent such as dichloromethane or 1,2-dichloroethane (Scheme 19). The reaction preferably takes place in the temperature range between -30 °C and 100 °C.

[0088] The compounds of the formula (I) according to the invention (and / or salts thereof), hereinafter referred to collectively as "compounds according to the invention", have excellent herbicidal activity against a broad spectrum of economically important mono- and dicotyledonous annual weeds. The present invention therefore also provides a method for controlling undesirable plants or for regulating the growth of plants, preferably in plant crops, in which one or more compounds according to the invention are applied to the plants (e.g. weeds such as mono- or dicotyledonous weeds or undesirable crop plants), the seed (e.g. grains, seeds or vegetative propagation organs such as tubers or shoot parts with buds) or the area on which the plants are growing (e.g. the cultivated area). The compounds according to the invention can be applied, for example, in the pre-sowing (if appropriate) phase.(also by incorporation into the soil), pre-emergence, or post-emergence. Some examples of monocotyledonous and dicotyledonous weed flora that can be controlled by the compounds according to the invention are mentioned, without implying a restriction to specific species.

[0089] Monocotyledonous harmful plants of the genera: Aegilops, Agropyron, Agrostis, Alopecurus, Apera, Avena, Brachiaria, Bromus, Cenchrus, Commelina, Cynodon, Cyperus, Dactyloctenium, Digitaria, Echinochloa, Eleocharis, Eleusine, Eragrostis, Eriochloa, Festuca, Fimbristylis, Heteranthera, Imperata, Ischaemum, Leptochloa, Lolium, Monochoria, Panicum, Paspalum, Phalaris, Phleum, Poa, Rottboellia, Sagittaria, Scirpus, Setaria, Sorghum.

[0090] Dicotyledonous weeds of the genera: Abutilon, Amaranthus, Ambrosia, Anoda, Anthemis, Aphanes, Artemisia, Atriplex, Bellis, Bidens, Capsella, Carduus, Cassia, Centaurea, Chenopodium, Cirsium, Convolvulus, Datura, Desmodium, Emex, Erysimum, Euphorbia, Galeopsis, Galinsoga, Galium, Hibiscus, Ipomoea, Kochia, Lamium, Lepidium, Lindernia, Matricaria, Mentha, Mercurialis, Mullugo, Myosotis, Papaver, Pharbitis, Plantago, Polygonum, Portulaca, Ranunculus, Raphanus, Rorippa, Rotala, Rumex, Salsola, Senecio, Sesbania, Sida, Sinapis, Solanum, Sonchus, Sphenoclea, Stellaria, Taraxacum, Thlaspi, Trifolium, Urtica, Veronica, Viola, Xanthium.

[0091] If the compounds according to the invention are applied to the soil surface before germination, either the emergence of weed seedlings is completely prevented or the weeds grow to the cotyledon stage but then stop growing.

[0092] When the active ingredients are applied to the green parts of the plant using the post-emergence method, growth stops after treatment and the weeds remain in the growth stage present at the time of application or die completely after a certain time, so that in this way weed competition that is harmful to the crops is eliminated very early and sustainably.

[0093] The compounds of the invention can exhibit selectivities in crops and can also be used as non-selective herbicides.

[0094] Due to their herbicidal and plant growth regulatory properties, the active ingredients can also be used to control weeds in crops of known or yet-to-be-developed genetically modified plants. Transgenic plants are generally characterized by particularly advantageous properties, for example, resistance to certain active ingredients used in the agricultural industry, especially certain herbicides, resistance to plant diseases or pathogens of plant diseases such as certain insects or microorganisms such as fungi, bacteria, or viruses. Other special properties affect, for example, the harvested crop in terms of quantity, quality, storability, composition, and specific ingredients. For example, transgenic plants with increased starch content or altered starch quality, or those with a different fatty acid composition of the harvested crop, are known.Other special properties include tolerance or resistance to abiotic stressors such as heat, cold, drought, salt and ultraviolet radiation.

[0095] The use of the compounds of formula (I) according to the invention or their salts in economically important transgenic crops of useful and ornamental plants is preferred,

[0096] The compounds of formula (I) can be used as herbicides in crops which are resistant to the phytotoxic effects of the herbicides or which have been made genetically resistant.

[0097] Conventional approaches to producing new plants with modified traits compared to existing plants include classical breeding methods and the creation of mutants. Alternatively, new plants with modified traits can be created using genetic engineering techniques (see, for example, EP 0221044, EP 0131624). For example, several cases have been described of genetic modifications of crop plants for the purpose of modifying the starch synthesized in the plants (e.g. WO 92 / 011376 A, WO 92 / 014827 A, WO 91 / 019806 A), transgenic crop plants which are resistant to certain herbicides of the glufosinate type (cf. e.g. EP 0242236 A, EP 0242246 A) or glyphosate (WO 92 / 000377 A) or sulfonylureas (EP 0257993 A, US 5,013,659) or to combinations or mixtures of these herbicides by "gene stacking", such as transgenic crop plants, e.g.Corn or soybeans with the trade name or designation Optimum™< GAT™< (Glyphosate ALS Tolerant). Transgenic crops, such as cotton, capable of producing Bacillus thuringiensis toxins (Bt toxins), which render the plants resistant to certain pests (EP 0142924 A, EP 0193259 A). Transgenic crops with modified fatty acid composition (WO 91 / 013972 A). Genetically modified crops with new ingredients or secondary substances, e.g. new phytoalexins, which cause increased disease resistance (EP 0309862 A, EP 0464461 A) Genetically modified plants with reduced photorespiration, which have higher yields and higher stress tolerance (EP 0305398 A) Transgenic crops that produce pharmaceutically or diagnostically important proteins ("molecular pharming") Transgenic crops that are characterized by higher yields or better quality Transgenic crops that are characterized by a combination of, e.g., the above-mentioned new properties ("gene stacking")

[0098] Numerous molecular biological techniques for producing new transgenic plants with modified traits are known in principle; see, for example, I. Potrykus and G. Spangenberg (eds.) Gene Transfer to Plants, Springer Lab Manual (1995), Springer Verlag Berlin, Heidelberg, or Christou, "Trends in Plant Science" 1 (1996) 423-431.

[0099] For such genetic manipulations, nucleic acid molecules can be introduced into plasmids, allowing mutagenesis or sequence modification through recombination of DNA sequences. Using standard procedures, base substitutions can be performed, partial sequences can be removed, or natural or synthetic sequences can be added. Adapters or linkers can be attached to the DNA fragments to connect them together, see, for example, Sambrook et al., 1989, Molecular Cloning, A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY; or Winnacker, "Genes and Clones," VCH Weinheim, 2nd ed., 1996.

[0100] The production of plant cells with reduced activity of a gene product can be achieved, for example, by expressing at least one corresponding antisense RNA, a sense RNA to achieve a cosuppression effect, or the expression of at least one appropriately constructed ribozyme that specifically cleaves transcripts of the aforementioned gene product. For this purpose, DNA molecules can be used that comprise the entire coding sequence of a gene product, including any flanking sequences present, or DNA molecules that comprise only parts of the coding sequence, whereby these parts must be long enough to produce an antisense effect in the cells. It is also possible to use DNA sequences that exhibit a high degree of homology to the coding sequences of a gene product, but are not completely identical.

[0101] When nucleic acid molecules are expressed in plants, the synthesized protein can be localized in any compartment of the plant cell. However, to achieve localization in a specific compartment, the coding region can be linked to DNA sequences that ensure localization in a specific compartment. Such sequences are known to the person skilled in the art (see, for example, Braun et al., EMBO J. 11 (1992), 3219-3227; Wolter et al., Proc. Natl. Acad. Sci. USA 85 (1988), 846-850; Sonnewald et al., Plant J. 1 (1991), 95-106). Expression of nucleic acid molecules can also occur in the organelles of plant cells.

[0102] The transgenic plant cells can be regenerated into whole plants using known techniques. The transgenic plants can, in principle, be plants of any desired plant species, i.e., both monocotyledonous and dicotyledonous plants. Thus, transgenic plants can be obtained which have altered properties through overexpression, suppression or inhibition of homologous (= natural) genes or gene sequences or expression of heterologous (= foreign) genes or gene sequences. The compounds (I) according to the invention can preferably be used in transgenic cultures which are resistant to growth factors, such as 2,4-D, dicamba, or to herbicides which inhibit essential plant enzymes, e.g.Inhibit acetolactate synthases (ALS), EPSP synthases, glutamine synthases (GS) or hydroxyphenylpyruvate dioxygenases (HPPD), or are resistant to herbicides from the group of sulfonylureas, glyphosates, glufosinates or benzoyl isoxazoles and analogous active substances, or to any combination of these active substances.

[0103] The compounds of the invention can be used particularly preferably in transgenic crop plants that are resistant to a combination of glyphosate and glufosinate, glyphosate and sulfonylureas, or imidazolinones. The compounds of the invention can be used very particularly preferably in transgenic crop plants such as maize or soybeans bearing the trade name or designation Optimum™ GATT™ (Glyphosate ALS Tolerant).

[0104] When the active compounds according to the invention are used in transgenic crops, in addition to the effects on weeds observed in other crops, effects often occur which are specific to the application in the respective transgenic crop, for example a modified or specifically expanded weed spectrum which can be controlled, modified application rates which can be used for the application, preferably good combinability with the herbicides to which the transgenic crop is resistant, and influence on the growth and yield of the transgenic crops.

[0105] The invention therefore also relates to the use of the compounds of formula (I) according to the invention as herbicides for controlling harmful plants in transgenic crops.

[0106] The compounds according to the invention can be applied in the form of wettable powders, emulsifiable concentrates, sprayable solutions, dusts, or granules in the usual preparations. The invention therefore also relates to herbicidal and plant growth-regulating compositions containing the compounds according to the invention.

[0107] The compounds according to the invention can be formulated in various ways, depending on the biological and / or chemical-physical parameters specified. Possible formulation options include, for example, wettable powders (WP), water-soluble powders (SP), water-soluble concentrates, emulsifiable concentrates (EC), emulsions (EW), such as oil-in-water and water-in-oil emulsions, sprayable solutions, suspension concentrates (SC), oil- or water-based dispersions, oil-miscible solutions, capsule suspensions (CS), dusts (DP), seed dressings, granules for broadcast and soil application, granules (GR) in the form of microgranules, spray granules, granules for coating, and adsorption, water-dispersible granules (WG), water-soluble granules (SG), ULV formulations, microcapsules, and waxes. These individual formulation types are known in principle and are described, for example, in: Winnacker-Küchler, "Chemical Technology", Volume 7, C. Hanser Verlag Munich, 4th edition.1986, Wade van Valkenburg, "Pesticide Formulations", Marcel Dekker, NY, 1973, K. Martens, "Spray Drying" Handbook, 3rd Ed. 1979, G. Goodwin Ltd. London.

[0108] The necessary formulation aids such as inert materials, surfactants, solvents and other additives are also known and are described, for example, in: Watkins, "Handbook of Insecticide Dust Diluents and Carriers", 2nd Ed., Darland Books, Caldwell NJ, Hv Olphen, "Introduction to Clay Colloid Chemistry", 2nd Ed., J. Wiley & Sons, NY, C. Marsden, "Solvents Guide", 2nd Ed., Interscience, NY 1963, McCutcheon's "Detergents and Emulsifiers Annual", MC Publ. Corp., Ridgewood NJ, Sisley and Wood, "Encyclopedia of Surface Active Agents", Chem. Publ. Co. Inc., NY 1964, Schönfeldt, "Grenzflächenaktive Äthylenoxid-addukte", Wiss. Verlagsgesell., Stuttgart 1976, Winnacker-Küchler, "Chemical Technology", Volume 7, C. Hanser Verlag Munich, 4th edition 1986. On the basis of these formulations, combinations with other active ingredients, such asInsecticides, acaricides, herbicides, fungicides, as well as with safeners, fertilizers and / or growth regulators, e.g. in the form of a ready-to-use formulation or as a tank mix.

[0109] As combination partners for the compounds according to the invention in mixture formulations or in tank mixes, known active ingredients based on the inhibition of, for example, acetolactate synthase, acetyl-CoA carboxylase, cellulose synthase, enolpyruvylshikimate 3-phosphate synthase, glutamine synthetase, p-hydroxyphenylpyruvate dioxygenase, phytoene desaturase, photosystem I, photosystem II, or protoporphyrinogen oxidase can be used, as described, for example, in Weed Research 26 (1986) 441-445 or "The Pesticide Manual", 16th edition, The British Crop Protection Council and the Royal Society of Chemistry, 2006, and the literature cited therein. Examples of known herbicides or plant growth regulators that can be combined with the compounds according to the invention are listed below.These active ingredients are designated either by their common name (according to the International Organization for Standardization (ISO)) or by their chemical name or code number. This always includes all application forms, such as acids, salts, esters, as well as all isomeric forms such as stereoisomers and optical isomers, even if these are not explicitly mentioned. Examples of such herbicidal mixture partners are: Acetochlor, acifluorfen, acifluorfen-sodium, aclonifen, alachlor, allidochlor, alloxydim, alloxydimsodium, ametryn, amicarbazone, amidochlor, amidosulfuron, 4-amino-3-chloro-5-fluoro-6-(7-fluoro-1H-indol-6-yl)pyridine-2-carboxylic acid, aminocyclopyrachlor, aminocyclopyrachlor-potassium, aminocyclopyrachlor-methyl, aminopyralid, amitrole, ammoniumsulfamate, anilofos, asulam, atrazine, azafenidin, azimsulfuron, beflubutamid, benazolin, benazolin-ethyl, benfluralin, benfuresate, bensulfuron, bensulfuron-methyl,bensulide, bentazone, benzobicyclon, benzofenap, bicyclopyron, bifenox, bilanafos, bilanafos-sodium, bispyribac, bispyribac-sodium, bixlozone, bromacil, bromobutide, bromofenoxim, bromoxynil, bromoxynil-butyrate, -potassium, -heptanoate und -octanoate, busoxinone, butachlor, butafenacil, butamifos, butenachlor, butralin, butroxydim, butylate, cafenstrole, carbetamide, carfentrazone, carfentrazone-ethyl, chloramben, chlorbromuron, 1-{2-Chlor-3-[(3-cyclopropyl-5-hydroxy-1-methyl-1H-pyrazol-4-yl)carbonyl]-6-(trifluormethyl)phenyl}piperidin-2-on, 4-{2-Chlor-3-[(3,5-dimethyl-1H-pyrazol-1-yl)methyl]-4-(methylsulfonyl)benzoyl}-1,3-dimethyl-1H-pyrazol-5-yl-1,3-dimethyl-1H-pyrazol-4-carboxylat, chlorfenac, chlorfenac-sodium, chlorfenprop, chlorflurenol, chlorflurenol-methyl, chloridazon, chlorimuron, chlorimuron-ethyl, 2-[2-Chlor-4-(methylsulfonyl)-3-(morpholin-4-ylmethyl)benzoyl]-3-hydroxycyclohex-2-en-1-on, 4-{2-Chlor-4-(methylsulfonyl)-3-[(2,2,2-trifluorethoxy)methyl]benzoyl}-1-ethyl-1H-pyrazol-5-yl-1,3-dimethyl-1H-pyrazol-4-carboxylat, chlorophthalim, chlorotoluron, chlorthal-dimethyl, chlorsulfuron, 3-[5-Chlor-4-(trifluormethyl)pyridin-2-yl]-4-hydroxy-1-methylimidazolidin-2-on, cinidon, cinidon-ethyl, cinmethylin, cinosulfuron, clacyfos, clethodim, clodinafop, clodinafop-propargyl, clomazone, clomeprop, clopyralid, cloransulam, cloransulam-methyl, cumyluron, cyanamide, cyanazine, cycloate, cyclopyranil, cyclopyrimorate, cyclosulfamuron, cycloxydim, cyhalofop, cyhalofop-butyl, cyprazine, 2,4-D, 2,4-D-butotyl, -butyl, - dimethylammonium, -diolamin, -ethyl, 2-ethylhexyl, -isobutyl, -isooctyl, -isopropylammonium, - potassium, -triisopropanolammonium und -trolamine, 2,4-DB, 2,4-DB-butyl, -dimethylammonium, isooctyl, -potassium und -sodium, daimuron (dymron), dalapon, dazomet, n-decanol, desmedipham, detosyl-pyrazolate (DTP), dicamba, dichlobenil, dichlorprop, dichlorprop-P, diclofop, diclofop-methyl, diclofop-P-methyl,diclosulam, difenzoquat, diflufenican, diflufenzopyr, diflufenzopyr-sodium, dimefuron, dimepiperate, dimethachlor, dimethametryn, dimethenamid, dimethenamid-P, 3-(2,6-Dimethylphenyl)-6-[(2-hydroxy-6-oxocyclohex-1-en-1-yl)carbonyl]-1-methylchinazolin-2,4(1H,3H)-dion, 1,3-Dimethyl-4-[2-(methylsulfonyl)-4-(trifluormethyl)benzoyl]-1H-pyrazol-5-yl-1,3-dimethyl-1H-pyrazol-4-carboxylat, dimetrasulfuron, dinitramine, dinoterb, diphenamid, diquat, diquat-dibromid, dithiopyr, diuron, DMPA, DNOC, endothal, EPTC, esprocarb, ethalfluralin, ethametsulfuron, ethametsulfuron-methyl, ethiozin, ethofumesate, ethoxyfen, ethoxyfen-ethyl, ethoxysulfuron, etobenzanid, Ethyl-[(3-{2-chlor-4-fluor-5-[3-methyl-2,6-dioxo-4-(trifluormethyl)-3,6-dihydropyrimidin-1 (2H)-yl]phenoxy}pyridin-2-yl)oxy]acetat, F-9960, F-5231, i.e. N-[2-Chlor-4-fluor-5-[4-(3-fluorpropyl)-4,5-dihydro-5-oxo-1H-tetrazol-1-yl]-phenyl]-ethansulfonamid, F-7967,i.e. 3-[7-Chlor-5-fluor-2-(trifluormethyl)-1H-benzimidazol-4-yl]-1-methyl-6-(trifluormethyl)pyrimidin-2,4(1H,3H)-dion, fenoxaprop, fenoxaprop-P, fenoxaprop-ethyl, fenoxaprop-P-ethyl, fenoxasulfone, fenquinotrione, fentrazamide, flamprop, flamprop-M-isopropyl, flamprop-M-methyl, flazasulfuron, florasulam, florpyrauxifen, florpyrauxifen-benzyl, fluazifop, fluazifop-P, fluazifop-butyl, fluazifop-P-butyl, flucarbazone, flucarbazone-sodium, flucetosulfuron, fluchloralin, flufenacet, flufenpyr, flufenpyr-ethyl, flumetsulam, flumiclorac, flumiclorac-pentyl, flumioxazin, fluometuron, flurenol, flurenol-butyl, - dimethylammonium und -methyl, fluoroglycofen, fluoroglycofen-ethyl, flupropanate, flupyrsulfuron, flupyrsulfuron-methyl-sodium, fluridone, flurochloridone, fluroxypyr, fluroxypyr-meptyl, flurtamone, fluthiacet, fluthiacet-methyl, fomesafen, fomesafen-sodium, foramsulfuron, fosamine, glufosinate, glufosinate-ammonium, glufosinate-P-sodium, glufosinate-P-ammonium, glufosinate-P-sodium,glyphosate, glyphosate-ammonium, -isopropylammonium, -diammonium, -dimethylammonium, - potassium, -sodium und -trimesium, H-9201, i.e. O-(2,4-Dimethyl-6-nitrophenyl)-O-ethyl-isopropylphosphoramidothioat, halauxifen, halauxifen-methyl, halosafen, halosulfuron, halosulfuronmethyl, haloxyfop, haloxyfop-P, haloxyfop-ethoxyethyl, haloxyfop-P-ethoxyethyl, haloxyfop-methyl, haloxyfop-P-methyl, hexazinone, HW-02, i.e. 1-(Dimethoxyphosphoryl)-ethyl-(2,4-dichlorphenoxy)acetat, 4-Hydroxy-1-methoxy-5-methyl-3-[4-(trifluormethyl)pyridin-2-yl]imidazolidin-2-on, 4-Hydroxy-1-methyl-3-[4-(trifluormethyl)pyridin-2-yl]imidazolidin-2-on, (5-Hydroxy-1-methyl-1H-pyrazol-4-yl)(3,3,4-trimethyl-1,1-dioxido-2,3-dihydro-1-benzothiophen-5-yl)methanon, 6-[(2-Hydroxy-6-oxocyclohex-1-en-1-yl)carbonyl]-1,5-dimethyl-3-(2-methylphenyl)chinazolin-2,4(1H,3H)-dion, imazamethabenz, Imazamethabenz-methyl, imazamox, imazamox-ammonium, imazapic, imazapicammonium, imazapyr, imazapyr-isopropylammonium, imazaquin,imazaquin-ammonium, imazethapyr, imazethapyr-immonium, imazosulfuron, indanofan, indaziflam, iodosulfuron, iodosulfuron-methyl-sodium, ioxynil, ioxynil-octanoate, -potassium und sodium, ipfencarbazone, isoproturon, isouron, isoxaben, isoxaflutole, karbutilate, KUH-043, i.e. 3-({[5-(Difluormethyl)-1-methyl-3-(trifluormethyl)-1H-pyrazol-4-yl]methyl}sulfonyl)-5,5-dimethyl-4,5-dihydro-1,2-oxazol, ketospiradox, lactofen, lenacil, linuron, MCPA, MCPA-butotyl, -dimethylammonium, -2-ethylhexyl, -isopropylammonium, -potassium und -sodium, MCPB, MCPB-methyl, -ethyl und -sodium, mecoprop, mecoprop-sodium, und -butotyl, mecoprop-P, mecoprop-P-butotyl, -dimethylammonium, -2-ethylhexyl und -potassium, mefenacet, mefluidide, mesosulfuron, mesosulfuron-methyl, mesotrione, methabenzthiazuron, metam, metamifop, metamitron, metazachlor, metazosulfuron, methabenzthiazuron, methiopyrsulfuron, methiozolin, 2-({2-[(2-Methoxyethoxy)methyl] -6-(trifluormethyl)pyridin-3 -yl} carbonyl)cyclohexan-1,3 -dion,methyl isothiocyanate, 1-Methyl-4-[(3,3,4-trimethyl-1,1-dioxido-2,3-dihydro-1-benzothiophen-5-yl)carbonyl]-1H-pyrazol-5-ylpropan-1-sulfonat, metobromuron, metolachlor, S-metolachlor, metosulam, metoxuron, metribuzin, metsulfuron, metsulfuron-methyl, molinat, monolinuron, monosulfuron, monosulfuron-ester, MT-5950, i.e. N-[3-chlor-4-(1-methylethyl)-phenyl]-2-methylpentanamid, NGGC-011, napropamide, NC-310, i.e. 4-(2,4-Dichlorbenzoyl)-1-methyl-5-benzyloxypyrazol, neburon, nicosulfuron, nonanoic acid (Pelargonsäure), norflurazon, oleic acid (fatty acids), orbencarb, orthosulfamuron, oryzalin, oxadiargyl, oxadiazon, oxasulfuron, oxaziclomefon, oxotrione (lancotrione), oxyfluorfen, paraquat, paraquat dichloride, pebulate, pendimethalin, penoxsulam, pentachlorphenol, pentoxazone, pethoxamid, petroleum oils, phenmedipham, picloram, picolinafen, pinoxaden, piperophos, pretilachlor, primisulfuron, primisulfuron-methyl, prodiamine, profoxydim, prometon, prometryn, propachlor, propanil,propaquizafop, propazine, propham, propisochlor, propoxycarbazone, propoxycarbazone-sodium, propyrisulfuron, propyzamide, prosulfocarb, prosulfuron, pyraclonil, pyraflufen, pyraflufen-ethyl, pyrasulfotole, pyrazolynate (pyrazolate), pyrazosulfuron, pyrazosulfuron-ethyl, pyrazoxyfen, pyribambenz, pyribambenz-isopropyl, pyribambenz-propyl, pyribenzoxim, pyributicarb, pyridafol, pyridate, pyriftalid, pyriminobac, pyriminobac-methyl, pyrimisulfan, pyrithiobac, pyrithiobac-sodium, pyroxasulfone, pyroxsulam, quinclorac, quinmerac, quinoclamine, quizalofop, quizalofop-ethyl, quizalofop-P, quizalofop-P-ethyl, quizalofop-P-tefuryl, QYM-201, QYR-301, rimsulfuron, saflufenacil, sethoxydim, siduron, simazine, simetryn, sulcotrion, sulfentrazone, sulfometuron, sulfometuron-methyl, sulfosulfuron, , SYN-523, SYP-249, i.e. 1-Ethoxy-3-methyl-1-oxobut-3-en-2-yl-5-[2-chlor-4-(trifluormethyl)phenoxy]-2-nitrobenzoat, SYP-300, i.e. 1-[7-Fluor-3-oxo-4-(prop-2-in-1-yl)-3,4-dihydro-2H-1,4-benzoxazin-6-yl]-3-propyl-2-thioxoimidazolidin-4,5-dion, 2,3,6-TBA, TCA (Trifluoressigsäure), TCA-sodium, tebuthiuron, tefuryltrione, tembotrione, tepraloxydim, terbacil, terbucarb, terbumeton, terbuthylazin, terbutryn, tetflupyrolimet, thenylchlor, thiazopyr, thiencarbazone, thiencarbazone-methyl, thifensulfuron, thifensulfuron-methyl, thiobencarb, tiafenacil, tolpyralate, topramezone, tralkoxydim, triafamone, tri-allate, triasulfuron, triaziflam, tribenuron, tribenuron-methyl, triclopyr, trietazine, trifloxysulfuron, trifloxysulfuron-sodium, trifludimoxazin, trifluralin, triflusulfuron, triflusulfuronmethyl, tritosulfuron, urea sulfate, vernolate, ZJ-0862, i.e. 3,4-Dichlor-N-{2-[(4,6-dimethoxypyrimidin-2-yl)oxy]benzyl} anilin.,

[0110] Examples of plant growth regulators as possible mixing partners are: acibenzolar, acibenzolar-S-methyl, 5-aminolevulinic acid, ancymidol, 6-benzylaminopurine, brassinolide, catechin, chlormequat chloride, cloprop, cyclanilide, 3-(cycloprop-1-enyl)propionic acid, daminozide, dazomet, n-decanol, dikegulac, dikegulac-sodium, endothelial, endothal-dipotassium, -disodium, and mono(N,N-dimethylalkylammonium), ethephon, flumetralin, flurenol, flurenol-butyl, flurprimidol, forchlorfenuron, gibberellic acid, inabenfide, indol-3-acetic acid (IAA), 4-indol-3-ylbutyric acid, isoprothiolane, probenazole, jasmonic acid, Jasmonic acid methyl ester, maleic hydrazide, mepiquat chloride, 1-methylcyclopropene, 2-(1-naphthyl)acetamide, 1-naphthylacetic acid, 2-naphthyloxyacetic acid, nitrophenolate mixture, 4-oxo-4[(2-phenylethyl)amino]butyric acid, paclobutrazol, N-phenylphthalamic acid, prohexadione, prohexadione-calcium, prohydrojasmone, salicylic acid, strigolactone, tecnazene, thidiazuron, triacontanol,trinexapac, trinexapac-ethyl, tsitodef, uniconazole, uniconazole-P.,

[0111] Safeners which can be used in combination with the compounds of formula (I) according to the invention and optionally in combination with other active ingredients such as insecticides, acaricides, herbicides, fungicides as listed above, are preferably selected from the group consisting of: S1) Compounds of formula (S1), where the symbols and indices have the following meanings: n A is a natural number from 0 to 5, preferably 0 to 3; RA 1< is halogen, (C 1 -C 4 )alkyl, (C 1 -C 4 )alkoxy, nitro or (C 1 -C 4 )haloalkyl; WA is an unsubstituted or substituted divalent heterocyclic radical from the group of partially saturated or aromatic five-membered ring heterocycles having 1 to 3 hetero ring atoms from the group N and O, wherein at least one N atom and at most one O atom is present in the ring, preferably a radical from the group (WA 1< ) to (WA 4< ), m A is 0 or 1; RA 2< is OR A 3< , SR A 3< or NR A 3< RA 4< or a saturated or unsaturated 3- to 7-membered heterocycle having at least one N atom and up to 3 heteroatoms, preferably from the group O and S, which is linked to the carbonyl group in (S1) via the N atom and is unsubstituted or substituted by radicals from the group (C 1 -C 4 )alkyl, (C 1 -C 4 )alkoxy or optionally substituted phenyl, preferably a radical of the formula OR A 3< , NHR A 4< or N(CH 3 ) 2 , in particular of the formula OR A 3< ; RA 3< is hydrogen or an unsubstituted or substituted aliphatic hydrocarbon radical, preferably having a total of 1 to 18 C atoms; RA 4< is hydrogen, (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy or substituted or unsubstituted phenyl;RA 5< is H, (C 1 -C 8 )alkyl, (C 1 -C 8 )haloalkyl, (C 1 -C 4 )alkoxy(C 1 -C 8 )alkyl, cyano or COOR A 9< , where RA 9< is hydrogen, (C 1 -C 8 )alkyl, (C 1 -C 8 )haloalkyl, (C 1 -C 4 )alkoxy-(C 1 -C 4 )alkyl, (C 1 -C 6 )hydroxyalkyl, (C 3 -C 12 )cycloalkyl or tri-(C 1 -C 4 )alkylsilyl; RA 6< , RA 7< , RA 8< are identical or different and are hydrogen, (C 1 -C 8 )alkyl, (C 1 -C 8 )haloalkyl, (C 3 -C 12 )cycloalkyl or substituted or unsubstituted phenyl; preferably: a) compounds of the dichlorophenylpyrazolin-3-carboxylic acid type (S1 a< ), preferably compounds such as 1-(2,4-dichlorophenyl)-5-(ethoxycarbonyl)-5-methyl-2-pyrazolin-3-carboxylic acid, 1-(2,4-dichlorophenyl)-5-(ethoxycarbonyl)-5-methyl-2-pyrazolin-3-carboxylic acid ethyl ester (S1-1) ("Mefenpyr-diethyl"), and related compounds as described in WO-A-91 / 07874;b) derivatives of dichlorophenylpyrazolecarboxylic acid (S1 b< ), preferably compounds such as ethyl 1-(2,4-dichlorophenyl)-5-methylpyrazole-3-carboxylate (S1-2), ethyl 1-(2,4-dichlorophenyl)-5-isopropylpyrazole-3-carboxylate (S1-3), ethyl 1-(2,4-dichlorophenyl)-5-(1,1-dimethylethyl)pyrazole-3-carboxylate (S1-4) and related compounds as described in EP-A-333 131 and EP-A-269 806; c) derivatives of 1,5-diphenylpyrazole-3-carboxylic acid (S1 c< ), preferably compounds such as ethyl 1-(2,4-dichlorophenyl)-5-phenylpyrazole-3-carboxylate (S1-5), methyl 1-(2-chlorophenyl)-5-phenylpyrazole-3-carboxylate (S1-6) and related compounds as described, for example, in EP-A-268554;d) compounds of the triazolecarboxylic acid type (S1 d< ), preferably compounds such as fenchlorazole(ethyl ester), ie 1-(2,4-dichlorophenyl)-5-trichloromethyl-(1H)-1,2,4-triazole-3-carboxylic acid ethyl ester (S1-7), and related compounds as described in EP-A-174 562 and EP-A-346 620;e) Compounds of the type 5-benzyl- or 5-phenyl-2-isoxazoline-3-carboxylic acid or 5,5-diphenyl-2-isoxazoline-3-carboxylic acid (S1 e< ), preferably compounds such as 5-(2,4-dichlorobenzyl)-2-isoxazoline-3-carboxylic acid ethyl ester (S1-8) or 5-phenyl-2-isoxazoline-3-carboxylic acid ethyl ester (S1-9) and related compounds as described in WO-A-91 / 08202, or 5,5-diphenyl-2-isoxazoline-3-carboxylic acid (S1-10) or 5,5-diphenyl-2-isoxazoline-3-carboxylic acid ethyl ester (S1-11) ("Isoxadifen-ethyl") or -n-propyl ester (S1-12) or the 5-(4-Fluorophenyl)-5-phenyl-2-isoxazoline-3-carboxylic acid ethyl ester (S1-13), as described in patent application WO-A-95 / 07897. S2) Quinoline derivatives of the formula (S2), ; where the symbols and indices have the following meanings: RB 1< is halogen, (C 1 -C 4 )alkyl, (C 1 -C 4 )alkoxy, nitro or (C 1 -C 4 )haloalkyl; n B is a natural number from 0 to 5, preferably 0 to 3; RB 2< is OR B 3< , SR B 3< or NR B 3< RB 4< or a saturated or unsaturated 3- to 7-membered heterocycle having at least one N atom and up to 3 heteroatoms, preferably from the group O and S, which is linked to the carbonyl group in (S2) via the N atom and is unsubstituted or substituted by radicals from the group (C 1 -C 4 )alkyl, (C 1 -C 4 )alkoxy or optionally substituted phenyl, preferably a radical of the formula OR B 3< , NHR B 4< or N(CH 3 ) 2 , in particular of the formula OR B 3< ; RB 3< is hydrogen or an unsubstituted or substituted aliphatic hydrocarbon radical, preferably having a total of 1 to 18 C atoms; RB 4< is hydrogen, (C 1 -C 6 )alkyl,(C 1 -C 6 )alkoxy or substituted or unsubstituted phenyl; TB is a (C 1 or C 2 )alkanediyl chain which is unsubstituted or substituted by one or two (C 1 -C 4 )alkyl radicals or by [(C 1 -C 3 )alkoxy]carbonyl; preferably: a) compounds of the 8-quinolinoxyacetic acid type (S2 a< ), preferably (5-chloro-8-quinolinoxy)acetic acid (1-methylhexyl) ester ("Cloquintocet-mexyl") (S2-1), (5-chloro-8-quinolinoxy)acetic acid (1,3-dimethyl-but-1-yl) ester (S2-2), (5-chloro-8-quinolinoxy)acetic acid 4-allyloxy-butyl ester (S2-3), (5-chloro-8-quinolinoxy)acetic acid 1-allyloxy-prop-2-yl ester (S2-4), (5-chloro-8-quinolinoxy)acetate ethyl ester (S2-5), (5-chloro-8-quinolinoxy)acetate methyl ester (S2-6), (5-chloro-8-quinolinoxy)acetate allyl ester (S2-7), (5-Chloro-8-quinolinoxy)acetic acid 2-(2-propylidene-iminoxy)-1-ethyl ester (S2-8), (5-Chloro-8-quinolinoxy)acetic acid 2-oxo-prop-1-yl ester (S2-9) and related compounds as described in EP-A-86 750,EP-A-94 349 and EP-A-191 736 or EP-A-0 492 366, and (5-chloro-8-quinolinoxy)acetic acid (S2-10), its hydrates and salts, for example its lithium, sodium, potassium, calcium, magnesium, aluminum, iron, ammonium, quaternary ammonium, sulfonium or phosphonium salts as described in WO-A-2002 / 34048; b) Compounds of the (5-chloro-8-quinolinoxy)malonic acid type (S2 b< ), preferably compounds such as (5-chloro-8-quinolinoxy)malonic acid diethyl ester, (5-chloro-8-quinolinoxy)malonic acid diallyl ester, (5-chloro-8-quinolinoxy)malonic acid methyl ethyl ester and related compounds as described in EP-A-0 582 198. S3) Compounds of the formula (S3) , where the symbols and indices have the following meanings: RC 1< is (C 1 -C 4 )alkyl, (C 1 -C 4 )haloalkyl, (C 2 -C 4 )alkenyl, (C 2 -C 4 )haloalkenyl, (C 3 -C 7 )cycloalkyl, preferably dichloromethyl; RC 2< , RC 3< are identical or different and are hydrogen, (C 1 -C 4 )alkyl, (C 2 -C 4 )alkenyl, (C 2 -C 4 )alkynyl, (C 1 -C 4 )haloalkyl, (C 2 -C 4 )haloalkenyl, (C 1 -C 4 )alkylcarbamoyl-(C 1 -C 4 )alkyl, (C 2 -C 4 )alkenylcarbamoyl-(C 1 -C 4 )alkyl, (C 1 -C 4 )alkoxy-(C 1 -C 4 )alkyl, dioxolanyl-(C 1 -C 4 )alkyl, thiazolyl, furyl, furylalkyl, thienyl, piperidyl, substituted or unsubstituted phenyl, or RC 2< and RC 3< together form a substituted or unsubstituted heterocyclic ring, preferably an oxazolidine, thiazolidine, piperidine, morpholine, hexahydropyrimidine or benzoxazine ring; preferably: active ingredients of the dichloroacetamide type, which are frequently used as pre-emergence safeners (soil-active safeners), such as"Dichlormid" (N,N-diallyl-2,2-dichloroacetamide) (S3-1), "R-29148" (3-dichloroacetyl-2,2,5-trimethyl-1,3-oxazolidine) from Stauffer (S3-2), "R-28725" (3-dichloroacetyl-2,2,-dimethyl-1,3-oxazolidine) from Stauffer (S3-3), "Benoxacor" (4-dichloroacetyl-3,4-dihydro-3-methyl-2H-1,4-benzoxazine) (S3-4), "PPG-1292" (N-allyl-N-[(1,3-dioxolan-2-yl)-methyl]-dichloroacetamide) from PPG Industries (S3-5), "DKA-24" (N-allyl-N-[(allylaminocarbonyl)methyl]-dichloroacetamide) from Sagro-Chem (S3-6), "AD-67" or "MON 4660" (3-dichloroacetyl-1-oxa-3-aza-spiro[4,5]decane) from Nitrokemia or Monsanto (S3-7), "TI-35" (1-dichloroacetyl-azepane) from TRI-Chemical RT (S3-8), "Diclonon" (dicyclonone) or "BAS145138" or "LAB145138" (S3-9) ((RS)-1-dichloroacetyl-3,3,8a-trimethylperhydropyrrolo[1,2-a]pyrimidin-6-one) from BASF, "Furilazol" or "MON 13900" ((RS)-3-Dichloroacetyl-5-(2-furyl)-2,2-dimethyloxazolidine) (S3-10); and its (R)-isomer (S3-11).S4) N-acylsulfonamides of the formula (S4) and their salts, . wherein the symbols and indices have the following meanings: AD is SO 2 -NR D 3< -CO or CO-NR D 3< -SO 2 XD is CH or N; RD 1< is CO-NR D 5< RD 6< or NHCO-R D 7< ; RD 2< is halogen, (C 1 -C 4 )haloalkyl, (C 1 -C 4 )haloalkoxy, nitro, (C 1 -C 4 )alkyl, (C 1 -C 4 )alkoxy, (C 1 -C 4 )alkylsulfonyl, (C 1 -C 4 )alkoxycarbonyl or (C 1 -C 4 )alkylcarbonyl; RD 3< is hydrogen, (C 1 -C 4 )alkyl, (C 2 -C 4 )alkenyl or (C 2 -C 4 )alkynyl, RD 4< is halogen, nitro, (C 1 -C 4 )alkyl, (C 1 -C 4 )haloalkyl, (C 1 -C 4 )haloalkoxy, (C 3 -C 6 )cycloalkyl, phenyl, (C 1 -C 4 )alkoxy, cyano, (C 1 -C 4 )alkylthio, (C 1 -C 4 )alkylsulfinyl, (C 1 -C 4 )alkylsulfonyl, (C 1 -C 4 )alkoxycarbonyl or (C 1 -C 4 )alkylcarbonyl;RD 5< is hydrogen, (C 1 -C 6 )alkyl, (C 3 -C 6 )cycloalkyl, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl, (C 5 -C 6 )cycloalkenyl, phenyl or 3- to 6-membered heterocyclyl containing v D heteroatoms from the group nitrogen, oxygen and sulfur, where the seven last-mentioned radicals are substituted by v D substituents from the group halogen, (C 1 -C 6 )alkoxy, (C 1 -C 6 )haloalkoxy, (C 1 -C 2 )alkylsulfinyl, (C 1 -C 2 )alkylsulfonyl, (C 3 -C 6 )cycloalkyl, (C 1 -C 4 )alkoxycarbonyl, (C 1 -C 4 )alkylcarbonyl and phenyl and in In the case of cyclic radicals, (C 1 -C 4 ) alkyl and (C 1 -C 4 )haloalkyl are also substituted; RD 6< is hydrogen, (C 1 -C 6 )alkyl, (C 2 -C 6 )alkenyl or (C 2 -C 6 )alkynyl, where the three last-mentioned radicals are substituted by radicals from the group halogen, hydroxy, (C 1 -C 4 )alkyl, (C 1 -C 4 )alkoxy and (C 1 -C 4 )alkylthio, or RD 5< and RD 6< together with the nitrogen atom carrying them form a pyrrolidinyl or piperidinyl radical;RD 7< is hydrogen, (C 1 -C 4 )alkylamino, di-(C 1 -C 4 )alkylamino, (C 1 -C 6 )alkyl, (C 3 -C 6 )cycloalkyl, where the last two radicals are substituted by v D substituents from the group halogen, (C 1 -C 4 )alkoxy, (C 1 -C 6 )haloalkoxy and (C 1 -C 4 )alkylthio and in the case of cyclic radicals also (C 1 -C 4 )alkyl and (C 1 -C 4 )haloalkyl; n D is 0, 1 or 2; m D is 1 or 2; v D is 0, 1, 2 or 3; of these, preference is given to compounds of the N-acylsulfonamide type, for example of the formula (S4 a< below), which, for example, B. are known from WO-A-97 / 45016 ; wherein RD 7< (C 1 -C 6 )alkyl, (C 3 -C 6 )cycloalkyl, where the last two radicals are substituted by v D substituents from the group halogen, (C 1 -C 4 )alkoxy, (C 1 -C 6 )haloalkoxy and (C 1 -C 4 )alkylthio and in the case of cyclic radicals also (C 1 -C 4 )alkyl and (C 1 -C 4 )haloalkyl; RD 4< halogen, (C 1 -C 4 )alkyl, (C 1 -C 4 )alkoxy, CF 3 , m D is 1 or 2; v D is 0, 1, 2 or 3; and acylsulfamoylbenzoic acid amides, e.g. of the following formula (S4 b< ), which are known e.g. from WO-A-99 / 16744, e.g. those in which RD 5< = cyclopropyl and (RD 4< ) = 2-OMe ("Cyprosulfamide", S4-1), RD 5< = cyclopropyl and (RD 4< ) = 5-Cl-2-OMe (S4-2), RD 5< = ethyl and (RD 4< ) = 2-OMe (S4-3), RD 5< = isopropyl and (RD 4< ) = 5-Cl-2-OMe (S4-4) and RD 5< = isopropyl and (RD 4< ) = 2-OMe (S4-5). as well as compounds of the N-acylsulfamoylphenylurea type of formula (S4 c< ), which are known, for example, from EP-A-365484, wherein RD 8< and RD 9< independently of one another are hydrogen, (C 1 -C 8 )alkyl, (C 3 -C 8 )cycloalkyl, (C 3 -C 6 )alkenyl, (C 3 -C 6 )alkynyl, RD 4< is halogen, (C 1 -C 4 )alkyl, (C 1 -C 4 )alkoxy, CF 3 m D 1 or 2; for example 1-[4-(N-2-methoxybenzoylsulfamoyl)phenyl]-3-methylurea, 1-[4-(N-2-methoxybenzoylsulfamoyl)phenyl]-3,3-dimethylurea, 1-[4-(N-4,5-dimethylbenzoylsulfamoyl)phenyl]-3-methylurea, and N-phenylsulfonylterephthalamides of the formula (S4 d< ), which are known, for example, from CN 101838227, e.g. those wherein RD 4< halogen, (C 1 -C 4 )alkyl, (C 1 -C 4 )alkoxy, CF 3 , m D 1 or 2; RD 5< hydrogen, (C 1 -C 6 )alkyl, (C 3 -C 6 )cycloalkyl, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl, (C 5 -C 6 )cycloalkenyl. S5) Active ingredients from the class of hydroxyaromatics and aromatic-aliphatic carboxylic acid derivatives (S5), e.g. ethyl 3,4,5-triacetoxybenzoate, 3,5-dimethoxy-4-hydroxybenzoic acid, 3,5-dihydroxybenzoic acid, 4-hydroxysalicylic acid, 4-fluorosalicyclic acid, 2-hydroxycinnamic acid, 2,4-dichlorocinnamic acid, as described in WO-A-2004 / 084631, WO-A-2005 / 015994, WO-A-2005 / 016001. S6) Active ingredients from the class of 1,2-dihydroquinoxalin-2-ones (S6), e.g. 1-methyl-3-(2-thienyl)-1,2-dihydroquinoxalin-2-one, 1-methyl-3-(2-thienyl)-1,2-dihydroquinoxalin-2-thione, 1-(2-aminoethyl)-3-(2-thienyl)-1,2-dihydroquinoxalin-2-one hydrochloride, 1-(2-methylsulfonylaminoethyl)-3-(2-thienyl)-1,2-dihydroquinoxalin-2-one, as described in WO-A-2005 / 112630.S7) Compounds of formula (S7) as described in WO-A-1998 / 38856. wherein the symbols and indices have the following meanings: RE 1< , RE 2< are independently of one another halogen, (C 1 -C 4 )alkyl, (C 1 -C 4 )alkoxy, (C 1 -C 4 )haloalkyl, (C 1 -C 4 )alkylamino, di-(C 1 -C 4 )alkylamino, nitro; AE is COOR E 3< or COSR E 4< RE 3< , RE 4< are independently hydrogen, (C 1 -C 4 )alkyl, (C 2 -C 6 )alkenyl, (C 2 -C 4 )alkynyl, cyanoalkyl, (C 1 -C 4 )haloalkyl, phenyl, nitrophenyl, benzyl, halobenzyl, pyridinylalkyl and alkylammonium, n E 1< is 0 or 1 n E 2< , n E 3< are independently 0, 1 or 2, preferably: diphenylmethoxyacetic acid, ethyl diphenylmethoxyacetate, methyl diphenylmethoxyacetate (CAS Reg. No. 41858-19-9) (S7-1). S8) Compounds of formula (S8) as described in WO-A-98 / 27049 wherein XF is CH or N, n F, in the case that XF is =N, is an integer from 0 to 4 and in the case that XF is =CH, is an integer from 0 to 5, RF 1< halogen, (C 1 -C 4 )alkyl, (C 1 -C 4 )haloalkyl, (C 1 -C 4 )alkoxy, (C 1 -C 4 )haloalkoxy, nitro, (C 1 -C 4 )alkylthio, (C 1 -C 4 )alkylsulfonyl, (C 1 -C 4 )alkoxycarbonyl, optionally substituted phenyl, optionally substitutedsubstituted phenoxy, RF 2< hydrogen or (C 1 -C 4 )alkyl RF 3< hydrogen, (C 1 -C 8 )alkyl, (C 2 -C 4 )alkenyl, (C 2 -C 4 )alkynyl, or aryl, where each of the aforementioned C-containing radicals is unsubstituted or substituted by one or more, preferably up to three identical or different radicals from the group consisting of halogen and alkoxy; or salts thereof, preferably compounds wherein XF is CH, n F is an integer from 0 to 2, RF 1< halogen, (C 1 -C 4 )alkyl, (C 1 -C 4 )haloalkyl, (C 1 -C 4 )alkoxy, (C 1 -C 4 )haloalkoxy, RF 2< hydrogen or (C 1 -C 4 )alkyl, RF 3< hydrogen, (C 1 -C 8 )alkyl, (C 2 -C 4 )alkenyl, (C 2 -C 4 )alkynyl, or aryl, where each of the aforementioned C-containing radicals is unsubstituted or substituted by one or more, preferably up to three identical or different radicals from the group consisting of halogen and alkoxy, or salts thereof.S9) Active ingredients from the class of 3-(5-tetrazolylcarbonyl)-2-quinolones (S9), e.g. 1,2-dihydro-4-hydroxy-1-ethyl-3-(5-tetrazolylcarbonyl)-2-quinolone (CAS Reg. No. 219479-18-2), 1,2-dihydro-4-hydroxy-1-methyl-3-(5-tetrazolylcarbonyl)-2-quinolone (CAS Reg. No. 95855-00-8), as described in WO-A-1999 / 000020. S10) Compounds of the formulas (S10 a< ) or (S10 b< ) as described in WO-A-2007 / 023719 and WO-A-2007 / 023764. wherein RG 1< halogen, (C 1 -C 4 )alkyl, methoxy, nitro, cyano, CF 3 , OCF 3 YG , ZG independently of one another are O or S, n G is an integer from 0 to 4, RG 2< (C 1 -C 16 )alkyl, (C 2 -C 6 )alkenyl, (C 3 -C 6 )cycloalkyl, aryl; benzyl, halobenzyl, RG 3< hydrogen or (C 1 -C 6 )alkyl. S11) Active ingredients of the oxyimino compound type (S11), which are known as seed dressing agents, such as, for example, B. "Oxabetrinil" ((Z)-1,3-dioxolan-2-ylmethoxyimino(phenyl)acetonitrile) (S11-1), which is known as a seed dressing safener for millet against metolachlor damage, "Fluxofenim" (1-(4-chlorophenyl)-2,2,2-trifluoro-1-ethanone-O-(1,3-dioxolan-2-ylmethyl)-oxime) (S11-2), which is known as a seed dressing safener for millet against metolachlor damage, and "Cyometrinil" or "CGA-43089" ((Z)-cyanomethoxyimino(phenyl)acetonitrile) (S11-3), which is known as a seed dressing safener for millet against metolachlor damage. S12) Active ingredients from the class of isothiochromanones (S12), such asMethyl [(3-oxo-1H-2-benzothiopyran-4(3H)-ylidene)methoxy]acetate (CAS Reg. No. 205121-04-6) (S12-1) and related compounds from WO-A-1998 / 13361. S13) One or more compounds from group (S13): "Naphthalic anhydride" (1,8-naphthalenedicarboxylic anhydride) (S13-1), known as a seed dressing safener for maize against damage from thiocarbamate herbicides, "Fenclorim" (4,6-dichloro-2-phenylpyrimidine) (S13-2), known as a safener for pretilachlor in sown rice, "Flurazole" (benzyl 2-chloro-4-trifluoromethyl-1,3-thiazole-5-carboxylate) (S13-3), known as a seed dressing safener for millet against damage from alachlor and metolachlor, "CL 304415" (CAS Reg. No. 31541-57-8) (4-carboxy-3,4-dihydro-2H-1-benzopyran-4-acetic acid) (S13-4) from American Cyanamid, which is known as a safener for corn against damage from imidazolinones, "MG 191" (CAS Reg. No. 96420-72-3) (2-Dichloromethyl-2-methyl-1,3-dioxolane) (S13-5) from Nitrokemia, which is known as a safener for corn, "MG 838" (CAS Reg.No. 133993-74-5) (2-propenyl 1-oxa-4-azaspiro[4.5]decane-4-carbodithioate) (S13-6) from Nitrokemia, "Disulfoton" (O,O-diethyl S-2-ethylthioethyl phosphodithioate) (S13-7), "Dietholate" (O,O-diethyl O-phenylphosphorothioate) (S13-8), "Mephenate" (4-chlorophenyl methylcarbamate) (S13-9). S14) Active ingredients which, in addition to herbicidal activity against weeds, also have safener effects on crops such as rice, such as"Dimepiperate" or "MY 93" (S-1-methyl-1-phenylethyl-piperidine-1-carbothioate), known as a safener for rice against damage from the herbicide molinate, "Daimuron" or "SK 23" (1-(1-methyl-1-phenylethyl)-3-p-tolylurea), known as a safener for rice against damage from the herbicide imazosulfuron, "Cumyluron" = "JC 940" (3-(2-chlorophenylmethyl)-1-(1-methyl-1-phenylethyl)urea, see JP-A-60087254), known as a safener for rice against damage from some herbicides, "Methoxyphenone" or "NK 049" (3,3'-dimethyl-4-methoxybenzophenone), known as a safener for rice against damage from some herbicides, "CSB" (1-Bromo-4-(chloromethylsulfonyl)benzene) from Kumiai, (CAS Reg. No. 54091-06-4), which is known as a safener against the damage of some herbicides in rice. S15) Compounds of formula (S15) or their tautomers. as described in WO-A-2008 / 131861 and WO-A-2008 / 131860, wherein RH 1< denotes a (C 1 -C 6 )haloalkyl radical and RH 2< denotes hydrogen or halogen and RH 3< , RH 4< independently of one another denote hydrogen, (C 1 -C 16 )alkyl, (C 2 -C 16 )alkenyl or (C 2 -C 16 )alkynyl, where each of the last-mentioned 3 radicals is unsubstituted or substituted by one or more radicals from the group halogen, hydroxy, cyano, (C 1 -C 4 )alkoxy, (C 1 -C 4 )haloalkoxy, (C 1 -C 4 )alkylthio, (C 1 -C 4 )alkylamino, di[(C 1 -C 4 )alkyl]amino, [(C 1 -C 4 )alkoxy]carbonyl, [(C 1 -C 4 )haloalkoxy]carbonyl, (C 3 -C 6 )cycloalkyl, which is unsubstituted or substituted, phenyl, which is unsubstituted or substituted, and heterocyclyl, which is unsubstituted or substituted, or (C 3 -C 6 )cycloalkyl, (C 4 -C 6 )cycloalkenyl, (C 3 -C 6 )cycloalkyl, which is condensed on one side of the ring with a 4 to 6-membered saturated or unsaturated carbocyclic ring,or (C 4 -C 6 )cycloalkenyl which is condensed on one side of the ring with a 4 to 6-membered saturated or unsaturated carbocyclic ring, wherein each of the last-mentioned 4 radicals is unsubstituted or substituted by one or more radicals from the group halogen, hydroxy, cyano, (C 1 -C 4 )alkyl, (C 1 -C 4 )haloalkyl, (C 1 -C 4 )alkoxy, (C 1 -C 4 )haloalkoxy, (C 1 -C 4 )alkylthio, (C 1 -C 4 )alkylamino, di[(C 1 -C 4 )alkyl]amino, [(C 1 -C 4 )alkoxy]carbonyl, [(C 1 -C 4 )haloalkoxy]carbonyl, (C 3 -C 6 )cycloalkyl, which is unsubstituted or substituted, phenyl which is unsubstituted or substituted, and heterocyclyl which is unsubstituted or substituted, is substituted, or RH 3< is (C 1 -C 4 )-alkoxy, (C 2 -C 4 )alkenyloxy, (C 2 -C 6 )alkynyloxy or (C 2 -C 4 )haloalkoxy and RH 4< is hydrogen or (C 1 -C 4 )-alkyl or RH 3< and RH 4< together with the directly bonded N atom form a four- to eight-membered heterocyclic ring,which, in addition to the N atom, may also contain further hetero ring atoms, preferably up to two further hetero ring atoms from the group N, O and S and which is unsubstituted or substituted by one or more radicals from the group halogen, cyano, nitro, (C 1 -C 4 )alkyl, (C 1 -C 4 )haloalkyl, (C 1 -C 4 )alkoxy, (C 1 -C 4 )haloalkoxy and (C 1 -C 4 )alkylthio. S16) Active substances that are primarily used as herbicides, but also have a safener effect on crops, e.g. (2,4-dichlorophenoxy)acetic acid (2,4-D), (4-chlorophenoxy)acetic acid, (R,S)-2-(4-chloro-o-tolyloxy)propionic acid (mecoprop), 4-(2,4-dichlorophenoxy)butyric acid (2,4-DB), (4-chloro-o-tolyloxy)acetic acid (MCPA), 4-(4-chloro-o-tolyloxy)butyric acid, 4-(4-chlorophenoxy)butyric acid, 3,6-dichloro-2-methoxybenzoic acid (dicamba), 1-(ethoxycarbonyl)ethyl 3,6-dichloro-2-methoxybenzoate (lactidichloroethyl).

[0112] Particularly preferred safeners are mefenpyr-diethyl, cyprosulfamide, isoxadifen-ethyl, cloquintocetmexyl, dichlormid and metcamifen.

[0113] Wettable powders are preparations that are evenly dispersible in water. In addition to the active ingredient, they contain a diluent or inert substance as well as ionic and / or non-ionic surfactants (wetting agents, dispersants), e.g., polyoxyethylated alkylphenols, polyoxyethylated fatty alcohols, polyoxyethylated fatty amines, fatty alcohol polyglycol ether sulfates, alkanesulfonates, alkylbenzenesulfonates, sodium ligninsulfonate, sodium 2,2'-dinaphthylmethane-6,6'-disulfonate, sodium dibutylnaphthalenesulfonate, or sodium oleoylmethyltaurine. To produce the wettable powders, the herbicidal active ingredients are finely ground in conventional equipment such as hammer mills, fan mills, and air jet mills and mixed simultaneously or subsequently with the formulation auxiliaries.

[0114] Emulsifiable concentrates are produced by dissolving the active ingredient in an organic solvent, e.g., butanol, cyclohexanone, dimethylformamide, xylene, or higher-boiling aromatics or hydrocarbons, or mixtures of organic solvents, with the addition of one or more ionic and / or non-ionic surfactants (emulsifiers). Examples of emulsifiers that can be used are: calcium salts of alkylarylsulfonic acid, such as calcium dodecylbenzenesulfonate, or non-ionic emulsifiers, such as fatty acid polyglycol esters, alkylaryl polyglycol ethers, fatty alcohol polyglycol ethers, propylene oxide-ethylene oxide condensation products, alkyl polyethers, sorbitan esters, such as sorbitan fatty acid esters, or polyoxyethylene sorbitan esters, such as polyoxyethylene sorbitan fatty acid esters.

[0115] Dusts are obtained by grinding the active ingredient with finely divided solid substances, e.g. talc, natural clays such as kaolin, bentonite and pyrophyllite, or diatomaceous earth.

[0116] Suspension concentrates can be water- or oil-based. They can be produced, for example, by wet grinding using commercially available bead mills and, if necessary, with the addition of surfactants, such as those listed above for the other formulation types.

[0117] Emulsions, e.g. oil-in-water emulsions (EW), can be prepared, for example, by means of stirrers, colloid mills and / or static mixers using aqueous organic solvents and, if appropriate, surfactants, such as those already listed above for the other formulation types.

[0118] Granules can be produced either by spraying the active ingredient onto adsorbent, granulated inert material or by applying active ingredient concentrates to the surface of carrier materials such as sand, kaolinite, or granulated inert material using adhesives such as polyvinyl alcohol, sodium polyacrylate, or mineral oils. Suitable active ingredients can also be granulated in the usual way for the production of fertilizer granules—if desired, mixed with fertilizers.

[0119] Water-dispersible granules are usually produced by conventional processes such as spray drying, fluidized bed granulation, disc granulation, mixing with high-speed mixers and extrusion without solid inert material.

[0120] For the production of disc, fluidized bed, extruder and spray granules see e.g. processes in "Spray-Drying Handbook" 3rd ed. 1979, G. Goodwin Ltd., London, JE Browning, "Agglomeration", Chemical and Engineering 1967, pages 147 ff, "Perry's Chemical Engineer's Handbook", 5th Ed., McGraw-Hill, New York 1973, pp. 8-57.

[0121] For further details on the formulation of pesticides see, for example, GC Klingman, "Weed Control as a Science", John Wiley and Sons, Inc., New York, 1961, pages 81-96 and JD Freyer, SA Evans, "Weed Control Handbook", 5th Ed., Blackwell Scientific Publications, Oxford, 1968, pages 101-103.

[0122] The agrochemical preparations generally contain 0.1 to 99% by weight, in particular 0.1 to 95% by weight, of compounds according to the invention. In wettable powders, for example, the active ingredient concentration is about 10 to 90% by weight, the remainder to 100% by weight consisting of conventional formulation components. In emulsifiable concentrates, the active ingredient concentration can be about 1 to 90, preferably 5 to 80% by weight. Dust-like formulations contain 1 to 30% by weight of active ingredient, preferably 5 to 20% by weight of active ingredient, while sprayable solutions contain about 0.05 to 80, preferably 2 to 50% by weight of active ingredient. In water-dispersible granules, the active ingredient content depends partly on whether the active compound is liquid or solid and which granulation aids, fillers, etc. are used. In the case of water-dispersible granules, the active ingredient content is, for example, between 1 and 95% by weight, preferably between 10 and 80% by weight.In addition, the active ingredient formulations mentioned may contain the usual adhesives, wetting agents, dispersing agents, emulsifying agents, penetration agents, preservatives, antifreeze agents and solvents, fillers, carriers and dyes, defoamers, evaporation inhibitors and agents which influence the pH value and viscosity.

[0123] Based on these formulations, combinations with other pesticidally active substances, such as insecticides, acaricides, herbicides, fungicides, as well as with safeners, fertilizers, and / or growth regulators, can also be produced, e.g., in the form of a ready-to-use formulation or as a tank mix. For application, the commercially available formulations are diluted in the usual way, e.g., with water in the case of wettable powders, emulsifiable concentrates, dispersions, and water-dispersible granules. Dust-like preparations, soil or broadcast granules, and sprayable solutions are not usually diluted with other inert substances before use.

[0124] The required application rate of the compounds of formula (I) and their salts varies with external conditions such as temperature, humidity, the type of herbicide used, among others. It can fluctuate within wide limits, e.g., between 0.001 and 10.0 kg / ha or more of active ingredient, but is preferably between 0.005 and 5 kg / ha, more preferably in the range from 0.01 to 1.5 kg / ha, and especially preferably in the range from 0.05 to 1 kg / ha. This applies to both pre-emergence and post-emergence applications.

[0125] Carrier means a natural or synthetic, organic or inorganic substance with which the active ingredients are mixed or combined for improved applicability, especially for application to plants, plant parts, or seeds. The carrier, which can be solid or liquid, is generally inert and should be suitable for agricultural use.

[0126] Suitable solid or liquid carriers include: ammonium salts and natural mineral flours such as kaolins, clays, talc, chalk, quartz, attapulgite, montmorillonite, or diatomaceous earth; and synthetic mineral flours such as highly dispersed silica, aluminum oxide, and natural or synthetic silicates, resins, waxes, solid fertilizers, water, alcohols, particularly butanol, organic solvents, mineral and vegetable oils, and derivatives thereof. Mixtures of such carriers can also be used. Suitable solid carriers for granules include: crushed and fractionated natural rocks such as calcite, marble, pumice, sepiolite, and dolomite; as well as synthetic granules made from inorganic and organic flours and granules made from organic material such as sawdust, coconut shells, corn cobs, and tobacco stalks.

[0127] Suitable liquefied gaseous extenders or carriers are liquids which are gaseous at normal temperature and pressure, e.g. aerosol propellants such as halogenated hydrocarbons, as well as butane, propane, nitrogen and carbon dioxide.

[0128] Adhesives such as carboxymethylcellulose, natural and synthetic powdered, granular, or latex-like polymers such as gum arabic, polyvinyl alcohol, and polyvinyl acetate, as well as natural phospholipids such as cephalins and lecithins, and synthetic phospholipids, can be used in the formulations. Other additives may include mineral and vegetable oils.

[0129] If water is used as an extender, organic solvents can also be used as co-solvents. The following liquid solvents are essentially suitable: aromatics such as xylene, toluene, or alkylnaphthalenes; chlorinated aromatics or chlorinated aliphatic hydrocarbons such as chlorobenzenes, chloroethylenes, or dichloromethane; aliphatic hydrocarbons such as cyclohexane or paraffins, e.g., petroleum fractions, mineral and vegetable oils; alcohols such as butanol or glycol and their ethers and esters; ketones such as acetone, methyl ethyl ketone, methyl isobutyl ketone, or cyclohexanone; strongly polar solvents such as dimethylformamide and dimethyl sulfoxide; and water.

[0130] The agents according to the invention may additionally contain further components, such as surfactants. Suitable surfactants are emulsifying and / or foam-forming agents, dispersing agents or wetting agents with ionic or non-ionic properties or mixtures of these surfactants. Examples include salts of polyacrylic acid, salts of lignosulphonic acid, salts of phenolsulphonic acid or naphthalenesulphonic acid, polycondensates of ethylene oxide with fatty alcohols or with fatty acids or with fatty amines, substituted phenols (preferably alkylphenols or arylphenols), salts of sulphosuccinic acid esters, taurine derivatives (preferably alkyl taurates), phosphoric acid esters of polyethoxylated alcohols or phenols, fatty acid esters of polyols, and derivatives of compounds containing sulphates, sulphonates and phosphates, e.g.Alkylaryl polyglycol ethers, alkyl sulfonates, alkyl sulfates, aryl sulfonates, protein hydrolysates, lignin sulfite waste liquors, and methylcellulose. The presence of a surfactant is necessary if one of the active ingredients and / or one of the inert carriers is not soluble in water and if the application is carried out in water. The proportion of surfactants is between 5 and 40 percent by weight of the agent according to the invention. Dyes such as inorganic pigments, e.g., iron oxide, titanium oxide, ferrocyanide blue, and organic dyes such as alizarin, azo, and metal phthalocyanine dyes, and trace nutrients such as salts of iron, manganese, boron, copper, cobalt, molybdenum, and zinc may be used.

[0131] Optionally, other additional components may also be included, e.g. protective colloids, binders, adhesives, thickeners, thixotropic substances, penetration enhancers, stabilizers, sequestering agents, complexing agents. In general, the active ingredients can be combined with any solid or liquid additive that is commonly used for formulation purposes. In general, the agents and formulations according to the invention contain between 0.05 and 99% by weight, 0.01 and 98% by weight, preferably between 0.1 and 95% by weight, particularly preferably between 0.5 and 90% active ingredient, very particularly preferably between 10 and 70% by weight. The active ingredients or agents according to the invention can be used as such or, depending on their respective physical and / or chemical properties, in the form of their formulations or the application forms prepared therefrom, such as aerosols, capsule suspensions, cold mist concentrates, hot mist concentrates, encapsulated granules,Fine granules, flowable concentrates for seed treatment, ready-to-use solutions, dustable powders, emulsifiable concentrates, oil-in-water emulsions, water-in-oil emulsions, macrogranules, microgranules, oil-dispersible powders, oil-miscible flowable concentrates, oil-miscible liquids, foams, pastes, pesticide-coated seeds, suspension concentrates, suspension-emulsion concentrates, soluble concentrates, suspensions, wettable powders, soluble powders, dusts and granules, water-soluble granules or tablets, water-soluble powders for seed treatment, wettable powders, active ingredient-impregnated natural and synthetic substances as well as ultrafine encapsulations in polymeric materials and in seed coatings, as well as ULV cold and warm fog formulations.

[0132] The formulations mentioned can be prepared in a manner known per se, e.g. by mixing the active ingredients with at least one conventional extender, solvent or diluent, emulsifier, dispersant and / or binder or fixing agent, wetting agent, water repellent, optionally siccatives and UV stabilizers and optionally dyes and pigments, defoamers, preservatives, secondary thickeners, adhesives, gibberellins and other processing aids.

[0133] The agents according to the invention include not only formulations which are already ready for use and can be applied to the plant or seed using suitable equipment, but also commercial concentrates which must be diluted with water before use.

[0134] The active ingredients according to the invention can be present as such or in their (commercially available) formulations as well as in the application forms prepared from these formulations in a mixture with other (known) active ingredients, such as insecticides, attractants, sterilants, bactericides, acaricides, nematicides, fungicides, growth regulators, herbicides, fertilizers, safeners or semiochemicals.

[0135] The treatment of the plants and plant parts with the active ingredients or agents according to the invention takes place directly or by acting on their environment, habitat or storage space according to the usual treatment methods, e.g. by dipping, spraying, atomizing, sprinkling, evaporating, atomizing, misting, scattering, foaming, coating, spreading, watering (drenching), drip irrigation and, in the case of propagation material, in particular seeds, furthermore by dry dressing, wet dressing, slurry dressing, encrusting, single- or multi-layer coating, etc. It is also possible to apply the active ingredients according to the ultra-low-volume method or to inject the active ingredient preparation or the active ingredient itself into the soil.

[0136] As also described further below, the treatment of transgenic seed with the active ingredients or compositions according to the invention is of particular importance. This relates to the seed of plants that contain at least one heterologous gene that enables the expression of a polypeptide or protein with insecticidal properties. The heterologous gene in transgenic seed can originate, for example, from microorganisms of the species Bacillus, Rhizobium, Pseudomonas, Serratia, Trichoderma, Clavibacter, Glomus or Gliocladium. This heterologous gene preferably originates from Bacillus sp., the gene product having an effect against the European corn borer and / or Western corn rootworm. The heterologous gene particularly preferably originates from Bacillus thuringiensis.

[0137] In the context of the present invention, the agent according to the invention is applied to the seed alone or in a suitable formulation. The seed is preferably treated in a state which is so stable that no damage occurs during treatment. In general, the seed can be treated at any time between harvest and sowing. Typically, seed is used which has been separated from the plant and freed from the cob, husks, stems, hull, wool or fruit pulp. For example, seed can be used which has been harvested, cleaned and dried to a moisture content of less than 15% by weight. Alternatively, seed can be used which has been treated with water, for example, and then dried again after drying.

[0138] In general, when treating seeds, care must be taken to ensure that the amount of the agent according to the invention and / or other additives applied to the seeds is selected so that seed germination is not impaired or the resulting plant is not damaged. This is especially important for active ingredients that can exhibit phytotoxic effects at certain application rates.

[0139] The compositions according to the invention can be applied directly, i.e., without containing any further components and without dilution. As a rule, it is preferable to apply the compositions to the seed in the form of a suitable formulation. Suitable formulations and methods for seed treatment are known to the person skilled in the art and are described, for example, in the following documents: US 4,272,417 A, US 4,245,432 A, US 4,808,430, US 5,876,739, US 2003 / 0176428 A1, WO 2002 / 080675 A1, WO 2002 / 028186 A2.

[0140] The active ingredients according to the invention can be converted into the usual seed dressing formulations, such as solutions, emulsions, suspensions, powders, foams, slurries or other coating compositions for seeds, as well as ULV formulations.

[0141] These formulations are prepared in a known manner by mixing the active ingredients with conventional additives, such as conventional extenders as well as solvents or diluents, dyes, wetting agents, dispersants, emulsifiers, defoamers, preservatives, secondary thickeners, adhesives, gibberellins and also water.

[0142] All dyes commonly used for such purposes are suitable as dyes that can be included in the mordant formulations used according to the invention. Both sparingly water-soluble pigments and water-soluble dyes can be used. Examples include the dyes known as Rhodamine B, CI Pigment Red 112, and CI Solvent Red 1.

[0143] Suitable wetting agents for use in the seed dressing formulations according to the invention include all wetting-promoting substances commonly used in the formulation of agrochemical active ingredients. Alkyl naphthalene sulfonates, such as diisopropyl or diisobutyl naphthalene sulfonates, are preferred.

[0144] Suitable dispersants and / or emulsifiers that can be present in the seed dressing formulations used according to the invention include all nonionic, anionic, and cationic dispersants commonly used for formulating agrochemical active ingredients. Nonionic or anionic dispersants or mixtures of nonionic or anionic dispersants are preferably used. Suitable nonionic dispersants include, in particular, ethylene oxide-propylene oxide block polymers, alkylphenol polyglycol ethers, and tristyrylphenol polyglycol ethers and their phosphated or sulfated derivatives. Suitable anionic dispersants include, in particular, ligninsulfonates, polyacrylic acid salts, and arylsulfonate-formaldehyde condensates.

[0145] Defoamers used in the seed dressing formulations according to the invention can include any foam-inhibiting substances commonly used in the formulation of agrochemical active ingredients. Silicone defoamers and magnesium stearate are preferred.

[0146] All substances used for such purposes in agrochemicals can be present as preservatives in the seed dressing formulations used according to the invention. Examples include dichlorophene and benzyl alcohol hemiformal.

[0147] Suitable secondary thickeners for use in the seed dressing formulations according to the invention include all substances suitable for such purposes in agrochemicals. Cellulose derivatives, acrylic acid derivatives, xanthan gum, modified clays, and highly dispersed silica are preferred.

[0148] Suitable adhesives for use in the mordant formulations according to the invention include all conventional binders used in mordants. Polyvinylpyrrolidone, polyvinyl acetate, polyvinyl alcohol, and Tylose are preferred.

[0149] The seed dressing formulations usable according to the invention can be used either directly or after prior dilution with water to treat a wide variety of seeds, including seeds of transgenic plants. Additional synergistic effects may also occur in conjunction with the substances formed by expression.

[0150] All mixing devices commonly used for seed dressing can be used to treat seed with the seed dressing formulations used according to the invention or with the preparations prepared from them by adding water. The procedure for seed dressing is as follows: the seed is placed in a mixer, the desired amount of seed dressing formulation is added, either as such or after prior dilution with water, and the mixture is mixed until the formulation is evenly distributed over the seed. A drying process follows if necessary.

[0151] The active ingredients according to the invention are suitable for protecting plants and plant organs, increasing crop yields, and improving harvest quality, with good plant tolerance, favorable warm-blooded toxicity, and good environmental compatibility. They can preferably be used as plant protection products. They are effective against normally sensitive and resistant species, as well as against all or individual developmental stages.

[0152] The following main crops may be mentioned as plants which can be treated according to the invention: maize, soybeans, cotton, Brassica oilseeds such as Brassica napus (e.g. canola), Brassica rapa, B. juncea (e.g. (field) mustard) and Brassica carinata, rice, wheat, sugar beet, sugar cane, oats, rye, barley, millet, triticale, flax, wine and various fruits and vegetables from different botanical taxa such as Rosaceae sp. (e.g. pome fruits such as apples and pears, but also stone fruits such as apricots, cherries, almonds and peaches and berries such as strawberries), Ribesioidae sp., Juglandaceae sp., Betulaceae sp., Anacardiaceae sp., Fagaceae sp., Moraceae sp., Oleaceae sp., Actinidaceae sp., Lauraceae sp., Musaceae sp. (e.g. banana trees and plantations), Rubiaceae sp. (e.g. coffee), Theaceae sp., Sterculiceae sp., Rutaceae sp. (e.g. lemons, oranges and grapefruit); Solanaceae sp.(e.g. tomatoes, potatoes, peppers, eggplants), Liliaceae sp., Compositae sp. (e.g. lettuce, artichoke and chicory - including root chicory, endive or common chicory), Umbelliferae sp. (e.g. carrot, parsley, celery and celeriac), Cucurbitaceae sp. (e.g. cucumber - including gherkin, pumpkin, watermelon, gourd and melons), Alliaceae sp. (e.g. leeks and onions), Cruciferae sp. (e.g. white cabbage, red cabbage, broccoli, cauliflower, Brussels sprouts, pak choi, kohlrabi, radishes, horseradish, cress and Chinese cabbage), Leguminosae sp. (e.g. peanuts, peas and beans - such as runner beans and broad beans), Chenopodiaceae sp. (e.g. chard, fodder beet, spinach, beetroot), Malvaceae (e.g. okra), Asparagaceae (e.g. asparagus); crops and ornamental plants in gardens and forests; as well as genetically modified species of these plants.

[0153] As mentioned above, all plants and their parts can be treated according to the invention. In a preferred embodiment, plant species and plant varieties, as well as parts thereof, that occur in the wild or that have been obtained by conventional biological breeding methods, such as crossing or protoplast fusion, are treated. In a further preferred embodiment, transgenic plants and plant varieties obtained by genetic engineering methods, optionally in combination with conventional methods (genetically modified organisms), and their parts are treated. The term "parts" or "parts of plants" or "plant parts" has been explained above. Particularly preferably, plants of the respective commercially available or currently used plant varieties are treated according to the invention. Plant varieties are understood to be plants with new properties ("traits") that have been bred either by conventional breeding, mutagenesis, or recombinant DNA techniques.These can be varieties, breeds, biotypes and genotypes.

[0154] The treatment method according to the invention can be used for the treatment of genetically modified organisms (GMOs), e.g., plants or seeds. Genetically modified plants (or transgenic plants) are plants in which a heterologous gene has been stably integrated into the genome. The term "heterologous gene" essentially means a gene that is provided or assembled outside the plant and that, upon introduction into the nuclear genome, the chloroplast genome, or the mitochondrial genome of the transformed plant, confers new or improved agronomic or other traits by expressing a protein or polypeptide of interest, or by downregulating or silencing another gene(s) present in the plant (for example, by means of antisense technology, cosuppression technology, or RNAi [RNA interference] technology).A heterologous gene present in the genome is also called a transgene. A transgene defined by its specific presence in the plant genome is called a transformation or transgenic event.

[0155] Depending on the plant species or plant varieties, their location and their growth conditions (soil, climate, growing season, nutrition), the treatment according to the invention can also lead to superadditive ("synergistic") effects.For example, the following effects are possible which go beyond the effects actually expected: reduced application rates and / or extended spectrum of action and / or increased efficacy of the active ingredients and compositions which can be used according to the invention, better plant growth, increased tolerance to high or low temperatures, increased tolerance to drought or water or soil salinity, increased flowering performance, easier harvesting, accelerated ripening, higher yields, larger fruits, greater plant height, more intense green leaf colour, earlier flowering, higher quality and / or higher nutritional value of the harvested products, higher sugar concentration in the fruits, better storability and / or processability of the harvested products.

[0156] Plants and plant varieties which are preferably treated according to the invention include all plants which have genetic material which confers particularly advantageous, useful traits on these plants (irrespective of whether this has been achieved by breeding and / or biotechnology).

[0157] Examples of nematode-resistant plants are described in the following US patent applications: 11 / 765,491, 11 / 765,494, 10 / 926,819, 10 / 782,020, 12 / 032,479, 10 / 783,417, 10 / 782,096, 11 / 657,964, 12 / 192,904, 11 / 396,808, 12 / 166,253, 12 / 166,239, 12 / 166,124, 12 / 166,209, 11 / 762,886, 12 / 364,335, 11 / 763,947, 12 / 252,453, 12 / 209,354, 12 / 491,396 and 12 / 497,221.

[0158] Plants that can be treated according to the invention are hybrid plants that already express the traits of heterosis or the hybrid effect, which generally leads to higher yield, higher vigor, better health, and better resistance to biotic and abiotic stresses. Such plants are typically produced by crossing one inbred male-sterile parent line (the female crossing partner) with another inbred male-fertile parent line (the male crossing partner). The hybrid seed is typically harvested from the male-sterile plants and sold to propagators. Male-sterile plants can sometimes (e.g., in maize) be produced by defatting (i.e., mechanical removal of the male sex organs or male flowers); however, it is more common for male sterility to be due to genetic determinants in the plant genome.In this case, especially when the desired product is the seeds, since one intends to harvest from the hybrid plants, it is usually beneficial to ensure that pollen fertility is fully restored in hybrid plants containing the genetic determinants responsible for pollen sterility. This can be achieved by ensuring that the male crossing partners possess appropriate fertility restorer genes capable of restoring pollen fertility in hybrid plants containing the genetic determinants responsible for pollen sterility. Genetic determinants for pollen sterility can be localized in the cytoplasm. Examples of cytoplasmic pollen sterility (CMS) have been described for Brassica species, for example. However, genetic determinants for pollen sterility can also be located in the nuclear genome.Male-sterile plants can also be obtained using plant biotechnology methods, such as genetic engineering. A particularly advantageous method for producing male-sterile plants is described in WO 89 / 10396, in which, for example, a ribonuclease such as barnase is selectively expressed in the tapetum cells in the stamens. Fertility can then be restored by expressing a ribonuclease inhibitor such as barstar in the tapetum cells.

[0159] Plants or plant varieties (obtained by plant biotechnology methods, such as genetic engineering) that can be treated according to the invention are herbicide-tolerant plants, i.e., plants that have been rendered tolerant to one or more given herbicides. Such plants can be obtained either by genetic transformation or by selection of plants containing a mutation conferring such herbicide tolerance.

[0160] Herbicide-tolerant plants include, for example, glyphosate-tolerant plants, i.e., plants that have been rendered tolerant to the herbicide glyphosate or its salts. Plants can be rendered tolerant to glyphosate using various methods. For example, glyphosate-tolerant plants can be obtained by transforming the plant with a gene encoding the enzyme 5-enolpyruvylshikimate 3-phosphate synthase (EPSPS). Examples of such EPSPS genes are the AroA gene (mutant CT7) of the bacterium Salmonella typhimurium (Comai et al., 1983, Science 221, 370-371), the CP4 gene of the bacterium Agrobacterium sp. (Barry et al., 1992, Curr. Topics Plant Physiol. 7, 139-145), the genes encoding an EPSPS from petunia (Shah et al., 1986, Science 233, 478-481), an EPSPS from tomato (Gasser et al., 1988, J. Biol. Chem. 263, 4280-4289), or an EPSPS from eleusine (WO 01 / 66704). It may also be a mutated EPSPS.Glyphosate-tolerant plants can also be obtained by expressing a gene encoding a glyphosate oxidoreductase enzyme. Glyphosate-tolerant plants can also be obtained by expressing a gene encoding a glyphosate acetyltransferase enzyme. Glyphosate-tolerant plants can also be obtained by selecting plants containing naturally occurring mutations of the above-mentioned genes. Plants expressing EPSPS genes, which confer glyphosate tolerance, have been described. Plants expressing other genes conferring glyphosate tolerance, such as decarboxylase genes, have been described.

[0161] Other herbicide-resistant plants include plants that have been rendered tolerant to herbicides that inhibit the enzyme glutamine synthase, such as bialaphos, phosphinotricin, or glufosinate. Such plants can be obtained by expressing an enzyme that detoxifies the herbicide or a mutant of the enzyme glutamine synthase that is resistant to inhibition. One such effective detoxifying enzyme is an enzyme that encodes a phosphinotricin acetyltransferase (such as the bar or pat protein from Streptomyces species). Plants that express an exogenous phosphinotricin acetyltransferase have been described. Other herbicide-tolerant plants also include plants that have been rendered tolerant to herbicides that inhibit the enzyme hydroxyphenylpyruvate dioxygenase (HPPD).Hydroxyphenylpyruvate dioxygenases are enzymes that catalyze the reaction in which para-hydroxyphenylpyruvate (HPP) is converted to homogentisate. Plants tolerant to HPPD inhibitors can be transformed with a gene encoding a naturally occurring resistant HPPD enzyme or a gene encoding a mutated or chimeric HPPD enzyme, as described in WO 96 / 38567, WO 99 / 24585, WO 99 / 24586, WO 2009 / 144079, WO 2002 / 046387, or US Pat. No. 6,768,044. Tolerance to HPPD inhibitors can also be achieved by transforming plants with genes encoding certain enzymes that enable the formation of homogentisate despite inhibition of the native HPPD enzyme by the HPPD inhibitor. Such plants are described in WO 99 / 34008 and WO 02 / 36787.Plant tolerance to HPPD inhibitors can also be improved by transforming plants with a gene encoding a prephenate dehydrogenase enzyme in addition to a gene encoding an HPPD-tolerant enzyme, as described in WO 2004 / 024928. Furthermore, plants can be made even more tolerant to HPPD inhibitors by inserting a gene encoding an enzyme that metabolizes or degrades HPPD inhibitors, such as CYP450 enzymes (see WO 2007 / 103567 and WO 2008 / 150473).

[0162] Other herbicide-resistant plants are those that have been rendered tolerant to acetolactate synthase (ALS) inhibitors. Known ALS inhibitors include, for example, sulfonylurea, imidazolinone, triazolopyrimidines, pyrimidinyloxy(thio)benzoates, and / or sulfonylaminocarbonyltriazolinone herbicides. Various mutations in the enzyme ALS (also known as acetohydroxyacid synthase, AHAS) are known to confer tolerance to different herbicides or groups of herbicides, as described, for example, in Tranel and Wright (Weed Science 2002, 50, 700-712). The production of sulfonylurea-tolerant and imidazolinone-tolerant plants has been described. Other sulfonylurea- and imidazolinone-tolerant plants have also been described.

[0163] Other plants tolerant to imidazolinones and / or sulfonylureas can be obtained by induced mutagenesis, selection in cell cultures in the presence of the herbicide or by mutation breeding (see, for example, for soybean US 5,084,082, for rice WO 97 / 41218, for sugar beet US 5,773,702 and WO 99 / 057965, for lettuce US 5,198,599 or for sunflower WO 01 / 065922).

[0164] Plants or plant varieties (obtained by plant biotechnology methods, such as genetic engineering) that can also be treated according to the invention are tolerant to abiotic stress factors. Such plants can be obtained by genetic transformation or by selecting plants containing a mutation that confers such stress resistance. Particularly useful plants with stress tolerance include the following: a. Plants containing a transgene capable of reducing the expression and / or activity of the gene encoding poly(ADP-ribose) polymerase (PARP) in the plant cells or plants. b. Plants containing a stress-tolerance-promoting transgene capable of reducing the expression and / or activity of the PARG-encoding genes in the plants or plant cells; c. Plants containing a stress-tolerance-promoting transgene encoding an enzyme of the nicotinamide adenine dinucleotide salvage biosynthesis pathway functional in plants, including nicotinamidase, nicotinate phosphoribosyltransferase, nicotinic acid mononucleotide adenyltransferase, nicotinamide adenine dinucleotide synthetase, or nicotinamide phosphoribosyltransferase.

[0165] Plants or plant varieties (obtained by methods of plant biotechnology, such as genetic engineering) which can also be treated according to the invention have an altered quantity, quality and / or storability of the harvested product and / or altered properties of certain components of the harvested product, such as: 1) Transgenic plants that synthesize a modified starch whose chemical-physical properties, in particular the amylose content or amylose / amylopectin ratio, degree of branching, average chain length, side-chain distribution, viscosity behavior, gel strength, starch grain size, and / or starch grain morphology, are altered compared to the synthesized starch in wild-type plant cells or plants, making this modified starch more suitable for specific applications. 2) Transgenic plants that synthesize non-starch carbohydrate polymers, or non-starch carbohydrate polymers whose properties are altered compared to wild-type plants without genetic modification.Examples include plants that produce polyfructose, particularly of the inulin and levan types, plants that produce alpha-1,4-glucans, plants that produce alpha-1,6-branched alpha-1,4-glucans, and plants that produce alternan. 3) Transgenic plants that produce hyaluronan. 4) Transgenic plants or hybrid plants such as onions with specific traits such as high soluble solids content ('high soluble solids content'), low pungency ('low pungency', LP), and / or long storage ('long storage', LS).

[0166] Plants or plant varieties (obtained by plant biotechnology methods, such as genetic engineering) that can also be treated according to the invention are plants, such as cotton plants, with modified fiber properties. Such plants can be obtained by genetic transformation or by selecting plants containing a mutation that confers such modified fiber properties; these include: a) Plants such as cotton plants that contain an altered form of cellulose synthase genes, b) Plants such as cotton plants that contain an altered form of rsw2- or rsw3-homologous nucleic acids, such as cotton plants with increased expression of sucrose phosphate synthase; c) Plants such as cotton plants with increased expression of sucrose synthase; d) Plants such as cotton plants in which the timing of gate regulation of the plasmodesmata at the base of the fiber cell is altered, e.g. by downregulation of fiber-selective β-1,3-glucanase; e) Plants such as cotton plants with fibers with altered reactivity, e.g. by expression of the N-acetylglucosamine transferase gene, including nodC, and chitin synthase genes.

[0167] Plants or plant varieties (obtained by plant biotechnology methods, such as genetic engineering) that can also be treated according to the invention are plants such as rapeseed or related Brassica plants with altered oil composition properties. Such plants can be obtained by genetic transformation or by selection of plants containing a mutation conferring such altered oil properties; these include: a) Plants such as rapeseed that produce oil with a high oleic acid content; b) Plants such as rapeseed that produce oil with a low linoleic acid content. c) Plants such as rapeseed that produce oil with a low saturated fatty acid content.

[0168] Plants or plant varieties (which can be obtained by methods of plant biotechnology, such as genetic engineering) which can also be treated according to the invention are plants such as potatoes which are virus-resistant, e.g. against potato virus Y (Event SY230 and SY233 from Tecnoplant, Argentina), or which are resistant to diseases such as potato late blight (e.g. RB gene), or which show reduced cold-induced sweetness (which carry the genes Nt-Inh, II-INV) or which show the dwarf phenotype (gene A-20 oxidase).

[0169] Plants or plant varieties (obtained by plant biotechnology methods, such as genetic engineering) that can also be treated according to the invention are plants such as rapeseed or related Brassica plants with altered seed shattering characteristics. Such plants can be obtained by genetic transformation or by selecting plants containing a mutation conferring such altered characteristics, and include plants such as rapeseed with delayed or reduced seed shattering.

[0170] Particularly useful transgenic plants that can be treated according to the invention are plants with transformation events or combinations of transformation events that are subject to granted or pending petitions for non-regulated status with the Animal and Plant Health Inspection Service (APHIS) of the United States Department of Agriculture (USDA) in the USA. Information on this is available at any time from APHIS (4700 River Road, Riverdale, MD 20737, USA), e.g., via the website http: / / www.aphis.usda.gov / brs / not_reg.html. On the filing date of this application, petitions with the following information were either granted or pending with APHIS: Petition: Identification number of the petition. The technical description of the transformation event can be found in the individual petition document available from APHIS on the website using the petition number. These descriptions are hereby incorporated by reference. Petition Extension: Reference to a previous petition for which an extension or extension is requested. Institution: Name of the person submitting the petition. Regulated Item: The affected plant species. Transgenic Phenotype: The trait conferred on the plant by the transformation event. Transformation Event or Line: The name of the event(s) (sometimes called line(s)) for which non-regulated status is requested. APHIS Documents: Various documents published by APHIS regarding the petition or available from APHIS upon request.

[0171] Particularly useful transgenic plants which can be treated according to the invention are plants having one or more genes encoding one or more toxins, are the transgenic plants which are offered under the following trade names: YIELD GARD ®< (for example maize, cotton, soybeans), KnockOut ®< (for example maize), BiteGard ®< (for example maize), BT-Xtra ®< (for example maize), StarLink ®< (for example maize), Bollgard ®< (cotton), Nucotn ®< (cotton), Nucotn 33B ®< (cotton), NatureGard ®< (for example maize), Protecta ®< and NewLeaf ®< (potato).Herbicide-tolerant crops worth mentioning include corn, cotton, and soybean varieties marketed under the following trade names: Roundup Ready® (glyphosate tolerance, e.g., corn, cotton, soybean), Liberty Link® (phosphinothricin tolerance, e.g., canola), IMI® (imidazolinone tolerance), and SCS® (sulfonylurea tolerance), e.g., corn. Herbicide-resistant crops (plants traditionally bred for herbicide tolerance) worth mentioning include varieties marketed under the name Clearfield® (e.g., corn).

[0172] The following examples illustrate the present invention. EXAMPLES

[0173] The present invention is explained in more detail with reference to the following examples, which, however, do not limit the invention in any way. A. Synthesis examples Methyl-(2R)-2-{[4-brom-1-(3-fluorpyridin-2-yl)-5-(6-fluorpyridin-3-yl)-1H-pyrazol-3-yl]oxy}propanoat (1-05)

[0174] N'-(3-Fluoropyridin-2-yl)-3-(6-methylpyridin-3-yl)prop-2-ynehydrazide: 6.6 g (10.38 mmol) of a 50% propanephosphonic anhydride solution in THF is added dropwise to a solution of 1.27 g (6.92 mmol) of 3-(6-fluoropyridin-3-yl)prop-2-ynoic acid, 1.32 g (10.38 mmol) of 2-fluoro-6-hydrazinopyridine, and 3.5 g (34.61 mmol) of triethylamine in 72 ml of THF. The mixture is stirred at room temperature for one hour. For workup, H2O is added, the organic phase is separated, and the aqueous phase is extracted several times with CH2Cl2. The combined organic phase is dried over Na2SO4 and concentrated. 2.25 g (95%) of crude product is obtained, which is used for the next reaction step without further purification.

[0175] 1-(3-Fluoropyridin-2-yl)-5-(6-fluoropyridin-3-yl)-1H-pyrazol-3-ol: A solution of 2.23 g (6.50 mmol) of N'-(3-fluoropyridin-2-yl)-3-(6-methylpyridin-3-yl)prop-2-ynehydrazide in 10 ml of CH 2 Cl 2 and 3 ml of DMF is treated with 99 mg (0.52 mmol) of CuI and stirred at 80 °C for one hour. The mixture is then filtered and concentrated, and the crude product is purified by column chromatography on silica gel using heptane / ethyl acetate (3:7). This yields 0.95 g (53%) of product as a solid.

[0176] 1< H-NMR (400MHz, DMSO-d 6 ): δ 6.25 (bs, 1H), 7.15 (d, 1H), 7.50 (bs, 1H), 7.78 (m, 1H), 7.95 (m, 1H), 8.10 (s, 1H), 8.20 (bs, 1H).

[0177] Methyl (2R)-2-{[1-(3-fluoropyridin-2-yl)-5-(6-fluoropyridin-3-yl)-1H-pyrazol-3-yl]oxy}propanoate: A solution of 0.34 g (1.25 mmol) of 1-(3-fluoropyridin-2-yl)-5-(6-fluoropyridin-3-yl)-1H-pyrazol-3-ol in 10 ml of DMF is treated successively with 0.61 g (1.87 mmol) of C 2 CO 3 and 0.18 g (1.50 mmol) of methyl (2S)-2-chloropropanoate and then stirred for 1 hour at 80°C. The reaction mixture is then evaporated to dryness, taken up in H 2 O and extracted several times with CH 2 Cl 2. The organic phase is dried over Na 2 SO 4 and then concentrated. Column chromatographic purification on silica gel with heptane / ethyl acetate (8.2) yields 0.4 g (87%) of product as a colorless oil.

[0178] 1< H-NMR (400 MHz, CDCl 3 ): δ 1.65 (d, 3H), 3.79 (s, 3H), 5.25 (q, 1H), 6.14 (s, 1H), 6.89 (m, 1H), 7.35 (m, 1H), 7.50 (m, 1H), 7.68 (m, 1H), 8.10 (s, 1H), 8.25 (d, 1H).

[0179] Methyl (2R)-2-{[4-bromo-1-(3-fluoropyridin-2-yl)-5-(6-fluoropyridin-3-yl)-1H-pyrazol-3-yl]oxy}propanoate: A solution of 0.38 g (1.05 mmol) of methyl (2R)-2-{[1-(3-fluoropyridin-2-yl)-5-(6-fluoropyridin-3-yl)-1H-pyrazol-3-yl]oxy}propanoate in 4 ml of DMF is treated with 0.22 g (1.26 mmol) of N-bromosuccinimide and stirred for 1 hour at 65°C. The reaction mixture is then poured onto H2O and extracted several times with CH2Cl2. The organic phase is dried over Na 2 SO 4 and concentrated, and the resulting crude product is purified by column chromatography on silica gel using heptane / ethyl acetate (8:2). This yields 0.45 g (95%) of product as a solid.

[0180] 1< H-NMR (400 MHz, CDCl 3 ): δ 1.70 (d, 3H), 3.78 (s, 3H), 5.70 (q, 1H), 6.95 (m, 1H), 7.30 (m, 1H), 7.50 (m, 1H), 7.84 (m, 1H), 8.12 S, 1H), 8.20 (d, 1H). Methyl-(2R)-2-{[4-cyan-1-(3-fluorpyridin-2-yl)-5-(6-fluorpyridin-3-yl)-1H-pyrazol-3-yl]oxy}propanoat (1-06)

[0181] Under argon, a mixture of 0.17 g (0.40 mmol) of methyl (2R)-2-{[4-bromo-1-(3-fluoropyridin-2-yl)-5-(6-fluoropyridin-3-yl)-1H-pyrazol-3-yl]oxy}propanoate, 0.045 g (0.38 mmol) of Zn(CN) 2 , and 0.046 g (0.040 mmol) of tetrakis(triphenylphosphine)palladium is placed in a heated MW vial, and 5 ml of N,N-dimethlacetamide is added. The vial is degassed, blanketed with argon, and the reaction mixture is stirred in a microwave oven at 180°C for 40 minutes. The reaction mixture is then concentrated, taken up in H 2 O, and extracted several times with CH 2 Cl 2 . The organic phase is dried over Na 2 SO 4 and concentrated, and the resulting crude product is purified by column chromatography on silica gel using heptane / ethyl acetate (8:2). This yields 0.082 g (52%) of product as a solid.

[0182] 1< H-NMR (400 MHz, CDCl 3 ): δ 1.70 (d, 3H), 3.79 (s, 3H), 5.77 (q, 1H), 7.00 (m, 1H), 7.45 (m, 1H), 7.68 (m, 1H), 7.92 (m, 1H), 8.12 (s, 1H), 8.29 (d, 1H). Methyl (2R)-2-{[4-chloro-5-(2-fluoropyridin-4-yl)-1-(pyridin-2-yl)-1H-pyrazol-3-yl]oxy}propanoate (..) and (2R)-2-{[4-Chloro-5-(2-fluoropyridin-4-yl)-1-(pyridin-2-yl)-1H-pyrazol-3-yl]oxy}propanoic acid (..) 5-Amino-4-chloro-1-(pyridin-2-yl)-1H-pyrazole-3-ol:

[0183] 1.10 g (12.48 mmol) of N-chlorosuccinimide is added portionwise to a solution of 2 g (11.35 mmol) of 5-amino-1-(pyridin-2-yl)-1H-pyrazol-3-ol in 80 ml of DMF. The reaction mixture is stirred at 50°C for 5 hours and then allowed to stand at room temperature for 12 hours. After addition of 80 ml of H 2 O and 60 ml of CH 2 Cl 2, the product precipitates as a solid. Filtration and drying under vacuum yields 1.43 g (60%) of product as a solid.

[0184] 1< H-NMR (400 MHz, DMSO-d 6 ): δ 7.10 (bs, 2H, NH2), 7.20 (dd, 1H), 7.55 (d, 1H), 7.90 (dd, 1H), 8.46 (d, 1H). Methyl (2R)-2-{[5-amino-4-chloro-1-(pyridin-2-yl)-1H-pyrazol-3-yl]oxy}propanoate:

[0185] To a solution of 1.4 g (6.64 mmol) of 5-amino-4-chloro-1-(pyridin-2-yl)-1H-pyrazol-3-ol is added 3.25 g (9.98 mmol) of C2CO3, and the mixture is stirred at room temperature for 10 minutes. After addition of 1.20 g (7.97 mmol) of methyl (2S)-2-chloropropanoate, the reaction mixture is stirred at room temperature for 12 hours. After filtration, the reaction solution is poured onto H2O and extracted several times with CH2Cl2. The organic phase is dried over Na2SO4 and concentrated. 1.56 g (75%) of product is obtained as a solid.

[0186] 1< H-NMR (400 MHz, CDCl 3 ): δ 1.65 (d, 3H), 3.75 (s, 3H), 5.18 (q, 1H), 6.00 (bs, 2H, NH2), 7.04 (dd, 1H), 7.63 (d, 1H), 7.72 (dd, 1H), 8.26 (d, 2H). Methyl (2R)-2-{[4-chloro-5-iodo-1-(pyridin-2-yl)-1H-pyrazol-3-yl]oxy}propanoate

[0187] A solution of 0.30 g (1.01 mmol) of methyl (2R)-2-{[5-amino-4-chloro-1-(pyridin-2-yl)-1H-pyrazol-3-yl]oxy}propanoate in 6 ml of acetonitrile is treated successively with 1.08 g (4.04 mmol) of diiodomethane and 0.23 g (2.02 mmol) of isopentyl nitrite and then stirred for 1 hour at 50°C. The reaction mixture is then poured into H 2 O and extracted several times with CH 2 Cl 2 . The organic phase is dried over Na 2 SO 4 and concentrated, and the crude product is purified by column chromatography on silica gel using heptane / ethyl acetate (1:1). This gives 0.24 g (55%) of product as an oil.

[0188] 1< H-NMR (400 MHz, CDCl 3 ): δ 1.68 (d, 3H), 3.75 (s, 3H), 5.20 (q, 1H), 7.21 (dd, 1H), 7.60 (d, 1H), 7.70 (dd, 1H), 8.45 (d, 1H). (2R)-2-{[4-Chlor-5-(2-fluorpyridin-4-yl)-1-(pyridin-2-yl)-1H-pyrazol-3-yl]oxy}propansäure (I-21):

[0189] Under argon, a mixture of 0.18 g (0.45 mmol) of methyl (2R)-2-{[4-chloro-5-iodo-1-(pyridin-2-yl)-1H-pyrazol-3-yl]oxy}propanoate, 0.16 g (1.13 mmol) of (2-fluoropyridin-4-yl)boronic acid, 0.055 g (0.067 mmol) of PdChdppf, DCM complex, and 0.44 g (1.35 mmol) of C2CO3 in 3 ml of 1,4-dioxane and 0.9 ml of H2O was stirred in a microwave oven at 130°C for 3.5 hours. The reaction mixture was then poured into a saturated aqueous NH4Cl solution and extracted several times with CH2Cl2. The organic phase is dried over Na 2 SO 4 and concentrated, and the resulting crude product is purified by column chromatography on silica gel using heptane / ethyl acetate (1:1). This yields 38 mg (21%) of the methyl ester. Concentration of the aqueous phase and subsequent purification by column chromatography on silica gel using heptane / ethyl acetate (3:7) yields 67 mg (33%) of the carboxylic acid.

[0190] 1< H-NMR (400 MHz, DMSO-d 6 ): δ 1.55 (d, 3H), 5.10 (q, 1H), 7.26 (m, 2H) 7.65 (d, 1H), 7.96 (m, 2H), 8.10 (d, 1H), 8.20 (s, 1H). Ethyl-{[4-brom-5-(2-fluorpyridin-4-yl)-1-(pyridin-2-yl)-1H-pyrazol-3-yl]oxy}acetat (I-01) 2-[3-(Benzyloxy)-1H-pyrazol-1-yl]pyridine:

[0191] A mixture consisting of 5 g (28.70 mmol) of 3-(benzyloxy)-1H-pyrazole, 6.80 g (43.05 mmol) of 2-bromopyridine, 0.77 g (4.02 mmol) of CuI, and 13.09 g (40.18 mmol) of Cs2CO3 in 40 ml of DMF is stirred for 5 hours under argon at 100°C. The reaction mixture is then filtered through kieselguhr, added to H2O, and extracted several times with CH2Cl2. The organic phase is dried over Na2SO4, concentrated, and the crude product is purified by column chromatography on silica gel using heptane / ethyl acetate (1:1). This gives 6.65 g (92%) of product as a solid.

[0192] 1< H-NMR (400 MHz, CDCl 3 ): δ 5.31 (s, 2H), 5.95 (s, 1H), 7.10 (dd, 1H), 7.35 (m, 3H), 7.50 (m, 2H), 7.75 (m, 1H), 7.80 (d, 1H), 8.35 (d, 1H), 8.40 (s, 1H). 2-[3-(Benzyloxy)-5-iodo-1H-pyrazol-1-yl]pyridine:

[0193] A solution of 4.70 g (18.70 mmol) of 2-[3-(benzyloxy)-1H-pyrazol-1-yl]pyridine in 130 ml of THF is added dropwise at -78°C under argon to a solution of 31.80 mmol of LDA in 140 ml of THF, and the mixture is stirred for a further 1.5 hours at -78°C. A solution of 7.6 g (30.00 mmol) of iodine in 130 ml of THF is then added dropwise to the reaction mixture, and the reaction mixture is stirred for a further 2 hours at -78°C before being allowed to warm to room temperature. The reaction mixture is then added to H2O and extracted several times with CH2Cl2. The organic phase is dried over Na2SO4 and concentrated, and the crude product is purified by column chromatography on silica gel using heptane / ethyl acetate (8:2). In this way, 3.83 g (54%) of product is obtained as oil.

[0194] 1< H-NMR (400 MHz, CDCl 3 ): δ 5.29 (s, 2H), 6.20 (s, 1H), 7.25 (m, 1H), 7.24 (m, 1H), 7.38 (m, 2H), 7.45 (m, 1H), 7.73 (d, 1H), 8.50 (s, 1H).

[0195] 4-[3-(Benzyloxy)-1-(pyridin-2-yl)-1H-pyrazol-5-yl]-2-fluoropyridine: To a solution of 0.50 g (1.32 mmol) of 2-[3-(benzyloxy)-5-iodo-1H-pyrazol-1-yl]pyridine in 8 ml of 1,4-dioxane, 0.65 g (2.91 mmol) of 2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine, 0.86 g (2.65 mmol) of Cs 2 CO 3 , 13 mg (0.066 mmol) of CuI, 1 ml of H 2 O and 77 mg (0.066 mmol) of tetrakis(triphenylphosphine)palladium(0) are added successively under argon. This mixture is stirred for 3.5 hours at 70°C and then allowed to stand overnight. After filtration, the reaction solution is concentrated, and the crude mixture is purified by column chromatography on silica gel using heptane / ethyl acetate (7:3). This yields 0.32 g (69%) of product as a solid.

[0196] 1-H NMR (400 MHz, CDCl3) d 5.35 (s, 1H), 6.10 (s, 1H), 6.85 (s, 1H), 7.08 (d, 1H), 7.20 (m, 1H), 7.40 (m, 3H) 7.50 (m, 2H), 7.70 (d, 1H), 7.82, (m, 1H), 8.20 (m, 2H), 8.40 (d, 1H).

[0197] 5-(2-Fluoropyridin-4-yl)-1-(pyridin-2-yl)-1H-pyrazol-3-ol: A solution of 0.44 g (0.63 mmol) of 5-(2-fluoropyridin-4-yl)-1-(pyridin-2-yl)-1H-pyrazol-3-ol in 18 ml of toluene is treated with 37 g (324.5 mmol) of trifluoroacetic acid (dried over a molecular sieve). The mixture is then stirred at 50°C for 3.5 hours and left to stand overnight at room temperature. A further 3 ml of trifluoroacetic acid is then added, and the mixture is stirred at 50°C for a further 3 hours. After filtration, the reaction solution is concentrated, and the crude product is purified by column chromatography on silica gel using heptane / ethyl acetate (1:1). The resulting mixture contains 50% product and is used in the next reaction step without further purification.

[0198] Ethyl {[5-(2-fluoropyridin-4-yl)-1-(pyridin-2-yl)-1H-pyrazol-3-yl]oxy} acetate: A solution of 0.07 g (0.273 mmol) of 5-(2-fluoropyridin-4-yl)-1-(pyridin-2-yl)-1H-pyrazol-3-ol in 5.5 ml of acetonitrile is treated with 0.23 g (1.64 mmol) of K 2 CO 3 and stirred at room temperature for 10 minutes. After adding 0.091 g (0.55 mmol) of ethyl bromoacetate, the reaction mixture is stirred under reflux for 5 hours and then left to stand at room temperature overnight. For workup, the mixture is evaporated to dryness, the residue is taken up in H 2 O and extracted several times with CH 2 Cl 2. The organic phase is dried over Na 2 SO 4 and concentrated, and the crude product is purified by column chromatography on silica gel using heptane / ethyl acetate (7:3). 0.036 g (38%) of product is obtained as a solid.

[0199] 1< H-NMR (400 MHz, CDCl 3 ): δ 1.32 (t, 3h), 4.30 (q, 2H), 4.90 (s, 2H), 6.15 (s, 1H), 6.85 (s, 1H), 7.08 (s, 1H), 7.08 (m, 1H), 7.15 (dd, 1H),7.65 (d, 1H), 7.80 dd, 1H), 8.15 (m, 2H).

[0200] Ethyl {[4-bromo-5-(2-fluoropyridin-4-yl)-1-(pyridin-2-yl)-1H-pyrazol-3-yl]oxy}acetate: A solution of 0.036 g (0.105 mmol) of ethyl {[5-(2-fluoropyridin-4-yl)-1-(pyridin-2-yl)-1H-pyrazol-3-yl]oxy}acetate in 0.6 ml of CH 2 Cl 2 is treated with 0.021 g (0.116 mmol) of N-bromosuccinimide and stirred at room temperature for 12 hours. The mixture is then evaporated to dryness, the residue is triturated with diethyl ether and filtered. The ether phase is evaporated, and the resulting crude product is purified over silica gel using heptane / ethyl acetate (1.1). In this way, 0.021 g (47%) of product is obtained as a solid.

[0201] 1< H-NMR (400 MHz, CDCl 3 ): δ 1.30 (t, 3H), 4.70 (q, 2H), 4.95 (s, 2H), 6.93 (6.93 (s, 1H), 7.12 (m, 2H), 7.62 (d, 1H), 7.69 (m, 1H), 8.08 (m, 1H), 8.25 (s, 1H). NMR data of selected examples NMR peak list method

[0202] The 1H NMR data of selected examples are recorded in the form of 1H NMR peak lists. For each signal peak, the δ value in ppm is listed first, followed by the signal intensity in parentheses.

[0203] The δ-value - signal intensity number pairs of different signal peaks are listed separated by semicolons.

[0204] The peak list of an example therefore has the form: δ 1 (intensity 1 )< ; δ 2 (intensity 2 );........; δ i (intensity i )< ;......; δ n (intensity n )

[0205] The intensity of sharp signals correlates with the height of the signals in a printed example of an NMR spectrum in cm and shows the true ratios of the signal intensities. For broad signals, multiple peaks or the center of the signal and their relative intensity compared to the most intense signal in the spectrum can be shown.

[0206] To calibrate the chemical shift of 1H NMR spectra, we use tetramethylsilane and / or the chemical shift of the solvent, especially in the case of spectra measured in DMSO. Therefore, the tetramethylsilane peak may or may not be present in NMR peak lists.

[0207] The lists of 1H NMR peaks are similar to the classical 1H NMR printouts and thus usually contain all peaks listed in a classical NMR interpretation.

[0208] In addition, like classical 1H-NMR printouts, they can show solvent signals, signals of stereoisomers of the target compounds, which are also the subject of the invention, and / or peaks of impurities.

[0209] When reporting compound signals in the delta region of solvents and / or water, our lists of 1H NMR peaks show the common solvent peaks, for example, peaks of DMSO in DMSO-D 6 and the peak of water, which usually have high intensity on average.

[0210] The peaks of stereoisomers of the target compounds and / or peaks of impurities usually have, on average, lower intensity than the peaks of the target compounds (e.g., with a purity of >90%).

[0211] Such stereoisomers and / or impurities may be typical for the respective manufacturing process. Their peaks can thus help identify the reproduction of our manufacturing process based on "byproduct fingerprints."

[0212] An expert who calculates the peaks of the target compounds using known methods (MestreC, ACD simulation, but also empirically evaluated expected values) can isolate the peaks of the target compounds as needed, applying additional intensity filters if necessary. This isolation would be similar to the peak picking involved in classical 1H NMR interpretation.

[0213] Further details on 1H NMR peak lists can be found in the Research Disclosure Database Number 564025. III-17: 1< H-NMR(400.6 MHz, CDCl3): δ= 8.2900 (1.0); 8.2858 (0.8); 8.2838 (1.1); 8.2369 (1.5); 8.2229 (1.5); 7.7967 (0.5); 7.7905 (0.5); 7.7784 (0.6); 7.7756 (0.7); 7.7721 (0.6); 7.7693 (0.6); 7.7572 (0.6); 7.7509 (0.6); 7.2622 (23.5); 7.2472 (1.5); 7.2431 (1.5); 7.2425 (1.5); 7.1074 (0.7); 7.1059 (0.7); 7.0998 (0.7); 7.0984 (0.7); 7.0862 (0.6); 7.0847 (0.7); 7.0786 (0.7); 7.0771 (0.7); 6.8507 (1.2); 6.8457 (1.1); 6.8367 (1.2); 6.8318 (1.2); 5.3008 (2.4); 4.9451 (6.9); 4.4248 (0.5); 4.4071 (0.5); 4.3977 (1.4); 4.3800 (1.5); 4.3691 (1.4); 4.3554 (1.5); 4.3420 (0.6); 4.3283 (0.5); 3.7264 (5.8); 3.6838 (16.0); 2.8442 (0.7); 2.8304 (0.7); 1.5598 (1.0); 1.2166 (6.4); 1.1985 (8.8); 1.1801 (2.8); 0.0080 (0.5); -0.0002 (20.0); -0.0085 (0.6) III-18: 1< H-NMR(400.6 MHz, CDCl3): . δ = 8.2943 (1.2); 8.2920 (0.9); 8.2880 (1.2); 8.2667 (1.9); 8.2527 (2.0); 7.7848 (0.6); 7.7785 (0.6); 7.7664 (0.7); 7.7636 (0.7); 7.7602 (0.7); 7.7574 (0.7); 7.7454 (0.6); 7.7391 (0.6); 7.2730 (2.0); 7.2718 (1.9); 7.2681 (2.3); 7.2669 (2.2); 7.2613 (66.1); 7.2571 (1.1); 7.2547 (0.6); 7.1186 (0.9); 7.1110 (0.9); 7.0974 (1.0); 7.0959 (0.9); 7.0898 (1.2); 6.8962 (1.4); 6.8913 (1.4); 6.8822 (1.4); 6.8773 (1.4); 5.3005 (5.6); 4.8910 (7.1); 4.7277 (0.8); 4.7097 (1.2); 4.6916 (0.8); 3.7897 (16.0); 2.0457 (0.9); 1.5610 (0.8); 1.5155 (6.4); 1.4976 (6.4); 1.2598 (0.8); 0.0080 (1.3); -0.0002 (43.5); -0.0085 (1.2) III-19: 1< H-NMR(400.6 MHz, CDCl3): . δ = 8.2865 (1.7); 8.2806 (1.7); 8.2423 (2.2); 8.2284 (2.2); 7.7914 (0.6); 7.7851 (0.6); 7.7728 (0.9); 7.7702 (1.0); 7.7667 (0.9); 7.7642 (0.9); 7.7518 (0.7); 7.7456 (0.7); 7.2618 (22.0); 7.2373 (2.4); 7.2328 (2.5); 7.1055 (1.1); 7.0987 (1.1); 7.0844 (1.0); 7.0776 (1.0); 6.8606 (1.5); 6.8557 (1.5); 6.8466 (1.5); 6.8417 (1.4); 5.3007 (3.1); 4.9430 (8.9); 4.5290 (2.3); 4.5135 (4.5); 4.4980 (2.3); 3.6977 (16.0); 2.7244 (2.3); 2.7090 (4.5); 2.6934 (2.2); 1.5550 (4.1); 0.0077 (1.0); -0.0002 (18.4); -0.0085 (0.8) III-20: 1< H-NMR(400.0 MHz, CDCl3): . δ= 8.8739 (2.0); 8.3010 (4.7); 8.2871 (7.3); 7.7875 (1.5); 7.7666 (2.3); 7.7485 (1.3); 7.5191 (0.9); 7.2606 (138.6); 7.2459 (5.6); 7.1329 (2.3); 7.1119 (2.3); 6.9969 (1.0); 6.8927 (2.9); 6.8787 (2.6); 5.3001 (6.6); 4.9916 (16.0); 4.3623 (1.9); 4.3410 (5.6); 4.3199 (5.6); 4.2984 (2.1); 3.7009 (1.1); 3.6783 (3.4); 2.3863 (1.1); 2.0480 (1.9); 1.2551 (5.1); 0.8813 (1.0); -0.0002 (86.1) III-21: 1< H-NMR(400.6 MHz, CDCl3): . δ = 8.2761 (1.6); 8,2700 (1.7); 8.2213 (2.2); 8.2074 (2.2); 7.7718 (0.8); 7.7655 (0.8); 7.7533 (1.0); 7.7506 (1.0); 7.7470 (1.0); 7.7444 (1.0); 7.7322 (0.9); 7.7259 (0.9); 7.3382 (2.1); 7.3341 (2.2); 7.2618 (48.0); 7.0931 (1.1); 7.0869 (1.0); 7.0720 (1.1); 7.0657 (0.9); 6.8511 (1.6); 6.8462 (1.6); 6.8371 (1.6); 6.8322 (1.8); 5.3006 (10.2); 5.1282 (8.2); 5.0132 (1.4); 4.1923 (7.1); 4.1629 (1.4); 3.8196 (2.8); 3.7545 (16.0); 3.7263 (1.9); 3.6778 (1.2); 3.1780 (15.4); 3.0640 (2.4); 2.0455 (1.5); 1.5623 (2.7); 1.2775 (0.5); 1.2596 (1.2); 1.1981 (0.9); 1.1800 (0.9); 0.0079 (1.2); -0.0002 (41.9); -0.0085 (1.3) III-22: 1< H-NMR(400.6 MHz, CDCl3): . δ = 8.2716 (1.1); 8.2695 (0.8); 8.2674 (0.9); 8.2653 (1.1); 8.2244 (1.7); 8.2233 (1.7); 8.2104 (1.8); 8,2093 (1.7); 7.7748 (0.6); 7.7685 (0.6); 7.7563 (0.7); 7.7536 (0.7); 7.7501 (0.7); 7.7473 (0.7); 7.7352 (0.6); 7.7289 (0.6); 7.2610 (18.5); 7.2044 (1.7); 7.2033 (1.8); 7.1995 (1.8); 7.1984 (1.7); 7.1034 (0.8); 7.1018 (0.8); 7.0957 (0.8); 7.0942 (0.8); 7.0822 (0.7); 7.0807 (0.8); 7.0746 (0.8); 7.0731 (0.7); 6.8187 (1.6); 6.8138 (1.5); 6.8047 (1.5); 6.7998 (1.5); 5.3003 (4.6); 5.2557 (1.5); 5.2383 (1.5); 3.8171 (16.0); 1.7238 (6.1); 1.7064 (6.0); 1.5446 (5.7); 0.0079 (0.8); -0.0002 (29.6); -0.0044 (0.7); -0.0085 (0.9) III-23: 1< H-NMR(400.6 MHz, d 6 -DMSO): δ= 8.3828 (3.2); 8.3765 (3.4); 8.3304 (5.1); 8.3293 (5.1); 8.3165 (5.3); 8.3153 (5.3); 8.1194 (1.3); 8.1132 (1.3); 8.1000 (1.7); 8.0982 (1.8); 8.0938 (1.7); 8.0920 (1.8); 8.0789 (1.4); 8.0726 (1.4); 7.4231 (1.9); 7.4175 (2.0); 7.4017 (2.0); 7.3962 (1.8); 7.3949 (1.8); 7.3413 (5.0); 7.3402 (5.4); 7.3365 (5.5); 7.3353 (5.0); 7.0466 (4.6); 7.0418 (4.3); 7.0327 (4.5); 7.0278 (4.5); 4.9455 (13.8); 4.0555 (1.0); 4.0377 (3.3); 4.0200 (3.4); 4.0022 (1.1); 3.3197 (14.5); 2.6746 (0.7); 2.6700 (1.0); 2.6654 (0.7); 2.5238 (2.6); 2.5191 (3.6); 2.5104 (53.3); 2.5058 (117.6); 2.5012 (165.8); 2.4966 (113.7); 2.4920 (50.1); 2.3329 (0.7); 2.3282 (1.0); 2.3236 (0.7); 1.9886 (16.0); 1.9084 (6.4); 1.1922 (4.8); 1.1744 (9.8); 1.1566 (4.6); 0.0079 (3.5); 0.0063 (0.8); 0.0055 (0.8); 0.0047 (1.0); 0.0039 (1.5); 0.0030 (2.6); 0.0022 (4.6); -0.0002 (126.0); -0.0027 (5.4); -0.0035 (3.7); -0.0043 (2.2); -0.0052 (1.6); -0.0060 (1.4); -0.0068 (1.2); -0.0085 (3.7); -0.0098 (0.8); -0.0107 (0.6) III-24: 1< H-NMR(400.6 MHz, CDCl3): δ= 8.2774 (2.2); 8.2755 (1.7); 8.2730 (1.8); 8.2712 (2.3); 8.2274 (3.4); 8.2135 (3.5); 7.7848 (1.1); 7.7785 (1.1); 7.7664 (1.2); 7.7637 (1.4); 7.7601 (1.3); 7.7574 (1.3); 7.7453 (1.2); 7.7390 (1.2); 7.2659 (5.4); 7.2566 (3.4); 7.2559 (3.3); 7.2518 (3.7); 7,1090 (1.5); 7,1076 (1.5); 7.1014 (1.6); 7,1000 (1.5); 7.0878 (1.4); 7.0865 (1.4); 7.0802 (1.5); 7.0789 (1.4); 6.8223 (2.7); 6.8174 (2.6); 6.8083 (2.6); 6.8034 (2.6); 5.3015 (10.6); 4.9365 (15.5); 4.3343 (2.0); 4.3165 (6.4); 4.2987 (6.4); 4.2809 (2.1); 1.5976 (1.8); 1.3536 (7.8); 1.3358 (16.0); 1.3180 (7.5); −0.0002 (7.7) II-05: 1< H-NMR(599.6 MHz, CDCl3): δ= 8.1957 (8.6); 8.1880 (8.5); 8.0835 (12.3); 8.0800 (12.8); 7.8348 (4.0); 7.8321 (4.4); 7.8195 (8.3); 7.8069 (4.3); 7.8042 (4.4); 7.7761 (3.9); 7.7721 (4.2); 7.7621 (6.7); 7.7597 (6.7); 7.7497 (4.1); 7.7456 (4.0); 7.2948 (6.5); 7.2866 (6.9); 7.2828 (6.7); 7.2740 (6.0); 7.2628 (23.5); 6.9817 (7.2); 6.9773 (7.4); 6.9676 (6.9); 6.9631 (6.9); 5.1781 (3.4); 5.1665 (10.9); 5.1549 (10.9); 5.1433 (3.4); 4.3424 (0.4); 4.3306 (0.3); 4.2776 (0.5); 4.2656 (1.4); 4.2596 (4.0); 4.2557 (4.8); 4.2477 (11.6); 4.2439 (12.5); 4.2358 (11.9); 4.2321 (12.2); 4.2240 (4.5); 4.2203 (4.1); 4.2140 (1.3); 4.2021 (0.4); 4.1278 (0.4); 4.1158 (0.4); 2.0443 (1.4); 1.6935 (42.5); 1.6819 (42.0); 1.6011 (0.4); 1.5896 (0.6); 1.5719 (39.4); 1.3895 (0.4); 1.3777 (0.8); 1.3660 (0.5); 1.3002 (1.1); 1.2766 (25.3); 1.2647 (50.0); 1.2529 (25.0); 1.2157 (0.3); 1.2037 (0.4); 0.8933 (2.0); 0.8819 (4.4); 0.8699 (2.2); -0.0001 (32.1) II-01: 1< H-NMR(400.0 MHz, CDCl3_5mm): δ= 8.2145 (1.4); 8.2105 (1.9); 8.2070 (1.5); 8.2025 (1.5); 8.1988 (1.9); 8.1949 (1.4); 8.0914 (2.7); 8.0853 (2.7); 7.8801 (1.2); 7.8756 (1.1); 7.8608 (1.5); 7.8568 (2.0); 7.8529 (1.3); 7.8381 (1.2); 7.8335 (1.2); 7.7941 (1.1); 7.7878 (1.1); 7.7754 (1.4); 7.7728 (1.6); 7.7692 (1.5); 7.7666 (1.4); 7.7542 (1.2); 7.7480 (1.1); 7.3180 (1.5); 7.3154 (1.5); 7.3058 (1.5); 7.3032 (1.5); 7.2987 (1.5); 7.2961 (1.4); 7.2866 (1.4); 7.2840 (1.3); 7.2629 (9.8); 6.9946 (1.8); 6.9882 (1.8); 6.9743 (1.6); 6.9733 (1.7); 6.9670 (1.6); 4.8918 (16.0); 4.3018 (2.0); 4.2840 (6.3); 4.2661 (6.4); 4.2483 (2.1); 2.0454 (0.9); 1.5681 (12.7); 1.3140 (7.4); 1.2962 (14.9); 1.2783 (7.6); 1.2596 (1.2); 0.8818 (1.2); 0.0079 (0.6); −0.0002 (13.6); −0.0084 (0.5) II-03: 1< H-NMR(599.6 MHz, CDCl3): δ= 8.2192 (7.4); 8.2115 (7.3); 8.1073 (11.4); 8.1034 (11.3); 7.9010 (3.7); 7.8981 (3.7); 7.8856 (7.1); 7.8730 (3.9); 7.8702 (3.6); 7.7990 (3.6); 7.7949 (3.6); 7.7848 (5.7); 7.7825 (5.5); 7.7725 (3.8); 7.7684 (3.4); 7.3295 (5.8); 7.3212 (6.1); 7.3169 (5.9); 7.3087 (5.3); 7.2638 (14.2); 7.0023 (6.5); 6.9979 (6.5); 6.9881 (6.3); 6.9837 (6.1); 5.9493 (0.3); 5.2999 (12.4); 5.0641 (0.3); 4.9612 (50.0); 2.1801 (2.2); 1.3126 (0.7); 1.3015 (1.4); 1.2897 (1.7); 1.2798 (1.6); 1.2652 (3.6); 0.8932 (3.4); 0.8817 (7.7); 0.8697 (3.7); -0.0001 (17.0) II-36: 1< H-NMR(400.0 MHz, CDCl3_5mm): δ= 8.2050 (0.8); 8.2012 (1.1); 8.1975 (0.9); 8.1930 (0.9); 8.1894 (1.1); 8.1855 (0.8); 8.0862 (1.6); 8.0801 (1.6); 7.8409 (0.6); 7.8363 (0.6); 7.8215 (0.8); 7.8176 (1.2); 7.8137 (0.8); 7.7989 (0.7); 7.7943 (0.7); 7.7831 (0.7); 7.7769 (0.6); 7.7644 (0.8); 7.7619 (0.9); 7.7583 (0.9); 7.7557 (0.8); 7.7433 (0.7); 7.7371 (0.6); 7.3053 (0.8); 7.3027 (0.8); 7.2932 (0.9); 7.2906 (0.9); 7.2861 (0.9); 7.2835 (0.8); 7.2739 (0.8); 7.2713 (0.9); 7.2624 (6.5); 6.9894 (1.0); 6.9884 (1.0); 6.9821 (1.0); 6.9682 (1.0); 6.9672 (1.0); 6.9608 (1.0); 5.2009 (1.7); 5.1834 (1.7); 3.7815 (16.0); 2.0454 (1.1); 1.7016 (6.8); 1.6841 (6.7); 1.5632 (8.5); 1.2773 (0.6); 1.2596 (1.2); 0.8818 (1.0); -0.0002 (9.3) III-01: 1< H-NMR(400.6 MHz, CDCl3): . δ= 8.2767 (2.0); 8.2745 (1.5); 8.2724 (1.6); 8.2704 (2.0); 8.2685 (1.3); 8.0783 (2.9); 8.0642 (3.0); 7.7967 (1.1); 7.7905 (1.1); 7.7784 (1.2); 7.7756 (1.3); 7.7721 (1.2); 7.7693 (1.3); 7.7572 (1.2); 7.7510 (1.2); 7.2610 (34.6); 7,1099 (1.4); 7,1083 (1.4); 7.1023 (1.4); 7.1007 (1.4); 7.0887 (1.4); 7.0872 (1.4); 7.0811 (1.4); 7.0795 (1.3); 6.8357 (1.1); 6.8328 (1.3); 6.8311 (1.5); 6.8283 (1.4); 6.8216 (1.0); 6.8187 (1.2); 6.8170 (1.6); 6.8143 (1.5); 6.7998 (2.1); 6.7966 (2.8); 6.7932 (1.6); 4.9354 (14.4); 4.3306 (1.8); 4.3128 (5.9); 4.2950 (6.0); 4.2772 (1.9); 2.0455 (0.9); 1.5450 (8.2); 1.3469 (7.6); 1.3291 (16.0); 1.3113 (7.5); 1.2641 (0.7); 1.2597 (1.0); 0.8820 (1.6); 0.8643 (0.6); 0.0080 (1.2); -0.0002 (46.5); -0.0085 (1.3) III-25: 1< H-NMR(400.6 MHz, d 6 -DMSO): δ= 12.6699 (1.3); 8.5145 (2.9); 8.4960 (3.0); 8.3741 (4.4); 8.3678 (4.5); 8.1583 (6.5); 8.1441 (6.8); 8.1147 (1.8); 8.1085 (1.8); 8.0953 (2.3); 8.0936 (2.5); 8.0891 (2.2); 8.0873 (2.4); 8.0742 (1.9); 8.0679 (1.9); 7.4245 (2.7); 7.4190 (2.7); 7.4046 (2.4); 7.4032 (2.6); 7.3977 (2.6); 7.3964 (2.4); 7.0636 (4.8); 7.0622 (4.9); 7.0059 (2.4); 7.0027 (3.1); 6.9984 (2.1); 6.9918 (2.4); 6.9886 (3.0); 6.9843 (2.1); 6.8707 (0.7); 4.8530 (15.4); 4.3384 (0.5); 4.3203 (2.6); 4.3020 (4.1); 4.2836 (2.7); 4.2656 (0.5); 3.6216 (0.9); 3.6177 (5.2); 3.6155 (2.9); 3.6114 (2.7); 3.6093 (2.0); 3.6074 (3.6); 3.6011 (12.2); 3.5989 (4.2); 3.5949 (3.8); 3.5930 (2.0); 3.5908 (2.7); 3.5866 (2.7); 3.5845 (5.4); 3.5806 (0.9); 3.3208 (25.7); 3.2024 (1.4); 2.6749 (0.6); 2.6703 (0.9); 2.6657 (0.6); 2.5409 (1.9); 2.5241 (2.4); 2.5195 (3.2); 2.5107 (48.1); 2.5061 (105.8); 2.5015 (148.8); 2.4969 (102.1); 2.4923 (44.6); 2.3332 (0.6); 2.3286 (0.9); 2.3239 (0.6); 2.1829 (1.2); 1.9949 (1.1); 1.9086 (0.8); 1.7809 (0.8); 1.7763 (5.3); 1.7686 (4.2); 1.7642 (2.5); 1.7597 (15.2); 1.7549 (2.6); 1.7507 (4.1); 1.7431 (5.2); 1.7385 (0.8); 1.3552 (11.4); 1.3254 (16.0); 1.3072 (15.9); 1.2363 (0.8); 1.0897 (0.6); 1.0743 (0.6); 0.0080 (1.4); 0.0039 (0.7); 0.0022 (1.9); -0.0002 (46.9); -0.0027 (1.9); -0.0034 (1.2); -0.0043 (0.6); - 0.0085 (1.2). III-26: 1< H-NMR(400.6 MHz, d 6 -DMSO): δ = 12.6543 (1.2); 8.4833 (1.4); 8.4686 (2.9); 8.4537 (1.4); 8.3683 (4.3); 8.3620 (4.4); 8.1613 (6.3); 8.1472 (6.6); 8,1062 (1.7); 8.0999 (1.6); 8.0850 (2.4); 8.0804 (2.2); 8.0788 (2.3); 8.0656 (1.8); 8.0594 (1.8); 7.4229 (2.7); 7.4172 (2.6); 7.4016 (2.6); 7.3959 (2.5); 7.0825 (5.1); 7.0259 (2.4); 7.0227 (3.1); 7.0186 (2.0); 7.0118 (2.3); 7.0086 (3.0); 7.0044 (2.0); 4.8783 (16.0); 3.8523 (8.0); 3.8376 (8.1); 3.6176 (0.8); 3.6072 (0.6); 3.6010 (1.9); 3.5948 (0.7); 3.5865 (0.5); 3.5844 (0.8); 3.3207 (28.0); 2.6747 (0.7); 2.6702 (1.0); 2.6657 (0.7); 2.5239 (2.7); 2.5193 (4.1); 2.5104 (54.6); 2.5059 (116.9); 2.5013 (161.6); 2.4968 (111.6); 2.4922 (49.2); 2.4737 (0.6); 2.4692 (0.7); 2.3331 (0.7); 2.3285 (1.0); 2.3238 (0.7); 1.7762 (0.8); 1.7686 (0.7); 1.7596 (2.4); 1.7506 (0.7); 1.7431 (0.8); 1.3550 (3.8); 0.0080 (1.2); -0.0002 (45.9); -0.0085 (1.3) III-02: 1< H-NMR(400.6 MHz, d6 -DMSO): δ= 13.1557 (0.6); 8.3798 (3.0); 8.3736 (3.1); 8.1842 (4.4); 8.1701 (4.5); 8.1164 (1.3); 8.1100 (1.2); 8.0969 (1.6); 8.0952 (1.8); 8.0908 (1.6); 8.0889 (1.7); 8.0758 (1.4); 8.0695 (1.4); 7.4184 (1.9); 7.4129 (1.9); 7.3971 (1.8); 7.3917 (1.8); 7.0277 (1.4); 7.0233 (2.1); 7.0201 (1.7); 7.0137 (1.4); 7.0093 (2.2); 7.0061 (1.8); 6.9802 (3.7); 4.9454 (12.8); 4.0554 (1.1); 4.0377 (3.4); 4.0199 (3.4); 4.0021 (1.1); 3.3185 (43.8); 2.6790 (0.6); 2.6744 (1.3); 2.6698 (1.8); 2.6652 (1.3); 2.6605 (0.6); 2.5342 (1.0); 2.5294 (1.5); 2.5236 (5.5); 2.5190 (7.4); 2.5102 (97.6); 2.5056 (219.0); 2.5010 (309.1); 2.4964 (217.1); 2.4918 (96.9); 2.4596 (0.7); 2.4561 (0.7); 2.3374 (0.6); 2.3327 (1.3); 2.3281 (1.8); 2.3234 (1.3); 2.3190 (0.6); 1.9885 (16.0); 1.9082 (6.6); 1.1922 (4.7); 1.1744 (9.7); 1.1566 (4.7); 0.1458 (1.0); 0.0294 (0.5); 0.0279 (0.8); 0.0174 (0.5); 0.0150 (0.6); 0.0143 (0.7); 0.0134 (0.7); 0.0127 (0.8); 0.0119 (0.9); 0.0111 (1.0); 0.0102 (1.4); 0.0080 (9.5); 0.0064 (2.4); 0.0055 (2.6); 0.0047 (3.2); 0.0038 (4.5); -0.0002 (322.9); -0.0050 (4.7); -0.0059 (3.4); -0.0067 (2.8); -0.0085 (9.1); -0.0107 (1.2); -0.0115 (1.1); -0.0122 (0.8); -0.0130 (0.6); -0.0394 (0.6); -0.1493 (1.0). III-07: 1< H-NMR(400.6 MHz, CDCl3): . δ= 8.2904 (1.3); 8.2861 (1.0); 8.2841 (1.3); 8.1193 (1.8); 8,1052 (1.9); 7.7981 (0.7); 7.7918 (0.7); 7.7798 (0.7); 7.7769 (0.8); 7.7735 (0.8); 7.7706 (0.8); 7.7586 (0.7); 7.7523 (0.7); 7.2633 (17.0); 7.1206 (0.9); 7.1193 (0.9); 7.1130 (0.9); 7.1117 (0.9); 7.0995 (0.8); 7.0980 (0.9); 7.0919 (0.8); 7.0905 (0.8); 6.9198 (0.8); 6.9170 (0.9); 6.9153 (0.9); 6.9126 (0.8); 6.9058 (0.7); 6.9030 (0.9); 6.9012 (0.9); 6.8985 (0.8); 6.8176 (1.2); 6.8141 (1.9); 6.8106 (1.1); 5.3011 (4.1); 4.9294 (7.5); 4.1853 (3.5); 4.1720 (3.4); 3.7992 (16.0); 2.0456 (1.8); 1.5772 (7.7); 1.2776 (0.5); 1.2597 (1.1); 1.2419 (0.5); -0.0002 (11.7) III-27: 1< H-NMR(400.6 MHz, CDCl3): . δ = 8.2873 (1.2); 8.2853 (0.9); 8.2831 (0.9); 8.2810 (1.2); 8.0864 (1.6); 8.0724 (1.6); 7.8080 (0.6); 7.8017 (0.6); 7.7896 (0.7); 7.7869 (0.8); 7.7834 (0.7); 7.7806 (0.7); 7.7685 (0.7); 7.7622 (0.7); 7.2627 (17.0); 7.1099 (0.8); 7.1084 (0.8); 7.1023 (0.8); 7.1008 (0.8); 7.0888 (0.8); 7.0872 (0.8); 7.0811 (0.8); 7.0796 (0.8); 6.8565 (0.6); 6.8537 (0.8); 6.8520 (0.9); 6.8492 (0.8); 6.8425 (0.6); 6.8396 (0.7); 6.8379 (0.9); 6.8351 (0.8); 6.8129 (1.2); 6.8096 (1.6); 6.8063 (0.9); 5.3009 (2.2); 4.9395 (8.0); 4.5278 (2.0); 4.5123 (3.8); 4.4969 (2.0); 3.6987 (16.0); 2.7208 (1.9); 2.7054 (3.7); 2.6899 (1.9); 1.5644 (10.0); -0.0002 (11.8) III-28: 1< H-NMR(400.6 MHz, CDCl3): . δ= 8.2929 (1.1); 8.2908 (0.9); 8.2885 (0.9); 8.2867 (1.2); 8.1171 (1.5); 8.1031 (1.5); 7.8021 (0.6); 7.7958 (0.6); 7.7838 (0.7); 7.7809 (0.7); 7.7775 (0.7); 7.7747 (0.7); 7.7626 (0.6); 7.7563 (0.6); 7.2643 (11.6); 7.1225 (0.8); 7.1211 (0.8); 7.1149 (0.9); 7.1135 (0.8); 7.1013 (1.0); 7.0999 (1.0); 7.0938 (1.1); 7.0924 (1.0); 6.9154 (0.7); 6.9126 (0.8); 6.9108 (0.8); 6.9082 (0.7); 6.9013 (0.6); 6.8985 (0.8); 6.8968 (0.8); 6.8941 (0.7); 6.8166 (1.0); 6.8132 (1.6); 6.8097 (1.0); 5.3014 (4.0); 4.8908 (7.1); 4.7269 (0.8); 4.7088 (1.2); 4.6908 (0.8); 3.7883 (16.0); 2.0458 (1.6); 1.5928 (5.1); 1.5143 (6.4); 1.4964 (6.3); 1.2777 (0.5); 1.2599 (1.1); - 0.0002 (8.1) I-23: 1< H-NMR(400.6 MHz, CDCl3): δ= 8.3881 (2.3); 8.3841 (2.4); 8.3764 (2.4); 8.3724 (2.4); 8.1389 (2.2); 8.1327 (2.4); 7.8626 (1.1); 7.8564 (1.0); 7.8438 (1.2); 7.8414 (1.3); 7.8376 (1.2); 7.8352 (1.3); 7.8227 (1.2); 7.8164 (1.1); 7.8012 (2.4); 7.7972 (2.4); 7.7811 (2.6); 7.7771 (2.6); 7.3335 (2.5); 7.3219 (2.5); 7.3135 (2.4); 7.3018 (2.3); 7.2617 (11.3); 6.9351 (1.5); 6.9280 (1.6); 6.9138 (1.5); 6.9067 (1.5); 4.9187 (16.0); 4.2820 (1.9); 4.2642 (6.0); 4.2464 (6.1); 4.2286 (2.0); 2.0453 (1.3); 1.5616 (5.4); 1.3002 (7.2); 1.2824 (14.6); 1.2646 (7.6); 1.2599 (1.5); 0.8821 (1.3); 0.8644 (0.5); -0.0002 (16.8); -0.0085 (0.6) I-24: 1< H-NMR(400.6 MHz, CDCl3): δ= 8.3500 (1.3); 8.3460 (1.4); 8.3384 (1.4); 8.3343 (1.4); 8.1353 (1.0); 8.1332 (0.8); 8.1311 (0.9); 8.1291 (1.1); 7.8576 (0.6); 7.8513 (0.6); 7.8388 (0.7); 7.8364 (0.7); 7.8325 (0.7); 7.8301 (0.7); 7.8176 (0.6); 7.8114 (0.6); 7.8028 (1.4); 7.7988 (1.4); 7.7827 (1.5); 7.7787 (1.5); 7.3170 (1.5); 7.3053 (1.5); 7.2969 (1.4); 7.2852 (1.4); 7.2619 (7.1); 6.9300 (0.7); 6.9286 (0.8); 6.9226 (0.8); 6.9211 (0.8); 6.9088 (0.8); 6.9073 (0.8); 6.9013 (0.8); 6.8998 (0.7); 5.2593 (1.5); 5.2419 (1.5); 4.1309 (0.6); 4.1130 (0.6); 3.7563 (16.0); 2.0453 (2.8); 1.6961 (6.3); 1.6787 (6.3); 1.5609 (3.4); 1.2773 (1.0); 1.2645 (0.8); 1.2595 (2.1); 1.2416 (0.9); 0.8818 (1.5); 0.8641 (0.6); -0.0002 (11.2) I-25: 1< H-NMR(400.6 MHz, CDCl3): δ= 8.3707 (3.6); 8.3667 (3.8); 8.3590 (3.8); 8.3550 (3.8); 8.1350 (3.4); 8.1287 (3.5); 7.8620 (1.7); 7.8557 (1.6); 7.8433 (2.0); 7.8408 (2.1); 7.8371 (2.0); 7.8346 (1.9); 7.8221 (1.8); 7.8158 (1.8); 7.8111 (3.8); 7.8071 (3.8); 7.7910 (4.1); 7.7870 (4.0); 7.3331 (4.0); 7.3214 (4.0); 7.3130 (3.8); 7.3012 (3.6); 7.2606 (50.9); 6.9398 (2.3); 6.9325 (2.4); 6.9186 (2.2); 6.9112 (2.2); 5.3337 (1.2); 5.3162 (4.6); 5.2988 (4.7); 5.2814 (1.3); 1.7459 (16.0); 1.7284 (15.9); 1.2644 (2.1); 0.8990 (1.1); 0.8821 (3.8); 0.8644 (1.5); 0.0080 (2.4); -0.0002 (81.0); -0.0086 (2.8) I-26: 1< H-NMR(400.6 MHz, CDCl3): δ= 8.3888 (3.3); 8.3872 (3.5); 8.3849 (3.6); 8.3771 (3.5); 8.3756 (3.7); 8.3732 (3.6); 8.1350 (4.4); 8.1291 (4.6); 7.8596 (1.8); 7.8534 (1.8); 7.8387 (2.6); 7.8327 (2.5); 7.8197 (2.0); 7.8135 (2.0); 7.8030 (4.1); 7.7990 (4.3); 7.7830 (4.6); 7.7790 (4.6); 7.3362 (4.0); 7.3245 (4.0); 7.3161 (3.9); 7.3044 (3.9); 7.2668 (73.3); 6.9349 (3.2); 6.9275 (3.3); 6.9137 (3.2); 6.9063 (3.2); 5.3020 (1.2); 4.9259 (16.0); 4.9220 (14.5); 4.0916 (0.8); 4.0876 (0.8); 2.5953 (1.2); 2.0982 (1.2); 1.2637 (2.1); 0.8983 (1.0); 0.8819 (2.9); 0.8641 (1.3); 0.0079 (2.0); -0.0002 (84.1); -0.0084 (4.0); -0.0266 (0.8) I-27: 1< H-NMR(400.6 MHz, CDCl3): δ= 8.3542 (2.5); 8.3502 (2.7); 8.3425 (2.7); 8.3385 (2.8); 8.1323 (2.4); 8.1261 (2.6); 7.8582 (1.2); 7.8520 (1.2); 7.8394 (1.4); 7.8371 (1.5); 7.8332 (1.4); 7.8309 (1.5); 7.8183 (1.3); 7.8120 (1.3); 7.7986 (2.6); 7.7946 (2.7); 7.7786 (2.9); 7.7745 (2.9); 7.3154 (2.8); 7.3038 (2.8); 7.2954 (2.7); 7.2837 (2.6); 7.2613 (17.2); 6.9288 (1.8); 6.9215 (1.8); 6.9076 (1.7); 6.9003 (1.7); 5.3002 (1.7); 5.2577 (0.9); 5.2403 (3.3); 5.2230 (3.4); 5.2056 (1.0); 4.2408 (1.8); 4.2230 (5.9); 4.2052 (6.2); 4.1875 (2.1); 2.1730 (1.1); 1.6909 (13.0); 1.6735 (13.0); 1.2677 (7.8); 1.2499 (16.0); 1.2321 (7.8); 0.0079 (0.8); -0.0002 (26.7); -0.0084 (1.2) I-28: 1< H-NMR(400.6 MHz, CDCl3): δ= 8.3902 (1.3); 8.3862 (1.4); 8.3785 (1.4); 8.3745 (1.4); 8.1420 (1.3); 8.1358 (1.4); 7.8654(0.6); 7.8591(0.6); 7.8466(0.7); 7.8442(0.8); 7.8404 (0.8); 7.8380(0.8); 7.8255(0.7); 7.8193(0.7); 7.8062(1.4); 7.8022(1.4); 7.7860 (1.6); 7.7821 (1.5); 7.3382(1.5); 7.3265 (1.5); 7.3182 (1.4); 7.3064 (1.4); 7.2610 (13.6); 6.9387 (0.9); 6.9314 (1.0); 6.9175 (0.9); 6.9101 (0.9); 5.3003 (0.6); 4.9372 (9.2); 3.7929 (16.0); 0.0079 (0.6); -0.0002 (21.5); -0.0085 (0.9) 1-08: 1< H-NMR(400.6 MHz, d 6 -DMSO): δ= 13.0716 (0.6); 8.2690 (2.0); 8.2666 (2.7); 8.2656 (2.6); 8.2635 (2.2); 8.2573 (2.3); 8.2551 (2.9); 8.2541 (2.6); 8.2518 (2.2); 8.2214 (3.2); 8.2151 (3.5); 7.9863 (3.0); 7.9826 (2.2); 7.9804 (1.8); 7.9653 (4.1); 7.9613(4.9); 7.9589 (2.9); 7.9578 (2.8); 7.9461 (1.8); 7.9401 (3.4); 7.9367 (2.2); 7.6052 (2.0); 7.5958 (2.4); 7.5936 (2.1); 7.5843 (3.7); 7.5750 (1.8); 7.5727 (1.9); 7.5634 (1.7); 7.2910 (2.0); 7.2897 (2.1); 7.2841 (2.2); 7.2828 (2.1); 7.2697 (2.0); 7.2684 (2.1); 7.2628 (2.1); 7.2614 (2.0); 5.7569 (1.2); 4.8568 (16.0); 3.3362 (17.9); 2.6709 (0.6); 2.5247 (1.5); 2.5200 (2.0); 2.5112 (28.2); 2.5067 (62.8); 2.5021 (89.3); 2.4975 (63.5); 2.4929 (30.3); 2.4693 (1.1); 2.3291 (0.6); 1.2472 (1.0); 0.8749 (0.5); 0.8581 (2.1); 0.8404 (0.7); 0.0080 (1.6); 0.0056 (0.5); 0.0047 (0.6); -0.0002 (52.2); -0.0050 (1.0); -0.0058 (0.9); -0.0067 (0.8); -0.0085 (1.7) I-08: 1< H-NMR(400.0 MHz, d 6 -DMSO): δ= 13.0690 (0.6); 8.2662 (2.8); 8.2549 (3.0); 8.2218 (3.5); 8.2155 (3.6); 7.9865 (2.8); 7.9825 (2.1); 7.9655 (3.8); 7.9614 (4.8); 7.9464 (1.6); 7.9401 (3.2); 7.9368 (1.9); 7.6053 (1.8); 7.5958 (2.2); 7.5939 (2.0); 7.5843 (3.2); 7.5749 (1.7); 7.5729 (1.8); 7.5634 (1.4); 7.2900 (2.2); 7.2838 (2.3); 7.2687 (2.2); 7.2623 (2.1); 5.7570 (1.2); 4.8573 (16.0); 3.1690 (1.0); 2.5247 (0.8); 2.5201 (1.2); 2.5112 (22.3); 2.5067 (49.8); 2.5021 (70.0); 2.4976 (49.8); 2.4930 (22.7); 1.2466 (1.1); 0.8747 (0.5); 0.8580 (1.9); 0.8403 (0.7); 0.0080 (1.0); -0.0002 (39.0); -0.0085 (1.2) I-18: 1< H-NMR(400.6 MHz, CDCl3): δ= 8.4613 (3.2); 8.4547 (3.3); 8.3036 (3.5); 8.2283 (2.4); 8.2263(2.5); 8.2183 (2.2); 8.2166 (2.5); 8.2147 (2.4); 7.5540 (1.6); 7.5496 (1.7); 7.5471 (1.8); 7.5427 (1.6); 7.5319(1.7); 7.5275 (1.9); 7.5250 (1.8); 7.5190 (2.2); 7.5142 (1.7); 7.4972 (2.2); 7.4939 (2.7); 7.4911 (1.9); 7.4740 (2.1); 7.4703 (2.0); 7.3554 (2.0); 7.3463 (2.3); 7.3438 (2.1); 7.3347 (3.5); 7.3257 (1.6); 7.3230 (1.7); 7.3141 (1.6); 7.2704 (1.0); 7.2697 (1.0); 7.2680 (1.1); 7.2672 (1.3); 7.2664 (1.6); 7.2606 (212.2); 7.2494 (0.5); 6.9970 (1.1); 5.3576 (1.2); 5.3401 (4.7); 5.3226 (4.8); 5.3052 (1.2); 5.3002 (0.9); 2.7754 (0.7); 1.7488 (16.0); 1.7313 (15.9); 1.7142 (0.6); 1.2425 (1.2); 1.2390 (1.2); 1.2222 (0.5); 0.0080 (3.7); 0.0056 (1.1); 0.0047 (1.5); -0.0002 (126.8); -0.0058 (1.4); -0.0066 (1.2); -0.0084 (3.3); -0.0115 (0.5) I-18: 1< H-NMR(599.6 MHz, d 6 -DMSO): δ= 8.6435 (2.3); 8.6390 (2.2); 8.3566 (2.4); 8.2335 (1.4); 8.2259 (1.4); 7.9829(0.7); 7.9667 (1.2); 7.9523(0.7); 7.8251(0.8); 7.8220(0.9); 7.8179 (0.6); 7.8093(0.8); 7.8062(0.9); 7.8021(0.6); 7.5878(0.6); 7.5812(0.9); 7.5739 (1.1); 7.5673(0.8); 7.5601(0.5); 5.0737 (0.4); 5.0622 (1.6); 5.0506 (1.6); 5.0390 (0.4); 3.3186 (21.5); 2.6135 (0.3); 2.5221 (1.2); 2.5191 (1.4); 2.5159 (1.6); 2.5042 (39.7); 2.5014 (50.0); 2.4985 (36.2); 1.5768 (5.4); 1.5651 (5.3); -0.0001 (5.4) I-17: 1< H-NMR(400.6 MHz, d 6 -DMSO): δ= 13.0891 (1.1); 8.6502(5.7); 8.6432(5.8); 8.3674 (3.0); 8.3633 (5.6); 8.3594 (2.8); 8.2467 (2.1); 8.2444 (2.7); 8.2434 (2.7); 8.2412 (2.2); 8.2351 (2.3); 8.2328 (2.9); 8.2296 (2.2); 7.9959 (1.8); 7.9924 (1.8); 7.9751 (2.1); 7.9711 (3.1); 7.9673 (2.0); 7.9500 (2.0); 7.9464 (1.9); 7.8428 (2.0); 7.8384 (2.0); 7.8359 (2.1); 7.8315 (1.9); 7.8191 (2.1); 7.8147 (2.3); 7.8122 (2.0); 7.8078 (1.9); 7.6008 (2.1); 7.5914 (2.4); 7.5892 (2.2); 7.5799 (3.7); 7.5706 (1.8); 7.5683 (1.9); 7.5590 (1.6); 5.7569 (4.0); 4.8613 (16.0); 3.6011 (0.5); 3.3203 (13.8); 2.6748 (0.7); 2.6702 (0.9); 2.6656 (0.7); 2.5239 (2.4); 2.5193 (3.3); 2.5105 (49.0); 2.5060 (107.5); 2.5014 (150.7); 2.4968 (103.1); 2.4922 (45.4); 2.3330 (0.6); 2.3284 (0.9); 2.3238 (0.6); 1.7595 (0.6); 1.3552 (1.4); 1.2355 (0.7); 0.0080 (1.6); 0.0040 (0.6); -0.0002 (56.7); -0.0050 (0.7); -0.0058 (0.6); -0.0085 (1.5) I-17: 1< H-NMR(400.6 MHz, d 6 -DMSO): δ= 13.0844 (1.7); 8.6499 (5.8); 8.6430 (5.8); 8.3670 (3.0); 8.3628 (5.8); 8.3589 (2.9); 8.2464 (2.1); 8.2440 (2.8); 8.2430 (2.8); 8.2409 (2.4); 8.2348 (2.4); 8.2325 (3.0); 8.2294 (2.3); 7.9959 (1.8); 7.9924 (1.8); 7.9750 (2.1); 7.9710 (3.2); 7.9672 (2.0); 7.9498 (2.1); 7.9463 (2.0); 7.8424 (2.0); 7.8381 (2.1); 7.8355 (2.1); 7.8311 (1.9); 7.8188 (2.2); 7.8144 (2.3); 7.8119 (2.0); 7.8075 (1.9); 7.6006 (2.1); 7.5913 (2.4); 7.5890 (2.2); 7.5797 (3.8); 7.5704 (1.8); 7.5682 (2.0); 7.5588 (1.7); 5.7568 (4.2); 4.8604 (16.0); 3.3190 (34.6); 2.6745 (1.0); 2.6698 (1.5); 2.6652 (1.1); 2.6607 (0.5); 2.5405 (1.2); 2.5237 (3.1); 2.5190 (4.7); 2.5102 (79.1); 2.5056 (175.0); 2.5011 (247.3); 2.4965 (172.8); 2.4919 (78.5); 2.4742 (3.7); 2.4703 (3.4); 2.3328 (1.0); 2.3281 (1.5); 2.3235 (1.1); 0.1457 (0.7); 0.0079 (6.6); 0.0055 (1.5); -0.0002 (243.0); -0.0068 (2.5); -0.0085 (7.4); -0.0139 (0.9); -0.0155 (0.8); -0.0187 (0.6); -0.0211 (0.6); -0.0226 (0.7); -0.0258 (0.5); -0.0275 (0.9); -0.0313 (0.9); -0.0322 (0.8); -0.0344 (0.5); -0.1495 (0.7). I-17: 1< H-NMR(599.6 MHz, d 6 -DMSO): δ= 8.6435 (2.3); 8.6390 (2.2); 8.3566 (2.4); 8.2335 (1.4); 8.2259 (1.4); 7.9829 (0.7); 7.9667 (1.2); 7.9523 (0.7); 7.8251 (0.8); 7.8220 (0.9); 7.8179 (0.6); 7.8093 (0.8); 7.8062 (0.9); 7.8021 (0.6); 7.5878 (0.6); 7.5812 (0.9); 7.5739 (1.1); 7.5673 (0.8); 7.5601 (0.5); 5.0737 (0.4); 5.0622 (1.6); 5.0506 (1.6); 5.0390 (0.4); 3.3186 (21.5); 2.6135 (0.3); 2.5221 (1.2); 2.5191 (1.4); 2.5159 (1.6); 2.5042 (39.7); 2.5014 (50.0); 2.4985 (36.2); 1.5768 (5.4); 1.5651 (5.3); -0.0001 (5.4) I-15: 1< H-NMR(400.6 MHz, CDCl3): δ= 8.4443 (1.3); 8.4376 (1.4); 8.2932 (1.5); 8.2037 (0.8); 8.2020 (0.9); 8.2002 (0.9); 8.1921 (0.9); 8.1904 (1.0); 8.1885 (1.0); 7.5266 (1.0); 7.5239 (0.9); 7.5221 (0.9); 7.5197 (1.0); 7.5152 (0.7); 7.5070 (1.0); 7.5040 (1.8); 7.5003 (1.2); 7.4973 (0.9); 7.4929 (0.7); 7.4838 (0.8); 7.4801 (0.8); 7.3419 (0.7); 7.3329 (0.8); 7.3303 (0.8); 7.3213 (1.3); 7.3123 (0.6); 7.3096 (0.7); 7.3007 (0.6); 7.2614 (30.4); 5.2864 (1.6); 5.2690 (1.6); 3.7710 (16.0); 2.0454 (0.6); 1.7015 (6.6); 1.6841 (6.6); 1.5664 (1.7); 1.2596 (0.6); 0.8820 (0.6); 0.0080 (0.6); -0.0002 (18.4); -0.0084 (0.7) I-15: 1< H-NMR(400.0 MHz, CDCl3): δ= 8.4434 (1.7); 8.4369 (1.6); 8.2926 (1.9); 8.2004 (1.3); 8.1903 (1.3); 7.5258 (1.3); 7.5027 (2.0); 7.4922 (0.8); 7.4826 (0.8); 7.3410 (0.7); 7.3304 (1.0); 7.3202 (1.3); 7.3101 (0.8); 7.2998 (0.7); 7.2600 (23.4); 5.3035 (0.5); 5.2860 (1.8); 5.2684 (1.7); 5.2511 (0.6); 3.7709 (16.0); 1.7012 (7.0); 1.6838 (6.8); 1.5459 (12.9); 0.0072 (1.4); -0.0002 (32.0); -0.0081 (1.2) I-29: 1< H-NMR(400.6 MHz, CDCl3): δ= 8.2558 (0.6); 8.2541 (0.7); 8.2522 (0.7); 8.2505 (0.6); 8.2442 (0.6); 8.2424 (0.7); 8.2406 (0.7); 8.2389 (0.7); 8.1338 (0.9); 8.1318 (0.7); 8.1296 (0.8); 8.1276 (1.0); 7.8457 (0.6); 7.8432 (0.6); 7.8395 (0.6); 7.8370 (0.6); 7.8245 (0.6); 7.8183 (0.5); 7.5051 (0.5); 7.4881 (0.7); 7.4845 (0.8); 7.4820 (0.6); 7.4650 (0.7); 7.4613 (0.7); 7.3557 (0.6); 7.3467 (0.7); 7.3441 (0.7); 7.3351 (1.1); 7.3260 (0.5); 7.3234 (0.6); 7.2612 (21.3); 6.9646 (0.6); 6.9631 (0.7); 6.9571 (0.7); 6.9556 (0.7); 6.9434 (0.6); 6.9418 (0.7); 6.9359 (0.6); 6.9344 (0.6); 4.9905 (6.9); 4.3640 (1.6); 4.3556 (0.9); 4.3523 (1.7); 4.3486 (0.9); 4.3404 (1.8); 3.6273 (2.0); 3.6190 (0.9); 3.6154 (1.8); 3.6121 (1.0); 3.6037 (1.9); 3.3659 (16.0); 1.5532 (10.3); 0.0079 (0.6); -0.0002 (24.7); -0.0085 (0.9) I-29: 1< H-NMR(400.6 MHz, CDCl3): δ= 8.2539 (1.0); 8.2523 (1.0); 8.2424 (1.0); 8.2407 (1.0); 8.1338 (1.3); 8.1277 (1.4); 7.8643 (0.6); 7.8581 (0.6); 7.8455 (0.7); 7.8432 (0.8); 7.8393 (0.7); 7.8371 (0.7); 7.8244 (0.6); 7.8182 (0.6); 7.5089 (0.6); 7.5052 (0.6); 7.4881 (0.9); 7.4848 (1.1); 7.4651 (0.8); 7.4615 (0.7); 7.3557 (0.7); 7.3465 (0.8); 7.3442 (0.8); 7.3350 (1.2); 7.3259 (0.6); 7.3236 (0.6); 7.3144 (0.5); 7.2615 (29.8); 6.9633 (0.9); 6.9560 (0.9); 6.9421 (0.9); 6.9347 (0.8); 4.9903 (8.3); 4.3638 (2.1); 4.3521 (2.3); 4.3485 (1.4); 4.3402 (2.2); 3.6271 (2.3); 3.6189 (1.4); 3.6152 (2.4); 3.6121 (1.4); 3.6035 (2.2); 3.3657 (16.0); 1.5595 (1.4); 0.0078 (0.7); -0.0002 (18.1); -0.0085 (0.7) I-30: 1< H-NMR(400.6 MHz, CDCl 3 ): δ= 8.2566 (2.4); 8.2467 (2.4); 8.1491 (3.1); 7.8691 (1.2); 7.8627 (1.1); 7.8482 (1.8); 7.8441 (1.7); 7.8292 (1.2); 7.8231 (1.1); 7.5227 (1.2); 7.5023 (2.4); 7.4823 (1.5); 7.3725 (1.2); 7.3630 (1.8); 7.3519 (2.0); 7.3425 (1.4); 7.3313 (0.9); 7.2610 (54.2); 6.9706 (2.0); 6.9643 (1.9); 6.9499 (1.9); 6.9430 (1.8); 5.0371 (14.5); 4.8405 (16.0); 4.3074 (0.7); 2.0454 (0.8); 1.5505 (2.2); 1.2596 (0.9); -0.0002 (32.7) I-30: 1< H-NMR(400.6 MHz, CDCl3): δ= 8.2583 (1.2); 8.2564 (1.3); 8.2466 (1.3); 8.2448 (1.3); 8.1494 (1.7); 8.1431 (1.8); 7.8692 (0.9); 7.8629 (0.9); 7.8505 (1.0); 7.8480 (1.1); 7.8443 (1.0); 7.8418 (1.1); 7.8293 (1.0); 7.8231 (1.0); 7.5260 (0.9); 7.5223 (0.9); 7.5190 (0.6); 7.5053 (1.2); 7.5019 (1.5); 7.4993 (1.0); 7.4823 (1.2); 7.4785 (1.2); 7.3724 (1.2); 7.3633 (1.3); 7.3608 (1.2); 7.3517 (2.0); 7.3426 (0.9); 7.3401 (0.9); 7.3310 (0.9); 7.2606 (84.6); 6.9705 (1.2); 6.9644 (1.2); 6.9492 (1.2); 6.9431 (1.2); 5.0371 (13.7); 4.8404 (16.0); 1.5427 (8.1); 0.0081 (2.8); -0.0002 (97.2); -0.0085 (3.3) I-31: 1< H-NMR(400.6 MHz, CDCl3): δ= 8.2951 (1.6); 8.2934 (1.9); 8.2915 (1.9); 8.2898 (1.8); 8.2835 (1.8); 8.2818 (2.0); 8.2799 (2.0); 8.2782 (1.8); 8.1602 (2.5); 8.1582 (1.9); 8.1559 (2.0); 8.1539 (2.7); 7.8498 (1.4); 7.8435 (1.4); 7.8312 (1.5); 7.8286 (1.7); 7.8249 (1.6); 7.8224 (1.6); 7.8100 (1.5); 7.8037 (1.5); 7.5386 (1.3); 7.5349 (1.4); 7.5179 (1.9); 7.5156 (1.9); 7.5143 (2.1); 7.5121 (1.6); 7.4950 (1.8); 7.4913 (1.8); 7.3980 (1.8); 7.3888 (2.0); 7.3864 (1.9); 7.3773 (3.2); 7.3681 (1.4); 7.3657 (1.5); 7.3566 (1.3); 7.2627 (20.5); 6.9737 (1.8); 6.9723 (1.8); 6.9663 (1.9); 6.9648 (1.8); 6.9526 (1.7); 6.9510 (1.8); 6.9451 (1.8); 6.9436 (1.8); 6.6525 (0.6); 5.9488 (0.6); 5.9350 (1.3); 5.9230 (0.8); 5.9214 (0.7); 5.9093 (1.4); 5.9060 (0.8); 5.8956 (0.7); 5.8922 (1.6); 5.8801 (0.9); 5.8786 (0.9); 5.8665 (1.6); 5.8528 (0.8); 5.2850 (0.8); 5.2808 (2.0); 5.2776 (2.2); 5.2734 (1.0); 5.2422 (0.7); 5.2379 (1.8); 5.2347 (1.9); 5.2305 (0.9); 5.1997 (0.9); 5.1961 (2.3); 5.1928 (2.3); 5.1893 (0.9); 5.1740 (0.8); 5.1704 (2.2); 5.1671 (2.2); 5.1636 (0.9); 4.8925 (16.0); 4.0378 (1.1); 4.0338 (2.1); 4.0299 (1.3); 4.0233 (2.2); 4.0196 (3.8); 4.0158 (2.3); 4.0093 (1.4); 4.0053 (2.2); 4.0013 (1.3); 2.0454 (0.7); 1.5810 (5.4); 1.2595 (0.7); 1.2558 (0.5); -0.0002 (19.4); -0.0085 (0.7). I-32: 1< H-NMR(400.6 MHz, CDCl3): δ= 8.2186 (2.6); 8.2085 (2.6); 8.1250 (3.4); 8.1191 (3.3); 7.8562 (1.3); 7.8501 (1.3); 7.8352 (1.9); 7.8312 (1.8); 7.8164 (1.4); 7.8101 (1.3); 7.5151 (1.4); 7.5115 (1.3); 7.4913 (2.7); 7.4712 (1.7); 7.4676 (1.6); 7.3406 (1.4); 7.3315 (1.9); 7.3200 (2.5); 7.3108 (1.6); 7.2995 (1.1); 7.2882 (0.7); 7.2607 (91.6); 6.9971 (0.5); 6.9611 (2.2); 6.9542 (2.2); 6.9398 (2.1); 6.9328 (2.0); 5.2846 (1.0); 5.2673 (3.4); 5.2499 (3.4); 5.2327 (1.1); 4.2557 (1.9); 4.2382 (5.8); 4.2205 (6.0); 4.2027 (2.1); 1.6950 (13.6); 1.6776 (13.5); 1.5614 (3.7); 1.2730 (7.9); 1.2553 (16.0); 1.2375 (7.6); -0.0002 (53.1); -0.0082 (2.8) I-32: 1< H-NMR(400.0 MHz, CDCl3): δ= 8.2276 (0.6); 8.2159 (0.7); 8.1274 (0.9); 8.1214 (0.9); 7.8382 (0.6); 7.8357 (0.6); 7.8319 (0.5); 7.8293 (0.5); 7.4966 (0.6); 7.4935 (0.8); 7.4734 (0.6); 7.4697 (0.6); 7.3439 (0.5); 7.3349 (0.6); 7.3323 (0.5); 7.3232 (0.9); 7.2606 (32.9); 6.9615 (0.6); 6.9553 (0.6); 6.9402 (0.6); 6.9326 (0.6); 5.2744 (1.0); 5.2569 (1.1); 4.2582 (0.6); 4.2403 (1.8); 4.2233 (1.8); 4.2053 (0.6); 1.6959 (4.9); 1.6785 (4.8); 1.5489 (16.0); 1.2744 (3.0); 1.2566 (6.3); 1.2388 (2.9); 0.0080 (0.9); -0.0002 (33.9); -0.0085 (1.0) I-33: 1< H-NMR(400.6 MHz, CDCl3): δ= 8.2173 (1.4); 8.2155 (1.6); 8.2137 (1.6); 8.2120 (1.4); 8.2057 (1.5); 8.2039 (1.6); 8.2020 (1.6); 8.2004 (1.4); 8.1339 (2.0); 8.1317 (1.6); 8.1295 (1.7); 8.1276 (2.2); 7.8630 (1.1); 7.8567 (1.1); 7.8442 (1.3); 7.8418 (1.3); 7.8380 (1.3); 7.8356 (1.3); 7.8230 (1.2); 7.8168 (1.2); 7.5079 (1.1); 7.5043 (1.1); 7.4873 (1.5); 7.4844 (1.8); 7.4838 (1.8); 7.4810 (1.3); 7.4641 (1.4); 7.4604 (1.4); 7.3362 (1.4); 7.3272 (1.6); 7.3246 (1.4); 7.3156 (2.5); 7.3066 (1.1); 7.3039 (1.2); 7.2950 (1.0); 7.2630 (25.4); 6.9575 (1.5); 6.9560 (1.5); 6.9501 (1.5); 6.9486 (1.4); 6.9363 (1.4); 6.9348 (1.4); 6.9289 (1.5); 6.9274 (1.4); 5.2827 (0.8); 5.2653 (3.1); 5.2479 (3.1); 5.2306 (0.8); 4.2547 (1.2); 4.2529 (1.2); 4.2369 (3.8); 4.2352 (3.7); 4.2190 (4.0); 4.2175 (3.8); 4.2011 (1.4); 4.1998 (1.3); 1.6937 (12.0); 1.6763 (12.0); 1.5810 (1.1); 1.2719 (7.7); 1.2592 (0.7); 1.2541 (16.0); 1.2363 (7.4); -0.0002 (15.3) I-33: 1< H-NMR(400.0 MHz, CDCl3): δ= 8.2157 (1.3); 8.2139 (1.3); 8.2040 (1.3); 8.2023 (1.3); 8.1334 (1.7); 8.1272 (1.8); 7.8631 (0.8); 7.8569 (0.8); 7.8443 (1.0); 7.8419 (1.0); 7.8381 (1.0); 7.8357 (1.0); 7.8231 (0.9); 7.8168 (0.8); 7.5072 (0.8); 7.5035 (0.8); 7.4865 (1.1); 7.4831 (1.4); 7.4803 (1.0); 7.4633 (1.0); 7.4596 (1.0); 7.3355 (1.0); 7.3265 (1.2); 7.3239 (1.1); 7.3149 (1.8); 7.3058 (0.9); 7.3032 (0.9); 7.2942 (0.8); 7.2615 (20.5); 6.9557 (1.2); 6.9495 (1.2); 6.9344 (1.1); 6.9283 (1.1); 5.2825 (0.6); 5.2651 (2.3); 5.2477 (2.3); 5.2303 (0.6); 4.2531 (1.0); 4.2369 (2.9); 4.2354 (3.0); 4.2190 (3.1); 4.2176 (3.0); 4.2011 (1.1); 2.0453 (0.6); 1.6936 (8.8); 1.6762 (8.7); 1.5569 (16.0); 1.2719 (5.6); 1.2594 (1.2); 1.2541 (11.3); 1.2363 (5.3); 0.8819 (1.1); 0.0079 (0.6); -0.0002 (20.9); -0.0085 (0.6) I-34: 1< H-NMR(400.6 MHz, CDCl3): δ= 8.2179 (0.6); 8.2162 (0.7); 8.2143 (0.7); 8.2126 (0.6); 8.2063 (0.6); 8.2045 (0.7); 8.2027 (0.7); 8.2010 (0.6); 8.1309 (0.9); 8.1246 (0.9); 7.8398 (0.5); 7.8373 (0.6); 7.8335 (0.5); 7.8311 (0.6); 7.4884 (0.6); 7.4850 (0.7); 7.4822 (0.5); 7.4652 (0.6); 7.4615 (0.6); 7.3394 (0.6); 7.3305 (0.6); 7.3279 (0.6); 7.3188 (1.0); 7.2613 (39.3); 6.9573 (0.6); 6.9558 (0.6); 6.9498 (0.6); 6.9483 (0.6); 6.9361 (0.6); 6.9346 (0.6); 6.9286 (0.6); 6.9271 (0.6); 5.3053 (1.2); 5.2879 (1.3); 4.3627 (0.6); 4.3512 (0.8); 4.3492 (0.6); 4.3376 (0.6); 4.3327 (0.6); 4.3215 (0.7); 4.3194 (0.8); 4.3084 (0.6); 3.7115 (0.8); 3.7080 (0.8); 3.7008 (1.0); 3.6974 (1.2); 3.6945 (1.1); 3.6868 (0.8); 3.6833 (0.8); 3.6121 (0.8); 3.6079 (0.8); 3.6015 (1.8); 3.5969 (1.0); 3.5940 (1.3); 3.5881 (1.3); 3.5859 (1.3); 3.5110 (2.1); 3.5055 (0.5); 3.5022 (1.0); 3.4984 (1.8); 3.4883 (1.0); 3.3607 (16.0); 1.7082 (4.7); 1.6908 (4.6); 0.0080 (0.7); -0.0002 (22.8); -0.0027 (1.2); -0.0034 (0.9); -0.0043 (0.6); -0.0084 (0.7) I-34: 1< H-NMR(400.0 MHz, CDC13_5mm): δ= 8.2157 (0.8); 8.2139 (0.8); 8.2058 (0.8); 8.2040 (0.8); 8.2022 (0.8); 8.1301 (1.1); 8.1239 (1.1); 7.8575 (0.5); 7.8512 (0.5); 7.8387 (0.6); 7.8363 (0.7); 7.8325 (0.6); 7.8300 (0.6); 7.8175 (0.6); 7.8112 (0.6); 7.5084 (0.6); 7.5047 (0.6); 7.4877 (0.8); 7.4844 (1.0); 7.4816 (0.7); 7.4645 (0.7); 7.4608 (0.7); 7.3389 (0.7); 7.3299 (0.8); 7.3273 (0.8); 7.3183 (1.2); 7.3092 (0.6); 7.3067 (0.6); 7.2976 (0.6); 7.2606 (37.3); 6.9553 (0.7); 6.9492 (0.8); 6.9341 (0.7); 6.9280 (0.7); 5.3047 (1.4); 5.2873 (1.5); 4.3622 (0.7); 4.3506 (1.0); 4.3370 (0.8); 4.3326 (0.7); 4.3194 (1.0); 4.3084 (0.8); 3.7111 (1.0); 3.7076 (1.0); 3.7004 (1.2); 3.6968 (1.6); 3.6865 (0.9); 3.6829 (0.9); 3.6119 (0.9); 3.6077 (0.9); 3.6013 (2.0); 3.5968 (1.2); 3.5939 (1.4); 3.5878 (1.5); 3.5858 (1.6); 3.5110 (2.4); 3.5055 (0.6); 3.5022 (1.2); 3.4984 (2.1); 3.4948 (0.6); 3.4882 (1.2); 3.3601 (16.0); 1.7080 (5.4); 1.6906 (5.4); 1.6265 (2.2); 0.0079 (1.9); -0.0002 (53.3); -0.0085 (1.8) I-35: 1< H-NMR(400.6 MHz, CDCl3): δ= 8.2149 (0.6); 8.2132 (0.7); 8.2113 (0.7); 8.2096 (0.6); 8.2033 (0.6); 8.2015 (0.7); 8.1997 (0.7); 8.1981 (0.6); 8.1294 (0.9); 8.1232 (1.0); 7.8593 (0.5); 7.8406 (0.6); 7.8381 (0.6); 7.8343 (0.6); 7.8319 (0.6); 7.8194 (0.5); 7.8131 (0.5); 7.5040 (0.5); 7.4870 (0.7); 7.4836 (0.8); 7.4808 (0.6); 7.4638 (0.6); 7.4601 (0.6); 7.3357 (0.6); 7.3268 (0.7); 7.3241 (0.6); 7.3151 (1.1); 7.3035 (0.5); 7.2609 (56.6); 6.9576 (0.6); 6.9561 (0.7); 6.9501 (0.7); 6.9486 (0.7); 6.9364 (0.6); 6.9349 (0.6); 6.9289 (0.6); 6.9274 (0.6); 5.3136 (1.3); 5.2962 (1.4); 4.3344 (0.8); 4.3281 (0.9); 4.3247 (0.9); 4.3214 (1.0); 4.3171 (1.0); 4.3138 (0.9); 4.3100 (1.0); 4.3045 (0.9); 3.6013 (1.0); 3.5974 (1.0); 3.5887 (1.7); 3.5861 (1.8); 3.5773 (0.9); 3.5734 (0.9); 3.3304 (16.0); 1.7121 (5.1); 1.6947 (5.1); 1.5523 (2.4); 0.0080 (1.0); -0.0002 (34.2); -0.0085 (0.9) I-35: 1< H-NMR(400.6 MHz, CDCl3): δ= 8.2149 (0.6); 8.2130 (0.7); 8.2112 (0.7); 8.2095 (0.7); 8.2032 (0.6); 8.2015 (0.7); 8.1996 (0.7); 8.1979 (0.7); 8.1293 (0.9); 8.1231 (1.0); 7.8593 (0.5); 7.8406 (0.6); 7.8381 (0.6); 7.8343 (0.6); 7.8319 (0.6); 7.8194 (0.5); 7.8131 (0.5); 7.5075 (0.5); 7.5038 (0.5); 7.4869 (0.7); 7.4834 (0.9); 7.4806 (0.6); 7.4636 (0.6); 7.4599 (0.6); 7.3355 (0.7); 7.3266 (0.7); 7.3239 (0.7); 7.3149 (1.2); 7.3059 (0.5); 7.3033 (0.5); 7.2607 (20.0); 6.9575 (0.6); 6.9560 (0.7); 6.9500 (0.7); 6.9486 (0.7); 6.9362 (0.6); 6.9347 (0.7); 6.9288 (0.6); 6.9273 (0.6); 5.3137 (1.4); 5.2963 (1.4); 4.3344 (0.8); 4.3281 (0.9); 4.3247 (0.9); 4.3213 (1.1); 4.3171 (1.1); 4.3138 (1.0); 4.3100 (1.0); 4.3045 (0.9); 3.6013 (1.0); 3.5973 (1.0); 3.5886 (1.7); 3.5860 (1.8); 3.5772 (0.9); 3.5733 (1.0); 3.3304 (16.0); 1.7120 (5.3); 1.6946 (5.2); 1.5480 (12.0); 0.0080 (0.8); -0.0002 (30.1); -0.0085 (0.9) I-36: 1< H-NMR(599.6 MHz, CDCl3): δ= 8.6302 (2.0); 8.2879 (2.2); 8.2811 (2.2); 8.1464 (3.1); 7.8591 (0.9); 7.8452 (1.7); 7.8326 (1.0); 7.5382 (1.0); 7.5230 (2.1); 7.5091 (1.2); 7.4030 (0.9); 7.3962 (1.5); 7.3894 (1.6); 7.3829 (1.2); 7.2602 (32.6); 6.9805 (1.7); 6.9665 (1.7); 4.9133 (10.7); 4.1279 (0.6); 4.1159 (0.6); 2.9962 (33.0); 2.0444 (2.6); 1.5479 (41.5); 1.2710 (1.1); 1.2592 (2.1); 1.2474 (0.9); 0.8933 (0.4); 0.8821 (0.9); 0.8702 (0.4); -0.0001 (50.0) I-36: 1< H-NMR(400.6 MHz, CDCl3): δ= 8.1481 (0.5); 8.1418 (0.5); 7.3910 (0.7); 7.2610 (11.3); 4.9143 (4.6); 2.9970 (16.0); 2.9898 (0.6); 2.0455 (1.0); 1.5538 (2.7); 1.2596 (0.7); -0.0002 (17.2) I-37: 1< H-NMR(400.0 MHz, CDCl3_5mm): δ= 8.2588 (0.8); 8.2572 (0.9); 8.2554 (0.9); 8.2472 (0.8); 8.2456 (0.9); 8.2438 (0.9); 8.1350 (1.2); 8.1289 (1.2); 7.8645 (0.6); 7.8582 (0.6); 7.8457 (0.7); 7.8433 (0.7); 7.8395 (0.7); 7.8371 (0.7); 7.8245 (0.6); 7.8183 (0.6); 7.5103 (0.6); 7.5066 (0.6); 7.4895 (0.8); 7.4862 (1.0); 7.4836 (0.7); 7.4665 (0.7); 7.4628 (0.7); 7.3588 (0.7); 7.3498 (0.8); 7.3472 (0.8); 7.3382 (1.2); 7.3291 (0.6); 7.3266 (0.6); 7.2622 (8.2); 6.9646 (0.8); 6.9633 (0.8); 6.9571 (0.8); 6.9433 (0.8); 6.9421 (0.8); 6.9359 (0.8); 4.9801 (7.5); 4.3790 (1.8); 4.3701 (1.3); 4.3670 (2.0); 4.3634 (1.2); 4.3548 (1.8); 3.7374 (2.1); 3.7289 (1.3); 3.7252 (2.1); 3.7220 (1.3); 3.7132 (1.8); 3.6404 (1.5); 3.6321 (1.6); 3.6295 (2.0); 3.6243 (1.6); 3.6174 (2.5); 3.5371 (2.6); 3.5302 (1.6); 3.5250 (1.9); 3.5224 (1.5); 3.5142 (1.4); 3.3724 (16.0); 1.5661 (7.2); 0.0079 (0.6); -0.0002 (12.7) I-37: 1< H-NMR(400.0 MHz, CDCl3): δ= 8.2569 (0.9); 8.2435 (1.0); 8.1350 (1.2); 8.1285 (1.2); 7.8644 (0.5); 7.8580 (0.5); 7.8432 (0.7); 7.8395 (0.7); 7.8244 (0.6); 7.8184 (0.6); 7.5196 (0.6); 7.5095 (0.5); 7.5059 (0.5); 7.4862 (1.0); 7.4657 (0.7); 7.4618 (0.7); 7.3581 (0.8); 7.3487 (0.9); 7.3373 (1.1); 7.3282 (0.6); 7.2606 (108.8); 6.9966 (0.6); 6.9641 (0.8); 6.9565 (0.9); 6.9427 (0.8); 6.9351 (0.8); 4.9798 (7.6); 4.3788 (1.7); 4.3668 (1.9); 4.3546 (1.9); 3.7371 (2.0); 3.7287 (1.2); 3.7250 (2.0); 3.7130 (1.8); 3.6403 (1.4); 3.6293 (1.9); 3.6241 (1.5); 3.6172 (2.6); 3.5369 (2.5); 3.5300 (1.4); 3.5249 (1.9); 3.5137 (1.4); 3.3724 (16.0); 1.5424 (12.2); 0.0080 (1.6); -0.0002 (66.1); - 0.0085 (2.1) I-38: 1< H-NMR(400.0 MHz, CDCl3): δ= 8.2633 (1.7); 8.2517 (1.7); 8.1287 (2.3); 8.1225 (2.3); 7.8610 (1.1); 7.8546 (1.1); 7.8422 (1.3); 7.8397 (1.3); 7.8359 (1.3); 7.8335 (1.2); 7.8210 (1.2); 7.8147 (1.1); 7.5198 (0.5); 7.5167 (1.1); 7.5130 (1.1); 7.4959 (1.5); 7.4925 (1.9); 7.4900 (1.2); 7.4728 (1.4); 7.4691 (1.3); 7.3620 (1.3); 7.3529 (1.6); 7.3504 (1.4); 7.3413 (2.3); 7.3322 (1.1); 7.3297 (1.1); 7.3206 (1.0); 7.2610 (70.8); 6.9676 (1.5); 6.9614 (1.5); 6.9476 (1.5); 6.9401 (1.4); 4.9380 (16.0); 4.2936 (1.9); 4.2757 (6.1); 4.2578 (6.2); 4.2400 (2.0); 1.5488 (5.2); 1.3054 (7.3); 1.2875 (15.0); 1.2697 (7.2); 0.0079 (1.2); -0.0002 (42.2); -0.0085 (1.2) I-38: 1< H-NMR(400.0 MHz, CDCl3): δ= 8.2620 (2.5); 8.2517 (2.5); 8.1287 (3.4); 7.8610 (1.2); 7.8550 (1.2); 7.8418 (1.9); 7.8358 (1.8); 7.8211 (1.2); 7.8150 (1.1); 7.5167 (1.3); 7.4933 (2.5); 7.4731 (1.6); 7.3624 (1.3); 7.3526 (1.9); 7.3417 (2.1); 7.3323 (1.5); 7.3212 (0.9); 7.2613 (42.9); 6.9688 (2.1); 6.9615 (2.0); 6.9477 (2.0); 6.9404 (1.8); 4.9383 (16.0); 4.2938 (2.1); 4.2758 (6.2); 4.2580 (6.2); 4.2401 (2.1); 1.5586 (2.2); 1.3054 (6.9); 1.2876 (13.5); 1.2697 (6.6); -0.0002 (26.0) I-39: 1< H-NMR(400.0 MHz, CDCl3_5mm): δ= 8.2605 (1.5); 8.2588 (1.8); 8.2570 (1.8); 8.2553 (1.6); 8.2489 (1.6); 8.2471 (1.8); 8.2453 (1.8); 8.2437 (1.5); 8.1378 (2.3); 8.1359 (1.9); 8.1336 (1.9); 8.1316 (2.4); 7.8678 (1.2); 7.8616 (1.1); 7.8490 (1.4); 7.8466 (1.5); 7.8428 (1.4); 7.8404 (1.4); 7.8278 (1.2); 7.8216 (1.1); 7.5103 (1.2); 7.5066 (1.2); 7.4896 (1.7); 7.4861 (2.0); 7.4836 (1.4); 7.4665 (1.5); 7.4628 (1.4); 7.3583 (1.5); 7.3492 (1.7); 7.3466 (1.6); 7.3376 (2.5); 7.3285 (1.2); 7.3260 (1.2); 7.3169 (1.0); 7.2641 (6.7); 6.9654 (1.6); 6.9640 (1.6); 6.9581 (1.6); 6.9566 (1.6); 6.9442 (1.5); 6.9428 (1.6); 6.9368 (1.5); 6.9353 (1.5); 5.3007 (3.1); 4.9373 (16.0); 4.2908 (2.0); 4.2729 (6.2); 4.2551 (6.3); 4.2372 (2.0); 1.5858 (5.0); 1.3037 (7.7); 1.2974 (0.6); 1.2858 (15.7); 1.2796 (0.7); 1.2679 (7.5); -0.0002 (10.6) I-39: 1< H-NMR(400.0 MHz, CDCl3): δ= 8.2585 (1.8); 8.2567 (1.7); 8.2468 (1.8); 8.2450 (1.7); 8.1373 (2.3); 8.1311 (2.3); 7.8676 (1.1); 7.8613 (1.1); 7.8488 (1.3); 7.8463 (1.4); 7.8426 (1.3); 7.8401 (1.3); 7.8276 (1.2); 7.8214 (1.1); 7.5198 (0.5); 7.5087 (1.1); 7.5049 (1.1); 7.4879 (1.6); 7.4845 (1.8); 7.4649 (1.4); 7.4611 (1.4); 7.3565 (1.4); 7.3474 (1.7); 7.3449 (1.4); 7.3358 (2.4); 7.3268 (1.2); 7.3242 (1.2); 7.3151 (1.0); 7.2609 (90.8); 6.9629 (1.6); 6.9567 (1.6); 6.9430 (1.5); 6.9356 (1.6); 4.9367 (16.0); 4.2909 (2.0); 4.2730 (6.1); 4.2552 (6.2); 4.2373 (2.0); 1.5461 (10.5); 1.3038 (7.5); 1.2859 (15.3); 1.2680 (7.3); 0.0079 (1.6); -0.0002 (53.6); -0.0085 (1.6) I-40: 1< H-NMR(400.6 MHz, CDCl3): δ= 8.2293 (1.2); 8.2274 (1.4); 8.2256 (1.4); 8.2239 (1.2); 8.2176 (1.2); 8.2157 (1.4); 8.2140 (1.4); 8.2122 (1.2); 8.1363 (1.9); 8.1342 (1.5); 8.1321 (1.5); 8.1301 (2.0); 7.7748 (1.0); 7.7686 (1.0); 7.7558 (1.2); 7.7537 (1.3); 7.7496 (1.2); 7.7475 (1.2); 7.7347 (1.1); 7.7285 (1.0); 7.4624 (1.0); 7.4586 (1.1); 7.4418 (1.4); 7.4385 (1.8); 7.4352 (1.2); 7.4184 (1.3); 7.4146 (1.3); 7.2867 (1.2); 7.2777 (1.4); 7.2751 (1.3); 7.2660 (2.7); 7.2614 (66.0); 7.2546 (1.2); 7.2455 (0.9); 6.9194 (1.3); 6.9179 (1.4); 6.9120 (1.4); 6.9105 (1.3); 6.8983 (1.3); 6.8968 (1.3); 6.8909 (1.3); 6.8894 (1.3); 4.8877 (14.6); 4.2747 (1.8); 4.2568 (5.8); 4.2390 (5.8); 4.2212 (1.9); 1.6015 (0.5); 1.5999 (0.6); 1.5951 (0.8); 1.5877 (0.6); 1.5808 (1.9); 1.5730 (0.6); 1.5675 (0.6); 1.5655 (0.7); 1.5611 (0.9); 1.5540 (7.6); 1.5465 (0.6); 1.3011 (7.6); 1.2833 (16.0); 1.2655 (7.6); 0.7979 (1.2); 0.7932 (3.7); 0.7902 (3.0); 0.7871 (3.2); 0.7843 (4.7); 0.7823 (3.2); 0.7794 (4.4); 0.7753 (2.3); 0.7679 (2.4); 0.7639 (3.4); 0.7609 (1.6); 0.7583 (1.5); 0.0080 (1.2); -0.0002 (41.0); -0.0085 (1.0). I-41: 1< H-NMR(400.6 MHz, CDCl3): δ= 8.2220 (0.7); 8.2202 (0.8); 8.2183 (0.8); 8.2166 (0.7); 8.2103 (0.8); 8.2085 (0.8); 8.2067 (0.8); 8.2051 (0.7); 8.1279 (1.1); 8.1258 (0.8); 8.1236 (0.9); 8.1218 (1.1); 7.8570 (0.6); 7.8507 (0.6); 7.8382 (0.7); 7.8357 (0.7); 7.8320 (0.7); 7.8295 (0.7); 7.8170 (0.6); 7.8108 (0.6); 7.5206 (0.7); 7.5169 (0.6); 7.5000 (0.8); 7.4970 (1.0); 7.4936 (0.7); 7.4767 (0.8); 7.4730 (0.7); 7.3441 (0.7); 7.3351 (0.8); 7.3325 (0.8); 7.3234 (1.3); 7.3145 (0.6); 7.3118 (0.6); 7.3028 (0.5); 7.2611 (44.6); 6.9634 (0.8); 6.9619 (0.8); 6.9559 (0.8); 6.9544 (0.8); 6.9421 (0.8); 6.9406 (0.8); 6.9347 (0.8); 6.9331 (0.7); 5.2926 (1.5); 5.2752 (1.5); 3.7708 (16.0); 1.7001 (6.4); 1.6828 (6.4); 1.5547 (1.0); 0.0080 (0.8); -0.0002 (27.8); -0.0085 (0.8) I-42: 1< H-NMR(400.6 MHz, CDCl3): δ= 8.2315 (0.7); 8.2296 (0.9); 8.2279 (0.9); 8.2261 (0.8); 8.2198 (0.8); 8.2179 (0.9); 8.2162 (0.9); 8.2144 (0.8); 8.1366 (1.2); 8.1303 (1.2); 7.7747 (0.6); 7.7685 (0.6); 7.7557 (0.7); 7.7536 (0.8); 7.7495 (0.7); 7.7474 (0.8); 7.7346 (0.7); 7.7284 (0.7); 7.5191 (0.6); 7.4641 (0.6); 7.4604 (0.7); 7.4436 (0.8); 7.4401 (1.2); 7.4370 (0.7); 7.4201 (0.8); 7.4164 (0.8); 7.2895 (0.7); 7.2805 (0.9); 7.2778 (0.9); 7.2689 (1.8); 7.2607 (110.2); 7.2509 (0.7); 7.2484 (1.0); 6.9970 (0.6); 6.9201 (0.8); 6.9186 (0.9); 6.9126 (0.9); 6.9111 (0.9); 6.8990 (0.8); 6.8975 (0.8); 6.8915 (0.8); 6.8900 (0.8); 4.9056 (8.5); 3.7858 (16.0); 1.5980 (0.8); 1.5811 (1.2); 1.5639 (1.2); 1.5473 (3.0); 0.7823 (10.1); 0.7652 (6.5); 0.0079 (1.9); -0.0002 (66.1); -0.0085 (2.0) I-43: 1< H-NMR(400.6 MHz, CDCl3): δ= 8.2723 (1.8); 8.2623 (1.8); 8.2607 (1.8); 8.1385 (2.7); 8.1324 (2.8); 7.7709 (1.1); 7.7647 (1.1); 7.7519 (1.4); 7.7499 (1.5); 7.7457 (1.4); 7.7437 (1.5); 7.7309 (1.2); 7.7247 (1.2); 7.4642 (1.1); 7.4607 (1.1); 7.4435 (1.6); 7.4404 (2.2); 7.4375 (1.4); 7.4203 (1.4); 7.4168 (1.4); 7.3098 (1.2); 7.3007 (1.5); 7.2984 (1.4); 7.2892 (2.1); 7.2801 (1.1); 7.2778 (1.2); 7.2686 (1.0); 7.2626 (34.1); 6.9256 (1.7); 6.9193 (1.7); 6.9044 (1.7); 6.8982 (1.6); 5.3001 (1.1); 4.9419 (16.0); 1.6072 (0.5); 1.5933 (1.0); 1.5867 (1.1); 1.5809 (0.7); 1.5731 (2.0); 1.5669 (0.8); 1.5590 (1.0); 1.5526 (1.1); 1.5389 (0.6); 1.4320 (1.2); 1.2644 (1.6); 0.8986 (0.9); 0.8817 (3.3); 0.8640 (1.2); 0.7961 (0.6); 0.7808 (1.8); 0.7762 (3.1); 0.7734 (2.1); 0.7697 (2.5); 0.7601 (2.0); 0.7574 (2.2); 0.7532 (4.2); 0.7495 (4.2); 0.7462 (3.1); 0.7386 (3.0); 0.7341 (3.6); 0.7312 (2.2); 0.7282 (2.1); 0.0079 (0.5); -0.0002 (20.9); -0.0085 (0.7) I-07: 1< H-NMR(400.6 MHz, CDCl3): δ= 8.2632 (0.8); 8.2614 (0.9); 8.2596 (0.9); 8.2578 (0.8); 8.2516 (0.9); 8.2498 (1.0); 8.2479 (0.9); 8.2463 (0.8); 8.1390 (1.2); 8.1369 (0.9); 8.1347 (1.0); 8.1328 (1.2); 8.1309 (0.8); 7.8678 (0.7); 7.8615 (0.6); 7.8490 (0.8); 7.8466 (0.8); 7.8428 (0.8); 7.8403 (0.8); 7.8279 (0.7); 7.8216 (0.7); 7.5122 (0.6); 7.5085 (0.7); 7.4915 (0.9); 7.4890 (1.0); 7.4880 (1.0); 7.4855 (0.7); 7.4685 (0.9); 7.4648 (0.8); 7.3610 (0.8); 7.3519 (1.0); 7.3494 (0.8); 7.3403 (1.4); 7.3312 (0.7); 7.3287 (0.7); 7.3197 (0.6); 7.2628 (6.7); 6.9662 (0.9); 6.9647 (0.9); 6.9588 (0.9); 6.9572 (0.8); 6.9451 (0.9); 6.9435 (0.8); 6.9376 (0.9); 6.9361 (0.8); 4.9572 (8.6); 3.8007 (16.0); 2.0453 (1.1); 1.5693 (1.3); 1.2595 (0.8); 0.8818 (0.5); -0.0002 (9.2) I-07: 1< H-NMR(400.6 MHz, CDCl3): δ= 8.2637 (0.8); 8.2618 (0.9); 8.2600 (0.9); 8.2583 (0.9); 8.2520 (0.9); 8.2502 (1.0); 8.2484 (1.0); 8.2467 (0.9); 8.1384 (1.2); 8.1364 (1.0); 8.1322 (1.3); 7.8677 (0.7); 7.8615 (0.6); 7.8490 (0.7); 7.8465 (0.8); 7.8428 (0.8); 7.8403 (0.8); 7.8278 (0.7); 7.8216 (0.7); 7.5116 (0.7); 7.5079 (0.7); 7.4909 (0.9); 7.4873 (1.1); 7.4848 (0.8); 7.4679 (0.9); 7.4641 (0.9); 7.3606 (0.8); 7.3516 (1.0); 7.3490 (0.9); 7.3399 (1.5); 7.3309 (0.7); 7.3283 (0.7); 7.3193 (0.6); 7.2612 (61.9); 7.2530 (0.7); 7.2522 (0.6); 6.9660 (0.9); 6.9645 (0.9); 6.9585 (0.9); 6.9570 (0.9); 6.9448 (0.8); 6.9433 (0.9); 6.9373 (0.9); 6.9358 (0.8); 4.9570 (8.7); 3.8011 (16.0); 1.5493 (7.5); 0.0079 (1.0); -0.0002 (37.0); -0.0051 (0.9); -0.0059 (0.7); -0.0068 (0.7); -0.0085 (1.3) I-10: 1< H-NMR(400.0 MHz, CDCl3): δ= 8.2644 (2.7); 8.2549 (2.8); 8.1326 (4.0); 8.1264 (4.0); 7.8656 (1.8); 7.8594 (1.7); 7.8468 (2.1); 7.8444 (2.2); 7.8406 (2.0); 7.8382 (1.9); 7.8257 (1.8); 7.8194 (1.7); 7.5058 (1.6); 7.5022 (1.7); 7.4851 (2.4); 7.4818 (3.0); 7.4620 (2.2); 7.4583 (2.1); 7.3557 (2.1); 7.3465 (2.4); 7.3441 (2.2); 7.3350 (3.6); 7.3259 (1.7); 7.3234 (1.6); 7.3142 (1.4); 7.2608 (37.3); 6.9669 (2.6); 6.9604 (2.5); 6.9454 (2.5); 6.9391 (2.4); 5.3739 (1.2); 5.3564 (4.4); 5.3389 (4.5); 5.3214 (1.2); 5.3000 (1.9); 1.7448 (16.0); 1.7273 (15.8); 1.7156 (0.9); 0.0079 (1.4); -0.0002 (48.8); -0.0085 (1.4) 1-10: 1< H-NMR(400.0 MHz, CDCl3_5mm): δ= 8.2667 (4.7); 8.2558 (3.8); 8.1301 (5.8); 7.8630 (2.7); 7.8568 (2.7); 7.8420 (3.4); 7.8231 (1.8); 7.8170 (1.5); 7.5001 (2.6); 7.4800 (4.0); 7.4596 (2.2); 7.3555 (3.1); 7.3446 (3.6); 7.3349 (3.6); 7.3257 (2.4); 7.3143 (1.6); 7.2620 (14.9); 6.9659 (4.0); 6.9591 (3.6); 6.9448 (3.2); 6.9382 (2.6); 5.3607 (2.1); 5.3438 (4.2); 5.3264 (3.8); 5.3088 (1.4); 5.3005 (1.4); 3.6410 (4.4); 1.7398 (16.0); 1.7224 (13.3); 1.2541 (2.3); -0.0002 (22.2) 1-10: 1< H-NMR(400.6 MHz, CDCl3): δ= 8.2713 (2.2); 8.2698 (2.6); 8.2677 (2.6); 8.2663 (2.5); 8.2597 (2.4); 8.2581 (2.7); 8.2561 (2.7); 8.2547 (2.5); 8.1313 (3.6); 8.1251 (3.9); 7.8663 (1.8); 7.8601 (1.7); 7.8476 (2.0); 7.8451 (2.2); 7.8414 (2.0); 7.8389 (2.1); 7.8264 (1.9); 7.8202 (1.8); 7.5034 (1.7); 7.4996 (1.8); 7.4826 (2.4); 7.4791 (2.9); 7.4766 (2.2); 7.4596 (2.3); 7.4559 (2.3); 7.3542 (2.3); 7.3452 (2.5); 7.3426 (2.4); 7.3335 (3.9); 7.3245 (1.8); 7.3219 (1.9); 7.3128 (1.6); 7.2615 (24.5); 6.9682 (2.3); 6.9669 (2.5); 6.9610 (2.4); 6.9596 (2.4); 6.9471 (2.2); 6.9457 (2.4); 6.9397 (2.3); 6.9383 (2.3); 5.3723 (1.2); 5.3549 (4.8); 5.3374 (4.9); 5.3199 (1.2); 2.1740 (1.2); 1.7423 (16.0); 1.7248 (15.9); 1.7111 (0.7); 0.8818 (0.6); 0.0080 (0.8); -0.0002 (31.7); -0.0085 (1.0) 1-10: 1< H-NMR(400.6 MHz, CDCl3): δ= 8.2697 (2.5); 8.2677 (2.6); 8.2595 (2.4); 8.2580 (2.7); 8.2560 (2.7); 8.1330 (3.5); 8.1268 (3.9); 7.8671 (1.6); 7.8608 (1.6); 7.8484 (1.9); 7.8458 (2.1); 7.8421 (2.0); 7.8397 (2.1); 7.8272 (1.8); 7.8210 (1.8); 7.5068 (1.6); 7.5031 (1.7); 7.4860 (2.3); 7.4827 (2.9); 7.4801 (2.1); 7.4630 (2.2); 7.4593 (2.2); 7.3572 (2.1); 7.3481 (2.5); 7.3455 (2.3); 7.3364 (3.7); 7.3274 (1.8); 7.3248 (1.8); 7.3158 (1.6); 7.2610 (26.2); 6.9684 (2.4); 6.9623 (2.4); 6.9611 (2.4); 6.9471 (2.4); 6.9410 (2.4); 6.9399 (2.3); 5.3734 (1.2); 5.3560 (4.6); 5.3385 (4.7); 5.3210 (1.3); 1.7447 (15.9); 1.7272 (16.0); 1.7147 (0.8); 0.8819 (0.7); 0.0079 (1.2); -0.0002 (40.7); - 0.0085 (1.6) I-05: 1< H-NMR(400.6 MHz, CDCl 3 ): δ= 8.2168 (0.7); 8.2151 (0.8); 8.2132 (0.8); 8.2115 (0.8); 8.2052 (0.7); 8.2034 (0.8); 8.2016 (0.8); 8.1999 (0.8); 8.1359 (1.1); 8.1340 (0.8); 8.1318 (0.8); 8.1297 (1.1); 7.8634 (0.6); 7.8572 (0.6); 7.8447 (0.7); 7.8423 (0.7); 7.8384 (0.7); 7.8360 (0.7); 7.8235 (0.6); 7.8172 (0.6); 7.5130 (0.6); 7.5093 (0.6); 7.4923 (0.8); 7.4888 (1.0); 7.4860 (0.7); 7.4690 (0.8); 7.4653 (0.8); 7.3390 (0.8); 7.3300 (0.8); 7.3274 (0.8); 7.3183 (1.3); 7.3094 (0.6); 7.3067 (0.6); 7.2977 (0.6); 7.2621 (21.6); 6.9586 (0.7); 6.9572 (0.8); 6.9512 (0.8); 6.9497 (0.8); 6.9374 (0.7); 6.9359 (0.8); 6.9300 (0.8); 6.9285 (0.8); 5.2887 (1.6); 5.2713 (1.6); 3.7688 (16.0); 2.0454 (0.5); 1.6986 (6.5); 1.6812 (6.5); 1.5647 (2.2); 1.2596 (0.5); 0.8818 (0.7); -0.0002 (13.4) I-05: 1< H-NMR(400.6 MHz, CDCl3): δ= 8.2164 (0.8); 8.2146 (0.9); 8.2128 (0.9); 8.2111 (0.7); 8.2048 (0.8); 8.2030 (0.9); 8.2011 (0.9); 8.1995 (0.7); 8.1362 (1.1); 8.1341 (0.9); 8.1319 (0.9); 8.1300 (1.2); 7.8635 (0.6); 7.8572 (0.6); 7.8447 (0.7); 7.8423 (0.7); 7.8384 (0.7); 7.8360 (0.7); 7.8236 (0.6); 7.8173 (0.6); 7.5130 (0.6); 7.5093 (0.6); 7.4923 (0.8); 7.4889 (1.0); 7.4861 (0.7); 7.4691 (0.8); 7.4654 (0.7); 7.3388 (0.8); 7.3298 (0.8); 7.3272 (0.8); 7.3182 (1.3); 7.3091 (0.6); 7.3066 (0.6); 7.2976 (0.6); 7.2625 (5.9); 6.9586 (0.8); 6.9571 (0.8); 6.9511 (0.9); 6.9497 (0.8); 6.9374 (0.8); 6.9359 (0.8); 6.9299 (0.8); 6.9285 (0.7); 5.2890 (1.6); 5.2716 (1.6); 3.7686 (16.0); 1.6986 (6.5); 1.6812 (6.4); 1.5702 (0.8); 0.8818 (0.6); -0.0002 (7.9) I-03: 1< H-NMR(400.0 MHz, CDCl3): δ= 8.5762 (1.6); 8.5671 (1.5); 8.5643 (1.6); 8.4971 (2.3); 8.4934 (2.3); 8.2124 (1.7); 8.2010 (1.7); 7.7525 (1.3); 7.7325 (1.4); 7.4880 (0.8); 7.4674 (1.6); 7.4444 (1.0); 7.3219 (1.8); 7.3110 (1.8); 7.3023 (2.4); 7.2903 (1.7); 7.2819 (0.7); 7.2620 (9.2); 5.3215 (0.6); 5.3040 (1.8); 5.2866 (1.8); 5.2691 (0.6); 3.7703 (16.0); 2.7737 (1.9); 1.7011 (7.5); 1.6837 (7.4); -0.0002 (10.4) I-06: 1< H-NMR(400.6 MHz, CDCl3): δ= 8.2844 (0.8); 8.2828 (0.8); 8.2808 (0.9); 8.2792 (0.8); 8.2729 (0.8); 8.2712 (0.9); 8.2692 (0.9); 8.2677 (0.8); 8.1353 (1.1); 8.1334 (0.8); 8.1309 (0.9); 8.1290 (1.2); 7.9558 (0.6); 7.9494 (0.6); 7.9376 (0.7); 7.9345 (0.8); 7.9312 (0.7); 7.9281 (0.7); 7.9163 (0.7); 7.9099 (0.6); 7.5892 (0.6); 7.5855 (0.6); 7.5684 (0.9); 7.5665 (0.8); 7.5648 (0.9); 7.5629 (0.7); 7.5457 (0.8); 7.5421 (0.8); 7.4541 (0.8); 7.4449 (0.9); 7.4425 (0.8); 7.4333 (1.3); 7.4241 (0.6); 7.4217 (0.6); 7.4125 (0.5); 7.2632 (5.3); 7.0251 (0.8); 7.0236 (0.8); 7.0176 (0.8); 7.0161 (0.8); 7.0038 (0.8); 7.0023 (0.8); 6.9962 (0.8); 6.9947 (0.8); 5.2648 (1.5); 5.2474 (1.6); 3.7689 (16.0); 2.0453 (0.6); 1.7006 (6.3); 1.6832 (6.2); 1.5683 (0.7); -0.0002 (7.0) I-09: 1< H-NMR(400.6 MHz, CDCl3): δ= 8.3199 (0.8); 8.3184 (0.9); 8.3164 (0.9); 8.3150 (0.9); 8.3083 (0.8); 8.3069 (1.0); 8.3048 (0.9); 8.1365 (1.2); 8.1302 (1.3); 7.9623 (0.7); 7.9559 (0.6); 7.9441 (0.7); 7.9410 (0.8); 7.9377 (0.7); 7.9346 (0.7); 7.9228 (0.7); 7.9164 (0.7); 7.5890 (0.6); 7.5854 (0.6); 7.5681 (0.9); 7.5667 (0.8); 7.5645 (1.0); 7.5457 (0.8); 7.5420 (0.8); 7.4696 (0.8); 7.4604 (1.0); 7.4581 (0.9); 7.4488 (1.4); 7.4395 (0.6); 7.4373 (0.6); 7.4280 (0.6); 7.2616 (11.6); 7.0326 (0.8); 7.0313 (0.9); 7.0251 (0.9); 7.0238 (0.9); 7.0113 (0.8); 7.0100 (0.9); 7.0038 (0.8); 7.0025 (0.8); 4.9528 (8.7); 4.1309 (0.5); 4.1131 (0.5); 3.8038 (16.0); 2.0454 (2.4); 1.5509 (1.2); 1.2775 (0.7); 1.2596 (1.4); 1.2418 (0.6); -0.0002 (15.2) I-04: 1< H-NMR(400.0 MHz, CDCl3): δ= 8.6474 (1.0); 8.6434 (1.1); 8.6352 (1.1); 8.6312 (1.1); 8.4585 (1.4); 8.4539 (1.4); 8.2784 (1.0); 8.2689 (1.0); 7.8547 (0.7); 7.8503 (0.9); 7.8448 (0.7); 7.8347 (0.8); 7.8301 (1.0); 7.8248 (0.7); 7.5667 (0.6); 7.5630 (0.6); 7.5456 (1.0); 7.5422 (1.0); 7.5232 (0.8); 7.5196 (0.8); 7.4361 (0.8); 7.4268 (0.9); 7.4246 (0.8); 7.4153 (1.3); 7.4060 (0.6); 7.4038 (0.6); 7.3945 (0.6); 7.3885 (0.8); 7.3761 (0.8); 7.3685 (0.8); 7.3564 (0.8); 7.2617 (9.5); 5.2775 (1.7); 5.2600 (1.7); 3.7702 (16.0); 2.1270 (0.5); 2.0913 (0.9); 1.7023 (6.6); 1.6848 (6.5); -0.0002 (14.9) I-44: 1< H-NMR(400.6 MHz, CDCl 3 ): δ= 8.2886 (0.9); 8.2869 (1.0); 8.2850 (1.1); 8.2834 (1.0); 8.2770 (1.0); 8.2753 (1.1); 8.2734 (1.1); 8.2718 (1.0); 8.1543 (1.4); 8.1480 (1.5); 7.8684 (0.7); 7.8622 (0.7); 7.8499 (0.8); 7.8472 (0.9); 7.8437 (0.8); 7.8410 (0.9); 7.8287 (0.8); 7.8224 (0.8); 7.5556 (0.7); 7.5519 (0.8); 7.5348 (1.0); 7.5312 (1.2); 7.5290 (0.9); 7.5119 (1.0); 7.5082 (1.0); 7.4147 (1.0); 7.4055 (1.1); 7.4031 (1.0); 7.3940 (1.7); 7.3848 (0.8); 7.3824 (0.8); 7.3732 (0.7); 7.2618 (17.1); 6.9914 (0.9); 6.9900 (1.0); 6.9840 (1.0); 6.9825 (1.0); 6.9702 (0.9); 6.9687 (1.0); 6.9627 (1.0); 6.9613 (1.0); 4.9522 (11.5); 3.3771 (16.0); 3.3705 (0.8); 2.1725 (3.9); 0.8819 (0.7); 0.0080 (0.6); -0.0002 (21.4); -0.0085 (0.7) I-45: 1< H-NMR(400.6 MHz, CDCl3): δ= 8.2753 (0.8); 8.2734 (0.8); 8.2637 (0.8); 8.2618 (0.8); 8.1311 (1.1); 8.1249 (1.2); 7.8640 (0.5); 7.8578 (0.5); 7.8452 (0.6); 7.8428 (0.7); 7.8390 (0.6); 7.8366 (0.6); 7.8241 (0.6); 7.8179 (0.6); 7.5011 (0.5); 7.4975 (0.5); 7.4804 (0.8); 7.4773 (0.9); 7.4747 (0.6); 7.4575 (0.7); 7.4538 (0.7); 7.3653 (0.7); 7.3562 (0.8); 7.3538 (0.7); 7.3446 (1.2); 7.3355 (0.6); 7.3331 (0.6); 7.2609 (29.4); 6.9670 (0.8); 6.9604 (0.8); 6.9466 (0.7); 6.9392 (0.7); 5.1198 (8.6); 2.0433 (14.2); 1.9725 (15.2); 1.5477 (16.0); 1.2599 (0.7); 0.0081 (1.0); -0.0002 (34.2); -0.0085 (1.2) I-46: 1< H-NMR(400.6 MHz, CDCl3): δ= 8.5752 (1.4); 8.5650 (1.4); 8.5631 (1.4); 8.2657 (1.6); 8.2639 (1.7); 8.2542 (1.7); 8.2523 (1.7); 8.1326 (2.2); 8.1263 (2.4); 7.8629 (1.1); 7.8567 (1.1); 7.8441 (1.3); 7.8418 (1.4); 7.8379 (1.3); 7.8355 (1.3); 7.8230 (1.2); 7.8168 (1.2); 7.6351 (1.0); 7.6306 (1.0); 7.6158 (2.0); 7.6114 (2.0); 7.5966 (1.2); 7.5921 (1.2); 7.5121 (1.0); 7.5084 (1.1); 7.4913 (1.6); 7.4882 (1.8); 7.4854 (1.2); 7.4684 (1.4); 7.4647 (1.4); 7.3682 (1.5); 7.3592 (3.6); 7.3570 (2.7); 7.3475 (2.6); 7.3387 (2.6); 7.3269 (1.1); 7.2609 (39.1); 7.2238 (1.1); 7.2115 (1.1); 7.2049 (1.1); 7.1927 (1.0); 6.9673 (1.6); 6.9599 (1.6); 6.9461 (1.5); 6.9387 (1.6); 5.3574 (11.4); 5.0698 (16.0); 2.1719 (0.9); 1.5601 (2.8); 1.2597 (0.6); 0.8819 (0.9); 0.0078 (1.5); 0.0053 (0.6); -0.0002 (53.1); -0.0085 (1.9) I-47: 1< H-NMR(400.6 MHz, CDCl3): δ= 8.2893 (1.8); 8.2875 (1.8); 8.2778 (1.8); 8.2759 (1.8); 8.1551 (2.4); 8.1488 (2.6); 7.8508 (1.1); 7.8446 (1.1); 7.8321 (1.3); 7.8297 (1.4); 7.8259 (1.4); 7.8235 (1.4); 7.8110 (1.2); 7.8048 (1.2); 7.5321 (1.1); 7.5285 (1.1); 7.5113 (1.6); 7.5085 (1.9); 7.4886 (1.5); 7.4849 (1.5); 7.3914 (1.4); 7.3822 (1.6); 7.3798 (1.5); 7.3707 (2.5); 7.3615 (1.2); 7.3591 (1.2); 7.3500 (1.0); 7.2631 (14.3); 7.1166 (0.8); 6.9713 (1.7); 6.9640 (1.8); 6.9502 (1.7); 6.9428 (1.7); 4.8520 (15.0); 4.2002 (2.2); 4.1824 (6.8); 4.1646 (6.9); 4.1468 (2.3); 3.6798 (1.4); 3.6644 (3.8); 3.6492 (4.0); 3.6337 (1.6); 2.6179 (3.4); 2.6025 (5.4); 2.5874 (3.3); 1.5857 (5.6); 1.2918 (7.8); 1.2740 (16.0); 1.2562 (8.0); 0.0080 (0.6); -0.0002 (20.9); -0.0085 (0.8) I-48: 1< H-NMR(400.6 MHz, CDCl3): δ= 8.2969 (1.4); 8.2953 (1.6); 8.2934 (1.7); 8.2853 (1.6); 8.2837 (1.8); 8.2818 (1.7); 8.1577 (2.2); 8.1514 (2.4); 7.8583 (1.1); 7.8520 (1.1); 7.8396 (1.3); 7.8371 (1.4); 7.8334 (1.3); 7.8308 (1.3); 7.8184 (1.2); 7.8122 (1.2); 7.5328 (1.0); 7.5291 (1.1); 7.5120 (1.6); 7.5086 (1.8); 7.5064 (1.3); 7.4892 (1.5); 7.4855 (1.4); 7.3936 (1.4); 7.3844 (1.6); 7.3820 (1.5); 7.3729 (2.4); 7.3637 (1.1); 7.3613 (1.2); 7.3522 (1.0); 7.2631 (13.4); 7.1160 (0.8); 6.9741 (1.6); 6.9730 (1.6); 6.9667 (1.6); 6.9530 (1.6); 6.9518 (1.5); 6.9455 (1.6); 4.9173 (13.2); 4.2839 (2.0); 4.2661 (6.3); 4.2482 (6.4); 4.2304 (2.1); 4.1605 (6.3); 4.1474 (6.4); 4.1309 (0.9); 4.1131 (0.8); 2.0454 (3.7); 1.5810 (4.7); 1.3269 (7.8); 1.3091 (16.0); 1.2913 (7.9); 1.2774 (1.3); 1.2596 (2.6); 1.2417 (1.1); 0.8819 (1.2); 0.8642 (0.5); 0.0080 (0.5); -0.0002 (19.8); -0.0085 (0.7) I-49: 1< H-NMR(400.6 MHz, CDCl3): δ= 8.3109 (0.7); 8.3091(0.8); 8.3072(0.8); 8.3056 (0.7); 8.2992(0.7); 8.2976 (0.8); 8.2956 (0.8); 8.2941 (0.7); 8.1055 (1.3); 8.1038 (1.3); 8.0994 (1.4); 8.0977 (1.3); 7.5663 (1.3); 7.5602(1.2); 7.5448 (1.3); 7.5386 (1.3); 7.4810 (0.5); 7.4772(0.5); 7.4603 (0.8); 7.4581 (0.7); 7.4567 (0.8); 7.4546 (0.6); 7.4376 (0.7); 7.4338 (0.7); 7.3518 (0.7); 7.3427 (0.8); 7.3402 (0.8); 7.3311 (1.2); 7.3220 (0.5); 7.3196 (0.6); 7.2607 (18.0); 6.7239 (1.5); 6.7220 (1.6); 6.7023 (1.5); 6.7005 (1.5); 4.9554 (7.4); 3.9244 (16.0); 3.7958 (13.8); 2.0453 (1.4); 1.5491 (6.9); 1.2597 (1.0); 0.8821 (0.7); 0.0079 (0.8); -0.0002 (27.1); -0.0085 (0.8) I-50: 1< H-NMR(400.6 MHz, d 6 -DMSO): δ= 12.9883 (1.4); 8.3151 (0.8); 8.3128 (1.1); 8.3098 (0.9); 8.3035 (0.9); 8.3012 (1.2); 8.2983 (0.9); 8.1041 (1.7); 8.1024 (1.7); 8.0979 (1.8); 8.0962 (1.8); 7.9660 (0.6); 7.9625 (0.7); 7.9451 (0.8); 7.9415 (1.4); 7.9378 (0.8); 7.9205 (0.8); 7.9169 (0.8); 7.6123 (0.8); 7.6028 (1.0); 7.6007 (0.9); 7.5968 (1.7); 7.5909 (2.5); 7.5819 (0.8); 7.5799 (0.8); 7.5752 (1.8); 7.5690 (1.9); 6.8624 (1.9); 6.8606 (1.9); 6.8408 (1.9); 6.8390 (1.9); 5.7571 (0.6); 5.0423 (1.8); 5.0248 (1.9); 3.8484 (16.0); 3.3250 (4.9); 2.5199 (0.6); 2.5112 (8.7); 2.5066 (19.2); 2.5020 (27.1); 2.4975 (19.6); 2.4930 (9.6); 2.4707 (0.6); 2.0859 (1.4); 1.5681 (5.0); 1.5507 (5.0); 0.0080 (0.5); -0.0002 (17.6); -0.0085 (0.7) I-51: 1< H-NMR(400.0 MHz, CDCl3): δ= 8.4512 (3.8); 8.4445 (3.7); 8.2975 (4.0); 8.2458 (2.4); 8.2345 (2.3); 7.5282 (1.8); 7.5234 (2.9); 7.4995 (4.0); 7.4794 (1.5); 7.4759 (1.4); 7.3599 (1.5); 7.3507 (1.9); 7.3393 (2.4); 7.3301 (1.4); 7.3186 (1.0); 7.2616 (13.9); 5.3001 (6.2); 4.9384 (16.0); 4.2929 (2.2); 4.2751 (6.2); 4.2573 (6.2); 4.2394 (2.1); 2.7742 (0.7); 1.5650 (6.9); 1.3050 (7.0); 1.2872 (13.7); 1.2693 (6.7); - 0.0002 (19.9) I-52: 1< H-NMR(400.6 MHz, CDCl3): δ= 8.5510 (1.8); 8.5487 (2.0); 8.5467 (2.0); 8.5444 (1.7); 8.5390 (1.8); 8.5367 (2.1); 8.5345 (2.0); 8.5324 (1.6); 8.2331 (2.3); 8.2313 (2.5); 8.2294 (2.5); 8.2278 (2.1); 8.2214 (2.3); 8.2197 (2.6); 8.2178 (2.5); 8.1223 (3.2); 8.1161 (3.3); 7.8536 (1.6); 7.8473 (1.5); 7.8348 (2.0); 7.8324 (2.0); 7.8286 (1.9); 7.8262 (1.8); 7.8137 (1.6); 7.8074 (1.6); 7.5612 (1.2); 7.5567 (1.2); 7.5419 (2.6); 7.5375 (2.6); 7.5226 (1.7); 7.5185 (1.8); 7.5036 (1.6); 7.4999 (1.6); 7.4829 (2.4); 7.4795 (2.6); 7.4767 (1.8); 7.4598 (2.1); 7.4561 (2.0); 7.3511 (2.0); 7.3421 (2.5); 7.3395 (2.1); 7.3305 (3.8); 7.3216 (3.5); 7.3190 (2.1); 7.3098 (1.8); 7.3045 (2.4); 7.2605 (83.7); 7.1889 (1.5); 7.1756 (1.5); 7.1702 (1.5); 7.1581 (1.4); 6.9607 (2.3); 6.9533 (2.4); 6.9518 (2.1); 6.9395 (2.2); 6.9380 (2.1); 6.9320 (2.2); 6.9305 (1.9); 5.4288 (1.1); 5.4114 (4.3); 5.3940 (4.4); 5.3767 (1.1); 5.3338 (13.9); 1.7655 (16.0); 1.7481 (15.8); 1.5507 (10.8); 0.0079 (3.8); -0.0002 (129.1); -0.0061 (1.9); -0.0085 (3.8) I-53: 1< H-NMR(400.6 MHz, CDCl3): δ= 8.6885 (0.9); 8.2923 (0.8); 8.2907 (0.9); 8.2888 (1.0); 8.2873 (0.9); 8.2808 (0.9); 8.2791 (1.0); 8.2772 (1.0); 8.1466 (1.3); 8.1404 (1.4); 7.8679 (0.6); 7.8616 (0.6); 7.8493 (0.7); 7.8467 (0.8); 7.8431 (0.8); 7.8405 (0.8); 7.8281 (0.7); 7.8218 (0.7); 7.5445 (0.6); 7.5409 (0.6); 7.5237 (1.0); 7.5201 (1.1); 7.5182 (0.8); 7.5010 (0.9); 7.4973 (0.8); 7.4078 (0.8); 7.3987 (1.0); 7.3963 (0.9); 7.3871 (1.4); 7.3779 (0.7); 7.3755 (0.7); 7.3664 (0.6); 7.2613 (15.8); 6.9881 (0.8); 6.9868 (0.9); 6.9806 (0.9); 6.9793 (0.9); 6.9669 (0.8); 6.9655 (0.9); 6.9595 (0.9); 6.9581 (0.9); 4.8859 (9.7); 4.2566 (0.8); 4.2398 (1.2); 4.2230 (0.9); 2.9082 (16.0); 2.0455 (0.6); 1.5543 (8.7); 1.2596 (0.6); 1.1572 (13.6); 1.1404 (13.6); 0.8819 (0.5); 0.0080 (0.7); -0.0002 (24.3); -0.0085 (1.0) I-54: 1< H-NMR(400.0 MHz, CDCl3): δ= 9.1339 (2.0); 8.2860 (2.0); 8.2746 (2.0); 8.1517 (2.7); 8.1460 (2.7); 7.8574 (1.0); 7.8512 (1.0); 7.8362 (1.5); 7.8302 (1.4); 7.8175 (1.1); 7.8112 (1.0); 7.5408 (0.9); 7.5200 (2.3); 7.4967 (1.1); 7.4053 (1.1); 7.3942 (1.6); 7.3846 (2.0); 7.3734 (1.2); 7.3641 (0.8); 7.2612 (74.0); 6.9805 (1.8); 6.9731 (1.8); 6.9592 (1.8); 6.9519 (1.8); 5.3003 (3.1); 4.9221 (13.0); 4.2494 (1.5); 4.2316 (4.7); 4.2138 (4.8); 4.1960 (1.7); 4.1761 (9.3); 4.1311 (0.8); 4.1130 (0.8); 3.0726 (16.0); 2.0451 (3.6); 1.5673 (13.2); 1.3048 (5.6); 1.2869 (11.3); 1.2775 (1.8); 1.2690 (6.4); 1.2596 (4.0); 1.2418 (1.1); 0.8982 (0.6); 0.8818 (1.3); 0.8645 (0.7); 0.0080 (1.2); -0.0002 (39.5); -0.0084 (1.2) I-55: 1< H-NMR(400.0 MHz, CDCl3): δ= 8.2454 (1.1); 8.2356 (1.1); 8.1358 (1.4); 8.1295 (1.5); 7.8564 (0.7); 7.8502 (0.6); 7.8354 (0.9); 7.8314 (0.8); 7.8292 (0.8); 7.8165 (0.7); 7.8102 (0.7); 7.4959 (0.6); 7.4922 (0.6); 7.4752 (0.9); 7.4718 (1.2); 7.4522 (0.9); 7.4484 (0.8); 7.3429 (0.8); 7.3339 (1.0); 7.3314 (0.9); 7.3223 (1.5); 7.3131 (0.7); 7.3106 (0.7); 7.3017 (0.6); 7.2612 (42.3); 6.9602 (1.0); 6.9528 (1.0); 6.9390 (1.0); 6.9315 (0.9); 4.9300 (9.9); 4.2871 (1.2); 4.2692 (3.8); 4.2513 (3.8); 4.2335 (1.2); 1.5513 (16.0); 1.3026 (4.5); 1.2848 (9.2); 1.2669 (4.5); 0.0079 (0.8); -0.0002 (26.3); -0.0086 (0.7) I-56: 1< H-NMR(400.6 MHz, CDCl3): δ= 8.2591 (1.4); 8.2572 (1.4); 8.2475 (1.5); 8.2457 (1.5); 8.1173 (1.9); 8.1113 (2.0); 7.8362 (0.7); 7.8300 (0.7); 7.8156 (1.0); 7.8100 (1.0); 7.7965 (0.7); 7.7904 (0.7); 7.5148 (1.0); 7.5111 (1.0); 7.4940 (1.6); 7.4922 (1.5); 7.4903 (1.7); 7.4887 (1.3); 7.4715 (1.5); 7.4678 (1.4); 7.3878 (1.3); 7.3785 (1.5); 7.3763 (1.4); 7.3670 (2.1); 7.3577 (1.0); 7.3555 (1.0); 7.3462 (0.9); 7.2663 (4.6); 6.9493 (1.5); 6.9478 (1.5); 6.9418 (1.6); 6.9404 (1.5); 6.9281 (1.4); 6.9266 (1.4); 6.9207 (1.4); 6.9192 (1.4); 4.9394 (13.9); 4.2846 (2.0); 4.2667 (6.3); 4.2489 (6.3); 4.2311 (2.1); 3.8782 (0.5); 3.0300 (0.5); 2.9983 (0.5); 1.6151 (4.8); 1.3027 (0.7); 1.2975 (7.8); 1.2850 (1.6); 1.2797 (16.0); 1.2671 (0.8); 1.2619 (7.7); -0.0002 (6.3) I-57: 1< H-NMR(400.6 MHz, CDCl3): δ= 8.2960 (1.2); 8.2940 (1.2); 8.2845 (1.2); 8.2825 (1.2); 8.1270 (1.6); 8.1209 (1.6); 7.9824 (0.7); 7.9762 (0.7); 7.9639 (0.8); 7.9611 (0.9); 7.9577 (0.8); 7.9550 (0.8); 7.9427 (0.7); 7.9365 (0.7); 7.5492 (0.7); 7.5455 (0.7); 7.5281 (1.3); 7.5245 (1.3); 7.5061 (1.0); 7.5025 (1.0); 7.4495 (1.0); 7.4400 (1.2); 7.4381 (1.1); 7.4286 (1.6); 7.4191 (0.8); 7.4172 (0.8); 7.4078 (0.6); 7.2621 (11.3); 7.0078 (1.1); 7.0068 (1.1); 7.0005 (1.1); 6.9865 (1.0); 6.9854 (1.0); 6.9792 (1.1); 5.0231 (10.7); 4.2976 (1.4); 4.2797 (4.2); 4.2619 (4.3); 4.2441 (1.4); 2.0457 (0.9); 1.5588 (16.0); 1.3018 (5.0); 1.2840 (10.2); 1.2777 (0.6); 1.2661 (5.2); 1.2598 (0.9); 0.8819 (0.5); 0.0079 (0.6); -0.0002 (17.1); -0.0085 (0.6) I-16: 1< H-NMR(400.6 MHz, CDCl3): δ= 8.4532 (1.8); 8.4463 (1.9); 8.3017 (1.0); 8.2979 (1.8); 8.2940 (1.0); 8.2515 (0.8); 8.2497 (0.9); 8.2479 (0.9); 8.2461(0.8); 8.2399 (0.8); 8.2381 (0.9); 8.2362(0.9); 8.2345 (0.8); 7.5285(0.8); 7.5261(0.8); 7.5241(0.9); 7.5219 (1.2); 7.5172(0.8); 7.5057 (1.3); 7.5019 (1.9); 7.4994 (1.6); 7.4950 (0.8); 7.4823 (0.9); 7.4786 (0.9); 7.3640 (0.9); 7.3550 (1.0); 7.3524 (0.9); 7.3434 (1.5); 7.3343 (0.7); 7.3317 (0.7); 7.3227 (0.6); 7.2617 (36.6); 4.9588 (8.4); 3.8031 (16.0); 2.9631 (1.0); 2.7750 (0.6); 2.0454 (0.5); 1.5596 (5.9); 0.0080 (0.6); -0.0002 (21.9); -0.0084 (0.7) I-14: 1< H-NMR(400.0 MHz, d 6 -DMSO): δ= 13.1318 (0.6); 8.2740 (3.6); 8.2679 (3.6); 8.1682 (4.9); 8.1607 (5.2); 8.0299 (1.4); 8.0237 (1.4); 8.0090 (2.2); 8.0028 (2.1); 7.9891 (1.5); 7.9829 (1.5); 7.9601 (1.7); 7.9526 (1.5); 7.9395 (2.0); 7.9377 (2.3); 7.9301 (2.2); 7.9171 (2.0); 7.9095 (1.8); 7.7365 (2.8); 7.7268 (2.9); 7.7138 (2.4); 7.7042 (2.3); 7.3072 (2.3); 7.3009 (2.3); 7.2859 (2.2); 7.2797 (2.1); 4.9188 (16.0); 3.3231 (1.2); 2.5249 (0.8); 2.5202 (1.0); 2.5114 (16.8); 2.5069 (36.9); 2.5023 (51.5); 2.4978 (36.1); 2.4932 (16.1); 2.1834 (0.6); 1.3559 (4.6); 0.0080 (1.0); -0.0002 (37.2); -0.0085 (1.1) I-13: 1< H-NMR(599.6 MHz, CDCl3): δ= 8.1922 (12.8); 8.1884 (13.0); 7.9613 (0.4); 7.9565 (0.4); 7.9151 (14.6); 7.9102 (14.9); 7.8328 (4.0); 7.8288 (4.0); 7.8189 (6.7); 7.8161 (6.5); 7.8063 (4.3); 7.8022 (4.1); 7.6173 (6.5); 7.6110 (6.7); 7.6022 (7.7); 7.5959 (7.6); 7.5375 (0.4); 7.5334 (0.5); 7.4536 (4.7); 7.4487 (4.7); 7.4410 (5.6); 7.4386 (5.7); 7.4363 (6.0); 7.4339 (5.0); 7.4262 (4.2); 7.4212 (3.8); 7.4115 (0.4); 7.2607 (34.4); 7.0003 (7.3); 6.9959 (7.4); 6.9862 (7.2); 6.9818 (7.2); 6.6449 (0.4); 6.6292 (0.4); 5.3183 (3.0); 5.3067 (9.8); 5.2950 (9.9); 5.2833 (3.1); 5.2697 (0.4); 5.2580 (0.3); 3.9749 (0.7); 2.2711 (1.2); 1.7606 (39.1); 1.7489 (38.9); 1.7322 (1.3); 1.4320 (8.8); 1.2550 (2.8); 0.8797 (0.4); 0.0701 (0.6); 0.0052 (2.2); -0.0001 (50.0); -0.0056 (1.8) I-12: 1< H-NMR(400.0 MHz, CDCl3): δ= 8.1947 (1.3); 8.1885 (1.4); 7.9220 (1.8); 7.9152 (1.8); 7.8470 (0.7); 7.8408 (0.7); 7.8281 (0.8); 7.8259 (0.8); 7.8219 (0.8); 7.8197 (0.8); 7.8070 (0.7); 7.8008 (0.7); 7.6636 (0.8); 7.6540 (0.8); 7.6412 (1.1); 7.6315 (1.1); 7.5082 (0.8); 7.5008 (0.8); 7.4895 (0.9); 7.4857 (0.7); 7.4821 (0.8); 7.4783 (0.7); 7.4670 (0.7); 7.4596 (0.6); 7.2615 (20.4); 7.0048 (0.9); 6.9974 (1.0); 6.9849 (0.9); 6.9836 (0.9); 6.9776 (0.9); 4.9546 (8.7); 3.8287 (16.0); 1.5579 (1.6); 0.8819 (0.6); -0.0002 (14.2) I-11: 1< H-NMR(400.0 MHz, CDCl3): δ= 8.1907 (1.2); 8.1888 (1.0); 8.1865 (1.0); 8.1845 (1.2); 7.8990 (1.7); 7.8916 (1.7); 7.8418 (0.6); 7.8356 (0.6); 7.8229 (0.7); 7.8207 (0.8); 7.8167 (0.7); 7.8145 (0.7); 7.8018 (0.6); 7.7956 (0.6); 7.6469 (0.7); 7.6459 (0.7); 7.6372 (0.8); 7.6362 (0.8); 7.6243 (1.0); 7.6233 (1.0); 7.6147 (1.0); 7.6138 (1.0); 7.4984 (0.8); 7.4910 (0.7); 7.4796 (0.8); 7.4759 (0.6); 7.4722 (0.8); 7.4685 (0.6); 7.4571 (0.6); 7.4497 (0.6); 7.2629 (7.7); 7.0011 (0.8); 6.9998 (0.8); 6.9937 (0.8); 6.9925 (0.8); 6.9800 (0.8); 6.9787 (0.8); 6.9726 (0.8); 6.9712 (0.8); 5.2486 (1.6); 5.2312 (1.6); 3.7972 (16.0); 2.0449 (0.7); 1.7171 (6.3); 1.6996 (6.3); 1.5757 (0.7); 1.2641 (0.8); 1.2594 (0.9); 0.8816 (1.5); 0.8638 (0.6); -0.0002 (5.4) I-01: 1< H-NMR(400.0 MHz, CDCl3): δ= 8.2452 (2.7); 8.2322 (2.8); 8.0794 (1.6); 8.0768 (1.6); 8.0747 (1.5); 8.0691 (1.5); 8.0672 (1.7); 8.0645 (1.6); 8.0626 (1.4); 7.8012 (1.1); 7.7965 (1.0); 7.7826 (1.5); 7.7806 (1.8); 7.7780 (1.5); 7.7759 (1.6); 7.7621 (1.6); 7.7574 (1.5); 7.6457 (2.9); 7.6273 (1.5); 7.6251 (2.2); 7.5212 (1.0); 7.3121 (0.8); 7.2623 (166.4); 7.2124 (0.7); 7.1535 (1.4); 7.1510 (1.4); 7.1413 (1.5); 7.1388 (1.6); 7.1346 (2.5); 7.1325 (2.2); 7.1309 (2.3); 7.1263 (1.7); 7.1209 (2.4); 7.1177 (2.1); 7.1135 (1.4); 6.9983 (1.0); 6.9412 (3.2); 4.9451 (14.8); 4.7010 (0.5); 4.3221 (2.0); 4.3042 (6.2); 4.2864 (6.2); 4.2686 (2.0); 1.5859 (0.5); 1.3326 (8.0); 1.3147 (16.0); 1.2969 (8.6); 1.2533 (4.5); 0.8798 (1.0); 0.8621 (0.6); 0.0079 (2.9); -0.0002 (94.2); -0.0085 (4.0) I-01: 1< H-NMR(599.6 MHz, CDCl3): δ= 8.5362 (1.8); 8.5343 (1.9); 8.5284 (1.9); 8.5262 (1.8); 8.4282 (0.4); 8.2542 (11.2); 8.2456 (11.3); 8.0981 (6.6); 8.0963 (6.6); 8.0901 (6.7); 8.0883 (6.4); 7.8572 (1.2); 7.8543 (1.2); 7.8442 (2.0); 7.8416 (2.0); 7.8312 (1.4); 7.8281 (1.3); 7.7984 (3.7); 7.7954 (3.6); 7.7846 (6.5); 7.7828 (6.3); 7.7723 (4.6); 7.7693 (4.2); 7.7612 (0.3); 7.6572 (0.3); 7.6435 (0.4); 7.6225 (10.6); 7.6088 (9.0); 7.3077 (1.6); 7.2995 (1.7); 7.2954 (1.7); 7.2872 (1.6); 7.2656 (10.5); 7.1614 (5.6); 7.1532 (6.0); 7.1522 (5.9); 7.1475 (8.9); 7.1446 (8.8); 7.1416 (8.7); 7.1394 (7.9); 7.1360 (7.9); 6.9597 (13.5); 5.0092 (0.4); 4.9453 (50.0); 4.9007 (1.0); 4.8887 (15.3); 4.8780 (1.6); 4.3122 (6.6); 4.3003 (19.7); 4.2884 (19.8); 4.2765 (8.7); 4.2646 (6.3); 4.2527 (6.3); 4.2408 (2.1); 1.3248 (21.4); 1.3129 (41.8); 1.3010 (21.0); 1.2948 (7.2); 1.2829 (13.2); 1.2711 (6.6); 1.2556 (0.6); -0.0001 (10.6); -0.0054 (0.4) I-01: 1< H-NMR(400.6 MHz, CDCl3): δ= 8.2433 (1.6); 8.2419 (2.6); 8.2404 (1.5); 8.2306 (1.7); 8.2290 (2.7); 8.0776 (1.2); 8.0755 (1.3); 8.0729 (1.4); 8.0708 (1.3); 8.0654 (1.3); 8.0633 (1.4); 8.0608 (1.4); 8.0586 (1.3); 7.7983 (1.1); 7.7935 (1.1); 7.7798 (1.3); 7.7776 (1.6); 7.7751 (1.3); 7.7729 (1.6); 7.7592 (1.6); 7.7545 (1.6); 7.6490 (1.7); 7.6467 (2.9); 7.6443 (1.7); 7.6284 (1.4); 7.6261 (2.2); 7.6237 (1.2); 7.2629 (24.3); 7.2596 (0.6); 7.1495 (1.5); 7.1470 (1.4); 7.1374 (1.4); 7.1348 (1.6); 7.1327 (1.6); 7.1311 (2.0); 7.1285 (2.9); 7.1249 (1.3); 7.1191 (2.1); 7.1164 (2.8); 7.1119 (1.2); 6.9435 (1.4); 6.9418 (1.7); 6.9401 (2.0); 6.9385 (2.8); 6.9369 (1.9); 6.9353 (1.7); 6.9337 (1.3); 5.3005 (4.9); 4.9434 (14.5); 4.3211 (1.8); 4.3032 (5.8); 4.2854 (5.8); 4.2677 (1.9); 1.5809 (1.2); 1.3313 (7.6); 1.3135 (16.0); 1.2957 (7.4); -0.0002 (15.2) I-01: 1< H-NMR(400.0 MHz, CDCl3): δ= 8.2418 (2.8); 8.2289 (2.9); 8.0755 (1.5); 8.0728 (1.6); 8.0708 (1.4); 8.0633 (1.5); 8.0607 (1.6); 8.0588 (1.4); 7.7974 (1.1); 7.7927 (1.0); 7.7788 (1.4); 7.7768 (1.7); 7.7742 (1.4); 7.7722 (1.6); 7.7583 (1.6); 7.7536 (1.5); 7.6460 (3.1); 7.6253 (2.5); 7.2611 (59.1); 7.1488 (1.4); 7.1463 (1.5); 7.1366 (1.5); 7.1325 (1.9); 7.1280 (3.2); 7.1246 (1.4); 7.1183 (2.2); 7.1156 (3.1); 7.1117 (1.3); 6.9379 (3.1); 4.9718 (0.8); 4.9428 (16.0); 4.3210 (2.0); 4.3031 (6.2); 4.2928 (0.5); 4.2853 (6.3); 4.2674 (2.1); 1.6344 (1.2); 1.3312 (7.4); 1.3133 (15.1); 1.2955 (7.2); 1.2551 (0.6); 0.0080 (0.9); -0.0002 (37.0); -0.0085 (1.2) I-01: 1< H-NMR(400.0 MHz, CDCl3): δ= 8.2428 (2.7); 8.2298 (2.8); 8.0787 (1.3); 8.0766 (1.4); 8.0740 (1.5); 8.0720 (1.4); 8.0665 (1.3); 8.0645 (1.4); 8.0618 (1.4); 8.0598 (1.3); 7.7985 (1.1); 7.7938 (1.1); 7.7799 (1.4); 7.7779 (1.6); 7.7753 (1.4); 7.7732 (1.6); 7.7593 (1.6); 7.7546 (1.5); 7.6478 (1.7); 7.6455 (2.9); 7.6432 (1.7); 7.6272 (1.3); 7.6249 (2.2); 7.6226 (1.3); 7.2629 (20.8); 7.1502 (1.4); 7.1476 (1.5); 7.1380 (1.5); 7.1353 (1.8); 7.1339 (1.7); 7.1293 (3.0); 7.1259 (1.4); 7.1196 (2.0); 7.1169 (2.9); 7.1130 (1.3); 6.9445 (1.5); 6.9430 (1.8); 6.9397 (2.9); 6.9365 (1.7); 6.9350 (1.4); 5.3001 (5.2); 4.9431 (15.4); 4.3209 (2.0); 4.3031 (6.2); 4.2852 (6.2); 4.2674 (2.0); 1.3312 (7.7); 1.3134 (16.0); 1.2955 (7.6); -0.0002 (12.0) I-59: 1< H-NMR(400.6 MHz, CDCl3): δ= 8.2170 (1.3); 8.2109 (1.4); 8.0929 (0.7); 8.0831 (0.7); 7.8722 (0.6); 7.8661 (0.6); 7.8533 (0.7); 7.8512 (0.8); 7.8471 (0.7); 7.8450 (0.7); 7.8324 (0.7); 7.8262 (0.6); 7.8117 (0.5); 7.8071 (0.5); 7.7930 (0.7); 7.7910 (0.9); 7.7886 (0.8); 7.7865 (0.9); 7.7727 (0.8); 7.7681 (0.8); 7.7016 (1.2); 7.6810 (0.8); 7.2675 (2.8); 7.1558 (0.7); 7.1536 (0.7); 7.1437 (0.7); 7.1414 (0.7); 7.1376 (0.7); 7.1353 (0.6); 7.1254 (0.6); 7.1231 (0.6); 7.0153 (0.9); 7.0082 (0.9); 6.9942 (0.8); 6.9871 (0.9); 4.9144 (7.8); 4.7249 (0.9); 4.7068 (1.3); 4.6887 (0.9); 3.7815 (16.0); 2.0093 (0.8); 1.5140 (6.5); 1.4961 (6.5); -0.0002 (3.4) I-59: 1< H-NMR(400.0 MHz, CDCl3): δ= 8.2148 (1.4); 8.2088 (1.4); 8.0885 (0.9); 8.0857 (0.9); 8.0764 (0.9); 8.0737 (0.9); 7.8677 (0.6); 7.8615 (0.6); 7.8466 (0.8); 7.8425 (0.8); 7.8405 (0.8); 7.8277 (0.7); 7.8216 (0.6); 7.8071 (0.6); 7.8024 (0.6); 7.7865 (1.0); 7.7819 (0.9); 7.7681 (0.9); 7.7634 (0.9); 7.7052 (1.8); 7.6845 (1.1); 7.2619 (25.8); 7.1486 (1.1); 7.1462 (1.1); 7.1366 (1.1); 7.1340 (1.1); 7.1305 (1.0); 7.1279 (0.8); 7.1182 (0.8); 7.1157 (0.7); 7.0094 (1.0); 7.0023 (1.0); 6.9881 (0.9); 6.9812 (0.9); 4.9065 (8.6); 4.7245 (0.9); 4.7064 (1.3); 4.6882 (0.9); 4.1310 (1.2); 4.1131 (1.2); 3.7800 (16.0); 2.0452 (5.2); 1.5740 (1.0); 1.5119 (6.7); 1.4940 (6.6); 1.2773 (1.7); 1.2595 (3.4); 1.2416 (1.4); 0.8987 (0.5); 0.8819 (1.7); 0.8642 (0.7); 0.0079 (0.6); -0.0002 (14.9) I-60: 1< H-NMR(400.6 MHz, CDCl3): δ= 8.2130 (2.0); 8.2068 (2.2); 8.1268 (1.3); 8.1248 (1.3); 8.1222 (1.5); 8.1146 (1.4); 8.1100 (1.4); 7.8671 (1.0); 7.8609 (1.1); 7.8483 (1.3); 7.8460 (1.3); 7.8421 (1.3); 7.8398 (1.2); 7.8273 (1.1); 7.8222 (1.5); 7.8178 (1.2); 7.8019 (1.5); 7.7991 (1.4); 7.7972 (1.4); 7.7833 (1.5); 7.7786 (1.4); 7.6286 (2.7); 7.6081 (2.2); 7.5188 (0.9); 7.2603 (167.8); 7.1912 (1.4); 7.1887 (1.3); 7.1790 (1.4); 7.1765 (1.3); 7.1727 (1.3); 7.1702 (1.2); 7.1605 (1.3); 7.1580 (1.2); 7.0254 (1.4); 7.0182 (1.4); 7.0044 (1.5); 6.9968 (2.4); 5.0298 (0.7); 4.9840 (16.0); 4.3501 (1.6); 4.3287 (5.1); 4.3073 (5.3); 4.2859 (1.8); 1.6115 (4.3); 1.2538 (0.6); 0.1457 (0.7); 0.0080 (5.1); -0.0002 (208.2); -0.0085 (7.5); -0.0294 (0.6); -0.1494 (0.7) I-61: 1< H-NMR(400.6 MHz, CDCl3): δ= 8.2552 (1.8); 8.2422 (1.8); 8.0907 (0.9); 8.0881 (1.0); 8.0806 (0.9); 8.0786 (1.0); 8.0760 (1.0); 7.8361 (0.7); 7.8315 (0.6); 7.8176 (0.9); 7.8155 (1.1); 7.8129 (1.0); 7.8109 (1.0); 7.7971 (1.0); 7.7925 (1.0); 7.7156 (1.9); 7.6950 (1.3); 7.2606 (43.7); 7.1807 (0.9); 7.1781 (0.9); 7.1685 (0.9); 7.1660 (0.9); 7.1623 (1.0); 7.1598 (0.8); 7.1501 (0.9); 7.1475 (0.8); 7.1328 (0.8); 7.1293 (1.2); 7.1251 (0.9); 7.1199 (0.9); 7.1163 (1.2); 7.1122 (0.9); 6.9434 (1.9); 5.3003 (2.5); 4.9419 (8.0); 4.1829 (3.7); 4.1696 (3.7); 3.7948 (16.0); 1.5424 (16.0); 1.2556 (1.2); 0.0079 (2.2); -0.0002 (70.3); -0.0085 (2.7) I-62: 1< H-NMR(400.6 MHz, d 6 -DMSO): δ= 12.3088 (1.1); 8.2504 (2.8); 8.2443 (2.9); 8.1007 (1.7); 8.0988 (1.9); 8.0962 (2.0); 8.0941 (1.8); 8.0887 (1.8); 8.0867 (2.1); 8.0840 (2.0); 8.0820 (1.8); 8.0231 (1.2); 8.0169 (1.1); 8.0020 (1.8); 7.9958 (1.7); 7.9824 (1.3); 7.9762 (1.2); 7.9594 (1.5); 7.9547 (1.4); 7.9409 (1.8); 7.9388 (2.0); 7.9362 (1.8); 7.9341 (1.8); 7.9203 (1.8); 7.9155 (1.7); 7.6788 (2.0); 7.6766 (3.6); 7.6746 (2.4); 7.6582 (1.8); 7.6561 (3.2); 7.6539 (2.0); 7.3018 (1.9); 7.2960 (2.0); 7.2803 (2.1); 7.2785 (2.5); 7.2757 (3.0); 7.2663 (1.8); 7.2639 (2.0); 7.2599 (1.8); 7.2575 (1.6); 7.2478 (1.7); 7.2453 (1.7); 5.1825 (0.6); 5.1460 (2.1); 5.0933 (2.0); 5.0579 (0.6); 4.2193 (0.6); 4.1869 (0.6); 4.0986 (0.8); 4.0808 (0.8); 4.0557 (1.1); 4.0379 (3.4); 4.0201 (3.4); 4.0024 (1.2); 3.8076 (0.6); 3.7738 (0.6); 3.3220 (30.6); 3.1522 (0.7); 2.7920 (0.7); 2.6705 (0.5); 2.5680 (0.6); 2.5583 (1.1); 2.5484 (0.7); 2.5411 (2.1); 2.5301 (0.8); 2.5243 (1.4); 2.5197 (1.8); 2.5108 (24.5); 2.5063 (54.7); 2.5017 (77.4); 2.4971 (54.8); 2.4926 (25.3); 2.1832 (0.6); 1.9887 (16.0); 1.9090 (1.5); 1.8718 (0.9); 1.8258 (0.7); 1.6402 (0.5); 1.4102 (0.5); 1.3554 (5.2); 1.2351 (0.9); 1.2036 (1.0); 1.1922 (4.7); 1.1858 (2.3); 1.1745 (9.3); 1.1681 (1.1); 1.1567 (4.5); 0.0080 (1.3); -0.0002 (48.1); -0.0085 (1.5). I-63: 1< H-NMR(400.6 MHz, d 6 -DMSO): δ= 12.5889 (1.3); 8.2481 (6.1); 8.1032 (4.6); 8.0943 (4.5); 8.0215 (2.1); 8.0155 (2.2); 8.0009 (3.9); 7.9959 (3.8); 7.9808 (3.6); 7.9753 (3.6); 7.9595 (3.1); 7.7000 (3.0); 7.6799 (5.5); 7.6599 (2.8); 7.3025 (4.1); 7.2964 (4.3); 7.2822 (5.5); 7.2748 (7.1); 7.2566 (3.1); 6.8699 (0.6); 5.0144 (10.4); 4.9638 (0.7); 4.0552 (1.3); 4.0378 (3.7); 4.0200 (3.7); 4.0024 (1.3); 3.7947 (1.0); 3.7698 (1.8); 3.7501 (1.5); 3.6783 (1.6); 3.6607 (1.9); 3.6348 (1.6); 3.6097 (1.8); 3.5937 (2.7); 3.5751 (2.6); 3.5638 (4.3); 3.5448 (5.4); 3.5291 (2.7); 3.4985 (1.2); 3.4675 (1.4); 3.4491 (1.4); 3.4370 (1.0); 3.3927 (1.2); 3.3741 (2.3); 3.3206 (26.0); 3.2046 (1.4); 3.1859 (1.8); 3.1672 (1.3); 3.0778 (1.4); 3.0598 (1.9); 3.0420 (1.4); 2.6701 (1.6); 2.5404 (6.6); 2.5014 (226.7); 2.3286 (1.6); 2.2051 (1.2); 2.1850 (2.1); 2.1719 (1.6); 2.1444 (1.6); 2.1259 (1.8); 2.1129 (1.7); 2.0981 (1.7); 2.0809 (1.5); 2.0677 (1.2); 1.9886 (16.0); 1.9701 (1.8); 1.9576 (1.2); 1.9375 (0.9); 1.9087 (0.6); 1.7602 (0.6); 1.3551 (7.0); 1.2352 (3.8); 1.1921 (4.2); 1.1744 (8.0); 1.1565 (4.1); -0.0002 (65.7). I-64: 1< H-NMR(400.6 MHz, CDCl3): δ= 8.2200 (1.3); 8.2178 (1.0); 8.2157 (1.1); 8.2138 (1.3); 8.0980 (0.8); 8.0960 (0.8); 8.0934 (0.9); 8.0914 (0.8); 8.0859 (0.8); 8.0839 (0.9); 8.0813 (0.9); 8.0793 (0.8); 7.8677 (0.7); 7.8615 (0.7); 7.8488 (0.8); 7.8465 (0.8); 7.8426 (0.8); 7.8404 (0.8); 7.8277 (0.7); 7.8215 (0.7); 7.8132 (0.7); 7.8085 (0.6); 7.7948 (0.8); 7.7925 (1.0); 7.7901 (0.8); 7.7879 (1.0); 7.7742 (1.0); 7.7695 (1.0); 7.7110 (1.2); 7.7088 (1.9); 7.7064 (1.1); 7.6904 (0.8); 7.6882 (1.2); 7.6858 (0.7); 7.2623 (25.4); 7.1549 (0.9); 7.1523 (0.9); 7.1428 (0.8); 7.1402 (0.9); 7.1366 (0.9); 7.1340 (0.8); 7.1245 (0.8); 7.1218 (0.8); 7.0115 (1.0); 7.0101 (0.9); 7.0041 (1.0); 7.0026 (0.9); 6.9903 (0.9); 6.9889 (0.8); 6.9829 (0.9); 6.9815 (0.8); 5.3004 (0.9); 4.9476 (7.7); 4.1834 (3.5); 4.1699 (3.5); 3.7905 (16.0); 1.5837 (0.8); -0.0002 (15.3) I-64: 1< H-NMR(400.6 MHz, CDCl3): δ= 8.2218 (0.8); 8.2198 (1.2); 8.2178 (0.9); 8.2157 (0.9); 8.2136 (1.2); 8.2117 (0.8); 8.0975 (0.7); 8.0954 (0.8); 8.0928 (0.8); 8.0907 (0.8); 8.0854 (0.8); 8.0832 (0.8); 8.0807 (0.9); 8.0786 (0.8); 7.8676 (0.7); 7.8613 (0.7); 7.8487 (0.8); 7.8464 (0.8); 7.8426 (0.8); 7.8402 (0.8); 7.8276 (0.7); 7.8214 (0.7); 7.8129 (0.7); 7.8082 (0.6); 7.7946 (0.7); 7.7922 (1.0); 7.7899 (0.8); 7.7875 (1.0); 7.7739 (1.1); 7.7692 (1.0); 7.7117 (1.1); 7.7093 (1.8); 7.7069 (1.1); 7.6910 (0.7); 7.6887 (1.2); 7.6863 (0.7); 7.2624 (8.4); 7.1545 (0.9); 7.1519 (0.9); 7.1424 (0.8); 7.1397 (0.9); 7.1362 (0.9); 7.1335 (0.8); 7.1241 (0.9); 7.1214 (0.8); 7.0113 (0.9); 7.0097 (0.9); 7.0039 (0.9); 7.0023 (0.9); 6.9901 (0.8); 6.9885 (0.9); 6.9827 (0.8); 6.9811 (0.8); 5.3003 (3.8); 4.9474 (7.2); 4.1834 (3.2); 4.1699 (3.2); 3.7905 (16.0); 1.5748 (1.9); -0.0002 (13.5) I-65: 1< H-NMR(400.6 MHz, CDCl3): δ= 8.5021 (1.2); 8.4957 (1.3); 8.3435 (1.5); 8.1153 (1.2); 8.1122 (0.8); 8.1066 (0.8); 8.1034 (1.4); 8.1001 (0.8); 7.8413 (1.4); 7.8377 (2.5); 7.8293 (3.0); 7.8259 (2.5); 7.5117(0.7); 7.5049 (0.8); 7.5006 (0.7); 7.4894(0.7); 7.4852 (0.8); 7.4826(0.8); 7.4783(0.7); 7.2603 (46.8); 7.2092 (0.9); 7.1972 (1.4); 7.1867 (1.4); 7.1759 (0.8); 4.0858 (4.1); 4.0727 (4.2); 3.8973 (8.2); 3.7025 (16.0); 2.0455 (0.5); 1.5432 (6.4); 0.0081 (1.9); -0.0002 (73.8); -0.0085 (2.8) I-66: 1< H-NMR(599.6 MHz, d 6 -DMSO): δ= 13.0936 (0.3); 8.2586 (7.0); 8.2547 (7.0); 8.1131 (4.6); 8.1113 (4.8); 8.1102 (4.3); 8.1061 (4.2); 8.1050 (4.7); 8.1032 (4.6); 8.1022 (4.1); 8.0226 (2.2); 8.0184 (2.3); 8.0088 (3.9); 8.0050 (3.7); 7.9954 (2.4); 7.9913 (2.3); 7.9833 (3.0); 7.9802 (2.8); 7.9707 (4.2); 7.9696 (4.7); 7.9678 (4.4); 7.9667 (4.1); 7.9572 (3.3); 7.9541 (3.2); 7.6807 (7.5); 7.6669 (6.9); 7.2979 (4.2); 7.2938 (4.4); 7.2904 (4.5); 7.2889 (4.3); 7.2824 (6.5); 7.2805 (7.1); 7.2784 (6.3); 7.2699 (3.6); 7.2684 (3.5); 4.9262 (29.8); 4.8965 (0.4); 4.0479 (0.7); 4.0360 (2.2); 4.0242 (2.2); 4.0123 (0.7); 3.3890 (0.5); 3.3773 (0.6); 3.3655 (0.6); 3.3275 (6.4); 2.6153 (0.3); 2.5241 (1.1); 2.5211 (1.4); 2.5179 (1.5); 2.5089 (19.0); 2.5062 (37.4); 2.5032 (50.0); 2.5002 (37.1); 2.4974 (17.9); 1.9890 (9.4); 1.9106 (4.3); 1.3570 (0.7); 1.1869 (2.6); 1.1751 (5.1); 1.1632 (2.5); 1.0908 (0.5); 0.0053 (0.5); -0.0001 (11.6); -0.0056 (0.4) I-66: 1< H-NMR(400.0 MHz, d 6 -DMSO): δ= 8.2593 (3.4); 8.2532 (3.5); 8.1151 (2.2); 8.1124 (2.4); 8.1104 (2.2); 8.1029 (2.4); 8.1002 (2.3); 8.0983 (2.2); 8.0305 (1.4); 8.0242 (1.4); 8.0096 (2.2); 8.0033 (2.1); 7.9913 (2.2); 7.9869 (2.0); 7.9835 (1.6); 7.9728 (2.1); 7.9710 (2.4); 7.9682 (2.1); 7.9664 (2.2); 7.9523 (2.1); 7.9476 (1.9); 7.6826 (4.2); 7.6620 (3.8); 7.3034 (2.3); 7.2962 (4.2); 7.2818 (4.2); 7.2753 (4.0); 7.2655 (2.0); 7.2630 (1.9); 4.9246 (16.0); 4.0381 (1.0); 4.0203 (1.0); 3.3238 (8.0); 2.5246 (0.8); 2.5199 (1.0); 2.5111 (16.1); 2.5065 (35.7); 2.5020 (50.4); 2.4974 (35.8); 2.4929 (16.2); 1.9888 (4.3); 1.9093 (1.5); 1.3557 (0.5); 1.1923 (1.2); 1.1746 (2.4); 1.1568 (1.2); 0.0080 (0.6); −0.0002 (23.1); −0.0085 (0.7) I-66: 1< H-NMR(400.6 MHz, CDCl 3 ): δ= 8.2064 (2.4); 8.2002 (2.6); 8.1164 (1.5); 8.1143 (1.7); 8.1116 (1.8); 8.1096 (1.7); 8.1042 (1.7); 8.1021 (1.8); 8.0994 (1.8); 8.0974 (1.7); 7.8625 (1.4); 7.8563 (1.3); 7.8437 (1.6); 7.8414 (1.7); 7.8375 (1.6); 7.8352 (1.6); 7.8226 (1.4); 7.8164 (1.4); 7.7751 (1.2); 7.7704 (1.2); 7.7565 (1.5); 7.7545 (1.8); 7.7518 (1.5); 7.7498 (1.7); 7.7360 (1.7); 7.7312 (1.7); 7.6097 (3.2); 7.5891 (2.4); 7.5198 (1.8); 7.2891 (1.3); 7.2860 (0.7); 7.2724 (0.6); 7.2693 (1.3); 7.2669 (1.9); 7.2613 (330.6); 7.2547 (3.6); 7.2522 (2.2); 7.2515 (2.1); 7.2499 (1.4); 7.2490 (1.2); 7.2482 (1.2); 7.2283 (0.6); 7.1399 (1.7); 7.1373 (1.7); 7.1277 (1.6); 7.1252 (1.7); 7.1214 (1.8); 7.1189 (1.7); 7.1093 (1.6); 7.1067 (1.6); 7.0058 (1.7); 7.0043 (1.8); 6.9976 (3.3); 6.9847 (1.7); 6.9831 (1.7); 6.9774 (1.9); 5.4649 (0.6); 5.3006 (0.5); 5.0617 (0.6); 5.0243 (16.0); 4.1317 (0.6); 4.1138 (0.6); 2.2718 (0.6); 2.1063 (2.0); 2.0466 (4.4); 2.0037 (2.4); 1.4322 (4.5); 1.3325 (0.9); 1.2843 (1.4); 1.2776 (1.3); 1.2598 (3.5); 1.2540 (4.8); 1.2430 (1.9); 0.8800 (0.8); 0.1459 (0.6); 0.0276 (0.8); 0.0239 (0.5); 0.0080 (6.3); 0.0056 (1.9); -0.0002 (211.9); -0.0085 (6.0); -0.1494 (0.6). I-66: 1< H-NMR(400.0 MHz, d 6 -DMSO): δ= 8.2593 (2.9); 8.2532 (3.1); 8.1154 (1.9); 8.1127 (2.0); 8.1108 (2.0); 8.1033 (2.0); 8.1005 (2.0); 8.0987 (1.9); 8.0304 (1.2); 8.0242 (1.1); 8.0096 (1.9); 8.0033 (1.8); 7.9916 (1.8); 7.9899 (1.8); 7.9873 (1.7); 7.9835 (1.3); 7.9714 (2.0); 7.9686 (1.8); 7.9667 (1.9); 7.9527 (1.7); 7.9479 (1.6); 7.6826 (3.6); 7.6620 (3.2); 7.3035 (2.0); 7.2966 (3.6); 7.2822 (3.7); 7.2757 (3.5); 7.2659 (1.6); 7.2636 (1.7); 4.9253 (13.7); 4.0381 (0.6); 4.0203 (0.6); 3.3318 (16.0); 2.5660 (0.5); 2.5250 (0.6); 2.5203 (0.9); 2.5115 (15.3); 2.5070 (34.0); 2.5024 (47.9); 2.4979 (34.2); 2.4934 (15.6); 1.9889 (2.8); 1.9097 (1.6); 1.1924 (0.8); 1.1746 (1.6); 1.1568 (0.8) I-19: 1< H-NMR(400.6 MHz, CDCl3): δ= 8.2086 (1.0); 8.2064 (0.8); 8.2044 (0.8); 8.2024 (1.1); 8.0601 (0.7); 8.0580 (0.7); 8.0554 (0.8); 8.0533 (0.7); 8.0479 (0.7); 8.0459 (0.8); 8.0432 (0.8); 8.0412 (0.7); 7.8631 (0.6); 7.8569 (0.6); 7.8441 (0.7); 7.8419 (0.8); 7.8380 (0.7); 7.8357 (0.7); 7.8230 (0.6); 7.8169 (0.6); 7.7695 (0.6); 7.7648 (0.6); 7.7511 (0.7); 7.7488 (0.8); 7.7463 (0.7); 7.7441 (0.8); 7.7304 (0.9); 7.7257 (0.8); 7.6278 (0.9); 7.6255 (1.6); 7.6232 (0.9); 7.6071 (0.7); 7.6048 (1.2); 7.6025 (0.6); 7.2607 (14.6); 7.1086 (0.8); 7.1060 (0.8); 7.0964 (0.8); 7.0938 (0.8); 7.0901 (0.8); 7.0876 (0.7); 7.0780 (0.7); 7.0754 (0.7); 6.9958 (0.8); 6.9943 (0.8); 6.9884 (0.8); 6.9869 (0.8); 6.9746 (0.7); 6.9731 (0.8); 6.9673 (0.8); 6.9658 (0.7); 5.2765 (1.5); 5.2591 (1.5); 3.8014 (16.0); 1.7213 (6.3); 1.7038 (6.2); 1.5486 (1.1); 0.8819 (0.7); 0.0080 (0.6); -0.0002 (22.4); -0.0085 (0.7) I-19: 1< H-NMR(400.6 MHz, CDCl3): δ= 8.2105 (0.6); 8.2084 (1.0); 8.2064 (0.8); 8.2044 (0.8); 8.2022 (1.0); 8.2004 (0.7); 8.0601 (0.6); 8.0580 (0.7); 8.0554 (0.8); 8.0533 (0.7); 8.0479 (0.7); 8.0459 (0.8); 8.0432 (0.8); 8.0411 (0.7); 7.8632 (0.6); 7.8570 (0.6); 7.8443 (0.7); 7.8421 (0.7); 7.8381 (0.7); 7.8359 (0.7); 7.8231 (0.6); 7.8170 (0.6); 7.7702 (0.6); 7.7655 (0.6); 7.7518 (0.7); 7.7496 (0.9); 7.7471 (0.7); 7.7448 (0.8); 7.7312 (0.9); 7.7264 (0.8); 7.6274 (0.8); 7.6251 (1.6); 7.6228 (0.9); 7.6068 (0.7); 7.6044 (1.2); 7.6021 (0.7); 7.2632 (4.0); 7.1094 (0.8); 7.1068 (0.8); 7.0973 (0.7); 7.0947 (0.8); 7.0910 (0.8); 7.0885 (0.7); 7.0789 (0.7); 7.0763 (0.7); 6.9968 (0.7); 6.9953 (0.8); 6.9894 (0.8); 6.9879 (0.8); 6.9756 (0.7); 6.9740 (0.8); 6.9683 (0.7); 6.9667 (0.7); 5.3000 (9.1); 5.2769 (1.5); 5.2595 (1.5); 3.8016 (16.0); 1.7210 (6.2); 1.7036 (6.1); -0.0002 (5.3) I-67: 1< H-NMR(400.0 MHz, CDCl3): δ= 9.2223 (4.2); 8.7933 (9.7); 8.0386 (1.1); 8.0292 (1.1); 7.7968 (0.6); 7.7920 (0.6); 7.7751 (1.2); 7.7578 (1.2); 7.7530 (1.1); 7.7132 (2.1); 7.6926 (1.2); 7.2614 (56.4); 7.1244 (1.0); 7.1098 (1.1); 7.1066 (1.0); 7.0941 (0.8); 4.9797 (9.5); 4.9559 (0.6); 3.8404 (16.0); 3.8303 (1.3); 1.6019 (1.0); 1.4373 (0.5); 1.2539 (1.8); 0.0073 (2.0); -0.0002 (32.8); -0.0084 (1.5) I-68: 1< H-NMR(599.6 MHz, CDCl3): δ= 9.2245 (0.3); 8.7897 (0.7); 8.6074 (0.4); 7.2712 (3.2); 4.9556 (0.7); 4.3109 (0.3); 4.2995 (0.3); 2.7549 (23.2); 2.6273 (50.0); 2.0446 (0.3); 2.0335 (0.4); 1.8407 (0.6); 1.3738 (0.3); 1.3334 (2.0); 1.3234 (1.1); 1.3110 (1.1); 1.2849 (3.2); 1.2567 (12.3); 0.8911 (0.8); 0.8806 (1.4); 0.8690 (0.8); 0.8422 (0.4); 0.0699 (1.8); -0.0001 (4.0) I-68: 1< H-NMR(400.0 MHz, CDCl3): δ= 8.7895 (0.6); 7.2618 (20.5); 4.9549 (0.6); 2.7741 (16.0); 2.7495 (0.9); 1.3329 (1.3); 1.3232 (0.8); 1.3053 (0.7); 1.2844 (2.0); 1.2552 (6.7); 0.8800 (0.9); 0.0691 (1.8); -0.0002 (12.8) I-69: 1< H-NMR(400.0 MHz, d 6 -DMSO): δ= 8.6621 (4.8); 8.6551 (4.8); 8.4160 (2.8); 8.4120 (5.0); 8.4083 (2.6); 8.1422 (2.2); 8.1396 (2.4); 8.1378 (2.2); 8.1301 (2.3); 8.1275 (2.3); 8.1256 (2.1); 8.0476 (1.6); 8.0430 (1.4); 8.0272 (2.4); 8.0243 (2.1); 8.0226 (2.2); 8.0084 (1.9); 8.0038 (1.7); 7.8805 (1.7); 7.8762 (1.8); 7.8736 (1.9); 7.8693 (1.6); 7.8564 (1.7); 7.8521 (1.9); 7.8496 (1.8); 7.8452 (1.6); 7.8140 (4.0); 7.7935 (3.4); 7.3571 (1.9); 7.3548 (2.0); 7.3449 (1.8); 7.3426 (2.1); 7.3385 (2.0); 7.3362 (1.9); 7.3264 (1.7); 7.3240 (1.8); 5.7563 (10.1); 4.0370 (16.0); 2.5250 (1.3); 2.5115 (12.5); 2.5071 (26.1); 2.5026 (35.8); 2.4980 (25.6); 2.4936 (11.9); 1.9891 (0.7); 1.6758 (0.9); 1.3565 (2.4); 1.2341 (1.8); 1.1749 (0.7); 0.0080 (0.9); -0.0002 (25.8); -0.0085 (1.0) I-69: 1< H-NMR(400.0 MHz, CDCl3): δ= 8.5173 (1.6); 8.5102 (1.6); 8.3401 (1.4); 8.1395 (0.7); 8.1276 (0.6); 7.8251 (0.7); 7.8203 (0.6); 7.8063 (0.7); 7.8016 (0.6); 7.7028 (1.2); 7.6823 (0.9); 7.5141 (0.5); 7.5069 (0.6); 7.5027 (0.5); 7.4916 (0.6); 7.4875 (0.6); 7.2606 (54.9); 7.2211 (0.6); 7.2064 (0.6); 7.2024 (0.6); 7.2000 (0.6); 7.1904 (0.5); 6.9782 (0.9); 5.2999 (4.7); 3.9514 (6.4); 2.2715 (1.8); 1.6668 (3.8); 1.5605 (1.1); 1.5150 (8.0); 1.4321 (16.0); 1.2843 (0.5); 1.2550 (1.8); 1.2222 (0.5); 0.0079 (1.2); -0.0002 (43.4); -0.0085 (1.2) I-70: 1< H-NMR(400.6 MHz, CDCl3): δ= 8.2098 (1.4); 8.2076 (1.1); 8.2056 (1.2); 8.2037 (1.4); 8.0585 (0.8); 8.0565 (0.9); 8.0538 (1.0); 8.0518 (0.8); 8.0463 (0.9); 8.0443 (0.9); 8.0417 (0.9); 8.0397 (0.8); 7.8172 (0.7); 7.8110 (0.6); 7.7980 (0.9); 7.7962 (0.9); 7.7918 (0.9); 7.7900 (0.8); 7.7771 (0.7); 7.7709 (0.7); 7.7492 (0.6); 7.7444 (0.6); 7.7309 (0.8); 7.7285 (1.1); 7.7262 (0.8); 7.7238 (1.0); 7.7103 (1.1); 7.7055 (1.0); 7.6507 (1.2); 7.6484 (1.9); 7.6461 (1.1); 7.6300 (0.8); 7.6278 (1.2); 7.6254 (0.6); 7.2617 (41.6); 7.0732 (1.0); 7.0705 (1.0); 7.0610 (1.2); 7.0583 (1.2); 7.0549 (1.2); 7.0522 (1.2); 7.0428 (1.2); 7.0401 (1.1); 6.9728 (1.0); 6.9714 (0.9); 6.9654 (1.0); 6.9518 (0.9); 6.9504 (0.9); 6.9444 (0.9); 5.3003 (2.0); 4.8918 (7.5); 4.1783 (3.4); 4.1656 (3.4); 3.7969 (16.0); 1.5643 (1.7); 1.5504 (0.8); 1.5424 (0.6); 1.5293 (1.2); 1.5161 (0.6); 1.5082 (0.7); 0.8240 (0.6); 0.8132 (1.6); 0.8079 (1.7); 0.8029 (0.8); 0.7975 (1.0); 0.7918 (1.6); 0.7867 (1.4); 0.7765 (0.8); 0.6697 (0.9); 0.6593 (1.7); 0.6560 (1.7); 0.6542 (1.6); 0.6463 (1.5); 0.6422 (1.5); 0.6301 (0.6); 0.0080 (0.7); -0.0002 (26.4); -0.0085 (0.7). I-71: 1< H-NMR(400.6 MHz, CDCl3): δ= 8.2101 (1.1); 8.2041 (1.2); 8.0361 (0.6); 8.0343 (0.7); 8.0315 (0.7); 8.0296 (0.7); 8.0240 (0.7); 8.0221 (0.7); 8.0194 (0.7); 8.0175 (0.6); 7.8217 (0.5); 7.8156 (0.5); 7.8024 (0.7); 7.8009 (0.7); 7.7962 (0.7); 7.7947 (0.7); 7.7815 (0.6); 7.7754 (0.5); 7.7207 (0.5); 7.7160 (0.5); 7.7023 (0.6); 7.7000 (0.8); 7.6977 (0.7); 7.6953 (0.8); 7.6817 (0.8); 7.6770 (0.7); 7.5932 (1.5); 7.5911 (0.9); 7.5726 (1.1); 7.5704 (0.6); 7.2613 (42.9); 7.2574 (0.7); 7.0382 (0.7); 7.0356 (0.7); 7.0260 (0.7); 7.0235 (0.7); 7.0199 (0.7); 7.0173 (0.6); 7.0078 (0.6); 7.0052 (0.6); 6.9609 (0.8); 6.9548 (0.8); 6.9411 (0.7); 6.9399 (0.7); 6.9338 (0.7); 6.9325 (0.7); 5.3003 (0.8); 4.8895 (7.8); 4.5046 (2.0); 4.4889 (4.0); 4.4732 (2.0); 3.6905 (16.0); 2.7120 (1.9); 2.6963 (3.8); 2.6806 (1.8); 1.5684 (0.6); 1.4835 (0.6); 1.4739 (0.5); 1.4703 (0.9); 1.4492 (0.6); 0.7779 (1.2); 0.7728 (1.2); 0.7654 (2.1); 0.7593 (1.2); 0.7518 (1.0); 0.7489 (0.5); 0.7397 (1.3); 0.7322 (1.2); 0.7278 (0.8); 0.7221 (0.6); 0.7191 (1.1); 0.7119 (1.3); 0.7063 (1.0); 0.0080 (0.7); -0.0002 (26.5); -0.0085 (0.8). I-72: 1< H-NMR(400.6 MHz, d 6 -DMSO): δ= 12.9557 (0.7); 8.2209 (3.2); 8.2147 (3.3); 8.0566 (2.0); 8.0545 (2.2); 8.0519 (2.6); 8.0498 (2.3); 8.0445 (2.2); 8.0424 (2.5); 8.0397 (2.5); 8.0377 (2.4); 7.9728 (1.5); 7.9665 (1.4); 7.9519 (2.2); 7.9457 (2.1); 7.9319 (1.6); 7.9257 (1.5); 7.9206 (2.0); 7.9158 (1.9); 7.9021 (2.2); 7.8999 (2.4); 7.8973 (2.2); 7.8952 (2.4); 7.8815 (2.4); 7.8767 (2.3); 7.6173 (2.4); 7.6150 (4.5); 7.6128 (2.7); 7.5967 (2.2); 7.5944 (4.1); 7.5921 (2.3); 7.2479 (2.1); 7.2422 (2.1); 7.2268 (2.0); 7.2211 (2.0); 7.2198 (2.0); 7.2013 (2.3); 7.1988 (2.4); 7.1891 (2.1); 7.1867 (2.4); 7.1829 (2.3); 7.1804 (2.1); 7.1707 (2.3); 7.1682 (2.2); 4.8305 (16.0); 4.0555 (1.1); 4.0377 (3.3); 4.0199 (3.4); 4.0022 (1.1); 3.3194 (16.8); 2.6746 (0.7); 2.6700 (1.0); 2.6653 (0.7); 2.5282 (0.8); 2.5238 (3.2); 2.5191 (4.1); 2.5103 (54.2); 2.5058 (121.3); 2.5012 (172.8); 2.4966 (121.6); 2.4920 (54.2); 2.3329 (0.7); 2.3283 (1.0); 2.3236 (0.7); 1.9886 (16.0); 1.9084 (3.2); 1.5421 (0.6); 1.5288 (1.4); 1.5212 (1.4); 1.5160 (0.9); 1.5080 (2.4); 1.5045 (1.2); 1.4945 (1.4); 1.4871 (1.5); 1.4738 (0.7); 1.3551 (1.3); 1.1922 (4.7); 1.1744 (9.9); 1.1566 (4.7); 0.7032 (1.2); 0.6997 (0.6); 0.6907 (2.5); 0.6855 (3.8); 0.6825 (2.0); 0.6778 (2.7); 0.6725 (1.4); 0.6697 (2.7); 0.6640 (3.7); 0.6570 (2.8); 0.6463 (1.1); 0.6409 (2.5); 0.6333 (3.7); 0.6277 (5.6); 0.6205 (3.9); 0.6152 (3.6); 0.6023 (1.2); 0.0080 (3.5); 0.0064 (0.9); 0.0055 (1.0); 0.0047 (1.2); 0.0039 (1.6); 0.0022 (4.6); -0.0002 (119.2); -0.0026 (6.1); -0.0051 (1.7); -0.0059 (1.3); -0.0067 (1.0); -0.0085 (3.4). I-73: 1< H-NMR(400.0 MHz, CDCl3): δ= 8.4859 (2.0); 8.4791 (2.0); 8.3722 (2.1); 8.0363 (1.0); 8.0336 (1.0); 8.0241 (1.0); 8.0216 (1.0); 7.7896 (0.6); 7.7849 (0.6); 7.7689 (1.0); 7.7643 (1.0); 7.7504 (0.9); 7.7458 (0.8); 7.6711 (1.9); 7.6504 (1.3); 7.5296 (0.7); 7.5230 (0.8); 7.5188 (0.8); 7.5072 (0.7); 7.5006 (0.8); 7.4960 (0.6); 7.2611 (40.5); 7.1071 (0.9); 7.0951 (0.9); 7.0913 (0.9); 7.0889 (0.9); 7.0792 (0.7); 7.0766 (0.8); 5.3001 (1.0); 5.2528 (0.5); 5.2356 (1.7); 5.2181 (1.8); 5.2008 (0.5); 4.4914 (1.0); 4.4836 (1.2); 4.4756 (2.2); 4.4681 (2.1); 4.4600 (1.2); 4.4524 (1.1); 3.7263 (0.7); 3.6581 (16.0); 2.6887 (1.8); 2.6729 (3.0); 2.6573 (1.6); 1.7082 (6.5); 1.6908 (6.5); 0.0079 (0.8); -0.0002 (24.2); -0.0084 (0.8) I-74: 1< H-NMR(400.6 MHz, CDCl3): δ= 8.4898 (1.6); 8.4829 (1.7); 8.3764 (0.9); 8.3725 (1.6); 8.3688 (0.9); 8.0743 (0.6); 8.0722 (0.7); 8.0696 (0.8); 8.0675 (0.7); 8.0621 (0.7); 8.0601 (0.8); 8.0575 (0.8); 8.0554 (0.7); 7.7962 (0.5); 7.7915 (0.5); 7.7778 (0.6); 7.7756 (0.8); 7.7731 (0.7); 7.7709 (0.8); 7.7572 (0.8); 7.7525 (0.8); 7.6721 (0.8); 7.6698 (1.6); 7.6675 (1.0); 7.6515 (0.6); 7.6492 (1.1); 7.6468 (0.6); 7.5349 (0.6); 7.5306 (0.6); 7.5280 (0.7); 7.5237 (0.6); 7.5124 (0.6); 7.5081 (0.6); 7.5055 (0.7); 7.5012 (0.6); 7.2611 (42.0); 7.1333 (0.7); 7.1308 (0.7); 7.1212 (0.7); 7.1186 (0.7); 7.1150 (0.8); 7.1124 (0.7); 7.1028 (0.7); 7.1002 (0.7); 4.9554 (7.2); 4.4230 (0.6); 4.4050 (0.6); 4.3959 (1.3); 4.3779 (1.4); 4.3527 (1.3); 4.3386 (1.4); 4.3256 (0.6); 4.3115 (0.6); 3.7263 (2.8); 3.7131 (0.6); 3.6746 (16.0); 2.8456 (0.7); 2.8315 (0.7); 1.2065 (6.6); 1.1981 (1.5); 1.1886 (6.5); 1.1800 (1.5); 0.0080 (0.6); -0.0002 (26.9); -0.0085 (0.8) I-75: 1< H-NMR(400.6 MHz, CDCl3): δ= 8.4904 (1.2); 8.4836 (1.3); 8.3754 (1.4); 8.0741 (0.7); 8.0720 (0.8); 8.0694 (0.9); 8.0674 (0.8); 8.0620 (0.8); 8.0599 (0.8); 8.0573 (0.8); 8.0552 (0.8); 7.8005 (0.6); 7.7958 (0.6); 7.7821 (0.7); 7.7798 (0.9); 7.7774 (0.8); 7.7751 (0.9); 7.7615 (0.9); 7.7567 (0.9); 7.6765 (1.0); 7.6742 (1.7); 7.6719 (1.0); 7.6559 (0.8); 7.6536 (1.2); 7.6513 (0.7); 7.5370 (0.6); 7.5327 (0.7); 7.5302 (0.7); 7.5259 (0.6); 7.5191 (0.6); 7.5145 (0.6); 7.5102 (0.7); 7.5077 (0.7); 7.5033 (0.6); 7.2606 (93.3); 7.1350 (0.8); 7.1324 (0.8); 7.1228 (0.8); 7.1202 (0.8); 7.1166 (0.8); 7.1140 (0.8); 7.1045 (0.8); 7.1019 (0.7); 6.9970 (0.5); 5.3002 (0.6); 4.9523 (8.3); 4.5262 (2.0); 4.5106 (4.1); 4.4949 (2.1); 3.6861 (16.0); 2.7200 (2.0); 2.7043 (3.9); 2.6886 (1.9); 0.0079 (1.6); -0.0002 (59.7); -0.0085 (1.7) I-76: 1< H-NMR(400.6 MHz, CDCl3): δ= 8.4909 (1.2); 8.4841 (1.3); 8.3698 (0.8); 8.3661 (1.3); 8.3626 (0.8); 8.0628 (0.6); 8.0608 (0.7); 8.0581 (0.8); 8.0561 (0.7); 8.0507 (0.7); 8.0486 (0.8); 8.0460 (0.8); 8.0439 (0.7); 7.7910 (0.5); 7.7863 (0.5); 7.7726 (0.6); 7.7703 (0.8); 7.7679 (0.6); 7.7656 (0.8); 7.7520 (0.8); 7.7473 (0.8); 7.6730 (0.8); 7.6707 (1.5); 7.6684 (0.9); 7.6524 (0.6); 7.6501 (1.0); 7.6477 (0.6); 7.5277 (0.6); 7.5234 (0.6); 7.5209 (0.7); 7.5165 (0.6); 7.5053 (0.6); 7.5009 (0.7); 7.4983 (0.6); 7.4940 (0.6); 7.2625 (15.4); 7.1263 (0.7); 7.1237 (0.7); 7.1141 (0.7); 7.1115 (0.7); 7.1079 (0.7); 7.1053 (0.7); 7.0958 (0.7); 7.0932 (0.6); 4.9541 (6.9); 4.4218 (0.6); 4.4039 (0.6); 4.3947 (1.3); 4.3768 (1.3); 4.3508 (1.3); 4.3367 (1.3); 4.3237 (0.6); 4.3096 (0.6); 3.6748 (16.0); 2.8441 (0.6); 2.8300 (0.6); 1.2054 (6.3); 1.1875 (6.2); -0.0002 (9.2) I-77: 1< H-NMR(400.6 MHz, CDCl3): δ= 8.4907 (1.0); 8.4840 (1.0); 8.3677 (1.2); 8.0635 (0.7); 8.0614 (0.8); 8.0588 (0.8); 8.0567 (0.8); 8.0514 (0.7); 8.0493 (0.8); 8.0467 (0.8); 8.0446 (0.7); 7.7950 (0.6); 7.7903 (0.6); 7.7766 (0.7); 7.7744 (0.9); 7.7719 (0.7); 7.7697 (0.9); 7.7560 (0.9); 7.7512 (0.9); 7.6765 (0.9); 7.6742 (1.7); 7.6719 (1.0); 7.6559 (0.7); 7.6536 (1.2); 7.6512 (0.7); 7.5262 (0.6); 7.5219 (0.7); 7.5195 (0.8); 7.5150 (0.6); 7.5038 (0.7); 7.4995 (0.7); 7.4969 (0.7); 7.4926 (0.6); 7.2614 (33.9); 7.1278 (0.8); 7.1252 (0.8); 7.1157 (0.8); 7.1131 (0.8); 7.1095 (0.8); 7.1068 (0.8); 7.0973 (0.8); 7.0947 (0.7); 4.9507 (8.0); 4.5244 (1.9); 4.5087 (4.0); 4.4930 (2.0); 3.6860 (16.0); 2.7187 (1.9); 2.7031 (3.8); 2.6874 (1.8); 0.0080 (0.6); -0.0002 (21.3); -0.0085 (0.6) I-78: 1< H-NMR(400.0 MHz, CDCl3): δ= 8.2065 (2.5); 8.2005 (2.5); 8.0335 (1.5); 8.0305 (1.6); 8.0213 (1.5); 8.0185 (1.5); 7.8191 (1.2); 7.8130 (1.1); 7.7984 (1.6); 7.7923 (1.5); 7.7788 (1.2); 7.7727 (1.1); 7.7079 (1.0); 7.7031 (1.0); 7.6894 (1.3); 7.6871 (1.7); 7.6825 (1.5); 7.6688 (1.5); 7.6641 (1.4); 7.5863 (3.1); 7.5656 (2.1); 7.2612 (36.6); 7.0326 (1.4); 7.0301 (1.4); 7.0205 (1.4); 7.0179 (1.4); 7.0144 (1.4); 7.0119 (1.3); 7.0022 (1.3); 6.9997 (1.2); 6.9599 (1.7); 6.9529 (1.6); 6.9389 (1.6); 6.9316 (1.5); 4.8882 (16.0); 4.3012 (2.1); 4.2834 (6.4); 4.2655 (6.4); 4.2477 (2.1); 1.5788 (0.8); 1.4995 (1.0); 1.4918 (1.1); 1.4787 (1.7); 1.4705 (0.6); 1.4652 (1.1); 1.4575 (1.1); 1.4442 (0.6); 1.3262 (7.4); 1.3084 (14.9); 1.2905 (7.2); 0.8055 (0.8); 0.8022 (0.6); 0.7921 (2.6); 0.7869 (3.0); 0.7792 (3.7); 0.7745 (3.0); 0.7659 (1.7); 0.7560 (0.7); 0.7481 (1.0); 0.7442 (1.9); 0.7356 (2.7); 0.7314 (2.0); 0.7232 (1.9); 0.7152 (2.5); 0.7098 (1.9); 0.7030 (0.7); 0.6969 (0.7); 0.0080 (0.9); -0.0002 (22.0); -0.0085 (0.7) I-79: 1< H-NMR(400.6 MHz, d 6 -DMSO): δ= 13.0812 (1.3); 8.6574 (7.1); 8.6503 (7.2); 8.4145 (3.8); 8.4103 (7.1); 8.4061 (3.5); 8.0895 (2.5); 8.0875 (3.0); 8.0849 (3.4); 8.0828 (3.1); 8.0774 (2.8); 8.0754 (3.3); 8.0728 (3.2); 8.0707 (3.0); 8.0018 (2.6); 7.9971 (2.3); 7.9833 (3.1); 7.9812 (3.2); 7.9786 (2.8); 7.9765 (3.0); 7.9627 (3.2); 7.9579 (2.8); 7.8770 (2.4); 7.8727 (2.6); 7.8700 (2.6); 7.8657 (2.3); 7.8529 (2.6); 7.8486 (2.8); 7.8459 (2.4); 7.8417 (2.3); 7.6726 (3.1); 7.6704 (6.0); 7.6682 (3.5); 7.6520 (3.0); 7.6498 (5.4); 7.6475 (3.0); 7.2915 (3.0); 7.2890 (3.2); 7.2794 (2.7); 7.2769 (3.1); 7.2730 (3.0); 7.2705 (2.7); 7.2608 (2.9); 7.2584 (2.8); 5.1724 (1.2); 5.1552 (5.6); 5.1378 (5.6); 5.1203 (1.2); 4.0376 (1.1); 4.0198 (1.1); 3.3519 (0.7); 3.3195 (200.2); 2.6791 (1.0); 2.6743 (2.2); 2.6698 (3.1); 2.6651 (2.3); 2.6605 (1.2); 2.5404 (2.0); 2.5347 (1.6); 2.5317 (1.7); 2.5235 (8.1); 2.5189 (10.6); 2.5101 (161.1); 2.5055 (355.7); 2.5009 (499.5); 2.4964 (345.9); 2.4918 (155.2); 2.3326 (2.0); 2.3280 (2.9); 2.3233 (2.0); 2.3189 (0.9); 1.9884 (5.2); 1.9082 (0.5); 1.6011 (16.0); 1.5837 (15.8); 1.3549 (2.2); 1.2359 (0.9); 1.1921 (1.6); 1.1744 (3.3); 1.1566 (1.6); 0.1456 (1.0); 0.0111 (0.5); 0.0103 (0.6); 0.0080 (8.9); 0.0064 (1.9); 0.0056 (2.0); 0.0048 (2.4); 0.0039 (3.1); -0.0002 (326.8); -0.0050 (5.9); -0.0058 (4.6); -0.0067 (3.9); -0.0085 (10.1); -0.0114 (1.9); -0.0122 (1.4); -0.0131 (1.2); -0.0138 (1.2); -0.0146 (1.2); -0.0154 (1.0); -0.0162 (0.8); - 0.0170 (0.9); -0.0178 (0.7); -0.0186 (0.7); -0.0194 (0.7); -0.0210 (0.8); -0.0281 (1.0); -0.1494 (1.0). I-80: 1< H-NMR(400.6 MHz, d 6 -DMSO): δ= 12.6748 (1.4); 8.4653 (2.8); 8.4468 (2.9); 8.2494 (4.0); 8.2451 (3.1); 8.2433 (4.2); 8.0978 (2.6); 8.0958 (2.9); 8.0932 (3.4); 8.0911 (3.0); 8.0857 (2.8); 8.0837 (3.2); 8.0810 (3.2); 8.0789 (3.1); 8.0221 (1.9); 8.0158 (1.8); 8.0024 (2.4); 8.0009 (2.6); 7.9962 (2.4); 7.9947 (2.6); 7.9813 (2.1); 7.9747 (4.1); 7.9699 (2.4); 7.9561 (2.8); 7.9539 (3.2); 7.9514 (2.7); 7.9492 (3.1); 7.9355 (3.2); 7.9307 (3.0); 7.7671 (3.1); 7.7648 (5.8); 7.7626 (3.4); 7.7464 (2.8); 7.7442 (5.0); 7.7419 (2.8); 7.3041 (2.7); 7.2985 (2.7); 7.2972 (2.5); 7.2832 (5.4); 7.2808 (3.9); 7.2773 (2.8); 7.2759 (2.7); 7.2711 (2.8); 7.2686 (3.0); 7.2648 (3.0); 7.2623 (2.7); 7.2527 (3.0); 7.2501 (2.9); 4.8393 (16.0); 4.3306 (2.6); 4.3123 (4.1); 4.2940 (2.6); 4.2758 (0.5); 3.6216 (0.9); 3.6177 (5.2); 3.6155 (2.9); 3.6115 (2.7); 3.6093 (2.1); 3.6074 (3.6); 3.6028 (3.9); 3.6011 (12.0); 3.5989 (4.3); 3.5950 (3.8); 3.5930 (2.1); 3.5908 (2.7); 3.5867 (2.8); 3.5845 (5.4); 3.5806 (1.0); 3.3212 (11.7); 2.6751 (0.6); 2.6705 (0.8); 2.6658 (0.6); 2.5242 (2.1); 2.5196 (2.8); 2.5108 (40.1); 2.5062 (91.1); 2.5016 (129.2); 2.4970 (90.8); 2.4924 (40.8); 2.3333 (0.5); 2.3287 (0.8); 2.3241 (0.5); 2.1829 (0.8); 1.9087 (0.7); 1.7808 (0.8); 1.7761 (5.3); 1.7685 (4.2); 1.7640 (2.6); 1.7595 (15.2); 1.7548 (2.7); 1.7505 (4.2); 1.7429 (5.2); 1.7384 (0.8); 1.3554 (7.3); 1.3262 (15.9); 1.3080 (15.8); 0.1457 (0.6); 0.0079 (6.1); 0.0062 (1.3); 0.0054 (1.5); 0.0045 (1.9); - 0.0002 (240.5); -0.0028 (10.9); -0.0052 (2.8); -0.0061 (2.2); -0.0069 (1.9); -0.0085 (6.9); -0.0108 (0.9); -0.0117 (0.8); -0.0124 (0.8); -0.0132 (0.6); -0.0140 (0.6); -0.1495 (0.7). I-81: 1< H-NMR(400.0 MHz, d 6 -DMSO): δ= 13.1448 (1.5); 8.6646 (5.2); 8.6577 (5.2); 8.4348 (2.9); 8.4308 (5.3); 8.4269 (2.7); 8.1063 (2.2); 8.1036 (2.4); 8.1017 (2.2); 8.0941 (2.4); 8.0915 (2.4); 8.0896 (2.1); 8.0078 (1.7); 8.0031 (1.6); 7.9891 (2.2); 7.9872 (2.3); 7.9845 (2.1); 7.9826 (2.1); 7.9686 (2.1); 7.9639 (1.9); 7.8960 (1.8); 7.8918 (1.9); 7.8890 (1.9); 7.8848 (1.7); 7.8719 (1.9); 7.8676 (2.0); 7.8650 (1.8); 7.8607 (1.6); 7.7018 (4.2); 7.6812 (3.7); 7.3075 (2.1); 7.3051 (2.1); 7.2954 (1.9); 7.2929 (2.1); 7.2890 (2.1); 7.2866 (2.0); 7.2768 (2.0); 7.2744 (1.9); 4.9418 (16.0); 4.0380 (0.8); 4.0201 (0.9); 3.3191 (15.8); 2.6705 (0.8); 2.5239 (1.8); 2.5191 (2.7); 2.5104 (43.0); 2.5059 (93.5); 2.5013 (129.9); 2.4967 (92.1); 2.4922 (41.8); 2.3283 (0.7); 1.9885 (3.7); 1.1923 (1.1); 1.1745 (2.1); 1.1567 (1.1); 0.0080 (1.8); -0.0002 (61.1); -0.0086 (1.9) I-82: 1< H-NMR(400.6 MHz, CDCl3): δ= 8.5045 (1.9); 8.4976 (1.9); 8.3531 (1.0); 8.3493 (1.8); 8.3455 (1.0); 8.1167 (0.7); 8.1146 (0.8); 8.1121 (0.8); 8.1100 (0.8); 8.1046 (0.7); 8.1024 (0.8); 8.1001 (0.8); 8.0979 (0.8); 7.8481 (0.5); 7.8455 (1.0); 7.8437 (0.6); 7.8409 (1.0); 7.8276 (1.1); 7.8230 (1.1); 7.8043 (1.0); 7.8015 (1.7); 7.7991 (1.2); 7.7838 (0.6); 7.7813 (0.7); 7.5112 (0.7); 7.5068 (0.8); 7.5043 (0.8); 7.4999 (0.7); 7.4888 (0.7); 7.4845 (0.8); 7.4820 (0.8); 7.4776 (0.7); 7.2645 (5.7); 7.2098 (0.8); 7.2067 (0.8); 7.1977 (0.8); 7.1945 (0.8); 7.1919 (0.8); 7.1888 (0.8); 7.1798 (0.8); 7.1766 (0.7); 5.3006 (3.1); 3.8261 (7.5); 3.5681 (0.9); 3.5552 (16.0); 3.5380 (2.0); 3.5226 (0.9); 2.5160 (1.6); 2.5007 (2.4); 2.4860 (1.6); -0.0002 (8.4) I-83: 1< H-NMR(400.6 MHz, CDCl3): δ= 8.0422 (0.6); 8.0403 (0.6); 8.0377 (0.7); 8.0357 (0.6); 8.0301 (0.6); 8.0282 (0.7); 8.0256 (0.7); 8.0236 (0.6); 7.7573(0.6); 7.7551(0.7); 7.7526(0.6); 7.7504 (0.7); 7.7367(0.7); 7.7320 (0.6); 7.6417 (0.8); 7.6396 (1.3); 7.6374 (0.8); 7.6211(0.6); 7.6190 (1.0); 7.6168 (0.6); 7.2612 (30.9); 7.1092 (0.6); 7.1068 (0.6); 7.0971 (0.6); 7.0946 (0.6); 7.0909 (0.6); 7.0884 (0.6); 7.0788 (0.6); 7.0762 (0.6); 5.3001 (0.8); 5.2732 (1.3); 5.2558 (1.3); 3.8017 (16.0); 1.7227 (5.8); 1.7052 (5.7); 0.0080 (0.5); -0.0002 (19.0); -0.0085 (0.6) I-84: 1< H-NMR(400.0 MHz, d 6 -DMSO): δ= 13.1203 (0.9); 8.6592 (2.8); 8.6523 (2.8); 8.4198 (1.5); 8.4157 (2.9); 8.4116 (1.4); 8.0955 (1.1); 8.0927 (1.2); 8.0832 (1.2); 8.0806 (1.2); 8.0010 (0.9); 7.9963 (0.8); 7.9804 (1.2); 7.9759 (1.2); 7.9619 (1.0); 7.9571 (1.0); 7.8808 (0.9); 7.8766 (1.0); 7.8740 (1.0); 7.8697 (0.9); 7.8568 (1.0); 7.8525 (1.1); 7.8499 (1.0); 7.8456 (0.9); 7.6977 (2.2); 7.6771 (2.0); 7.2981 (1.1); 7.2958 (1.1); 7.2860 (1.0); 7.2836 (1.1); 7.2797 (1.1); 7.2773 (1.0); 7.2675 (1.1); 7.2651 (1.0); 4.9299 (8.4); 4.0377 (0.6); 4.0199 (0.6); 3.3182 (16.0); 2.6700 (0.6); 2.5236 (1.2); 2.5189 (1.7); 2.5101 (30.8); 2.5056 (68.0); 2.5010 (95.4); 2.4964 (67.4); 2.4919 (30.4); 2.3278 (0.6); 1.9884 (2.7); 1.1922 (0.7); 1.1744 (1.5); 1.1566 (0.7); 0.0080 (1.4); -0.0002 (51.8); -0.0086 (1.5) I-85: 1< H-NMR(400.6 MHz, CDCl3): δ= 8.4868 (3.2); 8.4799 (3.3); 8.3688 (1.7); 8.3650 (3.2); 8.3610 (1.7); 8.0758 (1.2); 8.0737 (1.3); 8.0711 (1.4); 8.0690 (1.4); 8.0636 (1.3); 8.0616 (1.4); 8.0589 (1.4); 8.0569 (1.4); 7.7869 (1.1); 7.7822 (1.1); 7.7685 (1.2); 7.7663 (1.6); 7.7638 (1.3); 7.7616 (1.6); 7.7478 (1.6); 7.7431 (1.6); 7.6592 (1.6); 7.6568 (3.0); 7.6546 (1.9); 7.6386 (1.2); 7.6362 (2.1); 7.6339 (1.3); 7.5221 (1.3); 7.5178 (1.3); 7.5153 (1.4); 7.5109 (1.3); 7.4996 (1.3); 7.4953 (1.4); 7.4927 (1.3); 7.4884 (1.2); 7.2625 (8.6); 7.1299 (1.4); 7.1273 (1.5); 7.1178 (1.4); 7.1152 (1.4); 7.1115 (1.4); 7.1089 (1.4); 7.0994 (1.4); 7.0968 (1.4); 5.2998 (5.8); 4.9501 (15.3); 4.3264 (1.9); 4.3086 (6.0); 4.2908 (6.1); 4.2730 (2.0); 1.3350 (7.6); 1.3172 (16.0); 1.2994 (7.5); -0.0002 (12.4) I-86: 1< H-NMR(400.6 MHz, CDCl3): δ= 8.4890 (3.0); 8.4821 (3.0); 8.3634 (1.6); 8.3597 (3.0); 8.3560 (1.6); 8.0641 (1.2); 8.0620 (1.3); 8.0594 (1.4); 8.0573 (1.3); 8.0519 (1.3); 8.0499 (1.4); 8.0473 (1.4); 8.0452 (1.3); 7.7815 (1.0); 7.7767 (1.0); 7.7630 (1.3); 7.7608 (1.6); 7.7583 (1.3); 7.7561 (1.5); 7.7424 (1.6); 7.7377 (1.5); 7.6598 (1.7); 7.6574 (2.9); 7.6551 (1.7); 7.6391 (1.3); 7.6368 (2.1); 7.6344 (1.2); 7.5194 (1.3); 7.5151 (1.3); 7.5125 (1.3); 7.5082 (1.2); 7.4969 (1.2); 7.4926 (1.3); 7.4900 (1.3); 7.4857 (1.2); 7.2615 (14.4); 7.1232 (1.4); 7.1206 (1.4); 7.1111 (1.4); 7.1084 (1.4); 7.1048 (1.4); 7.1022 (1.3); 7.0927 (1.3); 7.0901 (1.3); 4.9487 (14.7); 4.3246 (1.8); 4.3068 (5.8); 4.2890 (5.9); 4.2712 (1.9); 1.5849 (0.6); 1.3341 (7.6); 1.3163 (16.0); 1.2985 (7.4); 1.2649 (0.8); 0.8819 (1.5); 0.8643 (0.6); 0.0080 (0.6); -0.0002 (22.2); -0.0085 (0.6) I-87: 1< H-NMR(400.6 MHz, CDCl3): δ= 8.2227 (1.1); 8.2205 (0.9); 8.2184 (1.0); 8.2165 (1.1); 8.0974 (0.7); 8.0954 (0.8); 8.0927 (0.9); 8.0907 (0.7); 8.0853 (0.8); 8.0832 (0.8); 8.0806 (0.8); 8.0786 (0.7); 7.8710 (0.6); 7.8648 (0.6); 7.8521 (0.7); 7.8498 (0.7); 7.8459 (0.7); 7.8436 (0.7); 7.8310 (0.6); 7.8248 (0.6); 7.8107 (0.6); 7.8060 (0.5); 7.7923 (0.7); 7.7901 (0.9); 7.7876 (0.7); 7.7854 (0.8); 7.7718 (0.9); 7.7671 (0.9); 7.7070 (1.1); 7.7046 (1.7); 7.7023 (1.0); 7.6863 (0.8); 7.6840 (1.1); 7.6817 (0.6); 7.2617 (11.1); 7.1530 (0.8); 7.1504 (0.8); 7.1408 (0.9); 7.1381 (1.0); 7.1346 (1.1); 7.1320 (1.0); 7.1225 (1.0); 7.1198 (1.0); 7.0129 (0.8); 7.0114 (0.8); 7.0055 (0.9); 7.0040 (0.8); 6.9917 (0.8); 6.9902 (0.8); 6.9844 (0.8); 6.9829 (0.7); 5.3003 (1.2); 4.9085 (6.8); 4.7300 (0.8); 4.7119 (1.1); 4.6937 (0.8); 3.7782 (16.0); 1.5106 (6.3); 1.4927 (6.3); -0.0002 (16.0) I-88: 1< H-NMR(400.6 MHz, CDCl3): δ= 8.2170 (1.2); 8.2148 (0.9); 8.2127 (1.0); 8.2108 (1.2); 8.0814 (0.7); 8.0795 (0.7); 8.0768 (0.8); 8.0748 (0.7); 8.0693 (0.7); 8.0673 (0.7); 8.0646 (0.8); 8.0627 (0.6); 7.8706 (0.6); 7.8644 (0.6); 7.8517 (0.8); 7.8495 (0.8); 7.8455 (0.8); 7.8433 (0.7); 7.8306 (0.7); 7.8244 (0.6); 7.7887 (0.6); 7.7839 (0.6); 7.7702 (0.7); 7.7680 (0.9); 7.7655 (0.8); 7.7633 (0.9); 7.7496 (0.9); 7.7449 (0.8); 7.6603 (1.0); 7.6581 (1.5); 7.6559 (0.9); 7.6396 (0.7); 7.6375 (1.1); 7.6353 (0.6); 7.2625 (6.7); 7.1273 (0.7); 7.1248 (0.7); 7.1151 (0.7); 7.1126 (0.7); 7.1089 (0.8); 7.1064 (0.7); 7.0968 (0.7); 7.0942 (0.6); 7.0000 (0.8); 6.9987 (0.8); 6.9927 (0.9); 6.9913 (0.8); 6.9789 (0.8); 6.9774 (0.8); 6.9715 (0.8); 6.9701 (0.7); 5.3003 (1.5); 4.9496 (8.3); 4.5246 (2.0); 4.5090 (4.2); 4.4933 (2.1); 3.7260 (1.0); 3.6846 (16.0); 2.7198 (2.0); 2.7041 (4.0); 2.6884 (1.9); 1.5699 (0.6); -0.0002 (9.3) I-02: 1< H-NMR(400.0 MHz, CDCl3): δ= 8.2035 (2.2); 8.1974 (2.2); 8.0728 (1.3); 8.0709 (1.5); 8.0682 (1.5); 8.0662 (1.4); 8.0606 (1.4); 8.0587 (1.6); 8.0560 (1.5); 8.0540 (1.4); 7.8625 (1.1); 7.8563 (1.1); 7.8436 (1.4); 7.8414 (1.4); 7.8374 (1.3); 7.8353 (1.4); 7.8225 (1.2); 7.8163 (1.2); 7.7707 (1.1); 7.7660 (1.0); 7.7522 (1.3); 7.7501 (1.7); 7.7476 (1.3); 7.7454 (1.6); 7.7316 (1.6); 7.7269 (1.5); 7.6448 (1.8); 7.6426 (3.1); 7.6404 (1.9); 7.6242 (1.4); 7.6219 (2.3); 7.6197 (1.3); 7.2628 (17.0); 7.1173 (1.4); 7.1147 (1.4); 7.1051 (1.4); 7.1025 (1.5); 7.0989 (1.4); 7.0963 (1.4); 7.0867 (1.4); 7.0842 (1.3); 6.9960 (1.6); 6.9899 (1.6); 6.9886 (1.6); 6.9748 (1.5); 6.9687 (1.5); 6.9675 (1.5); 5.2996 (1.1); 4.9460 (16.0); 4.3225 (2.0); 4.3047 (6.3); 4.2868 (6.4); 4.2690 (2.1); 1.3331 (7.5); 1.3152 (15.4); 1.2974 (7.3); -0.0002 (10.3) I-02: 1< H-NMR(400.0 MHz, CDCl3): δ= 8.2031 (3.4); 8.0687 (2.3); 8.0591 (2.3); 7.8629 (1.1); 7.8569 (1.1); 7.8435 (2.0); 7.8376 (2.0); 7.8228 (1.2); 7.8169 (1.2); 7.7706 (1.1); 7.7497 (2.3); 7.7313 (1.6); 7.7268 (1.6); 7.6421 (3.7); 7.6215 (2.7); 7.2605 (79.7); 7.1172 (1.8); 7.1044 (2.0); 7.0866 (1.8); 6.9971 (2.4); 6,9900 (2.2); 6.9761 (2.1); 6.9688 (2.0); 4.9720 (0.7); 4.9461 (16.0); 4.3231 (2.0); 4.3052 (6.0); 4.2875 (6.2); 4.2696 (2.1); 4.2455 (0.6); 4.2325 (1.2); 2.8046 (0.5); 1.5504 (2.4); 1.3335 (6.9); 1.3156 (13.8); 1.2978 (7.1); 1.2847 (1.1); 1.2755 (1.0); 1.2551 (0.9); −0.0002 (55.3) I-02: 1< H-NMR(400.0 MHz, CDCl 3 ): δ= 8.2030 (2.2); 8.2011 (1.7); 8.1968 (2.1); 8.0723 (1.3); 8.0702 (1.4); 8.0676 (1.5); 8.0655 (1.4); 8.0601 (1.4); 8.0581 (1.5); 8.0555 (1.4); 8.0534 (1.3); 7.8619 (1.2); 7.8557 (1.1); 7.8430 (1.4); 7.8408 (1.5); 7.8368 (1.4); 7.8347 (1.4); 7.8219 (1.2); 7.8157 (1.2); 7.7695 (1.1); 7.7648 (1.1); 7.7511 (1.4); 7.7488 (1.7); 7.7464 (1.3); 7.7441 (1.6); 7.7304 (1.7); 7.7257 (1.6); 7.6446 (1.8); 7.6423 (3.2); 7.6400 (1.8); 7.6239 (1.4); 7.6216 (2.3); 7.6193 (1.2); 7.2607 (46.4); 7.1161 (1.5); 7.1135 (1.5); 7.1039 (1.5); 7.1013 (1.5); 7.0977 (1.5); 7.0951 (1.4); 7.0856 (1.4); 7.0830 (1.3); 6.9961 (1.7); 6.9946 (1.6); 6.9886 (1.6); 6.9872 (1.5); 6.9748 (1.4); 6.9734 (1.5); 6.9675 (1.5); 6.9661 (1.4); 4.9706 (0.7); 4.9451 (15.9); 4.3224 (2.0); 4.3046 (6.2); 4.2931 (0.5); 4.2867 (6.2); 4.2689 (2.1); 4.2609 (0.5); 4.2568 (0.6); 4.2541 (0.6); 4.2430 (1.5); 4.2314 (4.0); 4.2252 (1.5); 4.2072 (0.5); 3.9441 (0.6); 2.8027 (1.0); 1.5510 (5.8); 1.3329 (8.0); 1.3284 (0.7); 1.3150 (16.0); 1.3107 (3.1); 1.3055 (0.6); 1.2972 (8.2); 1.2929 (4.6); 1.2837 (1.0); 1.2803 (0.6); 1.2750 (2.1); 1.2656 (0.5); 1.2546 (0.5); 0.0079 (1.0); -0.0002 (31.2); -0.0085 (0.8). I-02: 1< H-NMR(400.0 MHz, CDCl3): δ= 8.2030 (2.3); 8.1969 (2.4); 8.0713 (1.5); 8.0686 (1.6); 8.0666 (1.5); 8.0610 (1.4); 8.0591 (1.6); 8.0564 (1.6); 8.0545 (1.4); 7.8627 (1.1); 7.8565 (1.1); 7.8437 (1.3); 7.8417 (1.5); 7.8376 (1.3); 7.8355 (1.4); 7.8227 (1.2); 7.8165 (1.2); 7.7708 (1.0); 7.7660 (1.0); 7.7522 (1.3); 7.7501 (1.7); 7.7476 (1.4); 7.7454 (1.6); 7.7317 (1.6); 7.7269 (1.5); 7.6421 (3.2); 7.6400 (2.0); 7.6215 (2.3); 7.6193 (1.4); 7.2617 (20.9); 7.1176 (1.4); 7.1151 (1.4); 7.1054 (1.4); 7.1029 (1.5); 7.0992 (1.4); 7.0966 (1.4); 7.0870 (1.3); 7.0845 (1.3); 6.9962 (1.6); 6.9889 (1.6); 6.9750 (1.5); 6.9677 (1.5); 4.9459 (16.0); 4.3228 (2.0); 4.3049 (6.2); 4.2871 (6.3); 4.2693 (2.1); 1.5631 (9.8); 1.3333 (7.4); 1.3155 (15.1); 1.2977 (7.2); 0.0697 (0.7); -0.0002 (17.4); -0.0085 (0.5) I-02: 1< H-NMR(400.0 MHz, CDCl3_5mm): δ= 8.2030 (1.7); 8.1969 (1.7); 8.0734 (1.0); 8.0715 (1.1); 8.0688 (1.2); 8.0670 (1.0); 8.0613 (1.0); 8.0594 (1.1); 8.0567 (1.1); 8.0548 (1.0); 7.8629 (0.8); 7.8567 (0.8); 7.8438 (1.0); 7.8418 (1.0); 7.8377 (1.0); 7.8357 (1.0); 7.8229 (0.8); 7.8167 (0.8); 7.7708 (0.7); 7.7661 (0.7); 7.7522 (1.0); 7.7501 (1.2); 7.7476 (1.0); 7.7455 (1.1); 7.7317 (1.1); 7.7270 (1.0); 7.6419 (2.2); 7.6213 (1.5); 7.2611 (13.8); 7.1177 (1.0); 7.1152 (1.0); 7.1056 (1.0); 7.1030 (1.0); 7.0994 (1.0); 7.0969 (0.9); 7.0872 (0.9); 7.0847 (0.9); 6.9973 (1.2); 6.9901 (1.2); 6.9763 (1.1); 6.9689 (1.1); 4.9460 (10.9); 4.3230 (1.4); 4.3051 (4.2); 4.2873 (4.3); 4.2695 (1.4); 1.5528 (16.0); 1.3335 (5.0); 1.3157 (10.1); 1.2978 (4.8); 0.0079 (0.8); -0.0002 (21.2); -0.0085 (0.6) I-02: 1< H-NMR(400.0 MHz, CDCl3_5mm): δ= 8.2035 (2.5); 8.2019 (2.2); 8.1994 (2.2); 8.1975 (2.6); 8.0730 (1.5); 8.0711 (1.7); 8.0684 (1.8); 8.0665 (1.6); 8.0609 (1.6); 8.0589 (1.8); 8.0563 (1.8); 8.0544 (1.6); 7.8628 (1.2); 7.8566 (1.2); 7.8438 (1.5); 7.8418 (1.6); 7.8377 (1.5); 7.8356 (1.5); 7.8227 (1.2); 7.8166 (1.2); 7.7718 (1.1); 7.7671 (1.1); 7.7533 (1.4); 7.7512 (1.9); 7.7487 (1.6); 7.7465 (1.8); 7.7327 (1.6); 7.7280 (1.6); 7.6445 (2.0); 7.6424 (3.3); 7.6403 (2.2); 7.6239 (1.5); 7.6218 (2.4); 7.6197 (1.5); 7.2660 (4.0); 7.1184 (1.5); 7.1159 (1.6); 7.1062 (1.5); 7.1037 (1.6); 7.1000 (1.6); 7.0975 (1.5); 7.0879 (1.4); 7.0853 (1.4); 6.9970 (1.8); 6.9909 (1.7); 6.9897 (1.7); 6.9770 (1.6); 6.9759 (1.7); 6.9698 (1.6); 6.9685 (1.6); 4.9465 (16.0); 4.3226 (2.0); 4.3048 (6.3); 4.2869 (6.4); 4.2691 (2.1); 1.6396 (0.7); 1.3331 (7.5); 1.3153 (15.1); 1.2975 (7.3); -0.0002 (3.8) I-02: 1< H-NMR(599.6 MHz, CDCl3): δ= 8.2015 (9.8); 8.1979 (9.9); 8.0682 (6.6); 8.0665 (6.7); 8.0602 (6.6); 8.0585 (6.5); 8.0180 (0.5); 7.8543 (3.3); 7.8502 (3.4); 7.8405 (5.7); 7.8366 (5.3); 7.8276 (3.5); 7.8236 (3.3); 7.7621 (3.5); 7.7590 (3.5); 7.7483 (6.7); 7.7468 (6.5); 7.7360 (4.4); 7.7329 (4.4); 7.6389 (11.0); 7.6251 (8.6); 7.2618 (32.2); 7.1099 (5.4); 7.1017 (5.8); 7.0990 (5.5); 7.0977 (5.4); 7.0895 (4.9); 6.9907 (6.1); 6.9860 (6.0); 6.9766 (5.8); 6.9719 (5.6); 4.9453 (50.0); 4.3136 (6.4); 4.3017 (19.2); 4.2898 (19.3); 4.2779 (6.4); 2.9562 (3.2); 2.8836 (3.0); 2.7714 (1.3); 1.5695 (41.5); 1.3271 (21.2); 1.3152 (41.9); 1.3033 (20.7); 1.2924 (0.5); 1.2540 (0.5); 1.2195 (0.4); 1.2077 (0.6); -0.0001 (31.3) I-02: 1< H-NMR(400.6 MHz, CDCl3): δ= 8.2031 (2.1); 8.2010 (1.7); 8.1988 (1.8); 8.1969 (2.2); 8.0736 (1.4); 8.0716 (1.4); 8.0689 (1.6); 8.0670 (1.3); 8.0615 (1.5); 8.0595 (1.5); 8.0568 (1.5); 8.0549 (1.3); 7.8629 (1.2); 7.8568 (1.1); 7.8440 (1.4); 7.8419 (1.4); 7.8378 (1.4); 7.8357 (1.4); 7.8229 (1.2); 7.8168 (1.2); 7.7709 (1.1); 7.7662 (1.1); 7.7524 (1.4); 7.7502 (1.7); 7.7477 (1.4); 7.7455 (1.6); 7.7319 (1.6); 7.7271 (1.6); 7.6441 (1.9); 7.6419 (3.1); 7.6396 (1.8); 7.6235 (1.4); 7.6213 (2.2); 7.6190 (1.2); 7.2612 (21.0); 7.1178 (1.5); 7.1153 (1.4); 7.1057 (1.4); 7.1031 (1.4); 7.0995 (1.5); 7.0969 (1.4); 7.0873 (1.4); 7.0848 (1.3); 6.9977 (1.7); 6.9964 (1.5); 6.9904 (1.6); 6.9890 (1.5); 6.9766 (1.5); 6.9752 (1.4); 6.9692 (1.6); 6.9678 (1.4); 4.9462 (16.0); 4.3230 (2.0); 4.3051 (6.2); 4.2873 (6.3); 4.2695 (2.1); 1.5570 (3.7); 1.3335 (7.6); 1.3157 (15.6); 1.2979 (7.5); 0.0079 (0.8); -0.0002 (28.9); -0.0085 (1.0) I-02: 1< H-NMR(400.0 MHz, CDCl3): δ= 8.2031 (2.3); 8.1969 (2.3); 8.0711 (1.2); 8.0684 (1.3); 8.0588 (1.3); 8.0564 (1.2); 7.8625 (1.2); 7.8564 (1.2); 7.8436 (1.4); 7.8415 (1.6); 7.8374 (1.4); 7.8352 (1.4); 7.8225 (1.2); 7.8163 (1.3); 7.7702 (1.1); 7.7655 (1.1); 7.7518 (1.3); 7.7496 (1.7); 7.7471 (1.4); 7.7448 (1.6); 7.7311 (1.6); 7.7264 (1.6); 7.6423 (2.4); 7.6216 (1.8); 7.2604 (45.3); 7.1170 (1.2); 7.1146 (1.3); 7.1049 (1.2); 7.1024 (1.3); 7.0987 (1.3); 7.0962 (1.2); 7.0866 (1.1); 7.0841 (1.1); 6.9958 (1.7); 6.9896 (1.6); 6.9882 (1.6); 6.9758 (1.5); 6.9743 (1.6); 6.9683 (1.5); 4.9707 (0.7); 4.9457 (15.7); 4.3227 (2.0); 4.3049 (6.3); 4.2870 (6.4); 4.2692 (2.1); 4.2322 (0.5); 1.5533 (0.9); 1.3332 (7.9); 1.3154 (16.0); 1.3058 (0.8); 1.2976 (7.7); 1.2933 (1.5); 1.2844 (0.6); 1.2809 (0.6); 1.2753 (0.6); 1.2540 (0.5); 0.0079 (1.6); -0.0002 (53.8); -0.0085 (1.6) I-02: 1< H-NMR(400.0 MHz, CDCl3): δ= 8.2037 (1.8); 8.1977 (1.8); 8.0702 (0.8); 8.0617 (0.8); 7.8632 (1.1); 7.8570 (1.1); 7.8443 (1.3); 7.8421 (1.4); 7.8381 (1.3); 7.8359 (1.3); 7.8231 (1.2); 7.8169 (1.2); 7.7710 (0.9); 7.7664 (0.9); 7.7525 (1.1); 7.7503 (1.4); 7.7480 (1.2); 7.7457 (1.3); 7.7319 (1.3); 7.7273 (1.2); 7.6426 (1.0); 7.6217 (0.7); 7.2615 (41.8); 7.1182 (0.6); 7.1010 (0.7); 7.0881 (0.5); 6.9972 (1.5); 6.9909 (1.3); 6.9896 (1.3); 6.9771 (1.2); 6.9758 (1.3); 6.9697 (1.3); 6.9684 (1.2); 4.9466 (12.0); 4.8855 (0.9); 4.3229 (2.0); 4.3050 (6.2); 4.2872 (6.4); 4.2693 (2.4); 1.3333 (7.8); 1.3155 (16.0); 1.3025 (0.8); 1.2976 (7.6); 1.2847 (1.3); 1.2668 (0.7); 0.0080 (0.7); - 0.0002 (26.8); -0.0085 (0.8) I-02: 1< H-NMR(599.6 MHz, CDCl3): δ= 8.2023 (10.1); 8.1985 (9.6); 8.0674 (6.6); 8.0657 (6.6); 8.0594 (6.7); 8.0577 (6.3); 7.8542 (3.5); 7.8501 (3.4); 7.8403 (5.6); 7.8373 (5.3); 7.8275 (3.6); 7.8234 (3.3); 7.7620 (3.7); 7.7589 (3.4); 7.7482 (6.8); 7.7467 (6.2); 7.7359 (4.7); 7.7328 (4.2); 7.6398 (10.9); 7.6260 (8.6); 7.2627 (14.9); 7.1107 (5.4); 7.1095 (5.0); 7.1025 (5.6); 7.1012 (5.7); 7.0985 (5.6); 7.0903 (5.0); 7.0891 (4.5); 6.9908 (6.0); 6.9863 (5.9); 6.9767 (5.8); 6.9722 (5.6); 4.9454 (50.0); 4.3135 (6.5); 4.3016 (19.5); 4.2897 (19.6); 4.2778 (6.6); 2.7693 (1.1); 2.0440 (0.4); 1.5813 (11.2); 1.3269 (21.4); 1.3150 (42.4); 1.3031 (21.1); 1.2586 (0.7); 1.2073 (0.4); -0.0001 (23.3); -0.0055 (0.8) I-02: 1< H-NMR(400.0 MHz, CDCl3): δ= 8.2034 (2.4); 8 / 1970 (2.3); 8.0724 (1.5); 8.0697 (1.5); 8.0603 (1.5); 8.0554 (1.4); 7.8631 (1.1); 7.8570 (1.1); 7.8422(1.5); 7.8360 (1.5); 7.8233 (1.2); 7.8169 (1.2); 7.7706 (1.1); 7.7657 (1.0); 7.7499(1.7); 7.7452(1.6); 7.7315 (1.6); 7.7267 (1.6); 7.6412 (3.2); 7.6206 (2.2); 7.2601 (74.1); 7.1178 (1.4); 7.1153 (1.4); 7.1055 (1.4); 7.1031 (1.6); 7.0996 (1.4); 7.0969 (1.3); 7.0873 (1.2); 7.0847 (1.3); 6.9962 (2.0); 6.9888 (1.7); 6.9751 (1.6); 6.9689 (1.5); 5.0852 (0.8); 4.9459 (16.0); 4.7446 (0.9); 4.3228 (1.9); 4.3049 (6.1); 4.2871 (6.2); 4.2692 (2.0); 1.3333 (7.6); 1.3154 (15.2); 1.2976 (7.5); 1.2809 (0.8); 1.2545 (1.1); 0.0079 (2.9); -0.0002 (98.9); -0.0085 (2.7) I-89: 1< H-NMR(400.0 MHz, d 6 -DMSO): δ= 12.2270 (0.6); 8.2508 (1.4); 8.2446 (1.4); 8.1006 (1.2); 8.0959 (1.1); 8.0837 (1.9); 8.0223 (0.5); 8.0161 (0.5); 8.0016 (0.9); 7.9953 (0.9); 7.9876 (0.7); 7.9821 (1.0); 7.9752 (0.6); 7.9670 (0.9); 7.9642 (0.8); 7.9624 (0.9); 7.9483 (0.8); 7.9437 (0.7); 7.7125 (1.6); 7.6919 (1.4); 7.3045 (0.9); 7.2981 (0.9); 7.2829 (1.6); 7.2764 (0.9); 7.2727 (0.8); 7.2704 (0.9); 7.2663 (0.8); 7.2641 (0.8); 7.2542 (0.8); 7.2519 (0.8); 4.7456 (4.4); 4.1694 (0.6); 3.6177 (1.1); 3.6114 (0.7); 3.6074 (1.0); 3.6011 (2.8); 3.5951 (1.0); 3.5910 (0.7); 3.5846 (1.2); 3.3213 (16.0); 2.5243 (0.5); 2.5195 (0.7); 2.5108 (11.1); 2.5063 (24.1); 2.5017 (33.8); 2.4972 (24.0); 2.4927 (10.8); 2.4756 (1.1); 2.4604 (1.1); 2.3774 (1.1); 2.3589 (1.1); 2.3383 (0.7); 2.3199 (0.7); 1.7761 (1.2); 1.7682 (1.2); 1.7595 (3.5); 1.7508 (1.2); 1.7431 (1.2); 1.3556 (3.0); 1.2348 (0.6); 1.1383 (4.7); 1.1217 (4.6); -0.0002 (17.2); -0.0085 (0.5) I-90: 1< H-NMR(400.6 MHz, CDCl3): δ= 8.2013 (2.4); 8.1993 (1.9); 8.1952 (2.5); 8.0821 (1.5); 8.0801 (1.6); 8.0774 (1.7); 8.0755 (1.5); 8.0700 (1.6); 8.0680 (1.7); 8.0653 (1.8); 8.0634 (1.5); 7.8604 (1.2); 7.8542 (1.2); 7.8414 (1.5); 7.8393 (1.5); 7.8352 (1.5); 7.8331 (1.4); 7.8204 (1.3); 7.8142 (1.3); 7.7761 (1.2); 7.7714 (1.2); 7.7576 (1.6); 7.7555 (1.8); 7.7528 (1.6); 7.7508 (1.7); 7.7371 (1.7); 7.7323 (1.7); 7.6254 (2.1); 7.6234 (3.4); 7.6212 (1.9); 7.6049 (1.6); 7.6028 (2.5); 7.6005 (1.4); 7.2614 (20.9); 7.1265 (1.6); 7.1240 (1.5); 7.1143 (1.6); 7.1119 (1.6); 7.1081 (1.6); 7.1056 (1.5); 7.0959 (1.6); 7.0934 (1.4); 6.9999 (1.7); 6.9985 (1.7); 6.9926 (1.8); 6.9913 (1.6); 6.9788 (1.7); 6.9774 (1.6); 6.9714 (1.7); 5.3002 (2.4); 4.9648 (16.0); 4.2712 (1.4); 4.2552 (1.5); 4.2442 (2.2); 4.2282 (2.2); 4.1520 (2.3); 4.1322 (2.4); 4.1250 (1.6); 4.1052 (1.6); 3.8525 (0.7); 3.8387 (0.8); 3.8317 (1.5); 3.8179 (1.6); 3.8110 (2.9); 3.7974 (1.2); 3.7931 (1.9); 3.7888 (2.1); 3.7710 (2.0); 3.7453 (1.2); 3.7270 (1.8); 3.7086 (1.5); 3.6875 (0.9); 3.5632 (1.9); 3.5495 (2.0); 3.5410 (1.7); 3.5273 (1.7); 2.6265 (0.6); 2.6094 (0.8); 2.5922 (0.7); 2.0324 (0.7); 2.0200 (0.9); 2.0116 (0.5); 2.0070 (0.6); 1.9991 (0.9); 1.9872 (0.7); 1.9803 (0.6); 1.9666 (0.5); 1.6600 (0.5); 1.6426 (0.8); 1.6280 (1.0); 1.6085 (1.0); 1.5937 (0.7); 1.5767 (0.5); 1.5579 (5.7); 1.2556 (0.9); 0.0080 (1.0); -0.0002 (32.8); -0.0057 (0.7); -0.0065 (0.6); -0.0086 (1.1). I-92: 1< H-NMR(400.6 MHz, CDCl3): δ= 8.2153 (1.1); 8.2133 (0.9); 8.2112 (0.9); 8.2091 (1.2); 8.2073 (0.8); 8.0826 (0.6); 8.0805 (0.7); 8.0779 (0.8); 8.0758 (0.7); 8.0704 (0.7); 8.0684 (0.8); 8.0658 (0.8); 8.0637 (0.8); 7.8637 (0.6); 7.8575 (0.6); 7.8449 (0.7); 7.8426 (0.8); 7.8387 (0.8); 7.8364 (0.8); 7.8238 (0.7); 7.8176 (0.7); 7.8057 (0.6); 7.8010 (0.6); 7.7874 (0.7); 7.7851 (1.0); 7.7827 (0.7); 7.7804 (1.0); 7.7668 (1.0); 7.7621 (1.0); 7.7060 (0.9); 7.7036 (1.6); 7.7013 (1.0); 7.6854 (0.6); 7.6830 (1.0); 7.6807 (0.6); 7.2631 (7.7); 7.1452 (0.7); 7.1426 (0.8); 7.1331 (0.7); 7.1304 (0.8); 7.1269 (0.8); 7.1243 (0.8); 7.1148 (0.8); 7.1121 (0.9); 7.0094 (0.8); 7.0078 (0.8); 7.0020 (0.8); 7.0004 (0.9); 6.9882 (0.8); 6.9867 (0.8); 6.9808 (0.8); 6.9793 (0.8); 5.3006 (1.3); 4.8618 (8.2); 3.6806 (16.0); 2.6050 (3.3); 2.5917 (3.2); 1.5888 (1.5); 1.3186 (5.8); 1.3017 (5.8); -0.0002 (11.0) I-93: 1< H-NMR(400.6 MHz, CDCl3): δ= 8.1976 (2.5); 8.1914 (2.6); 8.0650 (1.5); 8.0631 (1.6); 8.0603 (1.8); 8.0584 (1.6); 8.0528 (1.7); 8.0509 (1.8); 8.0482 (1.8); 8.0464 (1.6); 7.8583 (1.3); 7.8522 (1.3); 7.8393 (1.5); 7.8373 (1.6); 7.8331 (1.6); 7.8311 (1.6); 7.8183 (1.4); 7.8121 (1.3); 7.7691 (1.2); 7.7644 (1.2); 7.7507 (1.4); 7.7484 (1.9); 7.7460 (1.5); 7.7438 (1.8); 7.7302 (1.9); 7.7254 (1.9); 7.6649 (2.1); 7.6627 (3.6); 7.6604 (2.1); 7.6442 (1.5); 7.6421 (2.4); 7.6398 (1.4); 7.2609 (37.0); 7.1145 (1.6); 7.1119 (1.6); 7.1024 (1.6); 7.0997 (1.6); 7.0962 (1.7); 7.0936 (1.5); 7.0841 (1.5); 7.0814 (1.5); 6.9975 (2.0); 6.9902 (1.9); 6.9765 (1.8); 6.9691 (1.8); 5.3002 (6.6); 5.0017 (16.0); 4.3332 (0.5); 4.3176 (2.3); 4.2984 (3.3); 4.2919 (0.7); 4.2822 (1.2); 4.1967 (1.3); 4.1810 (3.4); 4.1771 (2.0); 4.1618 (5.8); 4.1541 (1.3); 4.1515 (1.2); 4.1453 (1.1); 3.9016 (0.9); 3.8846 (1.6); 3.8807 (1.6); 3.8681 (1.1); 3.8638 (2.6); 3.8473 (1.3); 3.8124 (1.2); 3.7947 (1.7); 3.7788 (1.4); 3.7743 (1.2); 3.7581 (0.8); 2.0003 (0.7); 1.9877 (0.7); 1.9796 (0.9); 1.9653 (0.8); 1.9499 (0.7); 1.9350 (0.7); 1.9237 (0.7); 1.9196 (1.0); 1.9149 (0.9); 1.9071 (2.0); 1.9026 (1.3); 1.8990 (1.2); 1.8903 (1.9); 1.8863 (1.6); 1.8726 (0.9); 1.8691 (1.3); 1.6458 (0.9); 1.6413 (0.5); 1.6322 (0.7); 1.6241 (0.8); 1.6152 (0.8); 1.5974 (0.7); 1.5487 (8.9); 0.0079 (1.4); - 0.0002 (50.3); -0.0085 (1.9). I-94: 1< H-NMR(400.0 MHz, d 6 -DMSO): δ= 8.2765 (1.2); 8.2708 (1.3); 8.1417 (0.8); 8.1390 (0.9); 8.1295 (0.9); 8.1268 (0.9); 8.0737 (0.8); 8.0677 (0.7); 8.0145 (0.6); 8.0098 (0.6); 7.9942 (0.9); 7.9896 (0.9); 7.9753 (0.8); 7.9707 (0.7); 7.6634 (1.6); 7.6429 (1.4); 7.3508 (0.8); 7.3485 (0.8); 7.3386 (0.7); 7.3364 (0.8); 7.3321 (0.8); 7.3298 (0.7); 7.3201 (0.8); 7.3177 (0.7); 7.2963 (0.8); 7.2899 (0.9); 7.2750 (0.8); 7.2684 (0.8); 5.1911 (1.5); 5.1736 (1.5); 3.3189 (16.0); 2.5238 (0.7); 2.5191 (1.0); 2.5103 (18.0); 2.5057 (40.1); 2.5012 (56.5); 2.4966 (40.2); 2.4921 (18.2); 1.9884 (1.1); 1.5950 (4.6); 1.5776 (4.6); 1.3554 (0.8); 1.2356 (0.8); 1.1745 (0.6); 0.0080 (1.3); -0.0002 (50.2); - 0.0085 (1.5) I-95: 1< H-NMR(400.6 MHz, CDCl3): δ= 8.2023 (1.1); 8.1961 (1.2); 8.0763 (0.6); 8.0744 (0.7); 8.0717 (0.7); 8.0698 (0.7); 8.0642 (0.7); 8.0623 (0.7); 8.0595 (0.7); 8.0577 (0.7); 7.8609 (0.6); 7.8547 (0.5); 7.8419 (0.6); 7.8398 (0.7); 7.8357 (0.7); 7.8336 (0.7); 7.8209 (0.6); 7.8147 (0.6); 7.7755 (0.5); 7.7707 (0.5); 7.7570 (0.6); 7.7548 (0.8); 7.7523 (0.7); 7.7501 (0.8); 7.7365 (0.8); 7.7317 (0.8); 7.6538 (0.9); 7.6517 (1.5); 7.6496 (0.9); 7.6332 (0.6); 7.6311 (1.1); 7.6289 (0.6); 7.2612 (14.2); 7.1232 (0.7); 7.1206 (0.7); 7.1110 (0.6); 7.1085 (0.7); 7.1048 (0.7); 7.1023 (0.7); 7.0927 (0.6); 7.0901 (0.6); 6.9979 (0.8); 6.9917 (0.8); 6.9779 (0.7); 6.9706 (0.8); 4.9783 (7.7); 4.4228 (2.0); 4.4059 (4.1); 4.3890 (2.1); 2.7825 (2.2); 2.7657 (4.4); 2.7487 (2.1); 2.1441 (16.0); 1.5776 (0.9); -0.0002 (17.6); -0.0085 (0.6) I-96: 1< H-NMR(400.6 MHz, CDCl3): δ= 8.2002 (1.1); 8.1941 (1.2); 8.0656 (0.6); 8.0629 (0.7); 8.0535 (0.7); 8.0508 (0.7); 7.8599 (0.5); 7.8537 (0.5); 7.8408 (0.6); 7.8388 (0.7); 7.8347 (0.7); 7.8327 (0.6); 7.8199 (0.6); 7.8137 (0.6); 7.7512 (0.6); 7.7490 (0.8); 7.7466 (0.6); 7.7444 (0.7); 7.7307 (0.7); 7.7260 (0.7); 7.6545 (1.4); 7.6339 (1.0); 7.2613 (9.9); 7.1153 (0.6); 7.1128 (0.6); 7.1031 (0.6); 7.1006 (0.6); 7.0970 (0.7); 7.0945 (0.6); 7.0849 (0.6); 7.0823 (0.6); 6.9969 (0.8); 6.9896 (0.8); 6.9757 (0.7); 6.9684 (0.8); 5.0026 (7.3); 4.3973 (1.8); 4.3893 (1.0); 4.3858 (1.9); 4.3819 (1.0); 4.3741 (2.0); 3.6510 (2.1); 3.6431 (1.0); 3.6393 (2.0); 3.6357 (1.1); 3.6277 (2.0); 3.3793 (16.0); -0.0002 (12.0) I-96: 1< H-NMR(400.6 MHz, CDCl3): δ= 8.2008 (0.9); 8.1988 (0.7); 8.1966 (0.7); 8.1946 (0.9); 8.1928 (0.6); 8.0670 (0.6); 8.0649 (0.6); 8.0623 (0.7); 8.0602 (0.6); 8.0549 (0.6); 8.0528 (0.7); 8.0502 (0.7); 8.0481 (0.6); 7.8599 (0.5); 7.8537 (0.5); 7.8410 (0.6); 7.8388 (0.6); 7.8348 (0.6); 7.8326 (0.6); 7.8199 (0.6); 7.8137 (0.5); 7.7698 (0.5); 7.7514 (0.6); 7.7492 (0.8); 7.7467 (0.6); 7.7444 (0.8); 7.7308 (0.8); 7.7261 (0.8); 7.6579 (0.8); 7.6556 (1.4); 7.6533 (0.8); 7.6373 (0.6); 7.6350 (1.0); 7.6326 (0.5); 7.2628 (4.2); 7.1151 (0.7); 7.1125 (0.7); 7.1030 (0.6); 7.1003 (0.7); 7.0968 (0.7); 7.0941 (0.6); 7.0846 (0.6); 7.0820 (0.6); 6.9972 (0.7); 6.9957 (0.7); 6.9898 (0.7); 6.9883 (0.7); 6.9761 (0.6); 6.9746 (0.7); 6.9687 (0.6); 6.9672 (0.6); 5.3002 (2.8); 5.0027 (6.9); 4.3973 (1.7); 4.3893 (0.8); 4.3858 (1.7); 4.3819 (0.8); 4.3740 (1.8); 3.6509 (2.0); 3.6430 (0.9); 3.6392 (1.8); 3.6357 (0.9); 3.6344 (0.7); 3.6276 (1.9); 3.3789 (16.0); 1.5785 (0.9); -0.0002 (6.5) I-97: 1< H-NMR(400.6 MHz, CDCl3): δ= 8.2122 (1.2); 8.2082 (1.0); 8.2060 (1.3); 8.0905 (0.7); 8.0885 (0.8); 8.0859 (0.9); 8.0838 (0.8); 8.0784 (0.8); 8.0763(0.9); 8.0737 (0.9); 8.0717 (0.8); 7.8644(0.7); 7.8582(0.7); 7.8456(0.8); 7.8433 (0.8); 7.8394 (0.8); 7.8372(0.8); 7.8245(0.8); 7.8183(0.7); 7.8093 (0.6); 7.8046 (0.6); 7.7910 (0.7); 7.7887 (1.0); 7.7863 (0.8); 7.7840 (1.0); 7.7704 (1.0); 7.7657 (1.0); 7.7121 (1.0); 7.7097 (1.9); 7.7075 (1.2); 7.6915 (0.7); 7.6891 (1.2); 7.6868 (0.7); 7.2617 (15.3); 7.1504 (0.9); 7.1477 (0.9); 7.1382 (0.8); 7.1356 (0.9); 7.1321 (0.9); 7.1294 (0.9); 7.1199 (0.9); 7.1173 (0.8); 7.0091 (0.9); 7.0077 (0.9); 7.0017 (0.9); 7.0003 (0.9); 6.9880 (0.9); 6.9866 (0.9); 6.9806 (0.9); 6.9792 (0.9); 5.3003 (6.8); 4.9460 (7.7); 4.1838 (3.5); 4.1704 (3.5); 3.7928 (16.0); 1.5619 (8.1); 1.2557 (0.5); 0.0080 (0.5); -0.0002 (20.8); -0.0085 (0.8) I-98: 1< H-NMR(400.0 MHz, d 6 -DMSO): δ= 8.2778 (3.2); 8.2716 (3.4); 8.1260 (1.9); 8.1241 (2.1); 8.1214 (2.4); 8.1195 (2.1); 8.1138 (2.0); 8.1120 (2.3); 8.1093 (2.3); 8.1074 (2.1); 8.0448 (1.4); 8.0386 (1.3); 8.0238 (2.0); 8.0177 (2.0); 8.0040 (1.5); 7.9979 (3.1); 7.9932 (1.6); 7.9792 (2.1); 7.9774 (2.3); 7.9746 (2.0); 7.9727 (2.1); 7.9588 (2.0); 7.9540 (1.9); 7.6868 (4.1); 7.6662 (3.7); 7.3089 (2.2); 7.3020 (4.2); 7.2921 (2.1); 7.2894 (3.4); 7.2862 (3.1); 7.2831 (2.9); 7.2737 (2.0); 7.2713 (1.9); 4.9361 (16.0); 4.0561 (0.5); 4.0382 (1.7); 4.0205 (1.7); 4.0027 (0.6); 3.3224 (3.0); 2.5246 (0.7); 2.5199 (1.0); 2.5112 (17.3); 2.5066 (38.2); 2.5021 (53.5); 2.4975 (37.8); 2.4929 (16.9); 1.9889 (7.4); 1.9094 (3.8); 1.1925 (2.0); 1.1747 (4.0); 1.1569 (2.0); 0.0080 (1.2); -0.0002 (45.3); -0.0085 (1.3) I-99: 1< H-NMR(400.0 MHz, CDCl3): δ= 8.1584 (2.0); 8.1520 (2.2); 8.1026 (1.4); 8.1000 (1.4); 8.0878 (1.4); 7.8516 (0.8); 7.8459 (0.7); 7.8316 (1.2); 7.8118 (0.8); 7.8056 (0.8); 7.7909 (1.1); 7.7862 (1.0); 7.7704 (1.5); 7.7659 (1.4); 7.7517 (1.4); 7.7470 (1.3); 7.6111 (2.7); 7.5906 (2.1); 7.2605 (66.6); 7.1759 (1.3); 7.1637 (1.3); 7.1599 (1.2); 7.1453 (1.2); 6.9948 (1.6); 6.9869 (1.5); 6.9789 (1.2); 6.9730 (1.5); 6.9667 (1.4); 5.0311 (13.8); 5.0208 (0.9); 5.0075 (0.6); 4.9719 (0.6); 4.8594 (0.9); 3.8864 (1.1); 3.1157 (0.5); 2.2716 (1.8); 1.4322 (16.0); 1.2540 (2.8); 1.2224 (0.7); 0.8796 (0.5); 0.0690 (0.9); 0.0080 (2.0); -0.0002 (81.2); -0.0085 (2.6) I-100: 1< H-NMR(400.0 MHz, CDCl3): δ= 8.2105 (2.3); 8.2044 (2.3); 8.0800 (1.3); 8.0773 (1.4); 8.0679 (1.4); 8.0651 (1.4); 7.8667 (1.1); 7.8605 (1.1); 7.8477 (1.4); 7.8456 (1.4); 7.8415 (1.3); 7.8394 (1.4); 7.8266 (1.2); 7.8204 (1.2); 7.7752 (1.1); 7.7704 (1.0); 7.7566 (1.3); 7.7545 (1.7); 7.7520 (1.4); 7.7498 (1.6); 7.7360 (1.6); 7.7313 (1.5); 7.6423 (2.7); 7.6217 (1.9); 7.2617 (11.8); 7.1226 (1.3); 7.1201 (1.3); 7.1104 (1.3); 7.1079 (1.4); 7.1042 (1.3); 7.1017 (1.3); 7.0920 (1.2); 7.0895 (1.2); 6.9979 (1.7); 6.9905 (1.6); 6.9767 (1.6); 6.9694 (1.5); 4.9472 (16.0); 4.3248 (2.0); 4.3069 (6.3); 4.2891 (6.4); 4.2713 (2.1); 1.5627 (5.7); 1.3344 (7.5); 1.3165 (15.4); 1.2987 (7.4); 0.0080 (0.5); -0.0002 (15.4) 1-101: 1< H-NMR(400.0 MHz, CDCl3): δ= 8.1754 (2.3); 8.1693 (2.3); 8.0295 (1.4); 8.0275 (1.5); 8.0249 (1.6); 8.0229 (1.4); 8.0174 (1.4); 8.0154 (1.5); 8.0127 (1.5); 8.0107 (1.4); 7.8344 (1.2); 7.8282 (1.1); 7.8153 (1.4); 7.8134 (1.5); 7.8091 (1.4); 7.8072 (1.4); 7.7943 (1.2); 7.7881 (1.2); 7.7470 (1.1); 7.7422 (1.0); 7.7285 (1.2); 7.7262 (1.7); 7.7239 (1.3); 7.7215 (1.6); 7.7079 (1.7); 7.7031 (1.6); 7.6383 (1.8); 7.6361 (3.3); 7.6339 (2.0); 7.6177 (1.3); 7.6154 (2.2); 7.6131 (1.2); 7.2615 (16.8); 7.0810 (1.4); 7.0785 (1.5); 7.0689 (1.4); 7.0663 (1.5); 7.0628 (1.5); 7.0601 (1.4); 7.0506 (1.4); 7.0480 (1.3); 6.9933 (1.6); 6.9871 (1.6); 6.9721 (1.6); 6.9660 (1.5); 5.2437 (0.9); 5.2262 (3.1); 5.2088 (3.2); 5.1914 (0.9); 4.2901 (1.0); 4.2831 (1.1); 4.2722 (3.1); 4.2654 (3.2); 4.2544 (3.2); 4.2477 (3.1); 4.2366 (1.1); 4.2300 (1.0); 1.7114 (11.9); 1.6939 (11.9); 1.5609 (8.8); 1.3049 (7.9); 1.2871 (16.0); 1.2692 (8.6); 0.8987 (1.0); 0.8818 (3.6); 0.8641 (1.4); 0.0079 (0.5); -0.0002 (19.0); -0.0085 (0.6) 1-102: 1< H-NMR(400.6 MHz, CDCl3): δ= 8.1982 (2.3); 8.1921 (2.4); 8.0465 (1.4); 8.0445 (1.5); 8.0419 (1.6); 8.0399 (1.5); 8.0344 (1.5); 8.0324 (1.6); 8.0298 (1.6); 8.0277 (1.5); 7.8583 (1.2); 7.8521 (1.2); 7.8393 (1.4); 7.8372 (1.5); 7.8332 (1.4); 7.8311 (1.4); 7.8183 (1.3); 7.8121 (1.2); 7.7579 (1.1); 7.7531 (1.1); 7.7395 (1.3); 7.7372 (1.8); 7.7348 (1.4); 7.7325 (1.7); 7.7189 (1.7); 7.7141 (1.7); 7.6375 (1.8); 7.6354 (3.1); 7.6332 (1.9); 7.6169 (1.3); 7.6147 (2.2); 7.6125 (1.2); 7.2626 (23.6); 7.0980 (1.5); 7.0954 (1.5); 7.0859 (1.5); 7.0833 (1.6); 7.0797 (1.6); 7.0771 (1.5); 7.0675 (1.5); 7.0650 (1.4); 6.9934 (1.6); 6.9920 (1.6); 6.9861 (1.6); 6.9847 (1.6); 6.9722 (1.5); 6.9709 (1.6); 6.9650 (1.6); 6.9636 (1.5); 5.2555 (0.9); 5.2381 (3.2); 5.2207 (3.3); 5.2033 (0.9); 4.2935 (1.0); 4.2864 (1.1); 4.2757 (3.1); 4.2687 (3.1); 4.2578 (3.2); 4.2510 (3.1); 4.2401 (1.1); 4.2333 (1.0); 3.5060 (1.9); 3.4885 (6.0); 3.4710 (6.1); 3.4535 (2.0); 1.7152 (12.3); 1.6978 (12.2); 1.5835 (6.5); 1.3055 (7.7); 1.2877 (16.0); 1.2699 (7.7); 1.2263 (6.4); 1.2088 (12.8); 1.1912 (6.2); 0.8820 (0.5); -0.0002 (11.4). 1-103: 1< H-NMR(400.6 MHz, d 6 -DMSO): δ= 8.2163 (3.4); 8.2101 (3.6); 8.0964 (2.2); 8.0944 (2.4); 8.0917 (2.7); 8.0897 (2.5); 8.0843 (2.4); 8.0823 (2.6); 8.0796 (2.7); 8.0776 (2.4); 7.9897 (1.6); 7.9834 (1.6); 7.9723 (2.5); 7.9680 (3.6); 7.9637 (2.2); 7.9624 (2.3); 7.9538 (2.6); 7.9518 (2.9); 7.9491 (4.0); 7.9472 (3.0); 7.9427 (1.8); 7.9333 (2.6); 7.9285 (2.4); 7.6686 (2.6); 7.6664 (4.8); 7.6642 (2.8); 7.6480 (2.4); 7.6459 (4.3); 7.6436 (2.4); 7.2933 (2.3); 7.2876 (2.3); 7.2719 (2.4); 7.2693 (3.1); 7.2667 (4.5); 7.2572 (2.3); 7.2547 (2.5); 7.2508 (2.5); 7.2484 (2.2); 7.2387 (2.3); 7.2362 (2.3); 4.8941 (16.0); 4.0382 (0.8); 4.0204 (0.8); 3.3370 (9.0); 2.5256 (0.8); 2.5209 (1.1); 2.5122 (15.4); 2.5076 (34.1); 2.5030 (48.2); 2.4984 (34.1); 2.4939 (15.6); 1.9891 (3.6); 1.9100 (4.0); 1.3559 (1.3); 1.1924 (1.0); 1.1747 (2.2); 1.1569 (1.0) 1-104: 1< H-NMR(400.6 MHz, CDCl3): δ= 8.5475 (2.6); 8.5406 (2.6); 8.3448 (1.5); 8.3411 (2.6); 8.3375 (1.5); 8.1952 (1.2); 8.1930 (1.3); 8.1907 (1.4); 8.1885 (1.3); 8.1831 (1.2); 8.1807 (1.4); 8.1788 (1.4); 8.1764 (1.3); 7.9271 (0.7); 7.9225 (0.7); 7.9096 (0.6); 7.9066 (1.9); 7.9021 (1.9); 7.8892 (2.3); 7.8848 (2.3); 7.8811 (2.1); 7.8788 (2.4); 7.8774 (2.7); 7.8749 (2.4); 7.8606 (0.8); 7.8584 (0.9); 7.8570 (0.6); 7.5385 (1.2); 7.5341 (1.3); 7.5316 (1.3); 7.5272 (1.2); 7.5167 (1.3); 7.5123 (1.4); 7.5098 (1.3); 7.5054 (1.2); 7.3327 (1.4); 7.3289 (1.4); 7.3206 (1.4); 7.3166 (1.5); 7.3153 (1.6); 7.3115 (1.3); 7.3033 (1.4); 7.2993 (1.3); 7.2647 (10.0); 5.3012 (13.1); 4.4380 (15.8); 4.2762 (2.1); 4.2583 (6.8); 4.2405 (6.8); 4.2226 (2.2); 1.6028 (2.1); 1.2834 (7.6); 1.2656 (16.0); 1.2592 (0.6); 1.2568 (0.6); 1.2551 (0.6); 1.2477 (7.4); 0.0705 (3.1); -0.0002 (10.6) 1-105: 1< H-NMR(400.0 MHz, CDCl3): δ= 8.1519 (2.3); 8.1459 (2.3); 8.0663 (1.6); 8.0636 (1.6); 8.0543 (1.6); 8.0514 (1.6); 7.8464 (0.9); 7.8403 (0.8); 7.8259 (1.3); 7.8202 (1.2); 7.8067 (0.9); 7.8006 (0.9); 7.7838 (1.1); 7.7790 (1.2); 7.7633 (1.8); 7.7586 (1.7); 7.7446 (1.6); 7.7399 (1.5); 7.6305 (3.0); 7.6099 (2.3); 7.2608 (31.2); 7.1562 (1.4); 7.1537 (1.4); 7.1440 (1.5); 7.1416 (1.5); 7.1377 (1.5); 7.1351 (1.4); 7.1255 (1.4); 7.1230 (1.3); 6.9861 (1.7); 6.9788 (1.7); 6.9659 (1.7); 6.9579 (1.6); 5.2999 (5.7); 4.9538 (16.0); 4.9476 (1.4); 4.7851 (0.6); 4.3166 (2.1); 4.2987 (6.4); 4.2808 (6.6); 4.2686 (0.7); 4.2630 (2.2); 3.9012 (0.8); 1.5454 (11.2); 1.3279 (7.7); 1.3204 (1.2); 1.3101 (15.6); 1.3025 (1.0); 1.2991 (1.2); 1.2923 (7.6); 1.2812 (0.6); 1.2552 (0.8); 0.0080 (1.3); -0.0002 (42.0); -0.0085 (1.4) 1-106: 1< H-NMR(400.6 MHz, CDCl3): δ= 8.5338 (3.0); 8.5269 (3.1); 8.3349 (1.6); 8.3312 (3.0); 8.3276 (1.6); 8.1816 (1.2); 8.1794 (1.3); 8.1771 (1.4); 8.1749 (1.3); 8.1695 (1.3); 8.1672 (1.4); 8.1651 (1.4); 8.1628 (1.3); 7.9156 (0.8); 7.9110 (0.8); 7.8979 (0.7); 7.8951 (1.9); 7.8906 (1.8); 7.8775 (2.2); 7.8731 (2.2); 7.8668 (2.0); 7.8645 (2.4); 7.8633 (2.7); 7.8609 (2.3); 7.8463 (0.9); 7.8440 (1.0); 7.8428 (0.8); 7.8404 (0.6); 7.5133 (1.3); 7.5089 (1.3); 7.5064 (1.4); 7.5020 (1.2); 7.4913 (1.3); 7.4869 (1.4); 7.4845 (1.3); 7.4801 (1.3); 7.3059 (1.4); 7.3022 (1.4); 7.2937 (1.3); 7.2900 (1.4); 7.2883 (1.6); 7.2846 (1.3); 7.2762 (1.4); 7.2725 (1.4); 7.2626 (22.8); 5.3006 (9.1); 4.4170 (16.0); 4.2811 (1.7); 4.2633 (5.5); 4.2455 (5.8); 4.2277 (1.9); 1.5794 (5.8); 1.2966 (7.4); 1.2788 (15.6); 1.2609 (7.4); 0.0696 (3.7); 0.0080 (0.6); -0.0002 (24.8); -0.0085 (0.7) 1-107: 1< H-NMR(400.0 MHz, CDCl3): δ= 8.1455 (1.9); 8.1395 (1.9); 8.0421 (1.2); 8.0403 (1.3); 8.0376 (1.4); 8.0356 (1.2); 8.0301 (1.3); 8.0281 (1.4); 8.0254 (1.4); 8.0235 (1.3); 7.8393 (0.8); 7.8333 (0.7); 7.8187 (1.1); 7.8131 (1.1); 7.7993 (0.8); 7.7934 (0.8); 7.7702 (1.0); 7.7654 (1.0); 7.7516 (1.2); 7.7497 (1.5); 7.7469 (1.3); 7.7450 (1.4); 7.7311 (1.4); 7.7263 (1.4); 7.6239 (1.6); 7.6217 (2.8); 7.6011 (2.0); 7.2609 (25.4); 7.1369 (1.3); 7.1345 (1.3); 7.1248 (1.3); 7.1223 (1.3); 7.1184 (1.2); 7.1159 (1.1); 7.1063 (1.2); 7.1038 (1.2); 6.9814 (1.4); 6.9741 (1.4); 6.9603 (1.4); 6.9542 (1.3); 5.2716 (0.7); 5.2543 (2.5); 5.2369 (2.6); 5.2195 (0.8); 4.2856 (1.0); 4.2817 (1.0); 4.2678 (3.0); 4.2639 (3.0); 4.2499 (3.1); 4.2462 (2.9); 4.2320 (1.0); 4.2284 (1.0); 1.7113 (0.6); 1.6999 (10.5); 1.6942 (1.0); 1.6825 (10.3); 1.5508 (16.0); 1.3047 (0.6); 1.2986 (6.5); 1.2870 (1.4); 1.2808 (13.5); 1.2693 (1.3); 1.2630 (6.8); 0.8819 (0.6); 0.0080 (0.8); - 0.0002 (28.3); -0.0085 (0.8) 1-108: 1< H-NMR(400.6 MHz, CDCl3): δ= 8.2005 (1.1); 8.1943 (1.2); 8.0860 (0.6); 8.0750 (0.6); 7.8559 (0.6); 7.8496 (0.6); 7.8369 (0.7); 7.8348 (0.8); 7.8308 (0.7); 7.8286 (0.7); 7.8158 (0.6); 7.8097 (0.6); 7.7536 (0.6); 7.2606 (39.7); 6.9925 (0.7); 6.9853 (0.7); 6.9715 (0.7); 6.9642 (0.7); 5.3003 (5.3); 5.1175 (1.3); 5.0434 (0.9); 3.7107 (2.3); 3.6798 (1.6); 3.1571 (0.6); 2.0455 (1.2); 1.5446 (16.0); 1.2596 (0.9); 0.0080 (1.6); 0.0058 (0.5); 0.0050 (0.5); -0.0002 (64.7); -0.0085 (2.0) 1-109: 1< H-NMR(400.6 MHz, CDCl3): δ= 8.2018 (2.0); 8.2000 (2....

Claims

1. 1-Pyridyl-5-azinylpyrazolyl-3-oxyalkyl acids, 1-pyridyl-5-azinylpyrazolyl-3-sulfanylalkyl acids, 1-pyridyl-5-azinylpyrazolyl-3-sulfinylalkyl acids and 1-pyridyl-5-azinylpyrazolyl-3-sulfonylalkyl acids and derivatives thereof of the general formula (I) and the agrochemically compatible salts, N-oxides, hydrates, and hydrates of the salts and N-oxides thereof, where A is selected from the group consisting of A1-A15 Q is selected from the group consisting of Q1-Q3 R1 is -OR1a, -NR9R10 or -O(CH2)xO(CH2)yO(CH2)zH; R1a is hydrogen or is (C1-C6) -alkyl, (C3-C6) -cycloalkyl, each of which is unsubstituted or substituted by one or more substituents selected from the group consisting of halogen, (C1-C6) - alkyl, (C1-C6) -haloalkyl, (C3-C6) -cycloalkyl, (C1-C6) - alkoxy, (C1-C2) -haloalkoxy, (C1-C6) -alkoxycarbonyl, cyano and nitro, or is (C2-C4) -alkenyl, CH2C(COOMe)=CH2, (C2-C4) -alkynyl or is (C1-C6) -alkyl-S- (C1-C6) -alkyl-, (C1-C6) -alkyl-SO- (C1-C6) -alkyl-, (C1-C6) -alkyl-SO2- (C1-C6) -alkyl- or is -N= (C3-C6) -cycloalkyl, -N=C(CH3)2 or is heterocyclyl, heteroaryl, aryl or is heterocyclyl-(C2-C4)-alkyl-, heteroaryl-(C2-C4)-alkyl-, aryl-(C1-C4)-alkyl-, each of which is unsubstituted or substituted by one or more substituents selected from the group consisting of halogen, (C1-C6) -alkyl, (C1-C6)-haloalkyl; R9 is hydrogen, (C1-C12) -alkyl; R10 is hydrogen, aryl, heteroaryl, heterocyclyl, (C1-C12) -alkyl, (C3-C8) -cycloalkyl, (C3-C8) -cycloalkyl- (C1-C7) -alkyl-, (C2-C12) -alkenyl, (C5-C7) -cycloalkenyl, (C2-C12)-alkynyl, S(O)nR5, cyano, nitro, OR5, SO2NR6R7, CO2R8, CORB, NR6R8, NR6COR8, NR6CO2R8, NR6SO2R8, where the abovementioned alkyl, cycloalkyl, alkenyl, cycloalkenyl and alkynyl radicals are unsubstituted or each substituted independently of one another by "m" radicals selected from the group consisting of hydrogen, optionally mono- or polysubstituted aryl, halogen, cyano, nitro, OR5, S(O)nR5, SO2NR6R7, CO2R8, CONR6R8, COR6, NR6R8, NR6COR8, NR6CONR8R8, NR6CO2R8, NR6SO2R8, NR6SO2NR6R8, C(R6) =NOR8; or R9 and R10 together with the nitrogen atom to which they are bonded form a saturated or partly or fully unsaturated five-, six- or seven-membered ring which is optionally mono- to hexasubstituted by the following radicals from the group consisting of halogen, (C1-C6) - alkyl, (C1-C6) -haloalkyl, OR5, S(O)nR5, CO2R8, CONR6R8, COR6 and C (R6) =NOR8 and which, in addition to this nitrogen atom, contains "r" carbon atoms, "o" oxygen atoms, "p" sulfur atoms and "q" elements from the group consisting of NR7, CO and NCOR7 as ring atoms; R5 is (C1-C6) -alkyl, (C3-C6) -cycloalkyl, (C1-C6)-haloalkyl, aryl; R6 is hydrogen, (C1-C6) -alkyl, (C3-C6) -cycloalkyl, (C1-C6)-haloalkyl, aryl; R7 is hydrogen, (C1-C6) -alkyl, (C3-C6) -cycloalkyl, (C3-C4) -alkenyl, (C3-C4) -alkynyl, CH2-C(O)O(C1-C2)-alkyl; R8 is hydrogen, (C1-C6) -alkyl, (C3-C6) -cycloalkyl, (C3-C4)-alkenyl, (C1-C6) -alkyl-C (O) O (C1-C2) -alkyl or (C3-C4)-alkynyl; R2 is hydrogen, cyano, (C1-C6) -alkyl, (C1-C6) -alkoxy-(C1-C6) -alkyl-, (C1-C6)-haloalkyl, (C1-C6) -alkoxy, (C2-C6) - alkenyl, (C2-C6) -haloalkenyl, (C2-C6) -alkynyl, (C2-C6) - haloalkynyl, (C3-C6) -cycloalkyl; R3 is halogen, cyano, isocyano, NO2, (C3-C6) - cycloalkyl, (C1-C6)-alkyl, (C3-C6) -halocycloalkyl, (C1-C6)-haloalkyl, (C1-C6) -alkylcarbonyl-, (C1-C6) - haloalkylcarbonyl-, (C1-C6) -alkyloxycarbonyl-, (C2-C3) - alkenyl, (C2-C3) -haloalkenyl, (C2-C3) -alkynyl, (C2-C3)- haloalkynyl, (C1-C6) -alkyl-S(O), and (C1-C6) -haloalkylS(O)n, CHO, NH2; R12 is halogen, cyano, isocyano, NO2, (C1-C6) -alkyl, (C1-C6)-haloalkyl, (C1-C6) -alkylcarbonyl, (C1-C6) - haloalkylcarbonyl, (C1-C6) -alkyloxycarbonyl, (C1-C6) - alkoxy, (C1-C6)-haloalkoxy, (C1-C6)-alkyl-S(O)n, (C2-C3)-alkenyl, (C2-C3)-haloalkenyl, (C2-C3) -alkynyl, (C2-C3)-haloalkynyl, NH2; R13 is halogen, cyano, isocyano, NO2, (C1-C6) -alkyl, (C1-C6) -haloalkyl, (C1-C6) -alkylcarbonyl, (C1-C6)-haloalkylcarbonyl, (C1-C6) -alkyloxycarbonyl, (C1-C6)-alkoxy, (C1-C6) -haloalkoxy, (C1-C6)-alkyl-S(O)n, (C2-C3)-alkenyl, (C2-C3) -haloalkenyl, (C2-C3) -alkynyl, (C2-C3)-haloalkynyl, NH2; Y is oxygen, S(O)n; m is 0, 1 or 2; n is 0, 1 or 2; o is 0, 1 or 2; p is 0 or 1; q is 0 or 1; r is 3, 4, 5 or 6; s is 0, 1, 2, 3 or 4; x is 2 or 3: y is 2 or 3; z is 1 or 2.

2. Compounds of the formula (I) according to Claim 1 and the agrochemically compatible salts, N-oxides, hydrates, and hydrates of the salts and N-oxides thereof, where A is selected from the group consisting of A1-A4, A6, A8, A9, A12, A15 Q is selected from the group consisting of Q1-Q3 R1 is -OR1a, -NR9R10 or -O(CH2)xO(CH2)yO(CH2)zH; R1a is hydrogen or is (C1-C3) -alkyl, (C3-C6) -cycloalkyl, each of which is unsubstituted or substituted by one or more substituents selected from the group consisting of halogen, (C1-C4)-alkyl, (C1-C4) -haloalkyl, (C3-C6) -cycloalkyl, (C1-C4)-alkoxy, (C1-C4)-alkoxycarbonyl, cyano, or is (C2-C4) -alkenyl, (C2-C4) -alkynyl or is (C2-C3) -alkyl-SMe-, (C2-C3) -alkyl-SOMe-, (C2-C3) -alkyl-SO2Me- or is -N=C(CH3)2 or is heterocyclyl or is heterocyclyl-(C2-C2)-alkyl-, heteroaryl-(C2-C2)-alkyl-, aryl-(C1-C2)-alkyl-, each of which is unsubstituted or substituted by one or more substituents selected from the group consisting of halogen, (C1-C2) -alkyl, (C1-C2) - haloalkyl; R9 is hydrogen, (C1-C4) -alkyl; R10 is (C1-C4)-alkyl, (C2-C4)-alkenyl, (C2-C4)-alkynyl, S(O)nR5, SO2NR6R7, where the abovementioned alkyl, alkenyl and alkynyl radicals are unsubstituted or each substituted independently of one another by "m" radicals selected from the group consisting of halogen, cyano, S(O)nR5, SO2NR6R7, CO2R8, CONR6R8; or R9 and R10 together with the nitrogen atom to which they are bonded form a saturated or partly or fully unsaturated five-, six- or seven-membered ring which is optionally mono- or disubstituted by the following radicals from the group consisting of (C1-C4) -alkyl, (C1-C4) -haloalkyl, CO2R8 and CONR6R8; R5 is (C1-C4)-alkyl, (C3-C6)-cycloalkyl, (C1-C4)-haloalkyl, phenyl; R6 is hydrogen, (C1-C4)-alkyl, (C3-C6)-cycloalkyl, (C1-C4)-haloalkyl, phenyl; R7 is hydrogen, (C1-C4)-alkyl, (C3-C6)-cycloalkyl, (C3-C4)-alkenyl, (C3-C4)-alkynyl; R8 is hydrogen, (C1-C4)-alkyl, (C3-C6)-cycloalkyl, (C3-C4) -alkenyl, (C1-C4)-alkyl-C(O)O(C1-C2) -alkyl or (C3-C4)-alkynyl; R2 is hydrogen, (C1-C3)-alkyl, (C1-C3)-alkoxy, (C2-C3)-alkenyl, (C2-C3)-alkynyl, (C3-C6)-cycloalkyl; R3 is halogen, cyano, isocyano, NO2, (C3-C6)-cycloalkyl, (C1-C4)-alkyl, (C3-C6)-halocycloalkyl, (C1-C4)-haloalkyl, (C1-C4)-alkylcarbonyl-, (C1-C4)-haloalkylcarbonyl-, (C1-C4)-alkyloxycarbonyl-, (C2-C3)-alkenyl, (C2-C3)-haloalkenyl, (C2-C3)-alkynyl, (C2-C3)-haloalkynyl, CHO; R12 is halogen, cyano, NO2, (C1-C4)-alkyl, (C1-C4)-haloalkyl, (C1-C4)-alkylcarbonyl, (C1-C4)-haloalkylcarbonyl, (C1-C4)-alkyloxycarbonyl, (C1-C4)-alkoxy, (C1-C4)-haloalkoxy, (C2-C3)-alkenyl, (C2-C3)-haloalkenyl, (C2-C3)-alkynyl, (C2-C3)-haloalkynyl, NH2; R13 is halogen, cyano, NO2, (C1-C4)-alkyl, (C1-C4)-haloalkyl, (C1-C4)-alkylcarbonyl, (C1-C4)-haloalkylcarbonyl, (C1-C4)-alkyloxycarbonyl, (C1-C4)-alkoxy, (C1-C4)-haloalkoxy, (C2-C3)-alkenyl, (C2-C3)-haloalkenyl, (C2-C3)-alkynyl, (C2-C3)-haloalkynyl, NH2; Y is oxygen, S(O)n; m is 0 or 1; n is 0, 1 or 2; s is 0, 1, 2 or 3; x is 2: y is 2; z is 1.

3. Compounds of the formula (I) according to Claim 1 or 2 and the agrochemically compatible salts, N-oxides, hydrates, and hydrates of the salts and N-oxides thereof, where A is selected from the group consisting of A2, A3, A6 and A8 Q is selected from the group consisting of Q1-Q3 R1 is -OR1a, -NR9R10 or -O(CH2)2O(CH2)2OCH3; R1a is hydrogen or is (C1-C3)-alkyl which is unsubstituted or substituted by a substituent selected from the group consisting of-C(O)OMe, cyclopropyl, cyclopentyl, methoxy, cyano, trifluoromethyl or is (C3-C6)-cycloalkyl or is -N=C(CH3)2 or is prop-2-ynyl or is oxetan-3-yl-(C1-C2)-alkyl-, tetrahydrofuran-2-yl-(C1-C2)-alkyl-, tetrahydrofuran-3-yl-(C1-C2)-alkyl-, pyridin-2-yl- (C1-C2)-alkyl-, pyridin-3-yl- (C1-C2)-alkyl-, pyridin-4-yl-(C1-C2)-alkyl-, phenyl-(C1-C2)-alkyl-; R9 is hydrogen; R10 is (C1-C4)-alkyl where the alkyl radical is unsubstituted or monosubstituted by CO2R8, S(O)2R5 or SO2NR6R7 ; or R9 and R10 together with the nitrogen atom to which they are bonded form a saturated five-or six-membered ring monosubstituted by CO2R8; R5 is methyl, ethyl or CH2CF3; R6 is hydrogen or methyl; R7 is methyl or ethyl; R8 is hydrogen, methyl or ethyl; R2 is hydrogen, methyl or ethyl; R3 is halogen, cyano, NO2, (C3-C5) -cycloalkyl, (C3-C5) - halocycloalkyl, (C1-C2) -alkyl, (C1-C2)-haloalkyl; R12 is fluorine or chlorine; R13 is fluorine, chlorine, methyl, ethyl, methoxy, trifluoromethyl; Y is oxygen; s is 0, 1, 2.

4. Compounds of the formula (I) according to any of Claims 1 to 3 and the agrochemically compatible salts, N-oxides, hydrates, and hydrates of the salts and N-oxides thereof, where A is selected from the group consisting of A2, A3 and A6 Q is selected from the group consisting of Q1-Q3 R1 is -OR1a or -NR9R10; R1a is hydrogen or is methyl, ethyl, each of which is unsubstituted or substituted by a substituent selected from the group consisting of -C(O)OMe, cyclopropyl, cyclopentyl, methoxy, cyano, trifluoromethyl or is -N=C(CH3)2 or is prop-2-ynyl or is -CH2-tetrahydrofuran-2-yl, -CH2-tetrahydrofuran-3-yl, -CH2-oxetan-3-yl, -CH2-pyridyl-2-yl, -CH2-pyridin-3-yl, - CH2-pyridin-4-yl, -CH2-phenyl; R9 is hydrogen; R10 is methyl or ethyl, where the radicals are monosubstituted by CO2R8; or R9 and R10 together with the nitrogen atom to which they are bonded form a cyclopentyl or cyclohexyl radical monosubstituted by CO2R8; R8 is methyl or ethyl; R2 is hydrogen or methyl; R3 is halogen, cyano, NO2, cyclopropyl, cyclobutyl, 2,2-difluorocyclopropyl, trifluoromethyl; R12 is fluorine; R13 is fluorine, chlorine, methyl, trifluoromethyl; Y is oxygen; s is 0, 1, 2.

5. Compounds of the formula (I) according to any of Claims 1 to 4 and the agrochemically compatible salts, N-oxides, hydrates, and hydrates of the salts and N-oxides thereof, where A is selected from the group consisting of A2, A3 and A6 Q is selected from the group consisting of Q1-Q3 R1 is -OR1a; R1a is hydrogen, methyl, ethyl; R2 is hydrogen or methyl; R3 is fluorine, chlorine, bromine, cyano, NO2, cyclopropyl, trifluoromethyl; R12 is fluorine; R13 is fluorine, chlorine, trifluoromethyl; Y is oxygen; s is 0, 1, 2.

6. Compounds of the formula (Z) according to any of Claims 1-5 with Q = Q1, R1 = -OR1a and Y = O and the agrochemically compatible salts, N-oxides, hydrates, and hydrates of the salts and N-oxides thereof, where the substituents are defined according to any of Claims 1 to 5.

7. Compounds of the formula (Y) according to any of Claims 1-5 with Q = Q1, Y = O and A = A2 and the agrochemically compatible salts, N-oxides, hydrates, and hydrates of the salts and N-oxides thereof, where the substituents are defined according to any of Claims 1 to 5.

8. Process for preparing the compounds of the formula (Ic) or an agrochemically acceptable salt thereof according to any of Claims 1 to 5 by converting compounds of the general formulae (III) and (IV) in which R2, R1a, R3, A, Q and Y have the definitions given above and X is chlorine, bromine or iodine, in the presence of a thionating reagent, for example phosphorus pentasulfide or Lawesson's reagent.

9. Process for preparing the compounds of the formula (Ia) or an agrochemically acceptable salt thereof according to any of Claims 1 to 5 by converting a compound of the general formula (Ic) in which R2, R1a, R3, A, Q and Y have the definitions given above, in the presence of a base or a Lewis acid.

10. Process for preparing the compounds of the formula (Ib) or an agrochemically acceptable salt thereof according to any of Claims 1 to 5 by converting compounds of the general formulae (Ia) and (II) in which R9, R10, R2, R1a, R3, A, Q and Y have the definitions given above, in the presence of an amide coupling reagent.

11. Agrochemical composition comprising a) at least one compound of the formula (I) or an agrochemically acceptable salt thereof, as defined in one or more of Claims 1 to 5, and b) auxiliaries and additives customary in crop protection.

12. Agrochemical composition comprising a) at least one compound of the formula (I) or an agrochemically acceptable salt thereof as defined in one or more of Claims 1 to 5, b) one or more active agrochemical ingredients other than component a), and optionally c) auxiliaries and additives customary in crop protection.

13. Method of controlling unwanted plants or of regulating the growth of plants, wherein an effective amount of at least one compound of the formula (I) or an agrochemically acceptable salt thereof, as defined in one or more of Claims 1 to 5, is applied to the plants, the seed or the area in which the plants grow.

14. Use of compounds of the formula (I) or an agrochemically acceptable salt thereof, as defined in one or more of Claims 1 to 5, as herbicides or plant growth regulators.

15. Use according to Claim 14, wherein the compounds of the formula (I) or an agrochemically acceptable salt thereof are used for controlling harmful plants or for regulating growth in plant crops.

16. Use according to Claim 15, wherein the crop plants are transgenic or nontransgenic crop plants.